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ABSTRACT 
^Antimicrobial drug resistance is a growing threat and a topic of intense research 
f ^ ^ worldwide. The outbreak of infectious diseases plus emergence and re-
emergence of multi-drug resistant (MDR) pathogens such as bacteria, fungi, and 
viruses (Tenover, 2006) remain a major health concern, which in turn are responsible, for 
causing a large number of deaths and hospitalizations every year worldwide. Due to 
extensive use of P-lactam antibiotics over the last several decades, in the clinical 
practices, various p-lactamases has enierged. The production of extended-spectrum P-
lactamases (ESBLs) is an important mechanism,, which is responsible for resistance to the 
third-generation cephalosporins (Bradford, 2001). Infections caused by Staphylococcus 
sp, especially methicillin-resikant S. aureus (MRSA) and methicillin-resistant S. 
epidermidis (MRSE) are emerging as a major public health problem. MRSA has been 
associated with skin and soft tissue infections, endovascular infections, pneumonia, septic 
arthritides, endocarditis, osteomyelitis and sepsis (Lowy, 1998). The basic mechanism of 
resistance in most cases of MRSA is the production of an additional penicillin binding 
protein, PBP2' or PBP2a, mediated by the mecA gene. 
In recent years there has been considerable interest in the problems posed by the biofilm 
mode of bacterial and fungal growth. According to National Institute of Health, "more 
than 60% of all microbial infection is caused by biofilm" (Lewis, 2001). The continuing 
emphasis on healthcare costs, many researchers are trying to develop novel, effective 
antimicrobial agents, which are not only able to overcome the resistance of these 
pathogens, yet also remain cost-effective. Therefore, the development of new 
antimicrobial compounds or the modification of those available in order to improve 
antimicrobial activity for therapy, antisepsis or disinfection is a high priority area of 
research. In this endeavor, nanotechnology provides a means, to modify key features, oi 
different materials, including metal and metal oxides nanoparticles. A large group of 
studies includes the implementation of nanotechnologies, to create new antimicrobial 
nanomedicine with increased effectiveness and efficiency (Weir et al, 2008; Chun & 
Webster, 2009). 
ABstract 
The 21^' century may be called as 'nano-century' with nanotechnology making its 
presence felt in different spheres of our lives. In the present scenario, nanoscale materials 
have emerged up, as novel antimicrobial agents owing to their high surface area to 
volume ratio and the unique chemical and physical properties (Morones et al., 2005; Kim 
et al., 2007). Nowadays, one of the most studied aspects of nanotechnology is their 
ability to offer the opportunity to fight microbial infections through the synthesis of 
nanoparticles (Luo et al., 2007). The prefix "nano" is derived from a Greek word ''nanos" 
which means "dwarf. It refers to any engineered matter that is one billionth (10"'m) m 
size and expressed as nanometer (nm) or roughly the length of three atoms, side by side. 
Nanotechnology provides an excellent platform to modify and develop the important 
properties of metal in the form of nanoparticles. NPs has promising applications in 
diagnostics, biomarkers, cell labeling, contrast agents for biological imaging, 
antimicrobial agents, drug delivery systems and nano-drugs for treatment of various 
diseases (Singh & Singh, 2011). Therefore researchers are shifting towards nanoparticles 
to solve the problem of emergence of MDR pathogens (Gemmell et al., 2006). 
Silver has been used for thousands of years, as a precious metal by humans' in different 
applications as jewellery, tools, coins, photographic materials or explosives. Hippocrates 
described silver powder for its application in wound healing and in treatment of ulcers 
(Klasen, 2000). Ever since understanding about various properties of NPs has increased, 
an interesting area of research has emerged up regarding antimicrobial activities of 
nanoparticles, sometimes known as nanobiotics. The antibacterial activity of metal 
nanoparticles such as AgNPs in literature is well documented (Sondi & Salopek Sondi, 
2004; Kim et al., 2007; Pal et al., 2007; Lara et al., 2010; Ansari et al., 2011 a & b). The 
considerable antimicrobial activities of metal oxide nanoparticles such as ZnO (Reddy et 
al., 2007; Ansari et al., 2012 a & b), AI2O3 (Sadiq et al., 2009) and their selective toxicity 
to biological systems suggest their potential application as therapeutics, diagnostics, 
surgical devices and nanomedicine based antimicrobial agents. The development of 
antibiotic resistance in different microbes has made it imperative, that research should be 
focused on newer agents, which may be used alone or in combination, with other 
antimicrobial agents. This could prove effective in dealing with superficial infections or 
as a preventive measure. Many NPs have shown antimicrobial property in-vitro. 
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However, it is very important, to find out whether these promising NPs are safe, for use 
in-vivo. Hence, the first step would be, to test for histopathological and biochemical 
changes in an animal test model, using standard. International procedures and techniques. 
In comparison to rapid strides in the industrial and commercial applications of NPs, 
major efforts have been made in understanding their toxicological aspects and associated 
health hazards, if any (Donaldson et al, 2004; Oberdorster et al, 2005). The present 
informafion on Ag and ZnO NPs toxicity in vivo is quite limited. Furthermore, the 
majority of studies were performed in vitro and there is a very little evidence that these 
toxicity rankings directly translate into in vivo systems. One limitation of most toxicity 
studies so far is that these results have mainly been an outcome of using in vitro cell 
culture models. Plus there has been a very little correlation between in vivo and in vitro 
measurements. Therefore, the objective of this research work was to investigate the 
antimicrobial activities of metal and metal oxides NPs in vitro and to understand their 
potential adverse toxicological effects in animal mice in vivo for safe and therapeutic 
application of NPs and to treat the infections caused by MDR pathogens. In the present 
study different sizes of NPs of Ag (2, 5-10, 15, 35-50 & 100 nm), ZnO (20 &70 nm) and 
AI2O3 (45 & <50 nm) were used to evaluate their antibacterial properties against various 
drug resistant and non-resistant clinical isolates of E. coli (ESBL & non-ESBL), P 
aeruginosa (ESBL, non-ESBL & MBL), S. aureus (MRSA & MSSA) and Klebsiella spp 
and some standard bacterial strains. To assess the antibacterial activity of NPs in vitro 
MIC/MBC, optical density measurement, well-diffusion, SEM, HR-TEM methods were 
used and to assess the toxicological effects of NPs in mice in vivo biochemical, light and 
electron microscopic methods were applied. 
Based on the observations, it can be concluded that: 
• Out of total 163 clinical bacterial isolates. Staphylococcus spp 62 (38.04%) showed 
highest prevalence followed by P. aeruginosa 55 (33.7%), E. coli 40 (24.5%) and 
Klebsiella spp 6 (3.7%). On screening Staphylococcus for methicillin sensitivity, 48% 
5". aureus and 60% Coagulase negative Staphylococci were found to be resistant. On 
screening for ESBL production, 80% E. coli, 76.3% P. aeruginosa, and 66.7% f 
Klebsiella sp. were found to be ESBL producers, whereas 7.3% P. aeruginosa were 
MBL positive. 
• 
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The MIC values of small size AgNPs (2 & 5-10 nm) was found to be 3.13 and 11.25 
Hg/ml, respectively, while that of large size AgNPs (15, 35-50 & 100 nm) were in the 
range of 16-64, 400-1600 and 1300-2600 ng/ml, respectively, against tested bacterial 
isolates. 
The MIC of ZnO NPs (20 and 70 nm) was found to be in the range of 500-4000 and 
2000-8000 ]x%lm\, respectively, whereas, that of A1203 NPs (45 and <50 nm) were 
observed in the range of 1600-3200 and 1800-3600 |Jg/ml, respectively. 
Bactericidal effects were partly due to NPs induced production of intracellular ROS, 
but we rather think that the impairment of cell membrane integrity is the major cause 
of bacterial death. Taken together, these data give valuable information on the 
mechanisms leading to NPs-induced bacterial death. However, another possible 
reason of the bacterial damage could be the direct interaction between NPs and 
bacterial membrane surface. 
NPs are much smaller than the bacterial cells, they coated around the bacteria cell by 
electrostatic forces, neutralizing the bacterial surface charge and creating large 
aggregates. The large aggregates of NP-bacteria complexes would deposit quickly in 
the suspension. This indicates a particle size-dependant phenomenon. For negatively 
charged bacterial cells (a few micrometers in size), they could readily capture NPs by 
electrostatic attractive forces, while it would be difficult to attract bulk particles. 
From the results of MIC, it was inferred that small size NPs shows enhanced activity 
possibly due to the large surface area to volume ratio and this can be explained on the 
basis of the generation of highly reactive oxygen species, which cause fatal damage to 
the bacterial cells. 
SEM and HR-TEM analysis revealed that the action of Ag, ZnO and AI2O3 NPs was 
mild in S. aureus as compared with E. coli and P. aeruginosa; these results suggest 
that the antimicrobial effects of NPs may be associated with characteristics of certain 
bacterial species. The lower efficacy of the NPs against iS". aureus was possibly due to 
differences in membrane structure. 
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• It was observed from SEM and HR-TEM micrograph that NPs act primarily in four 
ways against bacteria: (1) nanoparticles attach to the surface of the bacterial cell 
membrane and cause pit formation, perforation, disorganization and thus drastically 
disturb its proper function (2) they to penetrate inside the bacteria and cause further 
damage (3) NPs were accumulated in bacterial periplasm, confirming that association 
between NPs and bacteria is a prerequisite for the expression of their toxicity 
(4) nanoparticles release ions which will have an additional contribution to the 
bactericidal effect of the NPs and finally caused cell death. 
• AgNPs show excellent antibiofilm properties against E.coli, P. aeruginosa and X 
aureus biofilms. AgNPs treated samples shows that most of the cells were dead and 
no exopolysachharides was observed. The CLSM micrograph shows that the number 
of live bacterial cells was reduced significantly as the concentration increased, and 
the 3-dimensional structure was also disrupted. 
• SEM observations showed that AgNPs damage the cells and reduced the surface 
coverage by E. coli, P. aeruginosa and S. aureus biofilms. 
• Treatment with ZnO and AgNPs caused changes in biochemical parameters such as 
TP, ALB, ALP, SGOT and CR reflected the renal and hepatic functions of 
experimental mice. 
• Significant increased level of CR was observed at high and exceptionally high-dose 
of ZnO NPs when exposed for 3 and 4 week indicate dysfunction of kidney. 
• No significant changes were observed in the level of CHO, HDL, TG and GLU at all 
doses after 1, 3 and 4 week of exposure to ZnO NPs indicates that ZnO NPs had no 
adverse effects on the lipid and glucose metabolism, however, on week 2 significant 
decreased in HDL level was noticed. 
• Significant decreased in TIBL and ALB levels when mice were exposed to AgNPs 
for 1, 2, 3 and 4 week at all doses and significant increased in SGPT levels at high-
dose indicates liver dysfunction. 
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Significant decreased in CR levels were observed at high-dose of AgNPs also indicate 
kidney dysfunction. A decreased level of CR with respect to renal dysfunction might 
be the result of the augmentation of CR secretion by PCT. 
No remarkable changes in TG and CHO levels were observed at any doses of AgNPs 
indicate lipid metabolism was not affected when mice were exposed to AgNPs for ], 
2 and 3 weeks, however, significant decreased in CHO level were noticed at high-
dose on week 4. 
One of the interesting finding of present work was that the glucose levels were 
significantly (p <0.05) decreased in all groups of treated mice at all doses in V\ 2"'', 
3'^'^ and 4"^  week of treated mice. 
The light microscopic histopathological observation showed, congestion, granular 
degeneration in the hepatocytes, inflammatory cells in the liver and vesicular change 
in the hepatocytes at exceptionally high-dose (5-g/kg) of ZnO and AgNPs when mice 
were exposed for 3"* and 4"" weeks. No obvious effect on the hepatic cytoarchitecture 
of liver at low- (0.5-g/kg), middle- (1-g/kg) and high-dose (3-g/kg) group were 
observed on 1, 2, 3 and 4 week of exposure to ZnO and AgNPs. 
Histopathological examination after one week treatment of ZnO and AgNPs had no 
perceptible effect on kidney structure at any doses; however, two weeks treatment 
had mild effect in terms of damage to the tubular epithelium at exceptionally high-
dose (5-g/kg). While, after '^^ ^ and '^ * week of exposure to similar dose damage to 
tubular epithelium of kidney and renal cast in the tubular lumen were observed. The 
renal histopathological examination revealed renal cast in the tubular lumen, damage 
of tubular epithelium and renal tubular dilatation at exceptionally high-dose (5-g/kg). 
Histopathological examination after one week treatment of ZnO and AgNPs had no 
observable changes in spleen structure at any doses and were very akin to control. 
However, at exceptionally high-dose (5-g/kg) after two week of treatment slight 
increased in the size of megakaryocytes was seen. After 3 '^' and 4"^  week of exposure 
to similar dose (5-g/kg) megakaryocyte hyperplasia was observed in the red pulp in 
the spleen and the number of megakaryocytes in the spleen were increased as 
compare to control group. 
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There is paucity of literature on electron microscopic ultrastructural changes caused 
by ZnO and AgNPs in mice liver, kidney and spleen. Administration of low-, middle-
and high-dose ZnO and AgNPs did not showed any significant changes in the 
ultrastructure of mice liver, kidney and spleen when exposed for 1^ ', 2"'^, 3'^ and 4"^  
week suggest that ZnO and AgNPs were non toxic at these doses. 
Mice exposed to exceptionally high-dose of ZnO and AgNPs for 3 and 4 weeks 
showed significant changes in the ultrastructure of liver, kidney and spleen. The 
ultrastructural damages observed were chromatin condensation, irregularity of 
nuclear membrane, swelling of mitochondria, polymorphic mitochondria with 
vacuoles, dilation of rough endoplasmic reticulum, vacuolation on the cytoplasm, 
suggesting an early necrosis and apoptosis. 
No obvious changes were observed at V\ 2"'^, 3^^ and 4*^  week of mice kidney when 
exposed at low- (0.5-g/kg), middle- (1-g/kg) and high-dose (3-g/kg) of AgNPs. Thus 
the long-term ZnO NPs exposures particularly at high dose may be advised with 
caution. 
No significant ultrastructural changes in spleen were observed at low-, middle- and 
high-dose when mice were sacrificed on T', 2"*^ , 3^^ and 4"^  week. However, long-term 
exposure of mice with exceptionally high-dose of ZnO and AgNPs, ultrastructure 
changes in splenocyte of mouse tissue presenting significant splenocyte tumescent 
mitochondria, vacuolization, and apoptosis when exposed for 3'^ '' and 4* week. 
From the available literature it appears that this is the first report of metal and metal 
oxide NPs-related ultrastructural cell damage in spleen. 
Thus both the light and electron microscopic examinations revealed that liver, kidney 
and spleen were the main target organs for ZnO and AgNPs following intraperitoneal 
administration. These were evident in all animals treated with exceptionally high-
dose of ZnO and AgNPs for 3''' and 4* week. The TEM results suggested that long-
term exposure with exceptionally high-dose (5-g/kg) of ZnO and AgNPs caused the 
necrosis / apoptosis. 
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The finding also suggests that ZnO and AgNPs appear to be systemically toxic to 
mice at exceptionally high-dose on long-term exposure and toxicity of nanoparticles 
is dependent on concentration and duration of exposure. 
Interestingly, NPs inhibited bacterial growth of MSSA, MRSA, MRSE, ESBL and 
non ESBL E. coli, P. aeruginosa and Klebsiella spp regardless of the resistance 
mechanisms that confer importance to these bacteria as an emerging pathogen 
suggests that NPs are effective broad-spectrum antibacterial agents. 
It was concluded that the bactericidal activity of NPs depends both on size and the 
concentration of nanoparticles and it was further concluded that AgNPs shows better 
antibacterial activity followed by ZnO and AI2O3 NPs. 
The results suggested that ZnO and AgNPs could be well tolerated in mice when 
given intraperitoneally at the dose level of 5-g/kg and more interestingly no mortality 
was noted up to 4 week. 
The significant decreased in glucose level after AgNPs administration suggest that 
AgNPs has the potential to lowered the blood glucose level after short- and long-term 
administration suggesting their future prospect as anti-hyperglycemic agents for 
diabetic patients. Though, additional work needs to be undertaken to elucidate the 
mechanisms at molecular levels before being applied as a therapeutic drug. 
In the future, Ag, ZnO and AI2O3 NPs-containing formulations may be utilized for 
external uses as antibacterial agents in ointments, lotions and surface coatings on 
various substrates to prevent microorganisms from attaching, colonizing, spreading 
and forming biofilms in indwelling medical devices. 
In the view of the present in vivo toxicological findings in mice it may be suggested 
that workers and researchers who are regularly exposed to nanoparticles should 
accordingly observe appropriate safety measures. In order to safeguard the human 
health and environment a risk assessment framework for nanoparticles should be built 
based upon their available toxicity studies. 
Data from this study will not only be useful for the toxicological evaluation of ZnO 
and AgNPs in animals, but will also shed light on future toxicological evaluation in 
humans. These results suggest the need for a complete risk assessment of any new 
engineered nanoparticle before its arrival into the consumer market. 
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1. INTRODUCTION 
Antimicrobial drug resistance is a growing threat and a topic of intense researcii worldwide. The outbreak of infectious diseases plus emergence and re-
emergence of multi-drug resistant (MDR) pathogens such as bacteria, fungi, and 
viruses (Tenover, 2006) remain a major health concern which are responsible for causing 
a large number of deaths and hospitalizations every year worldwide. Despite 
antimicrobial therapy, morbidity and mortality associated with these microbial infections 
remain high, partially due to the ability of these pathogens to develop resistance, to 
virtually all classes of antibiotics (Desselberger, 2000). Due to extensive use of p-iactam 
antibiotics over the last several decades in the clinical practices, various P-lactamases has 
emerged. The predominant mechanism for resistance to the p-lactam antibiotics in Gram-
negative bacteria is the production of enzyme P-lactamase. The production of extended-
spectrum P-lactamases (ESBLs) is an important mechanism which is responsible for 
resistance to the third-generation cephalosporins (Bradford, 2001). Infections caused by 
Staphylococcus sp, especially methicillin-resistant S. aureus (MRSA) and methicillin-
resistant S. epidermidis (MRSE) are emerging as a major public health problem. MRSA 
has been associated with skin and soft tissue infections, endovascular infections, 
pneumonia, septic arthritides, endocarditis, osteomyelitis and sepsis (Lowy, 1998). 
Methicillin, a penicillinase resistant semi-synthetic penicillin was introduced into therapy 
in Europe in 1959-1960 and in the United States in 1961 (Oliveira et al., 2002; Rice, 
2006). The first cases of MRSA were reported in the United Kingdom in 1961, followed 
soon by reports in other European countries, Japan, and Australia (Palavecino, 2004; 
Rice, 2006). The basic mechanism of resistance in most cases of MRSA is the production 
of an additional penicillin binding protein, PBP2' or PBP2a mediated by the mec.4 gene. 
This mecA gene is an additional gene found in methicillin-resistant staphylococci and 
with no allelic equivalent in methicillin susceptible staphylococci. Initially, MRSA was 
only observed in the hospital setting, but it is now clear that MRSA may infect people in 
the community without identifiable risk factors (Rice, 2006). In recent years there has 
been considerable interest in the problems posed by the biofilm mode of bacterial and 
fungal growth. Costerton, one of the founding fathers of biofilm research, described a 
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biofilm as a structured community of microbial ceils enclosed in a self-produced 
polymeric matrix and adherent to an inert or living surface (Costerton et al., 1999). 
According to National Institute of Health, "more than 60% of all microbial infection is 
caused by biofilm" (Lewis, 2001). Infections resulting from microbial biofilm formation 
remain a serious concern to patients worldwide. Particularly problematic are wound 
infections (Davis et al., 2008; James et al, 2008; Percival et al, 2008), with chronic 
wounds such as foot, leg, and pressure ulcers being particularly susceptible to biofilm 
infections (James et al, 2008). While most wound infections are polymicrobial i.e., 
caused by more than one species of bacteria or fungi, the most common isolated species 
include S. aureus, S. epidermidis, P. aeruginosa and Candida species. Nanotechnology 
may provide the answer to penetrate such biofilm and reduce biofilm formation as well as 
microbial colonization. The continuing emphasis on healthcare costs many researchers 
are trying to develop novel effective antimicrobial agents which are not only able to 
overcome the resistance of these pathogens, yet also remain cost-effective. Therefore, the 
development of new antimicrobial compounds or the modification of those available in 
order to improve antimicrobial activity for therapy, antisepsis or disinfection is a high 
priority area of research. In this endeavor, nanotechnology provides a means, to modify 
key features, of different materials, including metal and metal oxides nanoparticles. A 
large group of studies includes the implementation of nanotechnologies, to create new 
antimicrobial nanomedicine with increased effectiveness and efficiency (Weir et al., 
2008; Chun & Webster, 2009). 
The 21^' century may be called as 'nano-century' with nanotechnology making its 
presence felt in different spheres of our lives. In the present scenario, nanoscale materials 
have emerged up, as novel antimicrobial agents owing to their high surface area to 
volume ratio and the unique chemical and physical properties (Morones et al., 2005; Kim 
et al, 2007). Nowadays, one of the most studied aspects of nanotechnology is their 
ability to offer the opportunity to fight microbial infections through the synthesis of 
nanoparticles (Luo et al, 2007). The mechanism of prevention of microbial growth by 
antibiotics is quite different from the mechanisms by of nanoparticles. Therefore, 
nanoparticles have the potential to serve as alternatives to antibiotics and to control 
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microbial infections such as tliose caused by MDR pathogens (Luo et al, 2007). The 
prefix "nano" is derived from a Greek word ''nanos" which means "dwarf. It refers to 
any engineered matter that is one billionth (10~^ m) in size and expressed as nanometer 
(nm) or roughly the length of three atoms, side by side. According to the Royal Academy 
of Engineering, nanotechnology is the design, characterization, production and 
application of structures, devices and systems, by controlling shapes and size at 
nanometer scale. UK Royal Society defined, nanoscience as the study of phenomena and 
manipulation of materials, at atomic, molecular and macromolecular scales, where 
properties differ significantly from those at a larger scale (Royal Society & Royal 
Academy of Engineering, 2004). The term nanotechnology was coined by Professor 
Norio Taniguchi of Tokyo Science University in the year 1974 to describe precision 
manufacturing of materials at the nanometer level (Taniguchi, 1974). 
The celebrated Physicist and Nobel Laureate Richard Feynman, was the first person to 
work at the nanoscale and gave the concept of nanotechnology. In a lecture, at the 
Califomian Institute of Technology in 1959 titled 'There's plenty of room at the bottom', 
he postulated that- being able to manipulate atoms and molecules that would open up new 
avenues of technology. In his view: The Principles of Physics, as far as I can see. do not 
speak against the possibility of maneuvering things atom by atom. It is not an attempt to 
violate any laws: It is something in principle that can be done; but in practice it has not 
been done because we are too big (Feynman, 1959). Nanotechnolog> is a 
multidisciplinary field, which has attracted the attention of Material scientists, 
Mechanical and Electronics Engineers, Medical researchers, Biologists, Physicists, and 
Chemists. Nanotechnology provides an excellent platform to modify and develop the 
important properties of metal in the form of nanoparticles. NPs has promising 
applications in diagnostics, biomarkers, cell labeling, contrast agents for biological 
imaging, antimicrobial agents, drug delivery systems and nano-drugs for treatment of 
various diseases (Singh & Singh, 2011). Therefore researchers are shifting towards 
nanoparticles to solve the problem of emergence of MDR pathogens (Gemmell et al., 
2006). Nanoparticles (NPs) are typically defined as the minuscule constituents, within the 
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size range of 1 nm to 100 nm with large surface area and number of particles per unit 
mass. 
The considerable antimicrobial activities of metal and metal oxide NPs such as Ag, ZnO, 
AI2O3, Ti02, Si02 and their selective toxicity to biological systems, suggest their 
potential application as therapeutics, diagnostics, surgical devices and nanomedicine 
based antimicrobial agents (Sawai and Yoshikawa, 2004; Laura et al., 2006; Reddy et al., 
2007; Sobha et al., 2010; Ansari et al., 2011 a & b; Ansari et al., 2012 a & b). The 
advantages of using these metal and metal oxide n NPs, as antimicrobial agents is their 
greater effectiveness on resistant strains of microbial pathogens, lesser toxicity and heat 
resistance. 
Silver has been used for thousands of years, as a precious metal by humans' in different 
applications as jewellery, tools, coins, photographic materials or explosives. Hippocrates 
described silver powder for its application in wound healing and in treatment of ulcers 
(Klasen, 2000). In the 17th and 18th centuries, silver nitrate was used for ulcer treatment 
and its antimicrobial activity was established in the 19th century. Nevertheless, after the 
introduction of the antibiotics in 1940, the use of silver salts gradually declined. 
Subsequently, silver salts and silver compounds have been used in different biomedical 
fields, especially in bum treatment (Klasen, 2000). Ever since understanding about 
various properties of NPs has increased, an interesting area of research has emerged up 
regarding antimicrobial activities of nanoparticles, sometimes known as nanobiotics. 
Results have shown a definite antibacterial activity in cases of silver and some other NPs. 
Silver nanoparticles (AgNPs) have shown antibacterial activity against Escherichia coli 
(Sondi &. Salopek-Sondi, 2004), S. aureus (Shahverdi et al, 2007; Ansari et al, 201 la & 
b) as well as yeast (Kim et al, 2007). This antibacterial activity is also seen in some 
multidrug resistant strains such as MRSA (Panacek et al., 2006; Ansari et al., 2011 a & 
b). There is strong evidence that, a major cause of the current crisis in antimicrobial 
resistance is the uncontrolled and inappropriate use of antibiotic drugs, in both 
industrialized and developing countries (Park et al, 2008). The anfimicrobial activity of 
AgNPs appears significantly high. Silver is more toxic element to microorganisms than 
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other metals in the following sequence: Ag > Hg > Cu > Cd > Cr > Pb > Co> Au > Zn > 
Fe > Mn > Mo > Sn (Zhao and Stevens, 1998). AgNPs exert more efficient than silver 
ions and other silver salts in mediating their antimicrobial activity (Lok et al., 2006; Rai 
et ai, 2009). Silver exhibits low toxicity to mammalian cells (Zhao and Stevens, 1998). 
Silver has a lower propensity to induce microbial resistance than many other 
antimicrobial materials (Silver et al., 2006; Kim et al., 2007). As a result, AgNPs have 
been applied to a wide range of products, the most important current use is as 
antimicrobial agents to prevent infection, such as in burn and traumatic wound dressings, 
diabetic ulcers, coating of catheters, dental works, scaffold, and medical devices (Silver 
et al., 2006; Kim et al., 2007; Thomas et al., 2007; Law et al., 2008; Rai et al., 2009). 
Among metal oxide NPs, ZnO NPs as one of the multifunctional inorganic nanoparticles 
has many significant features such as chemical and physical stability, high catalysis 
activity, effective antibacterial activity as well as intensive ultraviolet and infrared 
adsorption with broad range of applications as semiconductors, sensors, transparent 
electrodes, solar cells, etc. (Kalyani et al., 2006; Matei et al., 2008). Plus in recent >ears 
ZnO has received considerable attention due to its unique optical, piezoelectric, and 
magnetic properties (Marcus and Paul, 2007). However, the interaction of NPs with 
microorganisms and biomolecules is an extensive field of research which stands largely 
unexplored. 
The development of antibiotic resistance in different microbes has made it imperative, 
that research should be focused on newer agents, which may be used alone or in 
combination, with other antimicrobial agents. This could prove effective in dealing with 
superficial infections or as a preventive measure. The field of nanotechnolog\ is one 
such area which holds a lot of significance. Many NPs have shown antimicrobial property 
in-vitro. However, it is very important, to find out whether these promising NPs are safe, 
for use in-vivo. Hence, the first step would be, to test for histopathological and 
biochemical changes in an animal test model, using standard International procedures and 
techniques. In comparison to rapid strides in the industrial and commercial applications 
of NPs, major efforts have been made in understanding their toxicological aspects and 
associated health hazards, if any (Donaldson et ai, 2004; Oberdorster et al.. 2005a). It is 
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understandable, that the nanoscale materials may easily be spread in the body, in 
unpredictable ways and preferentially accumulates in particular organelles (Mishra et ah, 
2005). It has been demonstrated that the ultrafme particle inhalation could induce toxicity 
due to the large surface area (Tran et al, 2000; Donaldson & Iran, 2002) as it enhances 
the complexity in biological system and induce adverse effects (Oberdorster et al, 
2005b). Any person could be exposed to nanometer sized foreign particles; through 
inhalation with every breath or consume them with any drink. The smallest particles 
contain tens or hundreds of atoms, with dimensions at the scale of nanometers -hence 
nanoparticles. They are comparable in size to viruses, where the smallest have 
dimensions of tens of nanometers (for example, a human immunodeficiency virus, or 
HIV, particle is 100 nm in diameter), and which in the emerging science of 
nanotechnology might be called 'nano-organisms'. Like viruses, some NPs could 
penetrate lung or dermal (skin) barriers and enter the circulatory and lymphatic systems 
of human beings and animals, reaching most bodily tissues and organs, and potentially 
disrupt cellular processes and cause disease. However, the toxicity of each of these 
materials depends greatly, upon the particular arrangement of its atoms. Considering all 
the possible variations in shape and chemistry of even the smallest NPs, with only tens of 
atoms, yields a huge number of distinct materials with potentially very different physical 
and toxicological properties. Asbestos is a good example of a toxic nonmaterial, causing 
lung cancer and other diseases. Asbestos exists in several forms, with slight variations in 
shape and chemistry yet significantly varying in toxicity. 
The present information on Ag and ZnO NPs toxicity in vivo is quite limited. 
Furthermore, the majority of studies were performed in vitro and there is a very little 
evidence that these toxicity rankings directly translate into in vivo systems. One 
limitation of most toxicity studies so far is that these results have mainly been an 
outcome of using in vitro cell culture models. Plus there has been a very little correlation 
between in vivo and in vitro measurements. Therefore, the objective of this research work 
was to investigate the antimicrobial activities of NPs in vitro and to understand their 
potential adverse toxicological effects in animal mice model in vivo for safe and 
therapeutic application of NPs, to treat the infections caused by MDR pathogens. 
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Aims of the Thesis 
The purpose of this PhD work was to investigate the antimicrobial and antibiofilm 
activity of various NPs on different clinical bacterial isolates in vitro and toxicological 
effects of NPs in mice model in vivo. 
The work is divided into two parts with following aims: 
Parti 
• To isolate and identify various gram positive and gram negative bacteria from 
human skin and skin exudates. 
• To study the drug susceptibility pattern of bacterial isolates against various 
antibacterial agents. 
• To investigate the antimicrobial properties of Ag, ZnO and AI2O3 NPs against 
various biochemically characterized skin isolates. 
• Detection of biofilm formation among the clinical isolates of staphylococci, E. coli. 
and Pseudomonas aeruginosa. 
• Characterization of structural analysis of antibiofilm efficacy of various 
nanoparticles by confocal laser scanning microscopy and scanning electron 
microscopy. 
• Scanning electron microscopic and transmission electron microscopic study of the 
antimicrobial mechanism of various NPs. 
Part II 
To assessed the toxicological effects of Ag and ZnO NPs in mice animal model in vivo 
with following main aims: 
• Toxicological effects of Ag and ZnO NPs on serum enzymes i.e., Biochemical 
assay of serum. 
• Histopathological (light microscopic) examinations of tissues/ organs due to the 
toxicity of Ag and ZnO NPs. 
• Transmission electron microscopic analysis of NPs-tissues interaction 
(ultrastructural changes). 
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2. REVIEW OF LITERATURE 
2.1. Concept of nanotechnology 
Nanotechnology is emerging as a rapidly growing field with its application in science and technology for the purpose of manufacturing new materials at the 
nanoscale level (Albrecht et al., 2006). The word "nano" is used to indicate one billionth 
of a meter or 10~^  The term nanotechnology was coined by Professor Norio Taniguchi of 
Tokyo Science University in the year 1974 to describe precision manufacturing of 
materials at the nanometer level (Taniguchi, 1974). Discovering DNA by Watson and 
Crick in 1953 has been one of the landmark accomplishments of science in the 
20"^  century. It was the first discovery at nanoscale level, which showed the natural 
existence of nanoscale material. The celebrated physicist and Nobel Laureate Richard 
Feynman was the first person to work at the nanoscale. In a lecture at the Californian 
Institute of Technology in 1959 titled 'There's plenty of room at the bottom', he 
postulated that being able to manipulate atoms and molecules at will would open up new 
avenues of technology. He pointed out that if a bit of information required only 100 
atoms, then all the books ever written could be stored in a cube with sides 0.02 inch long. 
In his view: "The principles of physics, as far as I can see, do not speak against the 
possibility of maneuvering things atom by atom: It is not an attempt to violate any laws: 
It is something in principle that can be done; but in practice it has not been done because 
we are too big" (Feynman, 1959). The idea of 'molecular manufacturing' was explored 
extensively by Eric Drexler in the 1980s (Drexler, 1986), and is seen by many as a way 
of mimicking organic systems through nanoscale engineering. It was Eric Drexler who is 
most accredited with pushing the nanotechnology revolution to where it is toda> b) 
raising public awareness, educating future researchers, and generally expounding upon 
the field. He was awarded the first Ph.D. in nanotechnology ever. 
The best known of the 'new' nanomaterials was carbon nanotubes-discovered in the 
1990s (lijima, 1991; Bethune et al, 1993). Current research is leading to the development 
of more sophisticated and heterogeneous materials and devices-based on an increasing 
ability to engineer in functionality at the nanoscale (Roco, 2005). The multicomponent 
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nanoscale particles are being developed for cancer treatment that will have the ability to 
attach to diseased cells, enable their position to be tracked, and destroy the cell while 
leaving surrounding tissue intact when signalled to do so (National Cancer Institute, 
2004). 
2.2. Importance of nanomaterials 
Nanomaterials are materials that have structural components smaller than 100 nm in at 
least one dimension. The interest and use of nanomaterials has increased tremendously in 
the past ten years. If the periodic table of elements is considered "a puzzle that has been 
given to us by "God" (Amato, 1991) imagine the possibilities that could arise from the 
use of nanoparticles. While chemistry is the study of atoms and molecules and condensed 
matter, physics involves the study of solid materials containing arrays of large atoms or 
molecules much larger than 100 nm, a significant gap exists between these two phases 
(Klabunde, 2001). It is in this gap that nanoparticles in the size range of I to 100 nm are 
placed and each one of these particles contains about 10 to 10^  atoms or molecules 
(Klabunde, 1994; Klabunde and Mohs, 1998). The interesting aspect of this regime is that 
here, neither quantum chemistry, nor classical laws of physics hold and we start to see 
structural changes with change in size (Klabunde, 2001). This in turn leads to chemical 
and physical properties that can be fine-tuned through a change in size of the particles. 
Examples of changed properties are melting points, specific heats, surface reactivity, 
magnetic and optical properties. With these changed properties, the possibilities are 
endless. 
2.3. Nanoparticles (NPs) 
NPs are typically defined as the minuscule constituents within size range of 1 nm to 100 
nm with large surface area and number of particles per unit mass or a "nanoparticle" is a 
particle with a nominal diameter smaller than about 100 nm. These characteristics may 
result in increased interactions between NPs and biological materials vis-a-vis larger 
particles (Donaldson et al., 2001). Many authors limit the size of nanomaterials to 50 nm 
(Kittelson, 2001) or 100 nm (Borm et al., 2006), the choice of this upper limit being 
justified by the fact that some physical properties of NPs approach those of bulk when 
'Review of Literature 
their size reaches these values. However, this size threshold varies with material type and 
cannot be the basis for such a classification. 
2.4. Differences between nanomaterials and bulk materials 
Two primary factors cause nanomaterials to behave significantly differently than bulk 
materials: surface effects (causing smooth properties scaling due to the fraction of atoms 
at the surface) and quantum effects (showing discontinuous behavior due to quantum 
confinement effects in materials with delocalized electrons) (Roduner, 2006), These 
factors affect the chemical reactivity of materials, as well as their mechanical, optical, 
electric, and magnetic properties. The fraction of the atoms at the surface in NPs is 
increased compared to microparticles or bulk. Compared to microparticles, NPs have a 
very large surface area and high particle number per unit mass. For illustration, one 
carbon microparticle with a diameter of 60 )j,m has a mass of 0.3 ng and a surface area of 
0.01 mm .^ The same mass of carbon in nanoparticulate form, with each particle having a 
diameter of 60 nm, has a surface area of 11.3 mm and consists of 1 billion NPs. 1 he 
ratio of surface area to volume (or mass) for a particle with a diameter of 60 nm is 1000 
times larger than a particle with a diameter of 60 |a,m. As the material in nanoparticulate 
form presents a much larger surface area for chemical reactions, reactivity is enhanced 
roughly 1000-fold. While chemical reactivity generally increases with decreasing particle 
size, surface coatings and other modifications can have complicating effects, even 
reducing reactivity with decreasing particle size in some instances. The atoms situated at 
the surface have less neighbors than bulk atoms, resulting in lower binding energy per 
atom with decreasing particle size. A consequence of reduced binding energy per atom is 
a melting point reduction with particle radius, following the Gibbs-Thomson equation 
(Roduner, 2006). For example, the melting temperature of 3 nm gold NPs is more than 
300 degrees lower. NPs are highly active species. The high surface area to mass ratio of 
NPs can greatly enhance the adsorption capacities of sorbent materials. In addition to 
having high specific surface areas, NPs also have unique adsorption properties due to 
different distributions of reactive surface sites and disordered surface regions. 
Fundamental electronic, magnetic, optical, chemical, and biological processes are also 
different at this level. 
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2.5. Classification of nanoparticles based on: 
Nanoparticles are generally classified based on their; 
(i) Dimensionality, 
(ii) Composition, 
(iii) Morphology, and 
(iv) Uniformity and agglomeration. 
2.5.1. Dimensionality 
Shape or morphology of NPs plays an important role in their toxicity, it is useful to 
classify them based on their number of dimensions. 
ID nanomaterial 
Materials with one dimension in the nanometer scale are typically thin films or surface 
coatings. Thin films have been developed and used for decades in various fields, such as 
electronics, chemistry and engineering. 
2D nanomaterials 
Two-dimensional nanomaterials have two dimensions in the nanometer scale. Asbestos 
fibers are an example of 2D nanoparticles. 
3D nanomaterials 
Materials that are nanoscaled in all three dimensions are considered 3D nanomaterials. 
These include thin films deposited under conditions that generate atomic-scale porosity, 
colloids, and free NPs with various morphologies. 
2.5.2. Nanoparticles composition 
NPs can be composed of a single constituent material or be a composite of several 
materials. The NPs found in nature are often agglomerations of materials with various 
compositions, while pure single-composition materials can be easily synthesized today by 
a variety of methods. 
2.5.3. Nanoparticles morphology 
Morphological characteristics to be taken into account are: flatness, sphericity, and aspect 
ratio. A general classification exists between high- and low-aspect rafio particles. High 
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aspect ratio NPs include nanotubes and nanowires, with various shapes, small-aspect 
ratio morphologies include spherical, oval, cubic, prism, helical or pillar. 
2.5.4. Nanoparticles uniformity and agglomeration 
Based on their chemistry and electro-magnetic properties, NPs can exist as dispersed 
aerosols, as suspensions/colloids, or in an agglomerate state. For example, magnetic NPs 
tend to cluster, forming an agglomerate state, unless their surfaces are coated with a non-
magnetic material. In an agglomerate state, NPs may behave as larger particles, 
depending on the size of the agglomerate. Hence, it is evident that NPs agglomeration, 
size and surface reactivity, along with shape and size, must be taken into account when 
deciding considering health and environmental regulation of new materials. 
2.6. Characterization of nanomaterials 
Characterization of nanomaterials and nanostructure has been largely based on the 
surface analysis technique and conventional characterization method developed for bulk 
material (Fig 1). X-ray diffraction (XRD) has been widely used for the determination of 
crystallinity, crystal structure and lattice constant of nanoparticles, nanowire and thin 
film. Transmission electron microscope (TEM), scanning tunnel microscope (STM), 
nuclear magnetic resonance (NMR), atomic force microscopy (AFM), Raman 
spectroscopy, light scattering and electro acoustics techniques are the instruments used to 
characterize the nanoparticles. SEM (scanning electron microscope) and TEM together 
with electron diffraction have been commonly used in characterization of nanoparticles; 
optical spectroscopy is used to determine the size of semiconductor quantum dot. 
Scanning probe microscopy is a relatively new characterization technique and has found 
widespread application in nanotechnology. Both STM and AFM are true surface image 
techniques that can produce topographic image of surface with atomic resolution in all 
three dimensions. Almost all solid surface, whether soft or hard, electrically conductive 
or not can be studied with STM and both of these are the two early versions of scanning 
probes that launched nanotechnology. Determination of particle size, shape, crystallinity 
and fractal dimensions are also necessary to characterize the NPs. 
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Figure 1. Tools used for characterization of nanoparticles. 
2.7. Application of nanoparticles 
Nanoscience and nanotechnology studies have received much attention in the last decade. 
These studies involve a wide spectrum of research area and industrial activities from 
fundamental science (that is, physics, chemistry and biology) to applied science 
(electronics & material) on the nanoscale. One of the major developments in 
nanotechnology and nanoscience studies is the production and application of NPs in 
biological sciences. The use of NPs have been reported in various areas such as advanced 
material, electronics, magnetic, optoelectronics, biomedicine, pharmaceuticals, cosmetic, 
energy, catalytic, environmental pollutant detection, bioremediation, water treatment and 
monitoring (Fig 2). Nanotechnology has become a top research priority in most of the 
industrialized world, including the USA, the EU and Japan. 
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Figure 2. Application of nanoparticles (adapted from Takuya, 2009). 
2.8. Sources of nanoparticles 
2.8.1. Natural sources of nanoparticles 
NPs are abundant in nature as they are produced in many natural processes including 
photochemical reactions, volcanic eruptions, forest fires, and simple erosion, and by 
plants and animals e.g. shed skin and hair. The natural events such as dust storms, 
volcanic eruptions and forest fires can produce such vast quantities of nanoparticulate 
matter that they profoundly affect air quality worldwide. The aerosols generated by 
human activities are estimated to be only about 10% of the total, the remaining 90% 
having a natural origin (Taylor, 2002). 
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Terrestrial dust storms 
Dust storms appear to be the largest single source of environmental NPs. Approximately 
50% of troposphere atmospheric aerosol particles are minerals originating from the 
deserts (Shi et ai. 2005). The size of particles produced during a dust storm varies from 
100 nm to several microns with one third to a half of the dust mass being smaller than 2.5 
microns (Taylor. 2002; Shi et al., 2005). 
Extraterrestrial dust 
NPs exist widely in extraterrestrial space. Examples of dust collected from space, from 
the moon, and on Mars. The lunar dust contains a considerable amount of magnetic NPs 
(Taylor et al., 2005). 
Forest fire 
Major fires can spread ash and smoke over thousands of square miles and lead to an 
increase of particulate matter (including nanoparticles) exceeding ambient air quality 
standards (Sapkota et al., 2005). 
Oceans 
A large amount of sea salt aerosols are emitted from seas and oceans around the world 
(Buseck et al., 1999). These aerosols are formed by water evaporation and when wave-
produced water drops are ejected into the atmosphere. Their size ranges from 100 nm to 
several microns. 
Volcanoes 
When a volcano erupts, ash and gases containing particulate matter ranging from the 
nanoscale to microns are propelled high into the atmosphere, sometimes reaching heights 
over 18000 meters. The quantity of particles released into the atmosphere is enormous; a 
single volcanic eruption can eject up to 30 million tons of ash (Taylor, 2002). 
2.8.2. Anthropogenic nanomaterials 
Humans have created nanomaterials for millennia, as they are byproducts of simple 
combustion and food cooking, and more recently, chemical manufacturing, welding, ore 
refining & smelting, combustion in vehicle and airplane engines (Rogers et al., 2005) and 
combustion of coal and fuel oil for power generation (Linak et al, 2000). The quantity of 
manmade NPs ranges from well-established multi-ton per year production of carbon 
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black (for car tires) to microgram quantities of fluorescent quantum dots (markers in 
biological imaging). 
Diesel and engine exhaust nanoparticles 
Diesel and automobile exhaust are the primary source of atmospheric nano- and 
microparticles in urban areas. Most particles from vehicle exhaust are in the size range of 
20-130 nm for diesel engines and 20-60 nm for gasoline engines (Sioutas et uL, 2005; 
Westerdahl et al., 2005) and are typically approximately spherical in shape. Carbon 
nanotubes and fibers, already a focus of ongoing toxicological studies, were recently 
found to be present in engine exhaust as a byproduct of diesel combustion and also in the 
environment near gas-combustion sources (Soto et al., 2005). 
Cigarette smoke 
As a combustion product, tobacco smoke is composed of NPs with size ranging from 
around 10 nm up to 700 nm, with a maximum located around 150 nm. The environmental 
tobacco smoke has a very complex composition, with more than 100,000 chemical 
components and compounds (Ning et al., 2006). 
2.8.3. Accidental nanomaterials 
Ever since humans first started deliberately using fire they have also been inadvertently 
making NPs. The accidental manufacture of NPs increased enormously with the onset of 
the industrial revolution and even more so with the widespread use of the internal 
combustion engine. In fact, it was the study of air pollution in the form of ultra-fine, or 
nanoscale, particles from vehicle exhaust fumes that first started ringing alarm bells about 
the potential for toxicity problems with engineered NPs. 
2.8.4. Deliberate nanomaterials 
Chemical companies have long been deliberately making substances with a very small 
particle size that would now fall under the definition of nanomaterials. Examples of 
deliberate NPs include: carbon black (a kind of soot) whose particle size typically falls 
between 400 and lOnm and which is used in tyres, rubber, plastics, pigments and printer 
toners; and silica fume (a byproduct of making silicon metal and alloys) which is used as 
an additive to cement, foods, plastics and pharmaceuticals. 
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2.9. Types of nanoparticles 
NPs are available commercially in the form of dry powders or liquid dispersions. The 
latter is obtained by combining NPs with an aqueous or organic liquid to form a 
suspension or paste. It may be necessary to use chemical additives (surfactants, 
dispersants) to obtain a uniform and stable dispersion of particles. Nanomaterials can be 
made of carbon (fullerenes, nanotubes, etc.) or inorganic based materials. The latter 
includes metal oxides (ZnO, Fe203, Ti02, CQOI, etc), metals (Ag, Au, Fe, etc.) and 
quantum dots (cadmium sulphide and cadmium selenide) (Ju- Nam & Lead, 2008). Some 
of the most commercially used nanomaterials are briefly described below, 
2.10. Bacterial structure in relation to pathogenecity 
2.10.1. The importance of the bacterial surface 
All of the various surface components of a bacterial cell are important in its ecology since 
they mediate the contact of the bacterium with its environment. The only "senses" that a 
bacterium has result from its immediate contact with its environment. It must use its 
surface components to assess the environment and respond in a way that supports its own 
existence and survival in that environment. The surface properties of a bacterium are 
determined by the exact molecular composition of its membrane and cell wall, including 
lipopolysaccharides (LPS), and the other surface structures such as flagella, fimbriae 
and capsules. Bacterial surface components may have a primary biological function that 
has nothing to do with pathogenecity. Thus, the function of the LPS in the outer 
membrane of Gram-negative bacteria has to do with its permeability characteristics, 
rather than its toxicity for animals. However, there are endless examples wherein a 
bacterial surface component plays an indispensable role in the pathogenesis of infectious 
disease. Bacterial surface structures may act as (1) permeability barriers that allow 
selective passage of nutrients and exclusion of harmful substances (e.g. antimicrobial 
agents); (2) adhesions used to attach or adhere to specific surfaces or tissues; (3) enzymes 
to mediate specific reactions on the cell surface important in the survival of the organism; 
(4) protective structures against phagocytic engulfment or killing; (5) antigenic disguises; 
(6) "sensing proteins" that can respond to temperature, osmolarity, salinity, light, oxygen, 
nutrients, etc., resulting in a molecular signal to the genome of the cell that will cause 
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expression of some determinant of virulence (e.g., an exotoxin). In medical situations, the 
surface components of bacterial cells are major determinants of virulence for many 
pathogens. Pathogens can colonize tissues, resist phagocytosis and the immune response, 
induce inflammation, complement activation and immune responses in animals by means 
of various structural components. 
2.10.2. The Structure of the bacterial surface 
Most bacteria contain some sort of a polysaccharide layer outside of the cell wall or outer 
membrane. Capsules, slime layers, and glycocalyx are known to mediate specific or non 
specific adherence of bacteria to particular surfaces. Capsules are known to protect 
bacteria from engulfment by predatory phagocytes and from attack by antimicrobial 
agents. The cell wall of a bacterium is an essential structure that protects the delicate cell 
protoplast from osmotic lysis. The cell wall of bacteria consists of a polymer of 
disaccharides cross-linked by short chains of amino acids (peptides). This molecule is a 
type of peptidoglycan called murein. Murein is unique to bacteria. In the Gram-positive 
bacteria, the cell wall is thick (15-80 nm), consisting of several layers of peptidoglycan 
complexed with molecules called teichoic acids. In the Gram-negative bacteria, the cell 
wall is relatively thin (10 nm) and is composed of a single layer of peptidoglycan 
surrounded by a membranous structure called the outer membrane. Murein is a substance 
unique in nature to bacterial cell walls. Also, the outer membrane of Gram-negative 
bacteria invariably contains a unique component, LPS or endotoxin, which is toxic to 
animals. The cell wall is a complicated structure, fundamentally different in Gram-
positive and Gram-negative bacteria (Fig 3). Cell wall components are major 
determinants of virulence in both groups of bacteria. Endotoxin, inherent to all Gram-
negative bacteria, is toxic to animals in a variety of ways. 
Peptidoglycan and LPS, as well as some teichoic acids, induce the alternate complement 
pathway leading to inflammation. Teichoic acids and 0-specific polysaccharides may be 
used as adhesive by Gram-positive and Gram-negative bacteria, respectively. Variations 
in the macromolecular structure of cell wall components may be the basis of antigenic 
variation as well as specific host resistance to pathogens. The essential outer membrane 
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of Gram-negative bacteria is the target for attack by complement, hydrophobic agents, 
certain antibiotics and AgNPs. Murein (peptidoglycan) is dismantled by a host enzyme, 
lysozyme, found in most body fluids. Several antibiotics, mainly the p-lactams, exert 
their antimicrobial effect by blocking the synthesis and assembly of peptidoglycan. In 
terms of pathogenesis of a bacterium, it is absolutely dependent upon the integrity and 
function of its plasma membrane. The membrane might be responsible for secretion of 
toxins, resistance to antimicrobial agents, tactic responses or sensing other environmental 
signals to turn on or off genes for virulence. 
TeichoicAcid 
Phospholipid 
Peptictoglycan 
I Phosphoiipkl 
I bilayer 
Gram-positive Gram-negative 
Figure 3. Schematic drawing of bacterial cell envelope. 
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2.11. Antimicrobial substances 
An antimicrobial is a substance that Icills or inhibits the growth of microbes such as 
bacteria (antibacterial activity), fungi (antifungal activity), viruses (antiviral activity), or 
parasites (anti-parasitic activity). 
2.11.1. Antimicrobial drug resistance 
Drug resistant bacteria have been posing a major challenge to the effective control of 
bacterial infections for quite some times. Drug resistance refers to a situation in which the 
drugs that usually destroy the bacteria no longer do so. It implies that people can no 
longer be effectively treated against the bacteria. There are many different mechanisms 
by which micro-organisms might exhibit resistance to drugs. 
2.11.2. Antibacterial-drug-resistance mechanisms 
> Microorganisms produce enzymes that destroy active drug:- Examples: 
Staphylococci resistant to penicillin G produce a P-lactamase that destroys the drug. 
Other P-lactamases are produced by Gram-negative rods. Gram-negative bacteria 
resistant to aminoglycosides (by virtue of a plasmid) produce adenylating, 
phosphorylating or acetylating enzymes that destroy the drug. 
> Microorganisms change their permeability to the drug:- Examples: Tetracyclines 
accumulate in susceptible bacteria but not in resistant bacteria. Resistance to polymyxins 
is also associated with a change in permeability to the drugs. Streptococci have a natural 
permeability barrier to aminoglycosides. This can be partly overcome by the 
simultaneous presence of a cell wall-active drug, e.g., penicillin. Resistance to Amikacin 
and to some other aminoglycosides may depend on a lack of permeability to the drugs, 
apparently due to an outer membrane change that impairs active transport into the ceil. 
> Microorganisms develop an altered structural target for the drug:-Examples: 
Erythromycin-resistant organisms have an altered receptor on the SOS subunit of the 
ribosome, resulting from methylation of a 23S ribosomal RNA. Resistance to some 
penicillins and cephalosporins may be a flinction of the loss or alteration of PBPs. 
Penicillin resistance in Streptococcus pneumoniae and enterococci is due to altered PBPs 
> Microorganisms develop an altered metabolic pathway that bypasses the reaction 
inhibited by the drug:- Example: Some sulfonamide-resistant bacteria do not require 
extracellular PABA but, like mammalian cells, can utilize preformed folic acid. 
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> Microorganisms develop an altered enzyme that can still perform its metabolic 
function but is much less affected by the drug:- Example: In trimethoprim-resistant 
bacteria, the dihydrofolic acid reductase is inhibited far less efficiently than in 
trimethoprim-susceptible bacteria. 
> Drug resistance can occur due to genetic or non-genetic causes:- Active replication 
of bacteria is required for most antibacterial drug actions. Consequently, microorganisms 
that are metabolically inactive (nonmultiplying) may be phenotypically resistant to drugs. 
However, their offspring are fully susceptible. Example: Mycobacteria often survive in 
tissues for many years after infection yet are restrained by the host's defenses and do not 
multiply. Such "persisting" organisms are resistant to treatment and cannot be eradicated 
by drugs. Yet if they start to multiply (e.g., following suppression of cellular immunity in 
the patient), they are fully susceptible to the same drugs. 
> Microorganisms may lose the specific target structure for a drug for several 
generations and thus be resistant:- Example: Penicillin-susceptible organisms may 
change to cell wall-deficient L forms during penicillin administration. Lacking cell walls, 
they are resistant to cell wall-inhibitor drugs (penicillins, cephalosporins) and may remain 
so for several generations. When these organisms revert to their bacterial parent forms by 
resuming cell wall production, they are again susceptible to penicillin. 
> Microorganisms may infect the host at sites where antimicrobials are excluded or 
are not active:- Examples: Aminoglycosides such as gentamicin are not effective in 
treating salmonella enteric fevers because the salmonellae are intracellular and the 
aminoglycosides do not enter the cells. Similarly, only drugs that enter cells are effective 
in treating Legionnaires 'disease because of the intracellular location of Legionella 
pneumophila. Most drug-resistant microbes emerge as a result of genetic change and 
subsequent selection processes by antimicrobial drugs. Chromosomal resistance develops 
as a result of spontaneous mutation in a locus that controls susceptibility to a given 
antimicrobial drug. The presence of the antimicrobial drug serves as a selecting 
mechanism to suppress susceptible organisms and favor the growth of drug-resistant 
mutants. Spontaneous mutation occurs with a frequency of 10''^ to 10"' and thus is an 
infrequent cause of the emergence of clinical drug resistance in a given patient. 
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However, chromosomal mutants resistant to rifampcin occur with high frequency (about 
10"^  to 10"^ ). Consequently, treatment of bacterial infections with rifampcin as the sole 
drug often fails. Chromosomal mutants are most commonly resistant by virtue of a 
change in a structural receptor for a drug. Thus, the P12 protein on the 308 subunit of the 
bacterial ribosome serves as a receptor for streptomycin attachment. Mutation in the gene 
controlling that structural protein results in streptomycin resistance. Mutation can also 
result in the loss of PBPs, making such mutants resistant to P-lactam drugs. Bacteria 
often contain extra chromosomal genetic elements called plasmids. Some plasm ids carry 
genes for resistance to one-and often several-antimicrobial drugs. Plasmid genes for anti-
microbial resistance often control the formation of enzymes capable of destroying the 
antimicrobial drugs. Thus, plasmids determine resistance to penicillins and 
cephalosporins by carrying genes for the formation of P-lactamases. Plasmids code for 
enzymes that acetylate, adenylate, or phosphorylate various aminoglycosides; for 
enzymes that determine the active transport of tetracyclines across the cell membrane; 
and for others (Brooks and Carroll, 2007). Genetic material and plasmids can be 
transferred by transduction, transformation and conjugation. In case of cross resistance 
microorganisms with similar mechanism of action may show similar resistance patterns. 
Such relationships exist mainly between agents that are closely related chemically (e.g., 
different aminoglycosides) or that have a similar mode of binding or action (e.g., 
macrolides-lincomycins). In certain classes of drugs, the active nucleus of the chemical is 
so similar among many congeners (e.g., tetracyclines) that extensive cross-resistance is to 
be expected. 
2.12. Extended-spectrum p-lactamases (ESBLs) 
ESBLs are a group of enzymes that break down antibiotics belonging to the penicillin and 
cephalosporin groups and render them ineffective. ESBL has traditionally been defined as 
transmissible beta-lactamases that can be inhibited by clavulanic acid, tazobactam or 
sulbactam, and which are encoded by genes that can be exchanged between bacteria. 
There is no consensus of the precise definition of ESBLs. A commonly used working 
definition is that the ESBLs are beta lactamases capable of conferring bacterial 
resistance to the penicillins, first, second, and third-generation cephalosporins, and 
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aztreonam (but not the cephamycins or carbapenems) by hydrolysis of these 
antibiotics, and which are inhibited by betalactamase inhibitors such as clavulanic 
acid. 
2.12.1. History, evolution and dissemination of P-lactamases 
The increase in antibiotic resistance among Gram-negative bacteria is a notable example 
of how bacteria can procure, maintain, and express new genetic information that can 
confer resistance to one or several antibiotics. This genetic plasticity can occur both inter-
and intragenerically. Gram-negative bacterial resistance possibly now equals to Gram-
positive bacterial resistance and has prompted calls for similar infection control measures 
to curb their dissemination. Reports of resistance vary, but a general consensus appears to 
prevail that quinolone and broad-spectrum p-lactam resistance is increasing in members 
of the family Enterobacteriaceae and Acinetobacter spp. and that treatment regimen for 
the eradication of P. aeruginosa infections are becoming increasingly limited. 
The introduction of the third-generation cephalosporins into clinical practice in the 
early 1980s was heralded as a major breakthrough in the fight against P-lactamase-
mediated bacterial resistance to antibiotics. These cephalosporins had been 
developed in response to the increased prevalence of beta lactamases in certain 
organisms (for example, ampicillin hydrolyzing TEM-1 and SHV-1 p-lactamases 
in E. coli and Klebsiella sp). Not only were the third generation cephalosporins 
effective against mos t |3-lactamase-producing organisms but they had the major 
advantage of lessened nephrotoxic effects compared to aminoglycosides and 
polymyxins. The first report of plasmid-encoded p-lactamases capable of hydrolyzing 
the extended-spectrum cephalosporins was published in 1983 (Knothe et al., 1983). 
The gene encoding the P-lactamase showed a mutation of a single nucelotide 
compared to the gene encoding SHV-1. Other p-lactamases were soon discovered 
wtiich were closely related to TEM-1 and TEM-2, but had the ability to confer 
resistance to the extended-spectrum cephalosporins (Brun-Buisson et al, 1987; Sirot 
et al, 1987). Hence these new P-lactamases were coined ESBLs. In the first 
substamial review of ESBLs in 1989, it was noted by Philippon, Labia, and Jacoby 
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that the ESBLs represented the first example in which p-lactamase-mediated 
resistance to P-lactam antibiotics resulted from fundamental changes in the 
substrate spectra of the enzymes (Philippon e/a/., 1989). 
Gram-negative bacteria have at their disposal a plethora of resistance mechanisms that 
they can sequester and/or evince, eluding the actions of carbapenems and other P-lactams. 
The common form of resistance is either through lack of drug penetration (i.e., outer 
membrane protein [OMP] mutations and efflux pumps), hyper production of an AmpC-
type p-lactamase, and/or carbapenem-hydrolyzing P-lactamases. Based on molecular 
studies, two types of carbapenem-hydrolyzing enzymes have been described: serine 
enzymes possessing a serine moiety at the active site, and metallo P-lactamases (MBLs), 
requiring divalent cations, usually zinc, as metal cofactors for enzyme activity (Bush et 
ai, 1998). 
ESBLs and AmpC p-lactamases are of increasing clinical concern. ESBLs are most 
commonly produced by Klebsiella spp. and Escherichia coli but may also occur in other 
gram-negative bacteria. They are typically plasmid mediated, ciavulanate susceptible 
enzymes that hydroiyze penicillins, expanded-spectrum cephalosporins (cefotaxime. 
ceftriaxone, ceftazidime, cefepime and others) and aztreonam. AmpC class p-lactamases 
are cephalosporinases that are poorly inhibited by clavulanic acid. They can be 
differentiated from other ESBLs by their ability to hydroiyze cephamycins as well a3 
other extended-spectrum cephalosporins. AmpC P-lactamases, demonstrated or presumed 
to be chromosomaily o;- plasmid mediated, have been described in pathogens e.g., K. 
pneumoniae, E. coli, Salmonella spp., Proteus mirabilis, Citrobacter freundii, 
Acinetobacter, Enterobacter spp and P. aeruginosa. Although reported with increasing 
frequency, the true rate of occurrence of AmpC P-iactamases in different organisms, 
including members of Enterobacteriaceae, remains unknown. 
In 2001, the ESBLs were reviewed by Bradford (2001). The body of knowledge 
pertaining to ESBLs has grown rapidly since that time. A Pub-Med search using the 
key-words ESBLs reveals more than 1,300 relevant articles, with more than 600 
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published since the time Bradford's review was written. The total number of ESBLs 
now characterized exceeds to 200. These are detailed on the website of the 
nomenclature of ESBLs hosted by George Jacoby and Karen Bush 
(http://www.lahey.org/studies/webt.htm). Published research on ESBLs has now 
originated from more than 30 diflFerent countries, reflecting the truly worldwide 
distribution of ESBL producing organisms. However, primarily due to genomic 
sequencing, increasingly more chromosomally mediated genes are being discovered but 
are often found in obscure nonclinical bacteria. 
2.12.2. Mechanism of action of p-lactamases 
P-lactamase enzymes destroy the (3-lactam ring by two major mechanisms of action. 
Firstly, most common P-lactamase has a serine based mechanism of action. They are 
divided in to three major classes (A, C and D) on the basis of the ammo acid sequences. 
They contain an active site consisting of a narrow longitudinal groove, with a cavity on 
its floor (the oxyanion pocket), which is loosely constructed in order to have 
conformational flexibility in terms of substrate binding. Close to this lies, the serine 
residue that irreversibly reacts with the carbonyl carbon of the p-lactam ring, resulting- in 
an open ring (inactive P-lactam) and regenerating the P-lactamase. These enzymes are 
active against many penicillins, cephalosporins and monobactam. Secondly a less 
commonly encountered group of P-lactamases is the metallo P-lactamases or class B P-
lactamases (Fig 4). These use a divalent transition metal ion most often zinc, linked to a 
histidine or cysteine residue or both, to react with the carbonyl group of the amide bond 
of most penicillins, cephalosporins and carbapcnems but not monobactams (Samaha-
Kfoury and Araj, 2003). 
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Figure 4: Site of P-lactamase attack (adapted from Neu & Gootz, 2004). 
2.13. Methicillin-resistant Staphylococcus aureus (MRSA) 
S. aureus has been recognized as a major human pathogen since it was discovered by Sir 
Alexander Ogston in the 1880s as the major cause of wound suppuration (Archer, 1998). 
The five stages in the pathogenesis of 5. aureus infections are (a) colonization, (b) local 
infection, (c) systemic dissemination and/or sepsis, (d) metastatic infection, and (e) 
toxinosis. S. aureus can be asymptomatically carried for weeks or months on mucous 
membranes and intact skin (Archer, 1998). The localized host response to staphylococcal 
infections is inflammation, characterized by an elevation of temperature at the site, 
swelling, accumulation of pus, and necrosis of tissue (Todar, 2005). Around the inflamed 
area, a fibrin clot may form, walling off the bacteria, as a pus-filled boil or abscess 
(Todar, 2005). Thereafter, superficial skin lesions such as boils, styes, and furunculosis 
can occur (Archer, 1998). The infection can spread locally or can gain access to the 
blood. If it spreads locally, it can progress to pneumonia, mastitis, phlebitis, meningitis, 
and urinary tract infection (Archer, 1998). Methicillin, originally called celbenine. is a 
semisynthetic derivative of penicillin, chemically modified to withstand the degradative 
action of penicillinase. The drug was introduced into therapy in Europe in 1959-1960 and 
in the United States in 1961 (Oliveira et al, 2002; Rice, 2006). MRSA is an important 
pathogen in the healthcare sector that has not been eliminated from the hospital nor 
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community environment. Nowadays, MRSA strains have a wide range of drug resistance, 
including to more tiian 16 types of antibiotics. 
The first cases of MRSA were reported in the United Kingdom in 1961, followed soon by 
reports in other European countries, Japan, and Australia (Palavecino, 2004; Rice, 2006). 
The first report of MRSA in the United States appeared in 1968 (Barrett et al., 1968; 
Rice, 2006). Periodic outbreaks of MRSA were observed in various countries throughout 
the world in the 1970s, but it was not until the 1980s that MRSA became a significant 
problem in United States hospitals (Palavecino, 2004; Rice, 2006). The emergence of 
MRSA is due to the mecA gene, a 2. Ikb stretch of DNA that is not native to S. aureus and 
is embedded in 60kb of additional DNA called the mec element or staphylococcal 
chromosomal cassette (SCCmec), which is incorporated into the S. aureus chromosome 
at a site-specific location (Katayama et al., 2000; Ito et al., 2001; Oliveira et al., 2002). 
The mecA gene encodes for a 78kDa alternative penicillin binding protein (PBP2a), 
which has a very low affinity for P-lactam antibiotics. P-lactams cannot bind as 
effectively to these PBP2as, and as a result, the P-lactams are ineffective at disrupting cell 
wall synthesis (Oliveira et al., 2002). According to Enright et al. (2002), evolutionarily, 
the mec genes that are responsible for SCCmec typing are thought to have initially been 
introduced into coagulase-negative Staphylocorci from an unknown source, where 
deletion of the mec regulatory genes occurred, and then they were introduced into 5'. 
aureus. The Staphylococcal species that donated SCCmec found in MRSA today is 
unknown but their patterns of presence indicates multiple introductions into S. aureus and 
that horizontal gene transfer of mec is possible in 5'. aureus (Enright et al., 2002). A 
survey of 500 women attending prenatal clinics in London in 1989 to 1990 found 2% of 
the staphylococcal strains isolated were MRSA (Abudu et al., 2001). Similarly, among 
National Nosocomial Infections Surveillance (NNIS) hospitals in 2003, 64.4% of health 
care-associated S. aureus infections occurring in ICUs were caused by MRSA, compared 
with 35.9% in 1992, representing a 3.1% increase per year (P<.001 ) (NNIS, 2004; 
Klevens et al., 2006). According to the World Health Organization, in some Asian 
countries, the incidence of MRSA has reached 70% to 80% of all the S. aureus isolates 
(WHO, 2004). The NNIS ystem determined that in hospitalized patients, the prevalence 
27 
(Review of Literature 
of MRSA strains raised from 4% in 1980 to 60.7% in 2004 in the USA (Bustos-Martinez 
et al. 2006). 
The Centers for Disease Control estimated for 2005 that invasive MRSA caused 94,360 
infections and 18,650 associated deaths. Of these infections, about 86% are healthcare-
associated and 14% are community-associated (Klevens et al, 2007). There have been 
multiple reports on the use of cefoxitin as a surrogate marker for detection of mec-A gene 
mediated methicillin resistance. Cefoxitin is a potent inducer of mec-a regulatory system. 
The clinical and laboratory standard institute (CLSI) guideline (2006) has recommended 
cefoxitin disc diffusion method for detection of MRSA. This is performed by using 30 |ig 
discs and an inhibition zone of < 19 mm is reported as methicillin resistant and >20 mm 
is reported as methicillin sensitive. The possibility that antibacterial formulations based 
on nanoparticles themselves may be effective in controlling the outbreak of new resistant 
strains of bacteria such as MRSA has also been reported (Tiller et al., 2001). 
2.14. Role of biofilm in drug resistant and antibiofllm properties nanoparticles 
The increased resistance of bacteria to antibiotic therapy is a growing concern for doctors 
and medical officials world-wide. In the last 2 decades, bacteria have developed 
resistance to almost all the commercially available antibiotics, and the number of new 
antibiotics expected to enter the market is limited. Now days, about 70% of the bacteria 
that cause infections in hospitals are resistant to at least one of the drugs most commonly 
used in treatment. Some organisms are resistant to all approved antibiotics and they can 
only be treated with experimental and potentially toxic drugs (Todar et al., 2008). ESBL 
producing microorganisms and MRSA are very dynamic and constitutes an increasing 
problem due to their hydrolyzing activity against extended spectrum third generation 
cephalosporins, such as cefotaxime, ceftriaxone, ceftazidime and the monobactam 
aztreonam often employed in the treatment of hospital acquired infections (Romero et al.. 
2005; Dechen et al., 2009). In recent years, there has been considerable interest in the 
problems posed by the biofilm mode of bacterial growth. One of the modes by which 
bacteria exert this resistance is their ability to develop biofilms (Davies, 2003). Costerton, 
one of the founding fathers of biofilm research, described a biofilm as a structured 
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community of bacterial cells enclosed in a self-produced polymeric matrix and adherent 
to an inert or living surface (Costerton et al., 1999). The biofilm matrix itself may inhibit 
the penetration of antibiotics and prevent them from reaching embedded cells (Davis et 
al, 2006). It has been shown that killing bacteria in a biofilm may require up to 1000 
times the antibiotic dose necessary to achieve the same result in a suspension of cells 
(Smith, 2005). 
Biofilm development is known to follow a series of complex but discrete and well-
regulated steps: (i) An initial reversible attachment of planktonic bacteria that approach 
the solid surface by fluid stream or through motility, and that have overcome the 
repulsive forces between the cell and the surface (ii) transition from reversible to 
irreversible attachment by production of extracellular polymers by the bacteria and/or by 
specific adhesins located on pili and fimbriae, which interact with the surface., (iii) 
growth and aggregation of cells into microcolonies; (iv) maturation and production of a 
protecting extracellular matrix; and (v) dissemination of progeny cells for the formation 
of new colonies (Fig 5) (O'Toole, 2000; Hall-Stoodley et al., 2004). An important 
characteristic of microbial biofilms is their innate resistance to immune system and 
antibiotic killing (Davies, 2003; Fux et al., 2005). This has made microbial biofilms a 
common and difficult to treat, cause of medical infections (Hall-Stoodley et al., 2004; 
Costerton et al., 1999). It has been estimated that over .60% of bacterial infections treated 
in hospitals are caused by bacterial biofilms (Costerton et al., 1999). A major 
contribution to this statistic comes from the fact that biofilms are a major cause of 
infections associated with medical implants. The number of implant-associated infections 
approaches 1 million/year in the US alone and their direct medical costs exceed $3 billion 
annually (Darouiche, 2004). Infections resulting from microbial biofilm formation remain 
a serious threat to patients worldwide. Particularly problematic are wound infections 
(Bjarnsholt et al., 2008; Davis et al., 2008; James et al., 2008; Percival et al., 2008), with 
chronic wounds such as foot, leg, and pressure ulcers being particularly susceptible to 
biofilm infections (James et al., 2008).While most wound infections are polymicrobial 
i.e., caused by more than one species of bacteria or fungi (Pruitt et al, 1998), the most 
common isolated species include gram-positive S. aureus, S. epidermidis and Gram-
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negative E. coli, P. aeruginosa, Acinetobacter baumannii, K. pneumoniae (Bjarnsholt et 
ah, 2008). Staphylococci are most often associated with chronic infections of implanted 
medical devices (Dunne, 1990; Raad, 2008). Biofilm producing Staphylococci 
frequently colonize catheters and medical devices and may cause foreign body related 
infections. They easily get attached to polymer surfaces (Schwank et al., 1998; Thomas 
and Day, 2007). Bacterial biofilms are a predominant challenge to wound healing 
(Rhoads et al., 2008). Certain surface protein, extracellular proteins, capsular 
polysaccharides, adhesins (PS/A) and autolysin (encoded by atlE gene) are involved in 
regulation of biofilm production (Thomas and Day, 2007). 
It is now well documented that biofilms are notoriously difficult to eradicate and are 
often resistant to systemic antibiotic therapy and removal of infected device becomes 
necessary (Schwank et al., 1998; Souli et al., 1998). Although only antibiotics or 
antiseptics are permitted for use in the human body, other biocides or combinations can 
be used to clean medical devices. Antiseptic wound dressings are currently the most 
common clinical strategy employed to address wound infections (White et al, 2006). 
Current clinical protocols call for applying creams, solutions, or wound dressings that 
contain antiseptics such as silver compounds (e.g., silver sulfadiazine, silver nitrate), 
iodine (e.g. povidone iodine), or chlorhexidine (White et al., 2006). Despite their success, 
Ag"^  and iodine wound treatments have some undesirable properties. For example, silver 
treatment has been reported to result in permanent skin discoloration (argyria) (Wright et 
al., 1998). Recently, both povidone iodine and chlorhexidine have been shown to be 
ineffective at treating biofilms of P. aeruginosa (Stickler and Hewett, 1991). Alarmingly, 
a growing number of reports document life-threatening anaphylactic shock in response to 
chlorhexidine treatment (Autegarden et al, 1999; Krautheim et al, 2004). In order to 
choose appropriate antimicrobial agents and to optimize the dosing strategy on a case-by-
case basis, it is necessary to improve our understanding of interaction between various 
antimicrobial agents and biofilm cells. 
Unlike planktonic populations, bacterial cells embedded in biofilms exhibit intrinsic 
resistance to antibiotics, due to several specific defense mechanisms conferred by the 
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biofilm environment, including the inactivation of antimicrobial agents by EPS, over 
expression of stress-responsive genes, oxygen gradients within the biofilm matrix, and 
differentiation of a subpopulation of biofilm cells into resistant dormant cells (Keren et 
al., 2004; Fux et al. 2005). The intrinsic resistance of bacterial cells within biofilms to 
conventional antimicrobials has motivated new approaches for treatment of biofilm-
associated infections, including the use of silver preparations. Several silver-containing 
dressings are recommended for long-term decontamination and wound healing based on 
silver's broad-spectrum, high-level antimicrobial activity (Leaper, 2006). In the long run 
they may be very damaging because of immune complex disease (Raad et al., 1995; Souli 
et al., 1998; Donlan and Costerton, 2002). The inherent resistance of biofilms to killing 
and their pervasive involvement in implant-related infections prompted the search for 
surfaces/coatings that inhibit bacterial colonization. 
One approach comes from recent progress in nanotechnology, which offers an 
opportunity for the discovery of compounds with antimicrobial activity as well as the use 
of "nano functionalization" surface techniques to prevent the biofilm formation. In order 
to kill or remove biofilms, antimicrobials must penetrate the polysaccharide matrix to 
gain access to the microbial cells. Nanotechnology may provide the answer to penetrate 
such biofilms and reduce biofilm formation. Penetration of a colloid to any depth in a 
biofilm is diffusion dependent with an inverse relationship to their size due to steric and 
mobility factors while plasma clearance plays a role in decreasing NPs local 
concentration (Sanders et al., 2000). NPs are small enough to penetrate the biofilm and 
additionally offer a surface to volume ratio optimized for mass loading of targeting 
moieties, drugs, and antibiotics (Suci et al., 2007). Other examples include the 
functionalization of biomaterials with antibacterial properties by coating (Roe et al., 
2008), impregnation (Flemming et al., 2000; Shi et al., 2006; Raad et al., 2008) or 
embedding nanomaterials (Beyth et al., 2008; Chang ei al., 2008). In literature, very little 
work has been done on anti-biofilm efficacy of NPs. Therefore, novel approaches to treat 
established biofilms are thus urgently needed. 
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Figure 5. Developmental stages of biofilm formation (adapted from Houdt and Michiels, 2005). 
2.15. Nanotechnology as a treatment modality 
Nanotechnology is an emerging field of research which consists of the study of fiinctional 
structures with dimensions in the l-IOO nm range (Jianrong et al, 2004). Nanoscience 
and nanotechnology also has a broad range of applications in the fields of biomedicine 
and biotechnology. Among these are drug delivery, cancer detection and diagnosis, 
labeling, biosensors, and several others. One of the most studied aspects of 
nanotechnology nowadays is their ability to offer the opportunity to fight microbial 
infections via the synthesis of NPs (Luo et al., 2007). As described earlier, antibiotic 
resistance is rampant. Due to the clinical misuse, the administration of low doses of 
antibiotics, and the changes in the target receptors of drugs, antibiotic resistance is a 
major problem (Luo et al, 2007). The mechanisms by which antibiotics prevent bacterial 
growth vary from the mechanisms by which NPs inhibit microbial growth. Therefore, 
NPs have the potential to serve as an alternative to antibiotics and to control microbial 
infections such as those caused by MRS A (Luo et al, 2007). Due to the outbreak of 
infectious diseases caused by different pathogenic bacteria and the development of 
antibiotic resistance, the pharmaceutical companies and researchers are searching for new 
antibacterial agents. In the present scenario, nanoscale materials have emerged up as 
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novel antimicrobial agents due to their high surface area to volume ratio and unique 
chemical and physical properties (Morones et al, 2005; Kim et al, 2007). Eventually, 
understanding about various NPs properties increased, an interesting area regarding 
antimicrobial activities of NPs emerged up, termed as nanobiotics. Various results have 
shown definite antimicrobial activity in cases of Ag, ZnO, AI2O3, Si02 and some other 
NPs (Turos et al., 2007). Nanotechnology has attracted global attention as NPs have 
properties unique from their bulk equivalents. The antimicrobial activity of NPs has been 
studied with human pathogenic bacteria, mainly E. coli, S. aureus, P. aeruginosa (Sondi 
& Salopek-Sondi, 2004; Shrivastava et al., 2007; Ansari et al., 201 la«&b, 2012a &b) and 
C. albicans (Kim et al., 2009). 
2.16. Silver and silver based compounds: history and applications 
2.16.1. Metallic silver 
Interestingly, throughout history, silver and its compounds have been extensively utilized 
in multiple applications due to their useful properties. Archeological evidence suggests 
usage of silver in civilizations since 3000 B.C. Ancient Egyptians and Persians used 
silver vessels to keep their water clean and safe. Romans and Greeks knew its powerful 
bactericidal effect and used it for wound healing. During World War I, silver compounds 
were used to prevent wound infection before the emergence of antibiotics. During the 
19* century, silver was used in practical medicine such as eye ailment and treatment of 
skin ulcers (Foot Defense, 2010). The US Food and Drug Administration approved silver 
solutions in the 1920s to be used as antibacterial (Wikipedia, 2010). Silver and its 
compounds have multiple applications during the 20* century widely in electrical 
conductors, electrical contacts, catalysis, photography, electronics, mirrors, drinking 
water filtration systems, swimming pool filtration systems, healthcare products and 
medical tools (Luoma, 2008; Wikipedia, 2010). Silver compound being toxic to some 
bacteria, virus, algae and fungi, rendered germicidal properties. In 1954, silver got 
registered in the US as a pesticide for its use in disinfectants, sanitizers and fungicides. 
Silver in its metallic state is inert but it reacts with the moisture in the skin and fluid of 
the wound and gets ionized. The ionized silver is highly reactive, as it binds to tissue 
proteins and brings structural changes in the bacterial cell wall and nuclear membrane, 
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leading to cell distortion and death. Silver also binds to bacterial DNA and RNA by 
denaturing and thereby inhibits bacterial replication (Lansdown, 2002; Castellano et al., 
2007). Silver is also used in catheters, rendering them effective for reducing urinary tract 
infection in adults, at hospitals while having short term catheterization (Sanjay et al., 
2009). Silver ions and compounds have been widely used in different biomedical fields 
such as wound and bum dressing materials, in management of wound and burn patients; 
(Parikh et al., 2005; Kim, 2007), dressing in case of mediastinitis patients (Totaro & 
Rambaldini, 2009), body wall repairs, tissue scaffolding and antimicrobial filters (Son et 
al., 2004). 
2.16.2. Silver sulfadiazine (SSD) 
SSD is commonly used as a 1% water-soluble cream and works as a broad-spectrum 
antimicrobial agent. It is used especially in treatment of bum wounds. SSD binds to cell 
components including DNA and cause membrane damage (Atiyeh et al., 2007). It 
achieves bacterial inhibition by binding to the base pairs in DNA helix and thereby 
inhibits transcription. SSD was prepared for the treatment of burns, which revealed strong 
antibacterial potential against E. coli, S. aureus, Klebsiella sp., Pseudomonas sp. 
2.16.3. Silver zeolite 
In Japan ceramics are manufactured, coated with silver zeolite to impart antimicrobial 
property to their products. These ceramics are used for food preservation, disinfection of 
medical products, and decontamination of materials (Matsumura et al., 2003). 
2.16.4. Silver nitrate 
Silver nitrate was popular for the treatment of venereal diseases, fistulae from salivary 
glands, bone and perianal abscesses during 1700's (Klasen, 2000; Lansdown, 2002). In 
the 19th century it was used to remove granulation tissues, to promote ephhelization and 
crust formation on the surface of wounds. In 1881, silver nitrate eye drops was used by 
Carl S. F. Crede to cure opthalmia neonatorum and later B. Crede designed silver 
impregnated dressings for skin grafting (Klasen, 2000; Lansdown, 2002). Spacciapoli et 
al. (2001) demonstrated the use of silver nitrate in treatment of periodontal pathogens. He 
found that silver nitrate were more efficient than antibiotics for treatment of oral cavity ol" 
periodontal infections. In 1884, silver nitrate aqueous drop was used to prevent the 
transmission of Neisseria gonorrhoeae from infected mothers to children during 
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childbirth (Silvestry-Rodriguez et ah, 2007). Silver nitrate in the form of 0.5% solution 
was used for the treatment of bums, stating that this solution has strong bactericidal 
potential against 5. aureus, P. aeruginosa and E. coli and does not interfere with 
epidermal proliferation (Moyer e/«/., 1965; Bellinger & Conway, 1970). 
2.17. Nanosilver: history and applications 
NPs are typically defined as the minuscule constituents within size range of 1 nm to 100 
nm with large surface area and number of particles per unit mass. Nanosilver is not a 
new discovery; it has been used for over a hundred years (USFDA, 2010). Previously, 
nanosilver or suspensions of nanosilver were referred to as colloidal silver (Lindeman, 
1997). Before the discovery of penicillin in 1928, colloidal silver had been used to treat 
various infections and ailments (Nano Health Solutions, 2010). By converting bulk silver 
into nanosized silver, its effectiveness for controlling bacteria, fungi, viruses and 
parasites were increased multifold, since nanomaterials exhibit extremely large surface 
area when compared to bulk silver, thus resulted in increased contact with 
microorganisms. Turkevich et al. (1951) reported a wet chemistry technique to synthesize 
nanosilver using silver nitrate as a silver ion source and sodium citrate as reducing agent 
for the first time. 
Recent advances in nanomaterials science in last two decades have enabled scientists to 
engineer silver nanomaterials by controlling their size, shape and surface properties. This 
has been motivated by the unique chemical, physical and optical properties of nanosilver 
compared to the parent silver metal. The unique properties of nanosilver are mainly 
attributed to high surface area to volume ratio, leading many industrial sectors to 
incorporate silver nanomaterials into their products. More than 200 products containing 
nanosilver are now available for public use (Tolaymat et al., 2010). Recently, due to the 
emergence of antibiotic-resistant bacteria and limitations of use of antibiotics, the 
clinicians have returned to silver wound dressings containing varying level of silver 
(Gemmell et al, 2006; Chopra, 2007). 
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2.17.1 Antimicrobial properties of AgNPs 
The current investigation supports that use of silver ion or metallic silver plus AgNPs can 
be exploited in medicine for burn treatment, dental materials, coating stainless steel 
materials, textile fabrics, water treatment, sunscreen lotions, etc. and as it exhibit low 
toxicity to human cells, high thermal stability and low volatility (Duran et a/., 2007). 
AgNPs have attracted much attention recently, not only due to their unique optical 
(Kreibig & Vollmer, 1995), electrical and magnetic properties but also due to their 
important applications in other overlapping fields of nanoscience and biology (Niemeyer 
et ai, 2001; Tian et al., 2007). Different types of NPs like copper, zinc, titanium 
(Retchkiman-Schabes et al., 2006), magnesium, gold (Gu et ah, 2003), alginate (Ahmad 
et ah, 2005) and silver has come up but AgNPs have proved to be most effective, as 
exhibit good antimicrobial efficacy against bacteria, viruses and other eukaryotic micro-
organisms (Gong et al., 2007). AgNPs is an effective killing agent against broad 
spectrum Gram-negative and Gram-positive bacteria (Wijnhoven et al, 2009), including 
antibiotic-resistant strains (Percival et al., 2007). 
Sondi and Salopek-Sondi (2004) reported the antimicrobial activity of AgNPs against E. 
coli and demonstrated the formation of AgNPs aggregates and bacterial cells death with 
the help of SEM. They reported that AgNPs interact with the building elements of 
bacterial membrane and cause damage to the cell. The TEM analysis and EDAX study 
confirmed the incorporation of AgNPs into the membrane, which was recognized by 
formation of pits on the cell surface. Panacek et al. (2006) reported a one step protocol 
for synthesis of silver colloid NPs. They found high antimicrobial and bactericidal 
activity of AgNPs on Gram-positive and Gram-negative bacteria, including multi-
resistant strains such as MRSA. The antibacterial activity of AgNPs was found to be size 
dependent, the NPs of size 25 nm possessed highest antibacterial activity. Pal et al. 
(2007) investigated the antibacterial properties of AgNPs of different shapes and found 
that antibacterial efficacy of AgNPs is shape dependent. Shrivastava et al. (2007) 
reported synthesis of AgNPs (10-15 nm) and its dose dependent effect, on Gram-negative 
and Gram-positive microorganisms. The antibacterial effect of NPs was independent ol 
acquisition of resistance by bacteria against antibiotics. 
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Ayala-Nunez et al. (2009) studied the antibacterial activity of AgNPs against MRSA and 
non-MRSA. They observed the dose dependent bactericidal activity of AgNPs and found 
that both MRSA and non MRSA were inhibited at concentrations over 1.35 mg/ml. 
Nanda and Saravanan (2009) reported synthesis of AgNPs by aqueous Ag"^  reduction 
with S. aureus. These AgNPs were used to evaluate their antimicrobial potential against 
MRSA, MRSE, S. pyogenes, S. typhi and K. pneumoniae. The authors further reported 
effective antimicrobial activity of AgNPs against the drug resistant bacteria MRSA and 
MRSE, which showed maximum activity against MRSA, followed by MRSE and S. 
pyogenes, but only moderate activity was observed against 5'. typhi and K. pneumoniae. 
Liu et al. (2010) reported the antibacterial effects of three different sizes of AgNPs. The 
antibacterial activity against E. coli started about 0.1 ppm, while that against S. aureus 
started at about 1 ppm, i.e., a 10-foId increase. The smaller the average size of the 
AgNPs, the greater the antibacterial effect observed. Li et al. (2010) investigated the 
antibacterial activity and acting mechanism of AgNPs on E. coli ATCC 8739. After 
being exposed to 10 |J.g/ml AgNPs, the membrane vesicles were dissolved and dispersed, 
and their membrane components became disorganized and scattered from their original 
ordered and close arrangement based on TEM observation. AgNPs resulted in the leakage 
of reducing sugars and proteins and induced the respiratory chain dehydrogenases into 
inactive state, suggesting that AgNPs were able to destroy the permeability of the 
bacterial membranes. 
Li et al. (2011) reported the antibacterial activity and mechanism of AgNPs on S. aureus 
and showed that the minimum bactericidal concentration (MBC) of AgNPs to S. aureus 
was 20 jig/ml. The TEM images shows that when cells were treated with AgNPs for 6 h, 
the nuclear region shrank in to an electron-light dot and even disappeared. This may 
indicate after 5". aureus cells exposed to AgNPs the DNA were condensed and could have 
lost their replicating ability. This might be one of the reasons for the death of bacteria 
cells. Subsequently, when S. aureus cells were exposed to AgNPs for 12 hours, cell wall 
breakdown and cytolysis happened, resulting in release of their cellular contents into the 
environment, and finally cytoplasm was emptied and AgNPs could reduce the enzymatic 
activity of respiratory chain dehydrogenase. 
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Mirzajani et al. (2011) investigated antibacterial activity of AgNPs against S. aureus 
PTCC1431 as a model of Gram-positive bacteria. Experimental data showed that AgNPs 
at a concentration of 4 [xg/ml completely inhibited bacterial growth. TEM results 
confirmed cell wall damage produced by AgNPs as well as accumulation of AgNPs in the 
bacterial membrane. Moreover, increasing the AgNPs concentration to 8 i^g/ml resulted 
in release of muramic acid (MA) into the medium, which could be attributed to cell wall 
disruption. With respect to all information provided, AgNPs may make a connection with 
both sides of the peptide and glycan ports of a bacterial cell wall and generate "pits" on it. 
AgNPs attach to P-1—>4 bonds of N-acetylglucosamine and N-acetylMA of glycan 
strands, destroy their bond and release them into the media. It was confirmed that 
membrane pit formation may be an important factor inhibiting bacterial growth of Gram-
positives. Ansari et al. (2011a & b) explored the antibacterial activity of AgNPs 
dispersion against MSSA and MRSA isolated from wounds and they found that typical 
MIC and MBC against standard reference strain as well as, MSSA and MRSA were in 
the range of 12-48 ng/ml and 12-96 ^g/ml, respectively. The MBC/MIC ratios against all 
strains were found in the range of <1 to <4, which shows that AgNPs inhibit bacterial 
growth in a bactericidal rather than a bacteriostatic manner. They suggested that AgNPs 
are effective broad-spectrum antibacterial agents regardless of their drug-resistance 
mechanisms. 
Guzman et al. (2012) prepared AgNPs with mean diameters of 9±2, 14±5, 24±6 and 30i^ 7 
nm by chemical reduction from aqueous solutions of silver nitrate. They demonstrated 
that the AgNPs inhibited the growth and multiplication of the tested bacteria, including 
highly multidrug-resistant bacteria such as MRSA, S. aureus, E. coli, and P. aeruginosa. 
A strong antibacterial activity was observed at very low total concentrations of silver 
(below 7 ppm). They concluded that, relationship exist between the size of the NPs and 
the bacterial activity. For instance, as the nanoparticles size decreases the MIC decreases 
for all bacteria. 
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2.17.2. Possible mechanisms of antibacterial action by AgNPs 
Recent studies have demonstrated that the antibacterial action of AgNPs may be assumed 
due to both AgNPs and Ag^ ions, which are released from AgNPs suspension (Sondi & 
Salopelc-Sondi, 2004; Morones et al., 2005; Choi et ai, 2008). 
Toxicity due to Ag^ ions 
As reported by relevant studies, Ag^ ions may be gradually released from AgNPs, which 
are coupled with silver oxidation (Equation 1) 
4Ag ^ O2 +2H2O = 4Ag^ + 40H" (Equation I) 
Since silver has a tendency to interact with sulfur- or phosphorus-containing soft bases 
(e.g. R-S-R, R-SH or RS'), it is highly possible that some functional groups which 
contain sulfur-containing proteins (e.g. enzymes on the membrane) and phosphorus-
containing elements (e.g. DNA) will binding with Ag"^  ions, which cause malfunction of 
those molecular groups (Sondi & Salopek-Sondi, 2004; Yamanaka et al., 2005). After 
Ag+ ions treatment, bacterial DNA loses its capability to replicate, to express ribosomal 
subunit proteins became inactivated, and some cellular proteins and enzymes which are 
essential for ATP production (Yamanaka et al., 2005). Ag^ ions were also hypothesized 
to affect the membrane-bound enzymes function (e.g. enzymes involved in the 
respiratory chain) and facilitate the generation of reactive oxygen species (ROS) 
(McDonnell & Russel, 1999; Pal et al., 2007). In addition, the electrostatic force between 
Ag+ ions and the negatively charged cell membrane/wall may result in the inhibition of 
respiratory chain enzyme, the change of membrane permeability, ultimate cell lysis and 
death (Ratte, 1999; Sambhy et al., 2006). Although research has revealed that some 
bacteria might possess self-defense mechanisms or silver resistant properties (Silver, 
2003; Morones et al., 2005), AgNPs are generally viewed as an excellent antimicrobial 
agent. 
Toxicity contributed by Ag NPs 
The possible mechanisms of inhibitory affects of AgNPs against bacteria were speculated 
to be similar to Ag"^ , although studies show no direct interactions occurred between 
AgNPs and cell DNA or protein profiles (Gogoi et al., 2006). Overall, nanosilver toxicity 
is size, shape, and concentration dependent. The degree of inhibition also depends on 
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initial microbial concentration (Pal et ah, 2007). The antibacterial mechanisms of AgNPs 
are related to interaction between nanoparticles and bacterial cells, resulting in membrane 
property changes, followed by increased membrane permeability and dysfunction of 
molecular transportation through the plasma membrane (Sondi & Salopek-Sondi, 2004; 
Morones et al., 2005; Lok et ah, 2006). The attachment of AgNPs to cell membrane 
surfaces and possible penetration of AgNPs inside the bacterial cells, may affect electron 
transfer in the respiratory chain, proton motive force and ATP pool, which might be 
related to high affinity of silver to some phosphorus-containing protein (located on 
membrane surface) and sulfur-containing materials mainly located inside the cell 
(Morones et al, 2005; Choi et al, 2008). The attachment of AgNPs to the vicinity of 
bacterial cell wall might reduce its oscillator strength, leading to decrease of fluorescence 
intensity from the cell (Sondi & Salopek-Sondi, 2004; Gogol et al, 2006). 
Recently research also demonstrated that AgNPs might cause bacterial cell structure 
change through the formation of "pits" on the surface (Amro et al, 2000), consistent with 
similar findings that AgNPs could attach to nitrifying bacterial cells, resulting in cell wall 
pitting (Choi et al, 2008). The change of cell morphology resulted in a notable increase 
in cell permeability by the release of LPS molecules and membrane proteins, although the 
outer cell membrane is mainly constructed by the tightly packed LPS molecules (Raetz, 
1990). As a result, the bacterial cell loses the capability of proper transport regulation via 
the cell membrane (Amro et al, 2000; Sondi & Salopek-Sondi, 2004). Ag NPs cause the 
loss of replication ability of DNA and inactivation of cellular proteins (Feng et al, 2000; 
Lok et al, 2006), eventually leading to the cell death. The oxidation of AgNPs often 
leads to the formation of partially oxidized AgNPs with chemisorbed Ag"^ . Studies have 
shown that the partial oxidation of AgNPs, which correlates with change of surface 
plasmon resonance adsorption, present higher toxicity (Lok et al, 2007). In addition to 
oxidation, crystallization, aggregation and dissolution involved in bacteria-NPs 
interactions are responsible for the antibacterial action of AgNPs (Sondi & Salopek-
Sondi, 2004; Choi et al, 2008). While few studies indicate direct effect of AgNPs on 
protein expression or intracellular DNA replication, it is suggested that generation of 
intracellular ROS due to AgNPs or Ag+ ion exposure might damage cellular constituent 
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and disrupt cell function, which provides an additional toxicity mechanism (Gogoi et al., 
2006; Kim et al., 2007; Choi et al., 2008). 
2.17.3. Antimicrobial properties of ZnO NPs 
Although the in vitro antibacterial activity and efficacy of regular zinc oxides have been 
investigated, little is known about the antibacterial activity of ZnO NPs. ZnO is a metal 
oxide, which is much more stable and has a longer life than organic-based disinfectants 
or antimicrobial agents. This is particularly important for harsh conditions such as high 
temperatures and/or pressures occurring during product manufacturing, storage and 
transportation (Hewitt et al., 2001). Preliminary growth analysis data suggest that 
nanoparticles of ZnO have significantly higher antibacterial effects on S. aureus than do 
other metal oxide NPs. In addition, studies also demonstrated that ZnO NPs have a wide 
range of antibacterial effects on a number of other microorganisms. The antibacterial 
activity of ZnO may be dependent on size and presence of normal visible light. The data 
suggest that ZnO NPs have potential application as a bacteriostatic agent in visible light 
and may have future applications in the development of derivative agents to control the 
spread and infection of a variety of bacterial strains. 
Though there are numerous reports in the literature on the biocidal effects of metal oxide 
NPs such as Si02, AI2O3, Fe304, T1O2, MgO and CaO, ZnO is of particular interest due to 
extensive applications of the material in the personal care and home care products 
(Schumacher et al., 2004; Axtell et al., 2005; Li et al., 2005), and the recent renewed 
interest associated with its piezoelectricity and band gap in the near ultraviolet and large 
exciting binding energy that could lead to lasting action based on exciting recombination 
even at the room temperature (Ozgur et al, 2005). Nanoscale (20-100 nm) ZnO can be 
employed as a safe physical sunscreen because it scatters and reflects UV in sunlight. 
ZnO NPs are believed to be nontoxic, biosafe and biocompatible and have been used in 
many applications in daily life, such as drug carriers and in cosmetics and fillings in 
medical materials (Ito, 1991). 
Preliminary studies indicate that ZnO NPs at concentration between 3 and 10 mM, caused 
100% inhibition of bacterial growth as a result of intracellular accumulation of NPs 
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(Brayner et al., 2006). The studies investigating tiie antibacterial activity of ZnO particles 
against E. coli, S. typhimurium, B. subtilis, and S. aureus etc. have shown the following 
results: ZnO particles are effective for inhibiting both Gram-positive and Gram-negative 
bacteria (Ansari et al., 2012 a & b). They even have antibacterial activity against spores 
that are high-temperature and high-pressure resistant (Sawai et al, 1995; 1996). Smaller 
ZnO particles have a better antibacterial activity (Sawai et al, 1996; Yamamoto, 2001; 
Makhluf et al, 2005). The antibacterial activity depends on surface area and 
concentration, while crystalline structure and particle shape have little effect. In a recent 
study, results propose ZnO NPs have bacteriostatic activity against E. coli. The 
antibacterial activity increases with increasing particle concentration and decreasing 
particle size. Particle concentration is observed to be more important than particle size 
(Zhang et al, 2007). 
2.17.4. Possible mechanisms of antibacterial action by ZnO NPs 
Several mechanisms for antimicrobial action by ZnO NPs have been proposed. These 
include disruption of cell wall and membrane integrity, generation of ROS and free 
radicals (Adams et al, 2006; Zhang et al, 2007). Firstly, electron micrographs have 
shown that ZnO NPs damage the bacterial cell wall, increase cell membrane permeability 
and change the cell morphology (Adams et al, 2006; Zhang et al, 2007; Huang el al, 
2008), which was assumed to be due to the interactions of ZnO NPs with bacterial 
membrane surface (e.g. the cellular internalization of ZnO NPs). This resulted in the 
membrane dysfunction (Nair et al, 2008), change of membrane permeability, leakage of 
intracellular substrates (Zhang et al, 2007; Huang et al, 2008) and finally cell death. 
Nair et al (2008) attributed this interaction to electrostatic effects due to the opposite 
surface charges of nanoparticles and cell membrane. These speculations were supported 
by the fact that starch-capped ZnO NPs are less toxic due to the protection caused by the 
OH-related quenching of the NPs positive charge (Nair et al, 2008). The proposed 
mechanism could also explain the reason why Gram-positive bacteria (e.g. S. aureus) 
were less sensitive to nanoparticles than the Gram-negative bacteria (e.g. E. coli). As 
Gram-positive bacteria have thicker peptidoglycan cell wall than Gram-negative bacteria, 
it is likely more difficult for ZnO NPs to induce membrane damage (Nair et al, 2008). 
The mechanisms of antibacterial activity of ZnO particles are not well understood 
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although Sawai et al. (1996) proposed the generation of hydrogen peroxide to be the 
main factor of antibacterial activity, while Stoimenov et al. (2002) indicated the binding 
of particles on bacterial surface due to the electrostatic forces to be a mechanism. Huang 
et al. (2008) proposed that the surface modification of ZnO NPs causes increase in 
membrane permeability and cellular internalization of these NPs whereas there is a ZnO 
NP structure change inside the cells. Furthermore, increase in oxidative stress, generated 
by ZnO NPs may also lead to observed cytotoxicity, followed by cell death and 
significant change in crystal structure of ZnO NPs (Huang et al., 2008). 
Another well accepted mechanism for inhibitory effects of nanosized metal oxide 
particles (e.g. ZnO, Ti02 and Si02) on bacteria (e.g. E.coli and B. subtilis) is generation 
of ROS in the presence of light (Adams et al, 2006). Unlike AgNPs, generation of 
photocatalytic ROS in the presence of UV or sunlight serve as an important factor for 
antibacterial action of ZnO NPs (Adams et ah, 2006; Jones et al., 2008). It is noted that 
the production of ROS such as hydrogen peroxide (H2O2) could damage cell membranes, 
cause dysfunction of cellular components, and finally cell death (Tam et al., 2008). 
2.17.5. Antimicrobial properties of alumina nanoparticles (AI2O3NPS) 
Aluminium is too reactive chemically to occur in nature as a free metal. AI2O3, 
commonly referred to as alumina, possesses strong ionic interatomic bonding, giving rise 
to its desirable material characteristics. It can exist in several crystalline phases, which all 
revert to the most stable hexagonal alpha phase at elevated temperatures (Meziani et al., 
2009). The large specific surface area, energy density and high reactivity of AI2O3 NPs 
made them unique combustible additives in propellant formulations for significantly 
higher and faster energy release. As one of the widely studied and used nanomaterials, 
AI2O3 NPs have been applied in catalysis (Jodin et al., 2006), structural ceramics for 
reinforcement (Bertsch et al., 2004), polymer modification (Cho et al., 2006), 
functionalization of textiles (Textor et al., 2006), heat transfer fluids (You et al., 2003) 
and waste water treatment (Pacheco et al., 2006). There have been very few studies 
available in the literature on the interaction of the AI2O3 NPs with microbes. One past 
study found no detrimental effect of an alumina slurry between 62.5 and 250 mg/L 
concentration range on E. colt (Sawai et al., 1995). 
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2,18. Nanotoxicology 
Nanotoxicology was proposed as a new branch of toxicology to address the adverse 
health effects caused by NPs (Donaldson et ah, 2004). The term "nanotoxicology" was 
proposed as a subcategory of toxicology by Donaldson and co-workers in 2004 to: 
"address gaps in knowledge and to specifically address the special problems likely to be 
caused by nanoparticles" (Donaldson et al., 2004). Despite suggestions that 
nanotoxicology should only address the toxic effects of engineered NPs and structures 
(Oberdorster et ai, 2005b) they recommend that nanotoxicology should also encompass 
the toxic effects of atmospheric particles, as well as the fundamentals of virology and 
bacteriology. While significant differences exist between the health effects of non 
biological particles and viruses and bacteria, there are significant common aspects of 
intrusion and translocation. 
Because of the small size and large surface area of nanomaterials, these materials have 
unique properties compared with their larger counterparts. The nanomaterials, even when 
they are made of inert elements like gold, become very active at a nanometer range. 
Nanotoxicological studies are intended to determine whether and to what extent these 
may pose a threat to the environment and to human beings. Typical NPs which have been 
studied are TiOi, alumina, ZnO, carbon black, and carbon nanotubes, and "nano-Ceo". 
The smaller a particle, the greater it's surface area to volume ratio and the higher its 
chemical reactivity and biological activity. The greater chemical reactivity of 
nanomaterials results in increased production of ROS, including free radicals (Nel et ai, 
2006). ROS production has been found in a diverse range of nanomaterials including 
carbon fullerenes, carbon nanotubes and NPs metal oxides. ROS and free radical 
production is one of the primary mechanisms of nanoparticles toxicity; which may result 
in oxidative stress, inflammation, and consequent damage to proteins, membranes and 
DNA (Fig 6) (Nel er a/., 2006). 
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Figure 6. Possible mechanisms by which nanomateiials interact with biological tissue 
(Adapted from Oberdorster et al., 2005a). 
2.18.1. Effect of nanoparticles on human health 
NPs can potentially cause adverse effects on organ, tissue, cellular, subcellular, and 
protein levels due to their unusual physicochemical properties. Metal NPs have received 
increasing interest in many fields. Due to tremendous advances for the utility of metal 
based NPs, large amount of data has been published on NP properties and toxicity. In this 
regard, it is extremely difficult to provide a completely comprehensive review or 
establish concrete conclusions at this point. For this reason, the goal of this review will be 
to provide a general update on the current status of metal NP toxicological assessment 
with an emphasis on commonly used metal NPs in medical, consumer, industrial and 
military applications. 
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2.18.2. Safety Issues of nanoparticles 
Although great strides have been made in worldwide production and use of metal-based 
NPs, there is a serious lack of information about the impact of NPs on human health and 
environment, especially the potential for NP-induced toxicity (Canesi et al., 2008). 
Preliminary reports of the inherent toxicity of some NPs are available and indicate that 
they can affect biological behavior at the organ, tissue, cellular, subcellular, and protein 
levels. However, deeply understanding the basis of NP toxicity is a requisite to the 
completion of occupational and environmental exposure risk-assessments, which must be 
overcome before large-scale production of NPs, can be safely and efficiently applied in 
the field of medicine. The current testing methods and potential routes of NPs exposure 
and biodistribution will be considered prior to data on current in vitro and in vivo toxicity 
assessments. 
2.18.3. Route of nanoparticles exposure 
Potential routes of NPs exposure include gastrointestinal tract, skin, lung, and systemic 
administration for diagnostic and therapeutic purposes. Human skin, lungs and gastro-
intestinal tract are in constant contact with the environment. While the skin is generally 
an effective barrier to foreign substances, the lungs and gastro-intestinal tract are more 
vulnerable. These three ways are most likely points of entry for natural or anthropogenic 
NPs. Injections and implants are other possible routes of exposure, primarily limited to 
engineered materials. Due to their small size, NPs can translocate from these entry portals 
into the circulatory and lymphatic systems, and ultimately to body tissues and organs. In 
Figure 7 the possible adverse health effects associated with inhalation, ingestion, and 
contact with NPs has been illustrated. 
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Figure 7. Schematics of human body with pathways of exposure to nanoparticles 
(adapted from Buzea et al., 2007). 
2.19. In vitro and in vivo toxicity of nanoparticles 
The toxicity of NPs is being addressed by a number of standardized approaches with in 
vitro, in vivo as well as detailed genomic or biodistribution studies. In vitro models (i.e., 
cells in culture) can act as a pre-screening tool for NPs bio-effects. In vitro studies in 
cultured cells have several advantages, including rapid results with low cost and 
decreasing the need for animal use, although they (in vitro tests) are not performed as a 
replacement for in vivo models. However, it has been shown that NPs may produce in 
vitro toxicity in some cell-based assays, but not in others. The various interactions of NPs 
with fluids, cells, and tissues need to be considered from the route of entry through the 
wide range of possible pathways ending at potential target organs. Although the 
epidermis is an excellent barrier to protect the body from external insult, NPs such as 
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T1O2 or ZnO in sunscreens have been shown to penetrate and be retained within the 
human stratum comeum and into some hair follicles. After inhalation of NPs, cells in the 
respiratory system such as macrophages and epithelial cells that line the lungs may come 
into direct contact with NPs. Further translocation to the lymphatic system could induce 
secretory immune responses. In contrast, when NPs enter the circulation, they may 
influence endothelial cell membrane toxicity and/or disrupt the tight junctions of the 
blood-brain barrier and gain access into the cerebral environment (Sharma & Sharma, 
2007). Ag and Cu NPs have demonstrated a greater potential to travel through the organ 
systems, compared to larger materials (Chen et al, 2007) and may not be detected by 
normal phagocytic defenses, allowing them to gain access to the blood or cross the 
blood-brain barrier into the nervous system. Furthermore, it has recently been 
demonstrated that certain metal NPs reduce spermatogonia! stem cell proliferation in 
vitro (Braydich-Stolle et al., 2005). 
2.19.1. In vivo and in vitro toxicity of AgNPs 
As previously mentioned, AgNPs have found widespread use in consumer and medical 
applications as antimicrobials. Studies have shown dose- and size-dependent toxicity, 
largely mediated through oxidative stress, induced by AgNPs in neuroendocrine cells, 
liver cells, lung cells, and germ line stem cells at concentrations between 5 and 100 fig/ml 
after 24 h of exposure (Braydich-Stolle et al., 2005; Hussain et al, 2005; Carlson et al., 
2008). Toxicity of AgNPs has been studied in different mammalian cell systems, 
including rat liver cells (Hussain et al., 2005), human keratinocytes and fibroblasts 
cultures (Burd et al., 2007), and human spermatogonia! stem cells (Braydich-Stolle et al.. 
2005). In vitro, an elevated dose of nanosilver induces oxidative stress (liberation of 
ROS) as a mechanism of cytotoxicity (Arora et al., 2008). At an innocuous concentration 
range, AgNPs have been described to exert anti-inflammatory effects as: acceleration of 
wound healing (Tian et al., 2007), modulation of cytokine production and induction of 
peripheral blood mononuclear cells proliferation (Shin et al., 2007), inhibition of allergic 
contact dermatitis in mice, suppression of the expression of TNF- a and IL-12, and 
induction of apoptosis of inflammatory cells (Bhol et al., 2005). Carlson et al. (2008) 
evaluated size-dependent cellular interactions of known biologically active AgNPs (15, 
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30 and 55 nm) in alveolar macrophages. Alveolar macrophages provide the first line of 
defense against foreign debris in the lung and were studied for their potential role in 
initiating oxidative stress. In vitro exposure produced morphologically abnormal sizes 
and adherence characteristics with significant NP uptake at high doses after 24 h. 
Toxicity evaluations using mitochondrial and cell membrane viability along with ROS 
showed a dose-dependent decrease in cell viability. A more than tenfold increase of ROS 
levels in cells exposed to 50 ^g/ml & 15 nm AgNPs suggest that the toxicity is likely to 
be mediated via oxidative stress. In addition, activation of the release of traditional 
inflammatory mediators was examined by measuring the levels of cytokines/chemokines, 
including TNF-a, macrophage inhibitory protein (MIP-2), and IL-6, released into the 
culture media. After 24 h of exposure to 15 nm Ag NPs, a significant inflammatory 
response was observed by the release of TNF-R (TNF alpha), MIP-2, and IL-1^. 
However, there was no detectable change in the level of lL-6 upon exposure to AgNPs. 
The possibility of using Ag NPs as biolabels was explored with Neuro-2A cells (Schrand 
et al., 2008). Schrand et al. (2008) found that two AgNPs, with different surface 
chemistries (hydrocarbon vs polysaccharide), produced strong optical labeling with high 
illumination light microscopy after 24 h of incubafion. This was due to the excitation of 
plasmon resonance by both types of Ag NPs. Both types of AgNPs were also bound to 
the exterior surface of the Neuro-2A cells and were internalized into intracellular 
vacuoles. However, ROS production, degradadon of mitochondrial membrane integrity, 
disruption of the actin cytoskeleton, and reduction in proliferation after stimulation with 
nerve growth factor were found after incubation with AgNPs at concentrations of 25 
.^g/ml or greater, with a more pronounced effect produced by the hydrocarbon-based 
AgNPs in most cases. 
Nanotoxicology assessment studies performed in vivo using appropriate dosing amounts 
and routes of exposure carry greater significance because of the diversity of systemic 
phenotypic response and the physiologic/anatomic influence that can be translatable from 
animal models to human exposures. The present information on AgNPs toxicity in vivo 
has been limited. In vivo studies with adult Sprague-Dawley rats dosed with AgNPs (60 
nm) at low (30 mg/kg), medium (300 mg/kg), and high doses (1000 mg/kg) for 28 days 
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showed significant dose-dependent changes in plasma alkaline phosphatase (ALP) and 
blood cholesterol Indicating that these NPs could damage the liver (Kim et ai, 2008). 
However, AgNPs did not induce genetic toxicity in either male or female rat bone 
marrow. Furthermore, a dose-dependent accumulation of AgNPs was observed in all 
tissues examined. In particular, a gender-related difference in the accumulation of silver 
was recorded in the kidneys, with a twofold increase in the female kidneys when 
compared with the male (Kim et ah, 2008). Male and female rats exposed to respiratory 
contact with 1.73 x \{flcm^ (low), 1.27 ^ 10 /^cm^ (medium), and 1.32 x 10*^  
particles/cm3(high) doses of Ag NPs for 6 h/day, 5 days/weeks for 4 weeks did not yield 
significant changes in body weight, hematology, or blood biochemical parameters. 
However, histopathological examination of the liver revealed cytoplasmic vacuolization 
and hepatic focal necrosis in some of the AgNP-treated rats (Ji et ai, 2007). As 
previously observed in the 28-day inhalation and 28-day oral dose studies (Kim et ai, 
2008), silver nanoparticles were distributed in all the tissues examined in this 
investigation. However, when compared with results of oral dose study, it was found that 
the upper nasal deposition caused olfactory bulb accumulation and thereby more silver 
accumulation within the brain. Similar histopathological observations for the 28-day oral 
dose study showed a dose-dependent increased incidence of bile duct hyperplasia around 
the central vein to the hepatic lobule with the infiltration of inflammatory cells, including 
eosinophils (Kim et al., 2008). 
Sung et al. (2008) in their work presented in this issue reports on a Sprague-Dawley rat 
whole exposure study for defining the subchronic 90-day inhalation toxicity of AgNPs. 
This subchronic 90-day silver studies on NPs inhalation indicated that the lungs and liver 
were the major target tissues for prolonged AgNPs exposure. The higher accumulation of 
silver nanoparticles in female kidneys was again found, and higher concentrations were 
determined to be located in the kidney basement membranes of the medulla and cortex. 
The exact functional toxicity consequence is not apparent for the gender difference with 
this higher concentration AgNPs since no significant kidney function or histopathologic 
changes were found in the 90-day time course for the female kidneys. This present 
inhalation study suggests accumulation of AgNPs in the female kidneys was not 
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dependent on route of administration as tlie same finding was discovered in oral studies 
(Kim et al, 2008). In contrast to the 28-day inhalation study, Sung et al. (2009) found a 
clear dose-dependent increase in the blood AgNPs concentration, indicating a systemic 
distribution of AgNPs by circulating blood. 
2.19.2. In vivo and in vitro toxicity of ZnO NPs 
The Neuro-2A cells exposed to ZnO NPs at doses >100 |ig/ml were reported to exhibit 
abnormality in size, cellular shrinkage, detachment from the surface of flask with 
significant decline in the mitochondrial function and ultimately trigger apoptosis (Anna 
& James 2006). Also, a recent report suggested the ZnO-induced DNA strand breaks, 
cytotoxicity and changes in the mitochondrial activity in A431 human skin cell line 
(Sharma et al, 2008). Zhu et al. (2008) compared the toxicity of several metal oxide 
aqueous suspensions to Zebrafish (Danio rerio) early developmental stage; of the 
substances tested, ZnO was the most toxic material to zebrafish embryos and larvae, the 
96-h LC50 of nano ZnO and ZnO/bulk aqueous suspensions on the zebrafish survival 
were 1.793 mg/L and 1.550 mg/L, respectively; and the 84-h EC50 on the zebrafish 
embryo hatching rate were 2.065 mg/L and 2.066 mg/L, respectively (Zhu et al, 2008). 
Wang et al. (2008) studied the acute toxicological impact of nano- and submicro-scaled 
zinc oxide powder on healthy adult mice in vivo. Combined with the results of zinc 
accumulation, pathological examination and biological indicators assays, the target 
organs for 20- and 120-nm ZnO acute oral administration are demonstrated to be the 
liver, heart, spleen, pancreas and bone. The biochemical and pathological investigation 
shows that the toxic effects between the 20 and 120 nm ZnO particles are a little 
different. For example, the blood viscosity could be induced by low and median dose of 
20 nm ZnO but high dose of fine ZnO after oral administration. The edema and 
degeneration of hepatocytes and inflammation of pancreas could be observed in most of 
the 20 nm ZnO treated mice. The 120 nm ZnO treated mice were found having dose-
effect pathological damage in gastric, liver, heart and spleen, however, the 20 nm ZnO 
treated mice presented lessened liver, spleen and pancreas damage with the increase of 
treated dose (Wang et al, 2008). Zi-hong et al. (2008) reported on the acute toxicity of 
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nano-sized ZnO in ICR Mice via intratracheal instillation. Histopathological observation 
showed that serious pulmonary inflammation, proliferation and thickening of alveolar 
walls existed in the lungs of all treated mice groups, which became more serious as the 
dose increased. The intratracheal instillation of nano ZnO induced significant pulmonary 
inflammation and marked body weight loss accompanied with anemia (Zi-hong et ah. 
2008). Ma-Hock et al. reported on the repeated dose toxicity of nano-scale zinc oxide and 
pigmentary zinc oxide by inhalation. The inhalation of Z-COTE HPl for 5 days resulted 
in local inflammations in the lungs of the rats, indicated by changes in several parameters 
in the bronchoalveolar lavage fluid (BALF) and histological examinations (Ma-Hock et 
al, 2008). 
Jeng & Swanson (2006) studied the toxicity of metal oxide NPs in mammalian cells. 
Dramatic changes in the cell morphology were observed after exposure to ZnO for 24 
hours, particularly at concentrations greater than 50 |xg/ml. The cells became irregular 
and shrank. At the concentration 50 |xg/ml, some cells retained an intact plasma 
membrane indicating that apoptosis occurred. At the concentration 100 |iig/ml, they 
became necrotic and detached from the culture dishes. At concentrations below 10 ^ g/ml, 
no distinct change in morphology of cells was observed. At concentrations of 50-100 
^g/ml, ZnO NPs caused 15% to 50% of the cells to die as detected by the trypan blue dye 
method. However, cell viability was not affected by ZnO exposure at a concentration less 
than 25 |Ag/ml for 48 hours (Jeng & Swanson, 2006). The mitochondrial function (MTT) 
results showed that ZnO exhibited more toxicity than other metal oxide NPs. A dose-
dependent increase in reduction of mitochondrial function was observed with ZnO 
exposure. After 24 hours of exposure, ZnO at a concentration of 100 ng/ml reduced the 
mitochondrial function >80% as compared to the control cells. At concentration of 
lO^g/ml, ZnO showed insignificant effects on the mitochondrial function (Jeng & 
Swanson, 2006). A significant increase in LDH leakage was observed with exposure to 
ZnO. At 4 hours of incubation, cells treated by ZnO at a concentration of 50 |j.g/ml started 
showing a decrease in mitochondrial function and LDH leakage. At lower concentrations, 
the effect appeared after 6 hours of contact time (Jeng & Swanson, 2006). 
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2.19.3. Comparative toxicity studies of nanoparticies 
Due to ease of duplication and rapid results produced by in vitro toxicity tests, many 
studies have simultaneously examined multiple compositions of metal NPs (i.e., Al, 
AI2O3, Ag, Cu, Fe203, Fe304, Mn, Mn02, M0O3, Si3N4, TiOa, CrOj, ZnO, and Zr02) 
under similar experimental conditions. In general, Zn-based NPs have demonstrated 
greater in vitro toxicity compared to many other metal NPs compositions such as Ag and 
Cu (Wang et al., 2006). For example, Jeng & Swanson (2006) examined the relative 
toxicity of TiOi, ZnO, Fe304, AI2O3, and Cr03 NPs with primary sizes ranging from 30 
to 45 nm and concentrations up to 200 ng/ml in Neuro-2A cells. It was found that ZnO 
was highly toxic, whereas AI2O3 was moderately toxic while Fe304 and Ti02 exhibited 
slight toxicity at high concentrations compared to low toxicity for Cr03 NPs. 
In an animal study, Wang et al. (2006) evaluated the acute oral toxicity of a very high 
dose of nano Zn powder (58 nm; 5-g/kg) in mice and found severe symptoms of lethargy, 
vomiting, and diarrhea along with significant elevation in biochemical parameters like 
ALAT, ALP, and LDH. Braydich-Stolle et al. (2005) studied 15 nm AgNPs, 30 nm 
M0O3 NPs, and 30 nm Al NPs along with their bulk counterparts in mouse 
spermatogonial stem cells at 5, 10, 25, 50, and 100 |xg/ml concentrations after 48 h. They 
found that the small (-15 nm) Ag NPs were more toxic than similar-sized Al or M0O3 
NPs. In studies by Soto et al. with murine alveolar macrophage cell lines, human 
macrophages, and epithelial lung cell lines exposed to Ag, Ti02, Fe203, AI2O3, Zr02, and 
Si3N4 NPs, they found that AgNPs displayed the greatest relative toxicity at multiple 
concentrations and in the different cell lines compared to moderate toxicity for Fe203, 
AI2O3, Zr02 and anatase Ti02 and low toxicity for rutile Ti02 and Si3N4 (Soto et al., 
2005; Soto et al., 2006; Soto et al., 2007). 
The reason to choose an in vivo instead of an in v/Yra model was that no solid in vitro 
model has been developed. Results from in vitro models often differ from those obtained 
in vivo (Maynard et al., 2006; Sayes et al., 2007; Donaldson et al., 2009). Furthermore, 
the majority of these studies are performed in vitro and there is very little evidence that 
these toxicity rankings directly translate into in vivo systems. One limitation of most 
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toxicity studies thus far is that these results have mainly come from using in vitro cell 
culture models and there has been little correlation between in vivo and in vitro 
measurements. Therefore, further in vivo studies should be conducted to broadl> 
characterize, explore and understand the biodistribution and potential adverse responses 
of NPs. Currently, reliable in vitro assays are not available for predicting the full effects 
of NPs. This prompted us to investigate the toxicological effects of NPs, in vivo, which 
includes the adverse effects of NPs on serum enzymes markers and liver, kidney, spleen 
as examined by light and electron microscopy. 
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3. MATERIALS AND METHODS 
3.1. Materials 
3.1.1. Standard Bacterial strains 
The bacterial cultures of Escherichia coli ATCC 25922, E. coll MTCC 1591, E. coli 
NCTC 10418, E. coli DH5a, Pseudomonas aeruginosa ATCC 27853, P. aeruginosa 
ATCC 25619, P. aeruginosa MTCC 3541, Staphylococcus aureus ATCC 25923, S. 
aureus MTCC 96, S. aureus NCTC 6571, 5*. epidermidis ATCC 155, S. epidermidis 
MTCC 3615, Streptococcus mutants MTCC 497, Proteus vulgaris MTCC 426, Bacillus 
subtilis MTCC 121 were obtained from Institute of Microbial Technology, Chandigarh, 
India. 
3.1.2. Chemical and regents 
Pure and analytical grade chemicals were used in all experiments including synthesis of 
ZnO and silver nanoparticles, media preparation for growth of bacterial cells. Sodium 
hydroxide (NaOH), Luria bertaini (LB), Muller Hinton Agar (MHA), Nutrient broth 
(NB), Nutrient agar (NA), agar, teepol agar, Trypticase soy broth (TSB), Brain heart 
infusion broth (BHI), Congo red dye, sodium acetate, crystal violet. Gram iodine. Sodium 
chloride (NaCl), were purchased from Himedia laboratories Pvt. Ltd., Mumbai, India. 
Acetone, glutaraldehyde, paraformaldehyde, formaldehyde, xylene, ethyl alcohol, DFX 
mountant from Loba Chemie Pvt. Ltd., Mumbai, India. Concanavalin A-conjugated 
fluorescein isothiocyanate (Con A-FITC, C-7642) and propldium iodide (PI, 81845) was 
purchased from Sigma Aldrich. USA. 
3.1.3. Glassware and apparatus 
Glass petri plates, plastic petri plates, glass test tube, glass slide, coverslips, conical flask, 
beaker, measuring cylinder, inoculation needle, gel puncture, micro-pipette, tips, falcon 
tubes, eppendrof, serum storage vials, blood colleting vials, 96-well microtitre tissue 
plates, 12 well- microtitre tissue plates. 
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3.1.4. Nanoparticles 
Commercially prepared NPs were obtained with known size and other specifications. 
Nanoparticles used were:-
• AgNPs water dispersion (2 nm, colorless and transparent, Product No. US7130, US 
Research Nanomaterials, Inc. USA) (Fig 8). 
• AgNPs dispersion (5-10 nm, spherical, Nanobiochemicals India Private Limited, 
Belgaum, India) (Fig 9). 
• AgNPs water dispersion (Ag, 15 nm, Mono Nanopowder, Tawny, Product No. 
US7140, US Research Nanomaterials, Inc. USA) (Fig 10). 
• Ag nanopowder/nanoparticles (30-50 nm, w/~0.2wt% PVP coated, Product No. 
US 1035, US Research Nanomaterials, Inc. USA) (Fig II). 
• Ag nanopowder (<100 nm. Product No. 576832, Sigma Aldrich, USA) (Figl2). 
• AI2O3 colloidal dispersion (45 nm. Product No. 44925, Alfa Aesar, USA) (Fig 13A). 
• AI2O3 nanoparticles powder (<50 nm. Product No. 544833, Sigma Aldrich, USA) 
(Figl3B). 
• ZnO colloidal dispersion (70 nm. Product No. 44905, Alfa Aesar, USA) (Fig 14). 
3.1.5. Preparation of nanoparticles solution 
NPs which were in powder form were brought in dispersion prior to use. Before using the 
NPs dispersion for the antibacterial tests, it was sonicated at 35 KHz for 30 minutes 
because particles got agglomerated. The reason for use of sonication was to break down 
the agglomerates and aggregation of NPs and make their dispersions. After 30 min of 
sonication, the so-called master nanofluids were produced. The master nanofluids were 
then diluted with double distilled water to different concentrations for the antibacterial 
tests. 
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Figure 8. HR-TEM image of AgNPs water dispersion (2 nm, colorless and transparent, 
Product No. US7130, US Research Nanomaterials, Inc. USA). 
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Figure 9. HR-TEM image of AgNPs dispersion (5-10 nm, spherical, Nanobiochemicals 
India Private Limited, Belgaum, India). 
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Figure 10. HR-TEM image of AgNPs water dispersion (Ag, 15 nm, Mono Nanopowder, 
Tawny, Product No. US7I40, US Research Nanomaterials, Inc. USA). 
Figure 11. HR-TEM image of Ag nanopowder/nanoparticles (30-50 nm, w/~0.2wt% 
PVP coated, Product No. US 1035, US Research Nanomaterials, Inc. USA). 
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Figure 12. HR-TEM image of Ag nanopowder (<100 nm, Product No. 576832, Sigma 
Aldrich, USA). 
Figure 13. HR-TEM image of (A) AI2O3 colloidal dispersion (45 nm) and (B) AI2O3 
nanoparticles powder (<50 nm). 
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Figure 14. HR-TEM image of ZnO colloidal dispersion (70 nm, Product No. 44905, Alfa 
Aesar, USA) 
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3.2. METHODS 
The present study was carried out in the Department of Microbiology, J. N. Medical 
College, A.M.U., Aligarh from January 2010 to March 2013. A total of 163 bacterial 
isolates were included in this study. 
3.2.1. Study groups 
This comprised samples of patients, received in the bacteriology section of our 
department, from Indoor patients and Outdoor patients. Bacteria were isolated from pus, 
skin exudates, urine and blood. 
3.2.2. Method of collection 
Samples were collected from skin lesions, either in sterile syringe or with sterile cotton 
swabs in sterile vials. When swabs were used, two swabs were taken for each specimen, 
one for bacterial culture and one for microscopy. Specimens were inoculated in Mueller 
Hinton broth immediately. 
3.2.3. Identification 
Bacterial identification: - identification was done as per standards (Baron & Finegold, 
1990). 
> Direct microscopic examination was carried out by Gram staining of the specimen. 
> Culture was performed on 5% sheep blood agar, teepol lactose agar and nutrient 
broth. These were incubated aerobically at 37°C for 18 to 24 hrs and colony characters 
assessed for identification. 
> Subculture was performed from nutrient broth if there was no growth on primary 
plates. 
> Gram staining was performed of respective colonies. 
> Motility was performed. 
> Biochemical tests- following biochemical tests were done for identification 
according to standard protocol (Forbes & Sahm, 2007) includes; Catalase, Oxidase, 
Sugars (Glucose, Lactose, Mannitol, Sucrose etc.), MR, VP, Indole, Urease, PPA, 
Nitrate Reduction , Kligler's Iron agar (KI), Aesculin hydrolysis. Citrate, Hugh Leifson's 
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test, Coagulase, CAMP, Bacitracin sensitivity, Hippurate hydrolysis, PYRase test, 
Optochin sensitivity, Bile solubility etc. 
3.2.4. Antimicrobial sensitivity testing of bacteria 
Individual isolates were tested, based on the recommendations of the Clinical and 
Laboratory Standards Institute (CLSI, 2006), by the Kirby-Bauer disc diffusion method 
for susceptibility to the following antibiotics: Amikacin (AK, 30 ng), Amoxicillin-
clavulanic acid (AMC, 20/10 |ig), Cefoperazone (Cs, 30 |xg), Cefoperazone-sulbactam 
(SCF, 75/10 ^g), Cefotaxime (Ce, 30 ^g), Ceftriaxone (Ci, 30 ^g). Ceftazidime (Ca, 30 
Jig), Ceftazidime-clavulanate (CaC, 30/10 ^g). Chloramphenicol (C, 30 ^g), Gatifloxacin 
(Gf, 5 i^g), Gentamycin (G, 10 |xg ), Tobramycin (Tb, 10 ng), Piperacillin-tazobactam 
(TZP, 100/10 i^g), Oxacillin (Ox, 1 ng), Methicillin (M, 5 ^g/ml). Vancomycin (Va, 30 
l^g ), Novobiocin (No, 30 ng), Levofloxacin (Le, 5 ng), Clindamycin (Cd, 1 |ig), 
Erythromycin (E, 1 fig). All antibiotics were purchased from Himedia, Mumbai, India. 
3.2.4.1 Detection of extended spectrum ^-lactamases (ESBLs) 
In this study, sensitivity disc of Aztreonam (30 |j,g), Cefotaxime (30 |j.g). Ceftazidime (30 
fig) and Ceftriaxone (30 (Ag) were used for screening of ESBL production. Diameter of 
zone of inhibition of growth was measured and interpreted according to CLSI (2006) 
criteria. The isolates with reduced sensitivity against two of four drugs mentioned above 
were interpreted as suspected ESBL producers. 
3.2.4.2. Phenotypic confirmatory method for ESBL detection 
Double Disk Synergy Test (DDST) 
Phenotypic confirmation of these provisional ESBL producers was done by testing with 
sensitivity disc of Ceftazidime and Cefotaxime alone and in combination with Clavulanic 
acid (10 fig) as recommended by CLSI (2006). For this purpose, discs of Ceftazidime + 
Clavulanic acid (30/10 fig) and Cefotaxime + Clavulanic acid (30/10 jig) were used. All 
the isolates showing increase in the zone of inhibition of 5 mm or more for either 
antimicrobial agent in combination with Clavulanic acid versus its zone when tested 
alone were labeled as confirmed ESBL producers. 
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3.2.4.3. Detection of MBL by Modified Hodge Test (MHT) 
A 0.5 McFarland dilution of the E. coli ATCC 25922 in 5 ml of broth or saline was 
prepared. A 1:10 dilution was streaked as lawn on to a MHA plate. A lO^g Imipenem 
susceptibility disk was placed in the center of the test area. Test organism was streaked in 
a straight line from the edge of the disk to the edge of the plate. The plate was incubated 
overnight at 35±2°C in ambient air for 16-24 hours (Lee et al., 2001). Quality control of 
the carbapenem disks were performed according to CLSI guidelines. After 24 hrs, MHT 
positive test showed a clover leaf-like indentation of the E. coli 25922 growing along the 
test organism growth streak within the disk diffusion zone. MHT negative test showed no 
growth of the E. coli 25922 along the test organism growth streak within the disk 
diffusion. 
4.2.4.4. Screening for methicillin resistance (Oxacillin disc test) 
Resistance to oxacillin was determined in all S. aureus isolates using an oxacillin broth 
screening test and by disc diffusion (Kampf et al., 1997). For the oxacillin broth 
screening test, two colonies were taken from an overnight culture from sheep blood agar 
and suspended in 2 ml nutrient broth, supplemented with 2% NaCl. Two drops were 
transferred to 2 ml nutrient broth, supplemented with 2% NaCl and 2 mg/L oxacillin. The 
tubes were incubated overnight at 30°C. Visible growth in the tube with oxacillin was 
regarded as evidence for oxacillin resistance and no growth in the same tube was 
regarded as evidence for oxacillin susceptibility, when a negative control (oxacillin-
susceptible S. aureus strain; ATCC 25923) remained clear and a positive control (MRSA 
strain; ATCC 43300) showed visible growth. For the disc diffusion test a sterile swab 
was dipped in the same S. aureus suspension as used for the oxacillin broth screening 
test. The swab was plated on MHA in order to get confluent growth (approx. McFarland 
standard 0.5). Oxacillin discs (I mg) were applied. Plates were incubated overnight at 
30°C. An isolate was classified as resistant to oxacillin when the inhibition zone was less 
than 16 mm (Kampf e/o/., 1997). 
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3.2.5. ZnO NPs synthesis 
ZnO NPs were prepared with slight modification in the sol-gel method as previously 
described (Chu et al., 2000). The sol was prepared, using zinc acetate dihydrate Zn 
(CH3COO)2. 2H2O (98%) (Sigma Aldrich, India), ethylene glycol CH2(OH)CH20H and 
2-propyl alcohol (CH3)2CHOH. In brief, lOOg of zinc acetate dihydrate was mixed with 
250 ml of ethylene glycol at 150 °C for 15 min to obtain a uniform transparent solution. 
The solution was solidified to a transparent brittle solid on cooling down to room 
temperature. This solid was then dissolved in 200 ml 2-propyl alcohol. The resulting 
solution was highly hydrophobic and converted to gel on addition of a few drops of 
water. Triethylamine (C2H5) N was also added to help hydrolysis of zinc acetate. 1 he 
solution was then incubated at 200 ^C, which transforms it into a light brown powder 
after 6 h. The powder was initially heated in a programmable furnace at 450 °C for 8 h 
and then at 700 '^ C for 5 h to remove all organics, yielding white pure ZnO powder. 
3.2.5.1. X-ray diffraction (XRD) pattern of synthesized ZnO nanopartides 
X-ray diffraction (XRD) pattern of ZnO NPs was recorded by Bruker D8 diffractometer 
using CuKa radiation {X^ 1.54056 A) in the range of 20^ ^ < 20< SO'^ at 40 keV. The lattice 
parameters were calculated by the PowderX software. The particle size {D) of the sample 
was calculated using the Scherrer relationship: 
D = °-^^ 
B cos e 
/I: Wavelength of x-ray, 
B: Broadening of the diffraction line measured half of its maximum intensity in radians 
0 : The Bragg's diffraction angle. 
3.2.5.2. SEM and AFM analysis of synthesized ZnO powder 
The scanning electron microscopy (SEM) images were taken on Carl Zeiss EVO 40 
(Germany). To image the synthesized ZnO nanopowder, atomic force microscopy (AFM) 
were taken (Veeco Innova) in tapping mode using commercial etched silicon tips as AFM 
probe with typical resonance frequency of ca. 300 Hz (RTESP, Veeco). 
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3.2.6. Characterization of nanoparticles 
3.2.6.1. Transmission Electron Microscopy (TEM) analysis of nanoparticles 
The size and morphology of the NPs were analyzed by high-resolution transmission 
electron microscope (HR-TEM). The sample was prepared by placing a drop of very 
dilute suspension of synthesized and commercially procured nanoparticles solution on 
carbon coated copper grid and allowed to dry by evaporation at ambient temperature and 
kept under a desiccator before loading them onto a specimen holder. The TEM 
measurements were performed at an accelerating voltage of 200 kV (Technai G2, FEI, 
Electron Optics, USA). 
3.2.7. Methods for evaluation of antimicrobial activity of nanoparticles 
3.2.7.1. Time-dependent growth inhibition assay 
To examine the bacterial growth curve in liquid broth, inoculations were taken from fresh 
colonies on MHA plates into 100 ml of LB culture medium. Growth was allowed till the 
optical density reached 0.1 at 600 nm (OD of 0.1 corresponding to 10* CFU/ml of 
medium). Subsequently, 2x10 CFU/ml from above was added to 100 ml of Erienmeyer 
necked flask containing liquid LB media supplemented with different concentration of 
various NPs (0-2000^g/ml). All the flasks were put on rotatory shaker (150 rpm) and 
incubated at 37 °C. Control broths were used without nanoparticles. The bacterial growth 
was determined by measuring optical density after every 2 hour (up to 16 h) at 600nm 
using spectrophotometer (VSP66, LOBA Life, India). 
3.2.7.2. Assay for MIC and MBC determination of nanoparticles/nanopowder 
Minimal inhibitory concentration (MIC)', Bacterial strains were grown overnight on 
MHA plates at 35 ''C before being used. The antimicrobial activity of different NPs used 
was examined using the standard agar and broth dilution method. The MIC was 
determined using serial two-fold dilutions of NPs with initial bacterial inoculums of 
2.5x10^ CFU/ml and time and temperature of incubation being 24 hrs at 37 °C, 
respectively. The MIC is the lowest concentration of antimicrobial agents that completely 
visually inhibits the 99% growth of the microorganisms. The MIC measurement was 
done in triplicate to confirm the value of MIC for each tested bacteria. 
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Minimal bactericidal concentration (MBC): After MIC determination of the NPs tested, 
an aliquots of 25 ^1 from all tubes in which no visible bacterial growth was observed 
were seeded in MHA plates not supplemented with NPs and were incubated for 24 hrs at 
37 °C. The MBC endpoint is defined as the lowest concentration of antimicrobial agent 
that kills 100% of the initial bacterial population. 
3.2.7.3. Determination of antibacterial activity of NPs by well-diffusion method 
A single colony of test strain was grown overnight in Mueller -Hinton broth at 35°C. The 
inoculums were prepared by diluting the overnight cultures with 0.9% NaCl to a 0.5 
McFarland standard. Zone of inhibition test was performed in MHA plates supplemented 
with 200ng/ml of ZnO and 50 and 100 \ig/m\ of AgNPs dispersion. For this, 20 ml MHA 
was poured in well-rinsed, autoclaved Petri plates, 1.0 ml of active bacterial culture was 
homogeneously spread in the agar plates and NPs solution filled in deep blocks, prepared 
by cutting the agar by gel puncture. The plates were incubated at 37°C for 24 hrs. The 
zone size was determined by measuring the radius of the zone. The test performed with 
high concentration of ZnO NPs did not show a large zone of inhibition because particles 
had settled at the bottom. 
3.2.8. Mechanism of interaction of nanoparticles with bacterial cell 
3.2.8.1 Characterization of nanoparticles and bacterial interaction by SEM 
The morphological changes of bacterial cells (E. coli, P. aeruginosa and S. aureus) on 
treatment with or without Ag, ZnO and AI2O3 NPs were carried out using SEM. Prior to 
SEM analysis; samples containing untreated and treated bacterial cells were deposited on 
a Millipore filter. Bacterial cells (10^ CFU/ml) were treated with 50 |ag/ml (AgNPs) and 
100 ng/ml (ZnO & A1203) for 24 hrs at 37 °C and centrifuged at 12000rpm for 10 min. 
The pellets were washed with phosphate buffered saline (PBS) three times and pre-fixed 
with 2.5% glutaraldehyde for 1 hrs at 4°C. The pre-fixed cells were washed with PBS two 
times and post-fixed with 1% osmium tetroxide for 1 hrs at 25 °C. After washing with 
PBS three times, dehydration process was conducted with 30, 50, 70, 80, 90 and 100% of 
ethanol (each for 10 minutes). The cell biomass were fixed on the aluminum stubs and 
then the fixed cell was dried overnight with CO2 in a critical point dryer, sputter-coated 
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with a thin layer of gold (Sputter coater- Polaron SC7640). The coated samples were 
observed under scanning electron microscope (Carl Zeiss EVO 40, Germany) with 
accelerating voltage of 20 kV. 
3.2.8.2. Characterization of nanoparticles and bacterial interaction by HR-TEM 
Electron micrographs of natural and Ag, ZnO and AI2O3 NPs-treated E. coli, P. 
aeruginosa and S. aureus were taken using a FEI Technai G2 TEM instrument operated 
at an accelerating voltage of 200 kV. To examine the nanoparticles interaction with 
bacterial strains, cells were grown in liquid LB medium at 35±2°C for 24 hrs. Growing 
cells were centrifuged at 12000 rpm for 10 minutes and pellets were mixed in PBS. 
Bacterial cells (10^ CFU/ml) were then treated with 50 ^g/ml (AgNPs) and 100 ng/ml 
(ZnO & A1203) of NPs and incubated at 37°C with shaking at 150 rpm for 24 h. Control 
experiment was conducted in absence of nanoparticles. The cultures were centrifuged and 
the supematants were discarded for preparation of ultrathin sections of cells. The pellets 
were washed with phosphate buffered saline (PBS) three times and pre-fixed with 2.5% 
glutaraldehyde for 1 hrs at 4 C and washed three times with a sodium cacodylate buffer. 
After every wash, the sample was centrifuged at 12 000 rpm for 5 min to separate the 
bacteria from solution. Samples were then post fixed in 1% osmium tetraoxide and was 
washed another three times and then dehydrated by washing with a series of graded 
acetone (30%, 50%, 60%, 70%, 80%, 90%, 95%, and 100% water/acetone mixtures for 5 
min apiece) and embedded in white resin overnight and held to polymerize. Then, ultra 
thin sections (50-70 nm thickness) were cut with a microtome diamond knife, stained 
with uranyl acetate and counter stained with 4% lead citrate. These sections were 
mounted on carbon coated copper grids and finally, the internal structure of cells was 
observed by transmission electron microscopy (Technai, FEI, Electron Optics, USA) 
instrument operating at an accelerating voltage of 120KeV. 
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3.2.9. Detection of biofilm formation 
3.2.9.1. Tissue culture plate method (TCP) 
The TCP assay described by Christensen et al. (1985) is most widely used and was 
considered as standard test for detection of biofilm formation. 10 ml of Trypticase soy 
broth with 1% glucose was inoculated with a loopful of test organism from overnight 
culture on nutrient agar. The broth was incubated at 37°C for 24 hours. The culture was 
further diluted 1:100 with fresh medium. 96 wells flat bottom tissue culture plates were 
filled with 0.2 ml of diluted cultures individually. Only sterile broth was served as blank. 
Similarly control organisms were also diluted and incubated. The culture plates were 
incubated at ST'^C for 24 hours. After incubation gentle tapping of plates was done. The 
wells were washed with 0.2 ml of phosphate buffer saline (pH 7.2) four times to remove 
free floating bacteria. Biofilms which remained adherent to the walls and the bottoms of 
the wells were fixed with 2% sodium acetate and stained with 0.1% crystal violet. Excess 
stain was washed with deionized water and plates were dried properly. Optical densities 
(OD) of stained adherent biofilm were obtained with a micro ELISA autoreader at wave 
length 570 nm. Experiment was performed in triplicate and repeated thrice. Average of 
OD values of sterile medium were calculated and subtracted from all test values (Lewis, 
2001; Mathure/a/. 2006). 
3.2.9.2 Tube method (TM) 
A qualitative assessment of biofilm formation was determined as previously described by 
Christensen et al. (1982). 10 ml Trypticase soy broth (TSB) with 1% glucose was 
inoculated with a loopful of microorganism from overnight culture plates and incubated 
for 24 hours at 37°C. The tubes were decanted and washed with PBS 0.1% (pH 7.3) and 
dried. Dried tubes were stained with crystal violet (0.1%). Excess stain was removed and 
tubes were washed with deionized water. Tubes were then dried in inverted position and 
observed for biofilm formation. Biofilm formation was considered as positive, when a 
visible film lined the wall and bottom of the tube. Ring formation at the liquid interface 
was not indicative of biofilm formation. Tubes were examined and the amount of biofilm 
formation was scored as (-) -negative, (+)-weakly positive, (++)-moderate positive and 
(+++)-strongly positive. Experiments were performed in triplicate and repeated three 
fimes. 
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3.2.9.3. Congo red agar method (CRA) 
Freeman et al. (1989) had described an alternative method of screening of biofilm 
formation; which requires the use of a specially prepared solid medium brain heart 
infusion broth (BHI) supplemented with 5% sucrose and Congo red for screening the 
formation of biofilm. The medium was composed of BHI (37 gms/L), sucrose (50 
gms/L), agar No.l (10 gms/L) and Congo red stain (0.8 gms/L). Congo red was prepared 
in the form of concentrated aqueous solution and was autoclaved at 121 °C for 15 min, 
separately from other medium constituents. Following autoclave, the concentrated 
solution was added to agar which was previously cooled to 55 C. Plates were inoculated 
and incubated aerobically for 24—48 h at 37 C. Positive result was indicated by black 
colonies with a dry crystalline consistency. Weak slime producers usually remained pink, 
though occasional darkening at the centers of colonies was observed. Darkening of the 
colonies with the absence of a dry crystalline colonial morphology indicated an 
indeterminate result. 
3.2.10. Characterization of antibiofilm activity of AgNPs 
3.2.10.1. Scanning electron microscopic examination 
Biofilms were assessed as previously described with or without AgNPs (30^g/ml). 
Firstly, the cells were washed with PBS, fixed with 2.5% glutaraldehyde, then fixed 
samples were subsequently washed again with PBS and dehydrated gently by washing in 
a series of ethanol alcohol (30%, 50%), 70%, 80%), 95%) and 100%o for 10 min) at room 
temperature, and critical point drying was performed. Afterwards, cells were then 
oriented, mounted on the aluminum stubs and coated with gold before imaging. The 
topographic features of the biofilms were visualized with a scanning electron microscope 
(Carl Zeiss EVO 40, Germany) with accelerating voltage of 20 kV. 
3.2.10.2. Confocal laser scanning microscopy study 
Biofilms for confocal analysis were grown on glass coverslips as previously described by 
Banas et al. (2001). Twelve-well microliter plate seeded with glass coverslips were 
incubated with 30^g/ml of AgNPs for 24 h at 37°C in 5 ml of BHI with 5% sucrose. The 
wells were inoculated with 100 nl of mid-exponential grown culture of different bacterial 
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isolates. After 24-hour, the cover slips were removed and gently washed with sterile PBS 
and were then stained with 15 \M propidium iodide (Sigma) for 15 minutes at room 
temperature in order to detect red bacterial cells. After being washed in PBS, the cultures 
were incubated with 50 |ig/ml of concanavalin A-conjugated fluorescein isothiocyanate 
(Con AFITC - Sigma) for 15 minutes at room temperature to stain the glycocalyx matrix 
green. The propidium iodide was excited at 520 nm, the emission was monitored at 620 
nm, and Con A-FITC was excited and monitored at 495 nm and 525 nm, respectively. 
Intact biofilms were examined non-destructively using a Fluoview FVIOOO Espectral 
Olympus CSLM (Olympus Latin America, Miami, FL, USA) equipped with a 
UPlanSApo lOOX/1.40 oil UIS2 Olympus oil immersion lens. Then, for each sample, 
images from three randomly selected positions were obtained and analyzed using an 
Olympus Fluoview FV 1000. Merged red and green images were obtained in single TIFF 
format and were converted to high quality JPEG files using Adobe Photoshop version 
7.0. 
3.2.11. In Vivo assessment of the toxicological effects of ZnO and AgNPs in mice 
The reason to choose an in vivo instead of an in vitro model was that no solid in vitro 
model has been developed. Results from in vitro models often differ from those obtained 
in vivo (Seagrave et al., 2005; Sayes et al., 2007; Donaldson et al., 2009). There are 
various reasons for these discrepancies, yet for nanotoxicology it's believed that the 
particles can interact with the measuring methods chosen, rendering them useless, unless 
further developed. For example, it has been shown that nanoparticles can interact with 
reagents when measuring cell survival and obscuring the results (Worle-Knirsch et al., 
2006). In in vivo systems, possible interactions between particles and different tissue cells 
are ensured, which allows for complex interactions that may occur in human exposures. 
Thus, we believe that it is important to use in vivo models to ensure that the possible 
toxicological effects of nanoparticles are investigated without the possibility that results 
are corrupted by interaction between particles and methods. Currently, reliable in vitro 
assays are not available for predicting the full effects of nanoparticles (Seagrave et al., 
2005; Maynard et al, 2006; Sayes et al, 2007). In order to study the toxicological effects 
of nanoparticles, in vivo models are necessary, which includes the adverse effects of 
nanoparticles on liver, kidney, spleen and serum enzymes markers. 
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3.2.11.1. Description of the method 
Animals and nanopartides treatment 
Animal experiments were performed according to the 'Guidelines for Animal 
Experimentation' duly approved by the Institutional Animal Ethical Committee of 
Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh India. 160 male 
mice of about 4 weeks old and 25-35 g weight were purchased from Indian Institute of 
Toxicological Research (IITR), Lucknow, India. The animals were randomly selected, 
marked to permit individual identification, and kept in clean polypropylene cages and 
maintained in an air-conditioned animal house at 23±28°C, 50-70% relative humidity and 
12-h light/dark cycle for at least 7 days prior to the start of dosing to allow for 
acclimatization to the laboratory conditions. The mice were allowed free access to 
commercial pellet diet and deionized water ad libitum. After 1 week acclimation, the 
mice were randomly divided into 3 groups: first group, mice treated with AgNPs (<100 
nm. Product No. 576832, Sigma Aldrich, USA), second group; mice treated with ZnO 
NPs (70 nm, Product No. 44905, Alfa Aesar, USA) and third the control group. 
Nanopartides were suspended in 1% normal saline and dispersed by ultrasonic vibration 
for 15 minutes. The animals were kept fasting overnight before treatment. The mice were 
administered by 0.5-, 1-, Z-, and 5-g/kg body weight of AgNPs and ZnO NPs 
intraperitoneally, and labeled them properly. The control group was given 1% normal 
saline solution instead. After administration, mice were observed daily for up to 28 days. 
The symptoms of observation included changes in skin and fur, eyes membranes, 
respiratory, and other behavior pattern. Special attention was given to tremors, 
convulsions, salivation, nausea, vomiting, diarrhea, lethargy, sleep and coma. The body 
weight of mice was recorded before and every 2 days after the administration. After the 
administration; mice were sacrificed on day 7, 14, 21 and 28 after being anaesthetized by 
diethyl ether and the blood was obtained from heart. Serum was obtained by centrifuging 
blood at 3500 rpm for 5 minutes and stored at -20 *^ C. The organic tissues of liver, spleen, 
and kidneys were collected and kept in 10% formalin for histopathological examination. 
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3.2.11.2. Biochemical analysis of serum enzymes markers 
3.2.11.2.1. Biochemical analysis of liver function 
The serum was obtained by centrifugation of the whole blood at 3000 rpm for 15 min. 
Liver function was evaluated with serum levels of alanine transaminase (ALT) or serum 
glutamic pyruvic transaminase (SGPT), aspartate transaminase (AST) or serum glutamic 
oxaloacetic transaminase (SGOT), alkaline phosphatase (ALP), total protein (TP). 
albumin (ALB), and total bilirubin level (TBIL). 
3.2.11.2.2. Biochemical analysis of renal function 
Nephrotoxicity was determined by serum levels of uric acid (UA), blood urea nitrogen 
(BUN), urea, and creatinine (CR). 
3.2.11.2.3. Biochemical analysis of blood sugar and lipid profile 
Blood sugar and lipid level were determined by serum levels of glucose (Glu), total 
cholesterol (TCHO), triglycerides (TO) and high-density lipoprotein cholesterol (HDL-
C). 
All biochemical assays were performed using a fully automated, random access, dry 
Biochemistry analyzer (Vitros-250, Johnson and Johnson Co. USA). 
3.2.11.3. Histopathological examination: light microscopic observation of liver, 
kidney and spleen 
At the end of the experimental period, all the animals were sacrificed and observed for 
gross lesion in the organs, and then liver, spleen and kidneys were collected and 
immersion fixed in Kamovsky's fixative and then processed paraffin embedding. 7 ^m 
thick sections were stained with haematoxylin and Eosin and examined under Olympus 
trinocular microscope. Sample photomicrographs were taken primarily under high power 
of magnification. 
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3.2.11.4. Ultrastructural changes in liver, kidney and spleen: High-resolution 
Transmission Electron Microscopic observation 
Liver, spleen and kidneys tissues were fixed for TEM, adopting an in-house method. 
Briefly, tissue was placed in 2% paraformaldehyde/2.5% glutaraldehyde in O.IM 
phosphate buffer (pH 7.4) for 2hrs, washed three times in O.IM phosphate buffer for 
5mins and fixed in 1% osmium tetroxide in phosphate buffer for 1 hour. The tissues were 
then washed in deionized water for 5 x 5 minutes, before being cut into Imm^ pieces and 
subsequently suspended in 2% uranyl acetate for 1 hour. The tissues were then 
dehydrated in an ethanol series: 30%, 50%, 70%, 90% and 100% (X2), respectively in 
each for 10 minutes and embedded in TAAB resin. The tissues were blocked in shallow 
planchets and placed in a 60°C oven for 20 hours. Tissues were sectioned on an ultra 
microtome (Ultracut, Reichert) and sections of the tissue were examined for structural 
alterations and subcellular localization of nanoparticles using a Technai G2 (FEI, 
Electron Optics, USA) and Morgagni 268D (Fei Electron Optics) transmission electron 
microscope. 
3.3. Statistical analysis 
Statistical analyses were done using SPSS 17 software. Results were expressed as mean ± 
standard deviation (SD). One-way analysis of variance (ANOVA) was carried out to 
compare the differences of means among multi-group data. The Dunnett's test was used 
to compare the differences between the experimental groups and the control group. 
Statistical significance for all tests was set at P<0.05. 
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4. RESULTS 
4.1. Distribution of different bacterial isolates 
A total of] 63 non-repetitive clinical isolates recovered from skin lesion such as pus, 
wounds, bum etc received in the laboratories of Department of Microbiology from 
patients admitted in the wards or attending the outpatient department of Jawaharlal Nehru 
Medical College, AMU, were subjected to the study. Out of total 163 bacterial isolates, 
the highest prevalence among the bacteria isolated from clinical origin was 
Staphylococcus spp 62 (38 %), followed by P. aeruginosa 55 (33.7%), E. coli 40 (24.5%) 
and Klebsiella spp 6 (3.7%) (Fig 15). On screening Staphylococcus for methicillin 
sensitivity, 48% S. aureus and 60% Coagulase negative Staphylococci were found to be 
resistant. While on screening for ESBL production, 80% E. coli, 76.3% P. aeruginosa, 
and 66.7% Klebsiella sp. were found to be ESBL producers, whereas 7.3% P. aeruginosa 
were found to be MBL positive (Table 1 & Fig 16). 
Klebsiella spp, 
3.70% 
E.coli, 24.50% 
Figure 15. Distribution of different clinical bacterial isolates. 
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Table 1. Bacteriological profile of different clinical isolates (163) 
Organism 
S. aureus 31.9%(52) 
Coagulase negative staph spp 
6.1%(10) 
£. co//24.5%(40) 
P. aeruginosa 33.7%(55) 
Klebsiella spp 3.1 %i6) 
MRSA 
MSSA 
Methicillin Resistant 
Methicillin Sensitive 
ESBL 
Non-ESBL 
ESBL 
Non-ESBL 
MBL 
ESBL 
Non-ESBL 
Percentage (%) 
isolates 
48.0 % (25) 
52.0 % (27) 
60.0% (6) 
40.0 % (4) 
80.0 % (32) 
20.0 %(8) 
76.3 % (42) 
16.4% (9) 
7.3% (4) 
66.7 % (4) 
33.3 % (2) 
100% 
80% 76.30% 
66.70% 
33.30% 
J"^ o^' . / ...» 5 ,<l „ ^ ,•<?' 
cT 4^ N' I? 
^v^ ^<f o^<> ^<f J" w 
Figure 16, Distribution of MRSA, MSSA, MR and MS CONS, ESBL and non ESBL E. 
coll, P. aeruginosa, MBL positive P. aeruginosa and ESBL and non ESBL Klebsiella 
spp. 
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4.2. Characteristics of synthesized ZnO nanoparticles 
The ZnO nanopowder was synthesized and characterized by x-ray diffraction (XRD) 
pattern. The data recorded using CuKa radiation {1= 1.5056 A) in the range of 20° < 2e< 
80° at 40 keV showed a typical spectral pattern, which confirms the nanoparticle 
formation in single phase with hexagonal crystal symmetry (Fig 17). All the peaks 
conform very well with the hexagonal structure with no signal of a secondary phase. The 
lattice parameters as determined using the PowderX software are a=b=3.248 A & 
c=5.205 A. The maximum deviation occurred between the observed and calculated 
values of interplanar spacing (d) remains below 0.0011 A. The particle size of the sample 
was found to be 19.82 nm, estimated from the line width of the (101) XRD peak. Table 2 
showed the experimental and calculated values of 20 and interplanar separation d along 
with values of hkl. Similarities in the experimental and calculated values reflect the 
crystalline quality of the sample and confirmed the formation of ZnO nanopowder. 
4.2.1. SEM and AFM analysis of ZnO NPs 
Figure 18 shows the SEM and AFM image of ZnO NPs synthesized by sol-gel method. 
From the SEM image of ZnO NPs, it is clear that the particles are spherical in shape with 
a diameter of ~ 19 nm. The AFM image shows the hexagonal crystal structure of 
synthesized ZnO NPs (Fig 18). 
tt 
2 0 3 0 A a S 0 6 0 7 0 eo 
Figure 17. XRD pattern of ZnO nanoparticles synthesized by sol-gel method. 
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Table 2. Experimental and calculated structural parameters of ZnO nanopowder 
Mi 
100 
002 
101 
102 
110 
103 
200 
112 
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004 
202 
M^qpkJ 
31.77 
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62.90 
6&43 
6&00 
69.14 
72.63 
77.01 
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Figure 18. SEM (a) and AFM (b) image of ZnO NPs synthesized by sol-gel method 
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4.3. Evaluation of antimicrobial activity of different nanoparticles by time-
dependent growth inhibition assay 
4.3.1. Antimicrobial Activity of AgNPs (2 nm) by time-dependent growth inhibition 
assay 
The dynamics of bacterial growth was monitored in LB broth supplemented with 
different concentrations of different nanoparticles at different time intervals by measuring 
absorbance at 595nm by using spectrophotometer as described previously. Figure 19a, b 
and c represents growth curves of £. coli ATCC 25922, ESBL producing and non ESBL 
strains in LB broth inoculated with 10^  Colony Forming Unit (CFU/ml) of bacteria at 
different concentrations (0, 5, 10 and 15(ig/ml) of 2 nm water soluble AgNPs. In the 
presence of different concentration of AgNPs, the growth curves of E. coli ATCC 25922, 
ESBL and non ESBL strains included three phases: lag phase, exponential phase, and 
stabilization phase. However, decline phases in each growth curve could not be revealed 
because we only assayed the total numbers of bacteria, including live and dead ones, 
based on the value of OD595. Under absence of AgNPs, E. coli ATCC 25922, ESBL and 
non ESBL strains reached exponential phase rapidly. The growth curves of bacterial cells 
treated with different concentration of AgNPs indicated that it could inhibit the growth 
and reproduction of bacterial cells. In figure 28a, b and c, 5)ag/ml nanoparticles caused no 
obvious effect of growth of E. coli isolates. When cells were exposed to different 
concentration of AgNPs, NPs solution of 10|j,g/ml was enough to inhibit the growth of all 
tested strains within 2 hrs. The growth curves indicated that the AgNPs produced 
immediate killing and a rapid rate of loss in viability, as the concentration of NPs 
increased. However, NPs with highest concentration (15^g/ml) showed almost negligible 
growth for up to 8 hrs for E. coli ATCC 25922 (Fig 19a), ESBL producing isolates of £ 
coli (Figure 19b) and non ESBL isolates (Figure 19c), representing good bactericidal 
activity of NPs. 
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Figure 19a. Growth curves of E. coli ATCC 25922 in the presence of different 
concentrations of 2 nm water soluble AgNPs. 
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Figure 19b. Growth curves of ESBL producing clinical isolates of £. coli in the presence 
of different concentrations of 2 nm water soluble AgNPs. 
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Figure 19c. Growth curves of non-ESBL clinical isolates of E. coli in the presence of 
different concentrations of 2 nm water soluble AgNPs. 
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Figure 20a, b and c represents growth curves of S. aureus ATCC 25923, MRSA and 
MSAA strains in LB broth inoculated with 10^  Colony Forming Unit (CFU/ml) of 
bacteria in the presence of different concentrations (0, 5, 10 and 15 ^g/ml) ) of 2 nm 
water soluble AgNPs. From the figure it was observed that, at all these concentrations, 
the nanoparticles caused a growth delay of S. aureus, MRSA and MSSA; increasing the 
concentration of nanoparticles increased this growth delay. In the presence of different 
concentration of AgNPs, the growth curves of S. aureus ATCC 25923, MRSA and 
MSAA included three phases: lag phase, exponential phase, and stabilization phase. 
However, decline phases in each growth curve could not be revealed because we only 
assayed the total numbers of bacteria, including live and dead ones, based on the value of 
OD595. Under absence of AgNPs, S. aureus ATCC 25923, MRSA and MSAA reached 
exponential phase rapidly. The growth curves of bacterial cells treated with different 
concentration of AgNPs indicated that it could inhibit the growth and reproduction of 
bacterial cells. When cells were exposed to different concentration of AgNPs, NPs 
solution of lO^g/ml was enough to inhibit the growth of all tested strains within 2 hrs. 
However, NPs with highest concentration (IS^g/ml) showed almost negligible growth for 
up to 8 hrs for S. aureus ATCC 2592 (Fig 20a), MRSA (Figure 20b) and MSSA (Figure 
20c), representing good bacteriostatic activity at lower concentration (5-10 ng/ml) and 
bactericidal activity at higher concentration (15ng/ml) of AgNPs. From the growth curve 
of the bacteria at different concentrations of AgNPs the logarithmic phase was identified 
between 8 and 16 hours. 
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Figure 20a. Growth curves o(S. aureus ATCC 25923 at different concentrations of 2 nm 
water soluble AgNPs. 
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Figure 20b. Growth curves of MRSA at different concentrations of 2 nm water soluble 
AgNPs. 
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Figure 20c. Growth curves of MSSA isolates at different concentrations of 2 nm water 
soluble AgNPs. 
Figure 21a, b, c and d represents growth curve of P. aeruginosa ATCC 27853, and 
clinical isolates of ESBL, non ESBL and MBL P. aeruginosa in LB medium inoculated 
with 10^  CFU of bacteria in the presence of different concentrations (0, 5, 10 and 15 
|ig/ml) of 2 nm water soluble AgNPs. In the presence of different concentration of 
AgNPs, the growth curves of P. aeruginosa ATCC 27853, and clinical isolates of ESBL, 
non ESBL and MBL P. aeruginosa included three phases: lag phase, exponential phase, 
and stabilization phase. However, decline phases in each growth curve could not be 
revealed because we only assayed the total numbers of bacteria, including live and dead 
ones, based on the value of OD595. Under absence of AgNPs, P. aeruginosa ATCC 
27853, and clinical isolates of ESBL, non ESBL and MBL P. aeruginosa reached 
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exponential phase rapidly. The growth curves of bacterial cells treated with different 
concentration of AgNPs indicated that it could inhibit the growth and reproduction of 
bacterial cells. Inhibitory action of AgNPs was observed at 5ng/ml initially up to for 4 
hrs against all strains of Z*. aeruginosa. However, NPs with highest concentration (15 
Hg/ml) showed almost no growth for up to 8 -10 hrs for P. aeruginosa ATCC 27853 (Fig 
21a), ESBL (Figure 21b), non- ESBL (Figure 21c), and MBL (Fig 21d), representing 
good bacteriostatic activity at lower concentration (5-10 ng/ml) up to for 10-12 hrs and 
bactericidal activity at higher concentration (15 |ig/ml) of AgNPs up to for 10 hrs. 
•Control 
•5ng/ml 
•lOng/ml 
•15ug/ml 
8 10 12 14 16 18 20 22 
Time (hrs) 
Figure 21a. Growth curves of P. aeruginosa ATCC 27853 in the presence of different 
concentrations of 2 nm water soluble AgNPs. 
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Figure 21b. Growth curves of ESBL isolates of P. aeruginosa at different concentrations 
of 2 nm water soluble AgNPs. 
81 
^fsuCts 
0.7 
0.6 -
- . 0 . 5 
E 
5 0.4 -
Jao.3 H 
o 
O 0.2 
0.1 
V ~f 
0 2 
" 
4 6 
r • • • 
8 
1 
10 12 
Time (hrs) 
14 16 18 20 
1 
22 
•Control 
•5ng/ml 
•lOng/ml 
•ISng/ml 
Figure 21c. Growth curves of non-ESBL isolates of P. aeruginosa at different 
concentrations of 2 nm water soluble AgNPs. 
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Figure 21d. Growth curves of MBL producing P. aeruginosa at different concentrations 
of 2 nm water soluble AgNPs. 
4.3.2. Antimicrobial Activity of AgNPs (5-10 nm) by time-dependent growth inhibition 
assay 
Figure 22a, b and c represents growth curves of E. coli ATCC 25922, ESBL producing 
and non ESBL strain in LB broth inoculated with 10 colony forming unit (CFU/ml) of 
bacteria in the presence of different concentrations (0, 5, 15 and 25 ng/ml) of 5-10 nm 
water soluble AgNPs. In the presence of different concentration of AgNPs, the growth 
curves of E. coli ATCC 25922, ESBL and non ESBL strains included three phases: lag 
phase, exponential phase, and stabilization phase. However, decline phases in each 
growth curve could not be revealed because we only assayed the total numbers of 
bacteria, including live and dead ones, based on the value of OD595. Under absence of 
AgNPs, E. coli ATCC 25922, ESBL and non ESBL strains reached exponential phase 
rapidly. The growth curves of bacterial cells treated with different concentration of 
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AgNPs indicated that it could inhibit the growth and reproduction of bacterial cells. It 
was found that at all these concentrations; the nanoparticles caused a growth delay of all 
tested strains of E. coli. When cells were exposed to different concentration of AgNPs, 
NPs solution of 5 and 15 ^g/ml was enough to inhibit the growth of all tested strains 
within 2 hrs. However, the concentration of 25 ng/ml was found to be strongly inhibitory 
for E. coli ATCC 25922 (Fig 22a), as it took about 10 h to initiate any noticeable growth. 
Similar results were obtained with either resistant (ESBL, Fig 22b) or non-resistant (non-
ESBL, Fig. 22c) strains of E. coli studied. 
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Figure 22a. Growth curves of £. coli ATCC 25922 at different concentrations of 5-10 
nm water soluble AgNPs. 
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Figure 22b. Growth curves of ESBL isolates of £. coli at different concentrations of 5-10 
nm water soluble AgNPs. 
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Figure 22c. Growth curves of non-ESBL isolates of E. coli at different concentrations of 
5-10 nm water soluble AgNPs. 
Figure 23a, b and c represents growth curves of S. aureus ATCC 25923, MRSA and 
MSAA strains in LB broth inoculated with 10"^  colony forming unit (CFU/ml) of bacteria 
at different concentrations (0, 5, 15 and 25 ^g/ml) of 5-10 nm water soluble AgNPs. In 
the presence of different concentration of AgNPs, the growth curves of 5. aureus ATCC 
25923, MRSA and MSAA included three phases: lag phase, exponential phase, and 
stabilization phase. However, decline phases in each growth curve could not be revealed 
because we only assayed the total numbers of bacteria, including live and dead ones, 
based on the value of OD595. Under absence of AgNPs, S. aureus ATCC 25923, MRSA 
and MSAA reached exponential phase rapidly. The growth curves of bacterial cells 
treated with different concentration of AgNPs indicated that it could inhibit the growth 
and reproduction of bacterial cells. From the figure 23, it is clear that, at all above 
concentrations, the nanoparticles caused a growth delay of 5. aureus, MRSA and MSSA. 
When cells were exposed to different concentration of AgNPs, NPs solution of 15|ig/ml 
was enough to inhibit the growth of all tested strains within 2 hrs. However, NPs with 
highest concentration (25 ng/ml) showed almost negligible growth for up to 10 hrs for S. 
aureus ATCC 2592 (Fig 23a). Similar results were obtained with either resistant (MRSA, 
Fig 23b) or non-resistant (MSSA, Fig. 23c) strains. 
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Figure 23a. Growth curves of 5. aureus ATCC 25923 at difTerent concentrations of 5-10 
nm water soluble AgNPs. 
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Figure 23b. Growth curves of MRSA at different concentrations of 5-10 nm water 
soluble AgNPs. 
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Figure 23c. Growth curves of MSSA at different concentrations of 5-10 nm water 
soluble AgNPs. 
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Figure 24a, b, c and d represents growth curve of P. aeruginosa ATCC 27853, and 
clinical isolates of ESBL, non ESBL and MBL P. aeruginosa in LB medium inoculated 
with lO' CFU of bacteria at different concentrations (0, 5, 15 and 25 i^g/ml) of 5-10 nm 
water soluble AgNPs. In the presence of different concentration of AgNPs, the growth 
curves of P. aeruginosa ATCC 27853, and clinical isolates of ESBL, non ESBL and 
MBL P. aeruginosa included three phases: lag phase, exponential phase, and stabilization 
phase. However, decline phases in each growth curve could not be revealed because we 
only assayed the total numbers of bacteria, including live and dead ones, based on the 
value of OD595. Under absence of AgNPs, P. aeruginosa ATCC 27853, and clinical 
isolates of ESBL, non ESBL and MBL P. aeruginosa reached exponential phase rapidly. 
The growth curves of bacterial cells treated with different concentration of AgNPs 
indicated that it could inhibit the growth and reproduction of bacterial cells. Inhibitory 
action of AgNPs was observed at 5 ng/ml initially for up to 4 hrs against all strains of P. 
aeruginosa. However, NPs with highest concentration (25 fig/ml) showed almost no 
growth for up to 8 -10 hrs for P. aeruginosa ATCC 27853 (Fig 24a), ESBL (Fig 24b), 
non- ESBL (Fig 24c), and MBL (Fig 24d), representing good bacteriostatic activity at 
lower concentration (5-15 ng/ml) and bactericidal activity at higher concentration 
(25^g/ml) of AgNPs. Increasing concentration of nanoparticles progressively inhibited 
the growth of resistant and nonresistant of P. aeruginosa (Fig 24b, c and d). 
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Figure 24a, Growth curves of P. aeruginosa ATCC 27853 at different concentrations of 
5-10 nm water soluble AgNPs. 
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Figure 24b. Growth curves of ESBL P. aeruginosa at different concentrations of 5-10 
nm water soluble AgNPs. 
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Figure 24c. Growth curves of non ESBL P. aeruginosa at different concentrations of 5-
10 nm water soluble AgNPs. 
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Figure 24d, Growth curves of MBL P. aeruginosa at different concentrations of 5-10 nm 
water soluble AgNPs. 
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4.3.3. Size dependent antimicrobial activity ofAgNPs (2, 5-10,15, 35-50 and 100 nm) 
by time-dependent growth inhibition assay 
The growth curves of £. coli ATCC 25922 treated with different sizes of (2, 5-10, 15, 35-
50 and 100 nm) AgNPs were shown in Figure 25. In the presence of different 
concentration of different size AgNPs, the growth curves of E. coli ATCC 25922 
included three phases: lag phase, exponential phase, and stabilization phase. However, 
decline phases in each growth curve could not be revealed because we only assayed the 
total numbers of bacteria, including live and dead ones, based on the value of OD595. 
Under absence of AgNPs, E. coli reached exponential phase rapidly. The growth curves 
of bacterial cells treated with different concentration of AgNPs indicated that it could 
inhibit the growth and reproduction of bacterial cells. From figure 25 it is clear that 2 and 
5-10 nm water soluble AgNPs inhibit the bacterial growth at a very low concentration 
i.e., 10 |ag/ml for up to 8 hrs, while 15 nm water soluble AgNPs is effective at 35 i^ g/ml, 
whereas 35-50 nm and 100 nm AgNPs powder inhibit bacterial growth at very high 
concentration i. e., 250 and 500 jig/ml for up to 8 hrs. As seen from the growth inhibition 
rates in Figure 25, small size AgNPs has a stronger inhibitory effect than large size 
AgNPs. For example, the rate of the growth inhibition of E. coli caused by 2 nm and 5-
10 nm AgNPs was 10 |ig/ml that were much lower than the one caused by 35-50 nm and 
100 nm AgNPs that were 250 and 500 \iglm\ respectively. These results indicate that the 
antibacterial activity of nanoparticles is size dependent as well as concentration 
phenomenon i.e., small size of nanoparticles shows better antibacterial activity in 
compared to large size nanoparticles, while as the concentration of nanoparticles 
increased, the antibacterial activity of nanoparticles also increased. These finding clearly 
showed that the antibacterial activity of AgNPs varied with particle sizes in the range of 2 
to 100 nm for E. coli. 
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Figure 25, Growth curves of E. coli ATCC 25922 in the presence of different 
concentrations of 2, 5-10, 15, 35-50 and 100 nm AgNPs. 
Figure 26 represents growth curves of S. aureus ATCC 25923 in LB broth inoculated 
with lO' Colony Forming Unit (CFU/ml) of bacteria at different concentrations of various 
sizes (2, 5-10, 15, 35-50 and 100 nm) of AgNPs. From figure 26 it is clear that 2 and 5-10 
nm water soluble AgNPs inhibit the bacterial growth at a very low concentration i.e., 10 
Hg/ml for up to 12 hrs, while 15nm water soluble AgNPs is effective at 35|ig/ml, whereas 
35-50 and 100 nm AgNPs powder inhibit bacterial growth at very high concentration i. 
e., 250 and 500 ^g/ml for up to 14 hrs. The results suggested that the control experiments 
have a robust growth of bacteria and no considerable antibacterial activity was observed 
for the large size AgNPs at lower concentration whereas smaller particles have a much 
better bacteriostatic activity even at very low concentration. These results indicate that 
the antibacterial activity of nanoparticles is size dependent as well as concentration 
phenomenon i.e., small size of nanoparticles shows better antibacterial activity in 
compared to large size nanoparticles, while increasing concentration of nanoparticles 
progressively inhibited the growth of 5". aureus ATCC 25923. 
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Figure 26. Growth curves of S. aureus ATCC 25923 in the presence of different 
concentrations of 2, 5-10, 15, 35-50 and 100 nm AgNPs. 
Figure 27 represents growth curves of P. aeruginosa ATCC 27853 in LB broth 
inoculated with 10^  Colony Forming Unit (CFU/ml) of bacteria at different 
concentrations of various sizes (2, 5-10, 15, 35-50 and 100 nm) of AgNPs. In the 
presence of different concentration of different size AgNPs, the growth curves of P. 
aeruginosa included three phases: lag phase, exponential phase, and stabilization phase. 
However, decline phases in each growth curve could not be revealed because we only 
assayed the total numbers of bacteria, including live and dead ones, based on the value of 
OD595. Under absence of AgNPs, P. aeruginosa reached exponential phase rapidly. The 
growth curves of bacterial cells treated with different concentration of AgNPs indicated 
that it could inhibit the growth and reproduction of bacterial cells. From figure 27 it is 
clear that 2 and 5-10 nm water soluble AgNPs inhibit the bacterial growth at a very low 
concentration i.e., 10 ^g/ml for up to 14 hrs, while I5nm water soluble AgNPs is 
effective at 35 ng/ml, whereas 35-50 and 100 nm AgNPs powder inhibit bacterial growth 
at very high concentration i. e., 250 and 500 ng/ml for up to 10 hrs. These results indicate 
that the antibacterial activity of nanoparticles is size dependent as well as concentration 
phenomenon i.e., small size of nanoparticles shows better antibacterial activity in 
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compared to large size nanoparticles, while as the concentration of nanoparticles 
increased, the antibacterial activity of nanoparticles also increased. This is manifested by 
a delay in entry to the logarithmic growth phase, and/or by a deceleration of the 
logarithmic growth. 
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Figure 27, Growth curves of P. aeruginosa ATCC 27853 in the presence of different 
concentrations of 2, 5-10, 15, 35-50 and 100 nm AgNPs. 
4.4. Antibacterial activity of ZnO NPs (70 nm) by time-dependent growth inhibition 
assay 
Figure 28a, b and c represents growth curves of E. coli ATCC 25922, ESBL producing 
and non ESBL strain in LB broth inoculated with lO' Colony Forming Unit (CFU/ml) of 
bacteria at different concentrations (0, 50, 200, 500 and 1000 ng/ml) of 70 nm ZnO NPs. 
It was found that at all these concentrations; the nanoparticles caused a growth delay of 
all tested strains of E. coli. The bacterial growth of the cells treated with 50 ^g/ml ZnO 
NPs was slightly lower than that of cells in the control group. When cells were exposed 
to different concentration of NPs, NPs solution of 200 and 500 fig/ml was enough to 
inhibit the growth of all tested strains for up to 2 and 4 hrs respectively. However, the 
bacterial growths of cells treated with 1000 fig/ml showed almost negligible growth for 
up to 10 hrs for E. coli ATCC 25922 (Fig 28a), ESBL producing isolates of £. coli (Fig 
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28b) and non ESBL isolates (Fig 28c). These findings indicate that the antibacterial 
activity of 50 ng/ml of ZnO NPs could slightly inhibit bacterial growth but not enough to 
outpace the speed of reproduction of the bacterial cells. 
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Figure 28a. Growth curves of £. coli ATCC 25922 at different concentrations of 70 nm 
ZnO NPs. 
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Figure 28b. Growth curves of ESBL producing isolates of E. coli at different 
concentrations of 70 nm ZnO NPs. 
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Figure 28c. Growth curves of non -ESBL isolates of £•. coli at different concentrations of 
70 ZnO nm NPs. 
Figure 29a, b and c represents growth curves of S. aureus ATCC 25923, MRSA and 
MSAA strains in LB broth inoculated with 10^  Colony Forming Unit (CFU/ml) of 
bacteria in the presence of different concentrations (0, 50, 200, 500 and 1000 ng/ml) of 
70 nm ZnO NPs. Figure 29 shows that at all above concentrations, the nanoparticles 
caused a growth delay of S. aureus, MRSA and MSSA. When cells were exposed to 
different concentration of AgNPs, NPs solution of 200 and 500 |ig/ml was enough to 
inhibit the growth of all tested strains within 2 hrs. However, the concentration of 1000 
|ag/ml was found to be strongly inhibitory for bacteria, as it took about 8 h to initiate any 
noticeable growth. Similar results were obtained with resistant or non-resistant strains 
i.e., MRSA (Fig 29b) and MSSA (Fig 29c) studied. 
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Figure 29a. Growth curves of 5. aureus ATCC 25923 in the presence of different 
concentrations of 70 nm ZnO NPs. 
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Figure 29b. Growth curves of MRSA in the presence of different concentrations of 70 
nm ZnO NPs. 
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Figure 29c. Growth curves of MSSA in the presence of different concentrations of 70 nm 
ZnO NPs. 
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Figure 30a, b, c and d represents growth curve of P. aeruginosa ATCC 27853, and 
clinical isolates of ESBL, non ESBL and MBL P. aeruginosa in LB medium inoculated 
with 10^  CFU of bacteria at different concentrations (0, 50, 200, 500 and 1000 ^ig/ml) of 
70 nm ZnO NPs. Inhibitory action of ZnO NPs was observed at 200 ng/ml initially for up 
to 4 hrs against all strains of P. aeruginosa. However, NPs with highest concentration 
(1000 i^ g/ml) showed almost no growth for up to 8-10 hrs for P. aeruginosa ATCC 
27853 (Fig 30a), ESBL (Fig 30b), non- ESBL (Fig 30c), and MBL (Fig 30d) for up to 8 
hrs. 
These findings indicate that the antibacterial activity of 50 pig/ml of ZnO NPs could 
slightly inhibit bacterial growth but not enough to outpace the speed of reproduction of 
the bacterial cells, while 1000 ng/ml of ZnO showed almost all bacterial cells were killed 
representing good bactericidal activity at this concentration of ZnO NPs. 
I 
8 
0.7 
0.6 
0.5 
0.4 
0.3 
0.2 
0.1 
O 
6 8 10 
Time (hrs) 
12 
^ * 
14 16 
- • — O M I / M 
-m— 50 M9/rr< 
- A — 2 0 0 pg/rrl 
-*<— SOOpg/rrt 
HK—1000 MB/rrtj 
Figure 30a. Growth curves of F. aeruginosa ATCC 27853 in the presence of different 
concentrations of 70 nm ZnO NPs. 
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Figure 30b. Growth curves of ESBL producing isolates of P. aeruginosa in the presence 
of different concentrations of 70 nm ZnO NPs. 
( 
o.e -
o.s -
_ O.A. -
I 0.3 
^ 0 .2 
0 .1 
0 0 2 4 
yt xe" 
8 S 1 0 
T i m * <Hrs> 
1 2 1 A i e 
— « SO MO/nr« 
— X — 5 0 0 MO/nr1 
Figure 30c. Growth curves of non ESBL P. aeruginosa in the presence of different 
concentrations of 70 nm ZnO NPs. 
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Figure 30d. Growth curves of MBL producing P. aeruginosa in the presence of different 
concentrations of 70 nm ZnO NPs. 
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4.5. Antibacterial activity of AI2O3 NPs by time-dependent growth inhibition assay 
Figure 31a, b and c represents growth curves of £. coli ATCC 25922, ESBL producing 
and non ESBL strain in LB broth inoculated with 10^  Colony Forming Unit (CFU/ml) of 
bacteria in the presence of different concentrations (0, 250, 500, 1000 and 2000 ^ig/ml) of 
<50 nm AI2O3 NPs, It was found that at all these concentrations; the nanoparticles caused 
a growth delay of all tested strains of E. coli. The bacterial growth of the cells treated 
with 250 fig/ml AI2O3 NPs was also slightly lower than that of cells in the control group. 
When cells were exposed to different concentration of NPs, NPs solution of 500 ^g/mI 
was enough to inhibit the growth of all tested strains within 2 hrs. However, NPs with 
highest concentration (1000 and 2000 |xg/ml) showed almost negligible growth for up to 
6 hrs for E. coli ATCC 25922 (Fig 31a) and ESBL producing isolates of £. coli (Fig 31b) 
and for up to 8 hrs for non ESBL isolates (Fig 31c), representing good bactericidal 
activity of NPs. It is very clear that increasing concentration of nanoparticles 
progressively inhibited the growth of standard, resistant and nonresistant E. coli (Fig 31a, 
b&c). 
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Figure 31a. Growth curves of £. coli ATCC 25922 at different concentrations of <50 nm 
AI2O3 NPs. 
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Figure 31b. Growth curves of ESBL producing isolates of £. coli at different 
concentrations of <50 nm Ai203 NPs. 
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Figure 31c. Growth curves of non- ESBL E. coli at different concentrations of <50nm 
AI2O3 NPs. 
The growth curves of bacterial cells treated with AI2O3 NPs indicated that it could inhibit 
the growth and reproduction of bacterial cells. Figure 32a, b and c represents growth 
curves of 5. aureus ATCC 25923, MRSA and MSAA strains in LB broth inoculated with 
10^  Colony Forming Unit (CFU/ml) of bacteria in the presence of different 
concentrations (0, 250, 500, 1000 and 2000 ^g/ml) of <50 nm water AI2O3 NPs. The 
figure clearly shows that, at all above concentrations, the nanoparticles caused a growth 
98 
<Resu£ts 
delay of 5*. aureus, MRSA and MSSA. The bacterial growth of the cells treated with 250 
|j.g/ml AI2O3 NPs was also slightly lower than that of cells in the control group. When 
cells were exposed to different concentration of AI2O3 NPs, NPs solution of 500 jig/ml 
was enough to inhibit the growth of all tested strains within 2 hrs. However, NPs with 
highest concentration (1000 and 2000 ng/ml) showed almost negligible growth for up to 
6 hrs for S. aureus ATCC 2592 (Fig 32a), MRSA (Fig 32b) and MSSA (Fig 32c), 
representing good bacteriostatic activity at lower concentration and bactericidal activity 
at higher concentration (2000 ng/ml) of AI2O3 NPs. 
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Figure 32a. Growth curves of 5. aureus ATCC 25923 at different concentrations of <50 
nm AI2O3 NPs. 
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Figure 32b. Growth curves of MRSA in the presence of different concentrations of <50 
nm AI2O3 NPs 
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Figure 32c. Growth curves of MSSA in the presence of different concentrations of <50 
nm AI2O3 NPs. 
Figure 33a, b, c and d represents growth curve of P. aeruginosa ATCC 27853, and 
clinical isolates of ESBL, non ESBL and MBL P. aeruginosa in LB medium inoculated 
with 10^  CFU of bacteria at different concentrations (0, 250, 500, 1000 and 2000 ng/ml) 
of <50 nm AI2O3NPS. The bacterial growth of the cells treated with 250 ^g/ml AI2O3 NPs 
was also slightly lower than that of cells in the control group. Inhibitory action of A1203 
NPs was observed at 500 ^g/ml for up to 4 hrs against all strains of P. aeruginosa. 
However, NPs with higher concentration (2000^g/ml) showed almost no growth for up to 
6 hrs for P aeruginosa ATCC 27853 (Fig 33a), ESBL (Fig 33b), non- ESBL (Fig 33c), 
and MBL (Fig 33d), representing good bactericidal activity at higher concentration (2000 
Hg/ml) of AI2O3 NPs. 
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Figure 33a. Growth curves o? P. aeruginosa ATCC 27853 in the presence of different 
concentrations of <50 nm AI2O3 NPs. 
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Figure 33b. Growth curves of ESBL producing isolates of P. aeruginosa in the 
presence of different concentrations of <50 nm AI2O3 NPs. 
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Figure 33c. Growth curves of non ESBL P. aeruginosa in the presence of different 
concentrations of <50 nm AI2O3 NPs. 
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Figure 33d. Growth curves of MBL producing P. aeruginosa in the presence of 
different concentrations of <50 nm AI2O3 NPs. 
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4.6. Evaluation of antibacterial activity by determining MIC and MBC of different 
nanoparticles 
4.6.1. Evaluation of antibacterial activity of AgNPs 
The antibacterial effects of water soluble AgNPs (2nm) were tested against clinical 
isolates of E. coli (ESBL and non-ESBL), S. aureus (MRSA and MSSA), CONS (MR 
and MS), P. aeruginosa (ESBL, non-ESBL and MBL) and Klebsiella spp (ESBL and 
Non-ESBL) by two fold broth dilution method. Silver nanoparticles affected bacterial 
cellular viability in a dose-dependent manner. The MIC values against the ESBL positive, 
non- ESBL, MBL, methicillin resistant and methicillin susceptible bacterial isolates 
ranged 3.13 to 12.5 |ig/ml, whereas MBC values were found to be in the ranged of 6.25 
to 25 ^g/ml (Table 3). 
Table 3 shows the MIC and MBC for ESBL and rton-ESBL E. coli, 31.25% ESBL 
positive isolates shows MIC of 3.13 |ig/ml and 62.5% shows 6.25 |ig/ml, whereas 
68.75% isolates had MBC of 12.5 ^g/ml. While 37.50% non-ESBL E. coli shows MIC of 
3.13 ng/ml and 62.5% shows MIC of 6.25 ^g/ml, whereas 75%. isolates had MBC of 12.5 
|ag/ml. The lowest MIC for both ESBL and non-ESBL E. coli were found to be 3.13 
fig/ml i.e., very low indicating very good bacteriostatic, while the lowest MBC was found 
to be 6.25 ng/ml indicating very good bactericidal activity of 2 nm AgNPs. 
Table 3. MIC and MBC c values of AgNPs water soluble (2 nm) tested against E. 
coli (n=40) isolates 
ESBL positive £. co//32 (80%) 
isolates 
31.25% 
62.5% 
6.25% 
MIC 
3.13 
6.25 
12.50 
isolates 
25.00% 
68.75% 
12.50% 
MBC 
6.25 
12.50 
25.00 
Non- ESBL E. coli 8 (20%) 
isolate 
37.50% 
62.50% 
— 
MIC 
3.13 
6.25 
- , -
isolate 
25.00% 
75.00% 
— 
MBC 
6.25 
12.5 
— 
Table 4 shows the MIC and MBC of MRSA and MSSA. Both MRSA and MSSA were 
inhibited at concentration of 3.13 |jg/ml. 24% MRSA shows MIC of 3.13 i^g/ml and 64% 
shows 6.25 Hg/ml, whereas 20% isolates shows MBC of 6.25 i^g/ml and 11% had MBC 
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of 12.5 ^g/ml. While in case of MSAA, 29.63% shows MIC of 3.13 ^g/inl and 51.85% 
had MIC of 6.25 ^g/ml, whereas 14.80% had MBC of 6.25 ^g/ml and 75% had 12.5 
|ig/ml. The lowest MIC for both MRSA and MSSA were found to be 3.13 ^g/ml whereas 
lowest MBC were 6.25 ^g/ml. While the highest MIC and MBC observed were 12.5 
fig/ml and 25 |Jg/ml respectively, for MRSA and MSAA. The result clearly shows that 
AgNPs exhibit excellent bacteriostatic and bactericidal effect regardless of their drug-
resistant mechanisms. 
Table 4, MIC and MBC (|ig/ml) values of AgNPs water soluble (2 nm) tested against S. 
aureus (n==52) isolates 
isolates 
24% 
64% 
12% 
MRSA 25 (48.1%) 
MIC 
3.13 
6.25 
12.5 
isolates 
20% 
72% 
8% 
MBC 
6.25 
12.50 
25.00 
isolates 
29.63% 
51.85% 
18.52% 
MSSA 27 (51.9%) 
MIC 
3.13 
6.25 
12.50 
isolates 
14.80% 
74.10% 
11.10% 
MBC 
6.25 
12.5 
25.00 
Table 5 shows the MIC and MBC of MR and MS CONS. Both MR and MS CONS \\ere 
inhibited at concentration of 3.13 ^g/ml. 33.33% MR CONS shows MIC of 3.13 |ig/ml 
and 66.67% shows 6.25 ^g/ml, whereas 16.67%) isolates shows MBC of 6.25 pg/ml and 
83.33% had MBC of 12.5 ng/ml. While in case of MS CONS, 25% shows MIC of 3.13 
^g/ml and 75% had MIC of 6.25 i^g/ml, whereas all MS CONS (100%) had MBC of 12.5 
Hg/ml. The lowest MIC for both MR and MS CONS were found to be 3.13 ^g/ml, 
whereas lowest MBC were 6.25 ^g/ml. While the highest MIC and MBC observed were 
6.25 \igln\\ and 12.5 \iqjm\ respectively, for MR and MS CONS. The result clearly 
shows that AgNPs exhibit excellent bacteriostatic and bactericidal effect regardless of 
their drug-resistant mechanisms. 
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Table 5. MIC and MBC ( i^g/ml) values of AgNPs water soluble (2 nm) tested against 
CONS (n= 10) 
MRSE 6(60%) 
isolates 
33.33% 
66.67% 
MIC 
3.13 
6.25 
isolates 
16.67% 
83.33% 
MBC 
6.25 
12.5 
MSSE 4(40%) 
isolates 
25% 
75% 
MIC 
3.13 
6.25 
isolates 
100% 
— 
MBC 
12.5 
— 
Table 6a shows the MIC and MBC values of ESBL positive and ESBL negative isolates 
of P. aeruginosa and table 6b shows the MIC and MBC of MBL producing P. 
aeruginosa. The MIC and MBC values for all isolates were ranged from 3.13 \ig/m\ to 
12.5 fig/ml and 6.25 ng/ml to 25 |ig/ml respectively. 28.57% ESBL positive isolates 
shows MIC of 3.13 ng/ml and 61.9%) shows 6.25 ng/ml, whereas 85.72% isolates had 
MBC of 12.5 ^g/ml. While 33.33% non-ESBL isolates shows MIC of 3.13 ng/ml and 
55.56% shows MIC of 6.25 |ig/ml, whereas 66.67% isolates had MBC of 12.5 ng/ml. 
The lowest MIC and MBC for ESBL, non-ESBL and MBL P. aeruginosa were found to 
be 3.13 ng/ml and 6.25 |ig/ml respectively i.e., very low indicating very good 
bacteriostatic, while the highest MIC and MBC was found to be 12.5 and 25 i^g/ml 
respectively, indicating very good bactericidal activity of 2 nm AgNPs. 
Table 6a. MIC and MBC (|ag/ml) values of AgNPs water soluble (2 nm) tested against 
P. aeruginosa (n=55) isolates 
ESBL positive P. aeruginosa 42 
(76.34%) 
isolates 
28.57% 
61.91% 
9.52% 
MIC 
3.13 
6.25 
12.5 
isolates 
9.52% 
85.72% 
4.76% 
MBC 
6.25 
12.5 
25.0 
Non- ESBL P. aeruginosa 9 
(16.36%) 
isolates 
33.33% 
55.56% 
11.11% 
MIC 
3.13 
6.25 
12.5 
isolates 
22.22% 
66.67% 
11.11% 
MBC 
6.25 
12.5 
25.00 
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Table 6b. MIC and MBC (pg/ml) values of AgNPs water soluble (2 nm) tested against 
MBL producing P. aeruginosa 
MBL producing P. aeruginosa 4 (7,3%) 
isolates 
25% 
75% 
MIC 
3.13 
6.25 
isolates 
100% 
MBC 
12.5 
Table 7 shows the MIC and MBC value of 2 nm water soluble AgNPs tested against 
ESBL and non-ESBL Klebsiella spp. 50% ESBL positive and 50% non ESBL isolates 
shows MIC of 3.13 ng/ml, while another 50%o ESBL and non-ESBL shows MIC of 6.25 
^g/ml. whereas all (100%) isolates of ESBL and 75% non ESBL had MBC of 12.5 
Hg/ml, while 25 % non-ESBL had MBC of 6.25 ng/ml. 
Table 7. MIC and MBC (fig/ml) values of AgNPs water soluble (2 nm) tested against 
Klebsiella spp (n=6) 
ESBL positive Klebsiella spp4 (66.67%) 
isolates 
50% 
50% 
MIC 
3.13 
6.25 
isolates 
100% 
MBC 
12.50 
Non- ESBL Klebsiella spp 2 (33.33%) 
isolates 
50% 
50% 
MIC 
3.13 
6.25 
isolates 
25% 
75% 
MBC 
6.25 
12.5 
Table 8 shows the MIC and MBC of 5-lOnm AgNPs dispersion tested against ESBL and 
non-ESBL E. coli isolates. 62.5% ESBL positive and 62.5%. non ESBL shows MK of 
11.25 i^g/ml, while 81.25% ESBL and 75% non ESBL had MBC of 45 ^g/ml. 
Table 8. MIC and MBC ( l^g/ml) values of AgNPs dispersion (5-10 nm) tested against E. 
coli (n=40) isolates 
ESBL positive E. coli 32 (80%) 
isolates 
12.5% 
62.5% 
25% 
MIC 
11.25 
22.50 
45.00 
isolates 
81.25% 
12.5% 
6.25% 
MBC 
45.00 
22.50 
11.25 
Non- ESBL E. coli 8 (20%) 
isolates 
25% 
62.5% 
12.5% 
MIC 
11.25 
22.50 
45.00 
isolates 
25% 
75% 
— 
MBC 
22.50 
45.00 
— 
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Table 9 shows the MIC and MBC of 5-10 nm AgNPs dispersion tested against MRS A 
and MSSA. Both MRSA and MSSA were inhibited at concentration of 11.25 ^g/ml. 48% 
MRSA shows MIC of 11.25 \ig/m\ and 32% shows 22.5 i^g/ml, while 72% isolates shows 
MBC of 22.5 ^g/ml and 28% had MBC of 45 ng/ml. Whereas in case of MSAA, 51.85% 
shows MIC of 11.25 ng/ml and 33.33% had MIC of 22.5 ^ig/ml, while 77.78% had MBC 
of 22.5 ng/ml and 22.2% had 45 ^g/ml. The lowest MIC for both MRSA and MSSA 
were found to be 11.25 \ig/ml while the lowest MBC were 22.5 pg/ml. The result clearly 
shows that AgNPs exhibit excellent bacteriostatic and bactericidal effect regardless of 
their drug-resistant mechanisms. 
Table 9. MIC and MBC (fig/ml) values of AgNPs dispersion (5-10 nm) tested against 5". 
aureus (n=52) isolates 
MRSA 25 (48.1%) 
isolates 
48% 
32% 
20% 
MIC 
11.25 
22.50 
45.00 
isolates 
72% 
28% 
— 
MBC 
22.50 
45.00 
— 
MSSA 27 (51.9%) 
isolates 
51.85% 
33.33% 
14.81% 
MIC 
11.25 
22.50 
45.00 
isolates 
77.78% 
22.22% 
— 
MBC 
22.50 
45.00 
— 
Table 10 shows the MIC and MBC of 5-10 nm AgNPs dispersion tested against MR and 
MS CONS. The lowest MIC and MBC for MR CONS were found to be 11.25 and 22.5 
|ig/ml respectively. While the lowest MIC and MBC for MS CONS were found to be 
22.5 and 45ng/ml respectively. 66.66 % MR CONS shows MIC of 22.5 ^g/ml while 
83.33% isolates shows MBC of 45 ng/ml. whereas in case of MS CONS 75% shows MIC 
of 22.5 ng/ml, while all MS CONS (100%) had MBC of 45 ^ig/rnl. 
Table 10. MIC and MBC (ng/ml) values of AgNPs dispersion (5-10 nm) tested against 
CONS (n= 10) 
MRSE 6(60%) 
isolates 
16.66% 
66.66% 
16.66% 
MIC 
11.25 
22.50 
45.00 
isolates 
16.67% 
83.33% 
— 
MBC 
22.50 
45.00 
— 
MSSE 4(40%) 
isolates 
75% 
25% 
— 
MIC 
22.50 
45.00 
— 
isolates 
100% 
— 
— 
MBC 
45.00 
— 
— 
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Table 11a shows the MIC and MBC values of 5-10 nm AgNPs dispersion tested against 
ESBL positive and ESBL negative isolates of P. aeruginosa and table l ib shows the 
MIC and MBC of MBL producing P. aeruginosa. 23.81% ESBL positive isolates shows 
MIC of 11.25 ng/ml and 71.42% shows 22.5 ng/ml, whiles 76.89 % isolates had MBC of 
45 ng/ml. whereas 33.33% non-ESBL isolates shows MIC of 11.25 l^g/ml and 44.44% 
shows MIC of 22.5 i^g/ml, while 77.78% isolates had MBC of 45 ^lg/ml. The lowest MIC 
for ESBL, non-ESBL and MBL P. aeruginosa were found to be 11.25 ng/ml i.e., very 
low indicating very good bacteriostatic, while the highest MBC was found to be 45 
\iq/m\, indicating very good bactericidal activity of 5-10 nm AgNPs. 
Table 11a. MIC and MBC (ng/ml) values of AgNPs dispersion (5-10 nm) tested against 
P. aeruginosa (n=55) isolates 
ESBL positive P. aeruginosa 42 
(76.34%) 
isolates 
23.81% 
71.42% 
4.76% 
MIC 
11.25 
22.50 
45.0 
isolates 
9.52% 
14.28% 
76.19% 
MBC 
11.25 
22.50 
45 
Non- ESBL P. aeruginosa 9 (16.36%) 
isolates 
33.33% 
44.44% 
22.22% 
MIC 
11.25 
22.50 
45 
isolates 
22.22% 
77.78% 
— 
MBC 
22.50 
45.00 
— 
Table l ib. MIC and MBC ( i^g/ml) values of AgNPs dispersion (5-10 nm) tested against 
MBL producing P. aeruginosa 
MBL producing P. aeruginosa 4 (7.3%) 
isolates 
25% 
75% 
MIC 
11.25 
22.50 
isolates 
25% 
75% 
MBC 
22.50 
45 
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Table 12 shows the MIC and MBC 5-10 nm AgNPs dispersion tested against ESBL and 
non-ESBL Klebsiella spp. 75% ESBL positive and 50% non ESBL isolates shows MIC 
of 22.5 ^g/ml, while another 25% ESBL and 50 % non-ESBL shows MIC of 11.25 
fig/ml. whereas 75% isolates of ESBL and non ESBL had MBC of MBC of 45 ^g/ml. 
The lowest MIC and MBC for both ESBL and non-ESBL isolates were found to be 11.25 
and 22.5 |J.g/ml respectively. 
Table 12. MIC and MBC (ng/ml) values of AgNPs dispersion (5-10 nm) tested against 
Klebsiella spp (n=6) 
ESBL positive Klebsiella spp4 (66.67%) 
isolates 
25% 
75% 
MIC 
11.25 
22.50 
isolates 
25% 
75% 
MIC 
22.50 
45.00 
Non- ESBL Klebsiella spp 2 (33.33%) 
isolates 
50% 
50% 
MIC 
11.25 
22.50 
isolates 
25% 
75% 
MBC 
22.50 
45.00 
Table 13 shows the MIC and MBC of 5-10 nm AgNPs dispersion tested against ESBL 
and non-ESBL E. coli tested against 15 nm water soluble AgNPs. The MIC and MBC for 
both ESBL and non ESBL isolates were ranged from 16 -64 and 32-128 |ig/ml 
respectively. 25% ESBL positive isolates shows MIC of 16 ng/ml and 62.5% shows 
32^g/ml, while 68.74% isolates had MBC of 64 jig/ml and 21.86% shows MBC of 128 
|ig/ml. Whereas in case of non ESBL, 50%) shows MIC of 32 i^g/ml and 15% shows 16 
^g/ml, while 37.5% isolates had MBC of 64 and 50% had 128 ^g/ml. The lowest MIC 
for both ESBL and non-ESBL E. coli were found to be 16 ng/ml i.e., very low indicating 
very good bacteriostatic, while the lowest MBC was found to be 32 ng/ml indicating very 
good bactericidal activity of 15 nm AgNPs. 
Table 13. MIC and MBC (|ig/ml) values of AgNPs water soluble (15 nm) tested against 
E. coli (n=40) isolates 
ESBL positive E. coli 32 (80%) 
isolates 
25% 
62.5% 
12.5% 
MIC 
16 
32 
64 
isolates 
9.40% 
68.74% 
21.86% 
MBC 
32 
64 
128 
Non- ESBL E. coli 8 (20%) 
isolates 
25% 
50% 
25% 
MIC 
16 
32 
64 
isolates 
12.5% 
37.5% 
50% 
MBC 
32 
64 
128 
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Table 14 shows the MIC and MBC values of 15 nm water soluble AgNPs tested against 
MRSA and MSSA. Both MRSA and MSSA were inhibited at concentration of 16 ng/ml. 
24% MRSA shows MIC of 16, 40% shows 32 and 36% shows 64 ng/ml, while 12% 
isolates shows MBC of 32, 44% shows 64 had 48% shows MBC of 128 ^g/ml. Whereas 
in case of MSAA, 7.4% shows MIC of 16, 59.3% shows 32 and 33.33% shows MIC of 
64\ig/m\, while 3.2% had MBC of 32,44.33 had 64 and 51.85% had MBC of 128 ^g/ml. 
The result clearly shows that AgNPs exhibit excellent bacteriostatic and bactericidal 
effect regardless of their drug-resistant mechanisms. 
Table 14. MIC and MBC (ng/ml) values of AgNPs water soluble (15 nm) tested against 
S. aureus (n=52) isolates 
MRSA 25 (48.1%) 
isolates 
24% 
40% 
36% 
MIC 
16 
32 
64 
isolates 
12% 
44% 
48% 
MBC 
32 
64 
128 
MSSA 27 (51.9%) 
isolates 
7.4% 
59.3% 
33.3% 
MIC 
16 
32 
64 
isolates 
3.72% 
44.33% 
51.85% 
MBC 
32 
64 
128 
Table 15 shows the MIC and MBC of 15 nm water soluble AgNPs tested against MR and 
MS CONS. The lowest MIC and MBC for MR and MS CONS were found to be 16 and 
64^g/ml respectively. 16.67 % MR CONS shows MIC of 16, 33.33% shows 32 and 50% 
shows 64 ^g/ml, while 16.67% isolates shows MBC of 64 and 83.33% shows 128^g/ml 
respectively, whereas in case of MS CONS 50% shows MIC of 32 |ig/ml, while, 75% 
hadanMBCof 128ng/ml. 
Table 15. MIC and MBC (^g/ml) values of AgNPs water soluble (15 nm) tested against 
CONS (n= 10) 
isolates 
16.67% 
33.33% 
50% 
MRSE 6(60%) 
MIC 
16 
32 
64 
isolates 
16.67% 
83.33% 
— 
MBC 
64 
128 
— 
isolates 
25% 
50% 
25 
MSSE 4(40%) 
MIC 
16 
32 
64 
isolates 
25% 
75% 
MBC 
64 
128 
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Table 16a shows the MIC and MBC values of 15 nm water soluble AgNPs tested against 
ESBL positive and ESBL negative isolates of P. aeruginosa and table 16b shows the 
MIC and MBC of MBL producing P. aeruginosa. The lowest MIC and MBC for ESBL, 
non ESBL and MBL were found to be 16 and 32 fig/rnl respectively, whereas the highest 
MIC and MBC values observed were 64 and 128 ng/ml respectively. 
Table 16a. MIC and MBC (^g/ml) values of AgNPs dispersion (15 nm) tested against P. 
aeruginosa (n=55) isolates 
ESBL positive P. aeruginosa 
42 (76.34%) 
isolates 
14.28% 
28.57% 
57.14% 
MIC 
16 
32 
64 
isolates 
7.14% 
33.33% 
59.52% 
MBC 
32 
64 
128 
Non- ESBL P. aeruginosa 
9 (16.36%) 
isolates 
22.22% 
22.22% 
55.56% 
MIC 
16 
32 
64 
isolates 
44.44% 
55.56% 
— 
MBC 
64 
128 
— 
Table 16b. MIC and MBC (ng/ml) values of AgNPs dispersion (15 nm) tested against 
MBL producing P. aeruginosa 
MBL producing P. aeruginosa 4 (7.3%) 
isolates 
25% 
50% 
25% 
MIC 
16 
32 
64 
isolates 
25% 
75% 
MBC 
64 
128 
Table 17 shows the MIC and MBC of 15 nm water soluble AgNPs tested against ESBL 
and non- ESBL isolates of Klebsiella spp. For both ESBL and non ESBL isolates the 
lowest MIC and MBC was found to be 32 and 64 ng/ml. 25% ESBL and 75% non ESBL 
isolates shows MIC of 32 and 64 ng/ml, while in case of non-ESBL 50%) shows 32 and 
remaining 50% shows 64 ng/ml. whereas 100% isolates of ESBL and 15% of non ESBL 
shows MBC I28^g/ml. 
10 
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Table 17. MIC and MBC (^g/ml) values of AgNPs dispersion (15 nm) tested against 
Klebsiella spp (n=6) 
ESBL positive Klebsiella spp4 (66.67%) 
isolates 
25% 
75% 
MIC 
32 
64 
isolates 
100% 
MBC 
128 
Non- ESBL Klebsiella spp 2 (33.33%) 
isolates 
50% 
50% 
MIC 
32 
64 
isolates 
25% 
75% 
MBC 
64 
128 
Table 18 shows the MIC and MBC for ESBL artd non-ESBL E. coli tested against 35-50 
nm AgNPs powder. The lowest MIC for both ESBL and non-ESBL E. coli were found to 
be 400 ng/ml, while highest MIC were found to be 1600 ^ig/ml. The MIC for ESBL 
isolates were ranged from 400 -1600 ng/ml, while MBC from 1600-3200 ng/ml, 
respectively. 9.38% ESBL isolates shows MIC of 400, 62.5% shows 800 and 28.12% 
showsl600 ^g/ml, while 62.5% isolates had MBC of 1600 pg/ml and 37.5 % shows 
MBC of 3200 ng/ml. Whereas in case of non ESBL, 12.50% shows MIC of 400, 37.5% 
shows 800 and 50% shows 1600 ^g/ml, while 25% isolates had MBC of 800 and 75% 
had MBC of 3200 ^g/ml. 
Table 18. MIC and MBC (^g/ml) values of AgNPs (35-50 nm) tested against E. coli 
(n=40) isolates 
ESBL positive E. coli 32 (80%) 
isolates 
9.38% 
62.50% 
28.12% 
MIC 
400 
800 
1600 
isolates 
62.50% 
37.50% 
— 
MBC 
1600 
3200 
— 
Non- ESBL E. coli 8 (20%) 
isolates 
12.5% 
37.50% 
50% 
MIC 
400 
800 
1600 
isolates 
25% 
75% 
— 
MBC 
800 
3200 
— 
Table 19 shows the MIC and MBC values of 35-50 nm AgNPs powder tested against 
MRSA and MSSA. The MIC values for both MRSA and MSSA were ranged from 400 -
1600 ng/ml, while MBC ranged from 800-3200 fig/ml. 16% MRSA shows MIC of 400, 
32% shows 800 and 52% shows 1600 ng/ml, while 8% isolates shows MBC of 800, 20% 
shows 1600 and 72% shows MBC of 3200 |ig/ml. Whereas in case of MSAA, 18.52% 
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shows MIC of 400, 33.33% shows 800 and 48.15% shows MIC of 1600 ^g/ml, while 
11.11% had MBC of 800,25.93% had 1600 and 62.96% had MBC of 3200 ng/ml. 
Table 19. MIC and MBC (ng/ml) values of AgNPs (35-50 nm) tested against 5'. aureus 
(n=52) isolates 
MRSA 25(48.1%) 
isolates 
16% 
32% 
52% 
MIC 
400 
800 
1600 
isolates 
8% 
20% 
72% 
MBC 
800 
1600 
3200 
MSSA 27 (51.9%) 
isolates 
18.52% 
33.33% 
48.15% 
MIC 
400 
800 
1600 
isolates 
11.11% 
25.93% 
62.96% 
MBC 
800 
1600 
3200 
Table 20 shows the MIC and MBC of 35-50 nm AgNPs powder tested against MR and 
MS CONS. The lowest MIC for both MR and MS CONS were found to be 800 ng/ml, 
while lowest MBC were 1600 ^g/ml, respectively. 33.33% MR CONS shows MIC of 
800 and 66.67% shows 1600 ng/ml, while 16.67% isolates shows MBC of 1600 and 
83.33% shows 3200 ng/ml respectively, whereas in case of MS CONS 25% shows MIC 
of 800 and 50% shows 1600 \xg/m\, respectively, while all MS CONS shows MBC of 
3200 |ig/ml. 
Table 20. MIC and MBC ([ig/rnl) values of AgNPs (35-50 nm) tested against 
CONS {n=]0) 
MRSE 6(60%) 
isolates 
33.33% 
66.67% 
MIC 
800 
1600 
isolates 
16.67% 
83.33% 
MBC 
1600 
3200 
MSSE 4 (40%) 
isolates 
25% 
75% 
MIC 
800 
1600 
isolates 
100% 
— 
MBC 
3200 
— 
Table 21a shows the MIC and MBC values of 35-50 nm AgNPs powder tested against 
ESBL positive and ESBL negative isolates of P. aeruginosa and table 21b shows the 
MIC and MBC of MBL producing P. aeruginosa. The lowest MIC and MBC for ESBL, 
non ESBL and MBL were found to be 400 and 800 (ig/ml respectively, whereas the 
highest MIC and MBC values observed were 1600 and 3200 ^g/ml, respectively. 
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Table 21a. MIC and MBC (fig/ml) values of AgNPs (35-50 nm) tested against P. 
aeruginosa (n=55) isolates 
ESBL positive P. aeruginosa 
42 (76.34%) 
isolates 
14.28% 
33.33% 
52.38% 
MIC 
400 
800 
1600 
isolates 
7.14% 
23.81% 
69.04% 
MBC 
800 
1600 
3200 
Non- ESBL P. aeruginosa 1 
9 (16.36%) ; 
i 
isolates 
22.22% 
33.33% 
44.44% 
MIC 
400 
800 
1600 
isolates 
11.11% 
22.22% 
66.67% 
MBC 
800 1 
1600 
3200 1 
i 
Table 21b. MIC and MBC ( i^g/ml) values of AgNPs (35-50 nm) tested against MBL P. 
aeruginosa 
MBL positive P. aeruginosa 4(7.3%) 
isolates 
500% 
50% 
MIC 
800 
1600 
isolates 
25% 
75% 
MBC 
1600 
3200 
Table 22 shows the MIC and MBC of 35-50 nm AgNPs powder tested against ESBL and 
non- ESBL isolates of Klebsiella spp. The lowest MIC for ESBL and non ESBL isolates 
was found to be 400 and 800 ng/ml, respectively, while Maximum MBC observed were 
3200 ng/ml for both ESBL and non ESBL isolates. 
Table 22. MIC and MBC (ng/ml) values of AgNPs (35-50 nm) tested against Klebsiella 
spp (n=6) 
ESBL positive Klebsiella spp 4 
(66.67%) 
isolates 
25% 
25% 
50% 
MIC 
400 
800 
1600 
isolates 
25% 
75% 
MBC 
1600 
3200 
Non- ESBL Klebsiella spp 2 (33.33%) 
isolates 
50% 
50% 
— 
MIC 
800 
1600 
isolates 
50% 
50% 
MBC 
1600 
3200 
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Table 23 shows the MIC and MBC for ESBL and non-ESBL E. coli tested against 100 
nm AgNPs powder. The lowest MIC and MBC for both ESBL and non-ESBL E. colt 
were found to be 1300 and 2600 fxg/ml respectively, while highest MIC and MBC were 
2600 and 5200 ^g/ml. 37.5% ESBL isolates shows MIC of 1300 and 62.5% shows 2600 
i^g/ml, while 28.13% isolates had MBC of 2600 ng/ml and 71.87 % shows MBC of 5200 
Hg/ml. Whereas in case of non ESBL, 37.5% shows MIC of 1300 and 62.5% shows 2600 
\ig/ml, while 25% isolates had MBC of 2600 and 75% had MBC of 5200 ^g/ml, 
respectively. 
Table 23. MIC and MBC (^g/ml) values of AgNPs (100 nm) tested against E. 
coli (n=40) isolates 
ESBL positive E. coli 32 (80%) 
isolates 
37.50% 
62.50% 
MIC 
1300 
2600 
isolates 
28.13% 
71.87% 
MBC 
2600 
5200 
Non- ESBL E. coli 8(20) 
isolates 
37.50% 
62.50% 
MIC 
1300 
2600 
isolates 
25% 
75% 
MBC 
2600 
5200 
Table 24 shows the MIC and MBC values of 100 nm AgNPs powder tested against 
MRSA and MSSA. The MIC values for both MRSA and MSSA were ranged from 1300 -
2600 ng/ml, while MBC ranged from 2600-5200 ng/ml. 40% MRSA shows MIC of 1300 
and 60% shows 2600 i^ g/ml, while 32% isolates shows MBC of 2600 and 68% shows 
MBC of 5200 iig/ml. Whereas in case of MSAA, 40.74% shows MIC of 1300 and 
59.26% shows MIC of 2600 ^g/ml, while 33.33% had MBC of 2600 and 6% had MBC 
of 5200 |ig/ml, respectively. 
Table 24. MIC and MBC (|ag/ml) values of AgNPs (100 nm) tested against S. 
aureus (n=52) isolates 
MRSA 25 (48.1%) 
isolates 
40% 
60% 
MIC 
1300 
2600 
isolates 
32% 
68% 
MBC 
2600 
5200 
MSSA 27(51.9%) 
isolates 
40.74% 
59.26% 
MIC 
1300 
2600 
isolates 
33.33% 
66.67% 
MBC 
2600 
5200 
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Table 25 shows the MIC and MBC of 100 nm AgNPs powder tested against MR and MS 
CONS. The lowest MIC for both MR and MS CONS were found to be 1300 ^g/ml. 
33.33% MR CONS shows MIC of 1300 and 66.67% shows 2600 ^ig/ml, while 16.67% 
isolates shows MBC of 2600 and 83.33% shows 5200 |ig/ml respectively, whereas in 
case of MS CONS 25% shows MIC of 1300 and 75% shows 2600 ^g/ml, respectively, 
while all MS CONS shows MBC of 5200 ng/ml. 
Table 25. MIC and MBC ( i^g/ml) values of AgNPs (100 nm) tested against CONS (n-10) 
MRSE 6(60%) 
isolates 
33.33% 
66.67% 
MIC 
1300 
2600 
isolates 
16.67% 
83.33% 
MBC 
2600 
5200 
isolates 
25% . 
75% 
MSSE 4(40%) 
MIC 
1300 
2600 
isolates 
100% 
— 
MBC 
5200 
— 
Table 26a shows the MIC and MBC values of 100 nm AgNPs powder tested against 
ESBL positive and ESBL negative isolates of P. aeruginosa and table 26b shows the 
MIC and MBC of MBL producing P. aeruginosa. The lowest MIC and MBC for ESBL, 
non ESBL and MBL were found to be 1300 and 2600 |ig/ml, respectively, whereas the 
highest MIC and MBC values observed were 2600 and 5200 ^g/ml, respectively. 42.86% 
ESBL shows MIC of 1300 and 57.14% shows 2600 ng/ml, while 35.71% had MBC of 
2600 and 64.29% had 5200 i^g/ml, respectively. Likewise in case of non ESBL, 33.33% 
shows MIC 1300 and 66.67% shows 2600 |ig/ml, respectively, while 22.22% had MBC 
2600 and 77.78% had 5200 ng/ml, respectively. 
Table 26a. MIC and MBC (ng/ml) values of AgNPs (100 nm) tested against P. 
aeruginosa (n=55) isolates 
ESBL positive P. aeruginosa 
42 (76.34%) 
isolates 
42.86% 
57.14% 
MIC 
1300 
2600 
isolates 
35.71% 
64.29% 
MBC 
2600 
5200 
Non 
isolates 
33.33% 
66.67% 
- ESBL P. aeruginosa 
9 (16.36%) 
MIC 
1300 
2600 
isolates 
22.22% 
11.1%% 
MBC 
2600 
5200 
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Table 26b. MIC and MBC (ng/ml) values of AgNPs (100 nm) tested against MBL P. 
aeruginosa 
MBL positive P. aeruginosa 4 (7.3%) 
isolates 
25% 
75% 
MIC 
1300 
2600 
isolates 
100% 
— 
MBC 
5200 
Table 27 shows the MIC and MBC of 100 nm AgNPs powder tested against ESBL and 
non- ESBL isolates of Klebsiella spp. The lowest MIC for ESBL and non ESBL isolates 
was found to be 1300 i^g/ml, while Maximum MBC observed were 5200 |ag/ml for both 
ESBL and non ESBL isolates. 
Table 27. MIC and MBC (^ig/ml) values of AgNPs (100 nm) tested against Klebsiella 
spp (n=6) 
ESBL positive Klebsiella spp 4 (66.67%) 
isolates 
50% 
50% 
MIC 
1300 
2600 
isolates 
25% 
75% 
MBC 
2600 
5200 
Non- ESBL Klebsiella spp 2 (33.33%) 
isolates 
50% 
50% 
MIC 
1300 
2600 
isolates 
100% 
MBC 
5200 
— 
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4.6.2. Evaluation of antibacterial activity of ZnO NPs 
Table 28 shows the MIC and MBC for ESBL and non-ESBL E. coli tested against 20 nm 
ZnO NPs powder. The lowest MIC and MBC for both ESBL and non-ESBL E. coli were 
found to be 500 and 1000 ng/ml, respectively, while highest MIC and MBC were 4000 
and 8000 ng/ml, respectively. 
Table 28. MIC and MBC (ng/ml) values of ZnO NPs (20 nm) tested against E. coli 
(n=40) isolates 
ESBL positive E. coli 32 (80%) 
isolates 
12.50% 
37.50% 
31.25% 
18.75% 
MIC 
500 
100 
2000 
4000 
isolates 
6.25% 
18.75% 
37.50% 
31.25% 
MBC 
1000 
2000 
4000 
8000 
Non- ESBL E. coli 8 (20%) 
isolates 
25% 
25% 
37.50% 
12.5% 
MIC 
500 
1000 
2000 
4000 
isolates 
50% 
12.5% 
37.50% 
MBC 
2000 
4000 
8000 
Table 29 shows the MIC and MBC values of 20 nm ZnO NPs powder tested against 
MRSA and MSSA. The MIC values for both MRSA and MSSA were ranged from 500 -
4000 ng/ml, while MBC ranged from 1000-8000 i^g/ml. Both MRSA and MSSA were 
inhibited at concentrations over 500 ng/ml. 
Table 29. MIC and MBC (|ig/ml) values of ZnO NPs (20 nm) tested against S 
aureus (n=52) isolates 
isolates 
12% 
40% 
32% 
16% 
MRSA 25(48.1%) 
MIC 
500 
1000 
2000 
4000 
isolates 
4% 
8% 
24% 
64% 
MBC 
1000 
2000 
4000 
8000 
MSSA 27(51.9%) 
isolates 
14.81% 
29.63% 
30.04% 
18.52% 
MIC 
500 
1000 
2000 
4000 
isolates 
3.70%) 
22.22% 
22.22% 
51.85% 
MBC 
1000 
2000 
4000 
8000 
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Table 30 shows the MIC and MBC of 20 nm ZnO NPs powder tested against MR and 
MS CONS. The lowest MIC for both MR and MS CONS were found to be 500 ng/ml. 
16.67% MR CONS shows MIC of 500, 33.33% shows MIC of 2000 and 50% shows 
4000 i^g/ml, while 16.67% isolates shows MBC of 1000, 33.33% shows 4000 ng/ml and 
50% shows 800 ^g/ml, respectively, whereas in case of MS CONS 25% shows MIC of 
500, 25% shows 2000 and 50% shows 4000 ng/ml, respectively, while 25% shows MBC 
of 2000 and 75% shows MBC of 8000 ^ig/ml, respectively. 
Table 30. MIC and MBC (ng/ml) values of ZnO NPs (20 nm) tested against CONS 
(n=10) 
MRSE 6(60%) 
isolates 
16.67% 
33.33% 
50% 
MIC 
500 
2000 
4000 
isolates 
16.67% 
33.33% 
50.00% 
MBC 
1000 
4000 
8000 
MSSE 4(40%) 
isolates 
25.00% 
25.00% 
50.00% 
MIC 
500 
2000 
4000 
isolates 
25.00% 
75.00% 
— 
MBC 
2000 
8000 
— 
Table 31a shows the MIC and MBC values of 20 nm ZnO NPs powder tested against 
ESBL positive and ESBL negative isolates of P. aeruginosa and table 31 b shows the 
MIC and MBC of MBL producing P. aeruginosa. The lowest MIC and MBC for ESBL, 
non ESBL and MBL were found to be 500 and 1000 ^g/ml, respectively, whereas the 
highest MIC and MBC values observed were 4000 and 8000 ^g/ml, respectively. 
Table 31a. MIC and MBC (ng/ml) values of ZnO NPs (20 nm) tested against P. 
aeruginosa (n=55) isolates 
ESBL positive P. aeruginosa 
42 (76.34%) 
isolates 
14.28% 
19.05% 
35.71% 
30.95% 
MIC 
500 
1000 
2000 
4000 
isolates 
7.15% 
14.28% 
33.33% 
45.24% 
MBC 
1000 
2000 
4000 
8000 
Non- ESBL P. aeruginosa 
9 (16.36%) 
isolates 
11.11% 
22.22% 
44.44% 
22.22% 
MIC 
500 
10.00 
2000 
4000 
isolates 
11.11% 
33.33% 
55.56% 
MBC 
2000 
4000 
8000 
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Table 31b. MIC and MBC ( l^g/ml) values of ZnO NPs (20 nm) tested against MBL P. 
aeruginosa 
MBL positive P. aeruginosa 4 (7.3%) 
isolates 
25% 
50% 
25% 
MIC 
500 
2000 
4000 
isolates 
25% 
75% 
MBC 
2000 
8000 
Table 32 shows the MIC and MBC of 20 nm ZnO NPs powder tested against ESBL and 
non- ESBL isolates of Klebsiella spp. The lowest MIC for ESBL and non ESBL isolates 
was found to be 500}ig/ml, while Maximum MBC observed were 4000 ng/m! for both 
ESBL and non ESBL isolates. In case of ESBL, 25% shows MIC 500, 25% shows 100 
and 50% shows 2000 ng/ml, respectively, while 25% shows MBC of 2000 and 75% 
shows 4000 ng/ml respectively, whereas in case of non ESBL, all isolates shows MIC 
1000 ng/ml, while 50% shows MBC 2000 and another 50% shows MBC of 4000 ^g/ml, 
respectively. 
Table 32. MIC and MBC (^g/ml) values of ZnO NPs (20 nm) tested against Klebsiella 
spp (n=6) 
ESBL positive JT/efoiW/fl spp 4 (66.67%) 
isolates 
25% 
25% 
50% 
MIC 
500 
1000 
2000 
isolates 
25% 
75% 
MBC 
2000 
4000 
Non- ESBL Klebsiella spp 2 (33.33%) 
isolates 
100% 
— 
— 
MIC 
1000 
— 
isolates 
50% 
50% 
MBC 
2000 
4000 
Table 33 shows the MIC and MBC for ESBL and non-ESBL E. coli tested against 70 nm 
ZnO NPs powder. The lowest MIC and MBC for both ESBL and non-ESBL E. coli were 
found to be 2000 and 4000 i^g/ml, respectively, while highest MIC and MBC were 8000 
and 16000 ng/ml, respectively. 
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Table 33. MIC and MBC (^g/ml) values of ZnO NPs (70 nm) tested against E. coli 
(n=40) isolates 
ESBL positive E. coli 32 (80%) 
isolates 
25% 
31.25% 
43.75% 
MIC 
2000 
4000 
8000 
isolates 
15.63% 
37.50% 
46.87% 
MBC 
4000 
8000 
16000 
Non- ESBL E. coli 8 (20%) 
isolates 
25% 
25% 
50% 
MIC 
2000 
4000 
8000 
isolates 
25% 
25% 
50% 
MBC 
4000 
8000 
16000 
Table 34 shows the MIC and MBC values of 70 nm ZnO NPs powder tested against 
MRSA and MSSA. The MIC values for both MRSA and MSSA were ranged from 2000 -
8000 ng/ml, while MBC ranged from 4000-16000 ^ig/ml. Both MRSA and MSSA were 
inhibited at concentrations over 2000 pg/ml. 
Table 34. MIC and MBC (i^g/ml) values of ZnO NPs (70 nm) tested against 5". aureus 
(n=52) isolates 
MRSA 25 (48.1%) 
isolates 
16% 
32% 
52% 
MIC 
2000 
4000 
8000 
isolates 
8% 
28% 
64% 
MBC 
4000 
8000 
16000 
MSSA 27 (51.9%) 
isolates 
11.11% 
37.04% 
51.85% 
MIC 
2000 
4000 
8000 
isolates 
7.40% 
40.74% 
51.85% 
MBC 
4000 
8000 
16000 
Table 35 shows the MIC and MBC of 70 nm ZnO NPs powder tested against MR and 
MS CONS. The lowest MIC for both MR and MS CONS were found to be 2000 ng/ml. 
16.67% MR CONS shows MIC of 2000, 16.67% shows MIC of 4000 and 66.66% shows 
8000 ng/ml, while 16.67% isolates shows MBC of 4000 and 83.33% shows 16000 i^g/ml, 
respectively, whereas in case of MS CONS 25% shows MIC of 2000 and 75% shows 
8000 respectively, while 25% shows MBC of 8000 and 75% shows MBC of 16000 
fig/ml, respectively. 
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Table 35. MIC and MBC ( i^g/ml) values of ZnO NPs (70 nm) tested against CONS 
(n=W) 
MRSE 6 (60%) 
isolates 
16.67% 
16.67% 
66.66% 
MIC 
2000 
4000 
8000 
isolates 
16.67% 
83.33% 
— 
MBC 
4000 
16000 
MSSE 4 (40%) 
isolates 
25.00% 
75.00% 
— 
MIC 
2000 
8000 
— 
isolates 
25.00% 
75.00% 
— 
MBC 
8000 
16000 
Table 36a shows the MIC and MBC values of 70 nm ZnO NPs powder tested against 
ESBL positive and ESBL negative isolates of P. aeruginosa and table 36b shows the 
MIC and MBC of MBL producing P. aeruginosa. The lowest MIC and MBC for ESBL, 
non ESBL and MBL were found to be 2000 and 4000 ^ig/nil, respectively, whereas the 
highest MIC and MBC values observed were 8000 and 16000 |ig/ml, respectively. 
Table 36a. MIC and MBC (^g/ml) values of ZnO NPs (70 nm) tested against P. 
aeruginosa (n=55) isolates 
ESBL positive P. aeruginosa 
42 (76.34%) 
isolates 
14.28% 
33.33% 
52.38% 
MIC 
2000 
4000 
8000 
isolates 
7.15% 
28.57% 
64.28% 
MBC 
4000 
8000 
16000 
Non- ESBL P. aeruginosa 1 
9 (16.36%) 
isolates 
22.22% 
33.33% 
44.44% 
MIC 
2000 
4000 
8000 
isolates 
11.11% 
22.22% 
66.67% 
MBC 
4000 ' 
8000 
16000 
Table 36b. MIC and MBC (ng/ml) values of ZnO NPs (70 nm) tested against MBL P 
aeruginosa 
MBL positive P. aeruginosa 4 (7.3%) 
isolates 
25% 
25% 
50% 
MIC 
2000 
4000 
8000 
isolates 
25% 
25% 
50% 
MBC 
4000 
8000 
16000 
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Table 37 shows the MIC and MBC of 70 nm ZnO NPs powder tested against ESBL and 
non- ESBL isolates of Klebsiella spp. The lowest MIC for ESBL and non ESBL isolates 
was found to be 2000|xg/ml, while highest MIC observed were 8000 |ig/ml for both 
ESBL and non ESBL isolates. In case of ESBL, 25% shows MIC 2000, 25% shows 4000 
and 50% shows 8000 |ig/ml, respectively, while 25% shows MBC of 4000, another 25% 
shows 8000 and remaining 50% shows 16000 |Jg/ml, respectively, whereas in case of non 
ESBL, 50% shows MIC 2000 and another 50% shows 8000 ng/ml, respectively, while 
50% shows MBC 8000 and remaining 50% shows MBC of 16000 ng/ml, respectively. 
Table 37. MIC and MBC (ng/ml) values of ZnO NPs (70 nm) tested against Klebsiella 
spp (n=6) 
ESBL positive Klebsiella spp 4 (66.67%) 
isolates 
25% 
25% 
50% 
MIC 
2000 
4000 
8000 
isolates 
25% 
25% 
50% 
MBC 
4000 
8000 
16000 
Non- ESBL Klebsiella spp 2 (33.33%) 
isolates 
50% 
50% 
— 
MIC 
2000 
8000 
isolates 
50% 
50% 
MBC 
8000 
16000 
4.6.3. Evaluation of antibacterial activity of AI2O3 NPs 
Table 38 shows the MIC and MBC for ESBL and non-ESBL E. coli tested against <50 
nm AI2O3 NPs powder. The lowest MIC and MBC for both ESBL and non-ESBL E. coli 
were found to be 1600 and 3200 ng/ml, respectively, while highest MIC and MBC were 
3200 and 6400 fig/ml, respectively. 
Table 38. MIC and MBC (ng/ml) values of AI2O3 NPs (<50 nm) tested against E. coli 
(n=40) isolates 
ESBL positive E. coli 32 (80%) 
isolates 
43.75% 
56.25% 
MIC 
1600 
3200 
isolates 
31.25% 
68.75% 
MBC 
3200 
6400 
Noa- ESBL E. coli 8 (20%) 
isolates 
37.5% 
62.5% 
MIC 
1600 
3200 
isolates 
25% 
75% 
MBC 
3200 
6400 
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Table 39 shows the MIC and MBC values of <50 nm AI2O3 NPs powder tested against 
MRSA and MSSA. The MIC values for both MRSA and MSSA were ranged from 1600-
3200 ^g/ml, while MBC ranged from 3200-6400 ^g/ml. Both MRSA and MSSA were 
inhibited at concentrations over 1600 |ig/ml. In case of MRSA, 44% isolates shows MIC 
1600 i^g/ml and 56% shows 3200 [ig/ml, respectively, while 36% shows MBC 3200 and 
64% shows MBC of 6400 i^g/ml, respectively, whereas in case of MSAA, 44.44% 
isolates shows MIC 1600 and 56.56% shows 3200 |ig/ml, respectively, while 37.04% 
shows MBC 3200 and 62.96% shows MBC 6400 ^g/ml, respectively. 
Table 39. MIC and MBC (ng/ml) values of AI2O3 NPs (<50 nm) tested against S. aureus 
(n=52) isolates 
MRSA 25 (48.1%) 
isolates 
44% 
56% 
MIC 
1600 
3200 
isolates 
36% 
64% 
MBC 
3200 
6400 
MSSA 27 (51.9%) 
isolates 
44.44% 
55.56%-
MIC 
1600 
3200 
isolates 
37.04% 
62.96% 
MBC 
3200 
6400 
Table 40 shows the MIC and MBC of <50 nm AI2O3 NPs powder tested against MR and 
MS CONS. The lowest MIC for both MR and MS CONS were found to be 1600 ^g/ml. 
33.33% MR CONS shows MIC of 1600 and 66.67% shows 3200 ^ig/ml, while 16.67% 
isolates shows MBC of 3200 and 83.33% shows 6400, ng/ml respectively, whereas in 
case of MS CONS 25% shows MIC of 1600 and 75% shows 3200, respectively, while 
50% shows MBC of 3200 and remaining 50%) shows MBC of 6400, )Lig/ml respectively 
Table 40. MIC and MBC (ng/ml) values of AI2O3 NPs (<50 nm) tested against CONS 
(n=10) 
isolates 
33.33% 
66.67% 
MRSE 6 (60%) 
MIC 
1600 
3200 
isolates 
16.67% 
83.33% 
MBC 
3200 
6400 
isolates 
25.00% 
75.00% 
MSSE 4(40%) 
MIC 
1600 
3200 
isolates 
50.00% 
50.00% 
MBC 
3200 
6400 
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Table 41a shows the MIC and MBC values of <50 nm AI2O3 NPs powder tested against 
ESBL positive and ESBL negative isolates of P. aeruginosa and table 41b shows the 
MIC and MBC of MBL producing P. aeruginosa. The lowest MIC and MBC for ESBL, 
non ESBL and MBL were found to be 1600 and 3200 ^g/ml, respectively, whereas the 
highest MIC and MBC values observed were 3200 and 6400 ng/ml, respectively. 69.05% 
ESBL, 77.78% non ESBL and 75%o MBL showed an MBC of 6400 ^g/ml, respectively. 
Table 41a. MIC and MBC (^ig/ml) values of AI2O3 NPs (<50 nm) tested against P. 
aeruginosa (n=55) isolates 
ESBL positive P. aeruginosa 
42 (76.34%) 
isolates 
38.10% 
61.90% 
MIC 
1600 
3200 
isolates 
30.95% 
69.05% 
MBC 
3200 
6400 
Non- ESBL P. aeruginosa 
9 (16.36%) 
isolates 
33.33% 
66.67% 
MIC 
1600 
3200 
isolates 
22.22% 
77.78% 
MBC 
3200 
6400 
Table 41b. MIC and MBC (ng/ml) values of AI2O3 NPs (<50 nm) tested against MBL P. 
aeruginosa. 
MBL positive P. aeruginosa 4 (7.3%) 
isolates 
50% 
50% 
MIC 
1600 
3200 
isolates 
25% 
75% 
MBC 
3200 
6400 
Table 42 shows the MIC and MBC of <50 nm AI2O3 NPs powder tested against ESBL 
and non- ESBL isolates of Klebsiella spp. The lowest MIC for ESBL and non ESBL 
isolates was found to be I600|xg/ml, while highest MIC observed were 3200 |ig/ml. In 
case of ESBL, 50% shows MIC 1600 and remaining 50% shows 3200 fig/ml, 
respectively, while 25%) shows MBC of 3200 and remaining 75% shows 6400 ng/ml, 
respectively, whereas in case of non ESBL, 50% shows MIC 1600 and another 50% 
shows 3200 |ig/ml, respectively, while 50% shows MBC 3200 and remaining 50% 
showed an MBC of 6400 ^g/ml, respectively. 
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Table 42. MIC and MBC (ng/ml) values of AI2O3 NPs (<50 nm) tested against Klebsiella 
spp (n=6) 
ESBL positive Klebsiella spp 4 (66.67%) 
isolates 
50% 
50% 
MIC 
1600 
3200 
isolates 
25% 
75% 
MBC 
3200 
6400 
Non- ESBL Klebsiella spp 2 (33.33%) 
isolates 
50% 
50% 
MIC 
1600 
3200 
isolates 
50% 
50% 
MBC 
3200 
6400 
Table 43 shows the MIC and MBC for ESBL and non-ESBL E. coli tested against 45 nm 
AI2O3 NPs powder. The lowest MIC and MBC for both ESBL and non-ESBL E. coli 
were found to be in the range of 1800 ^g/ml and 3600 ^g/ml, respectively, while highest 
MIC and MBC were 3600 and 7200 i^g/ml, respectively. 43.75% ESBL shows MIC of 
1800 and 56.25% shows 3600 ^g/ml, respectively, while 31.25% isolates of ESBL. shows 
MBC of 3600 and 68.75% shows 7200 pg/ml, respectively. Whereas in case of non 
ESBL, 37.5% isolates shows MIC of 1800 and 62.5% shows MBC of 3600 ^g/ml, 
respectively, while 25% shows MBC of 3600 and 75% showed an MBC value of 7200 
^g/ml, respectively. 
Table 43. MIC and MBC (ng/ml) values of AI2O3 NPs (45 nm) tested against E. coli 
(n=40) isolates 
ESBL positive E. coli 32 (80%) 
isolates 
43.75% 
56.25% 
MIC 
1800 
3600 
isolates 
31.25% 
68.75% 
MBC 
3600 
7200 
Non- ESBL E. coli 8 (20%) 
isolates 
37.5% 
62.5% 
MIC 
1800 
3600 
isolates 
25% 
75% 
MBC 
3600 
7200 
Table 44 shows the MIC and MBC values of 45 nm AI2O3 NPs powder tested against 
MRSA and MSSA. The MIC values for both MRSA and MSSA were ranged from 1800 -
3600 ^g/ml, while MBC ranged from 3600-7200 ^g/ml. Both MRSA and MSSA were 
inhibited at concentrations over 1800 pg/ml. In case of MRSA, AA% isolates shows MIC 
1800 ng/ml and 56% shows 3600 ng/ml, respectively, while 36%) shows MBC 3600 and 
64% shows MBC of 7200 fig/ml, respectively, whereas in case of MSAA, 44.44% 
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isolates shows MIC 1800 and 55.56% shows 3600 ^g/ml, respectively, while 37.04% 
shows MBC 3600 and 62.96% shows MBC 7200 i^g/ml, respectively. 
Table 44. MIC and MBC (^g/ml) values of AI2O3 NPs (45 nm) tested against S. aureus 
(n=52) isolates 
MRSA 25 (48.1%) 
isolates 
44% 
56% 
MIC 
1800 
3600 
isolates 
36% 
64% 
MBC 
3600 
7200 
MSSA 27(51.9%) 
isolates 
44.44% 
55.56% 
MIC 
1800 
3600 
isolates 
37.04% 
62.96% 
MBC 
3600 
7200 
Table 45 shows the MIC and MBC of 45 nm AI2O3 NPs powder tested against MR and 
MS CONS. The lowest MIC for both MR and MS CONS were found to be 1800 ng/ml. 
33.33% MR CONS shows MIC of 1800 and 66.67% shows 3600 |ag/ml, while 16.67% 
isolates shows MBC of 3600 and 83.33% shows 7200 ^g/ml, respectively, whereas in 
case of MS CONS 25% shows MIC of 1800 and 75% shows 3600, respectively, while 
50% shows MBC of 3600 and remaining 50% showed an MBC of 7200 ^g/ml, 
respectively. 
Table 45. MIC and MBC (^ig/ml) values of AI2O3 NPs (45 nm) tested against CONS 
(n-10) 
MRSE 6 (60%) 
isolates 
33.33% 
66.67% 
MIC 
1800 
3600 
isolates 
16.67% 
83.33% 
MBC 
3600 
7200 
MSSE 4(40%) 
isolates 
25.00% 
75.00% 
MIC 
1800 
3600 
isolates 
50.00% 
50.00% 
MBC 
3600 
7200 
Table 46a shows the MIC and MBC values of 45 nm AI2O3 NPs powder tested against 
ESBL positive and ESBL negative isolates of P. aeruginosa, while table 46b shows the 
MIC and MBC of MBL producing P. aeruginosa. The lowest MIC and MBC for ESBL, 
non ESBL and MBL were found to be 1800 and 3600 ^g/ml, respectively, whereas the 
highest MIC and MBC values observed were 3600 and 7200 ng/ml, respectively. 69.05% 
ESBL, 77.78% non ESBL and 75% MBL showed an MBC of 7200 ng/ml, respectively. 
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Table 46a. MIC and MBC (ng/ml) values of AI2O3 NPs (45 nm) tested against P. 
aeruginosa (n=55) isolates 
ESBL positive P. aeruginosa 
42 (76.34%) 
isolates 
38.10% 
61.90% 
MIC 
1800 
3600 
isolates 
30.95% 
69.05% 
MBC 
1800 
3600 
Non- ESBL P. aeruginosa 
9 (16.36%) 
isolates 
33.33% 
66.67% 
MIC 
1800 
3600 
isolates 
22.22% 
ii.n% 
MBC 
3600 
7200 
Table 46b. MIC and MBC (^g/ml) values of AI2O3 NPs (45 nm) tested against MBL P. 
aeruginosa 
isolates 
25% 
75% 
MBL positive P. aeruginosa 
MIC 
1800 
3600 
isolates 
25% 
75% 
4 (7.3%) 
MBC 
3600 
7200 
Table 47 shows the MIC and MBC of 45 nm AI2O3 NPs powder tested against ESBL and 
non- ESBL isolates of Klebsiella spp. The lowest MIC and MBC for ESBL and non 
ESBL isolates was found to be 1800 and 3600 |i'g/ml, respectively. In case of ESBL, 50% 
shows MIC 1800 and remaining 50% shows 3600 |^g/ml, respectively, while 25% shows 
MBC of 3600 and remaining 75% shows 7200 ng/ml, respectively, whereas in case of 
non ESBL, 50% shows MIC 1800 and another 50% shows 3600 ^g/ml, respectively. 
while 50% shows MBC 3600 and remaining 50% showed an MBC of 7200 ng/ml. 
respectively. 
Table 47. MIC and MBC ( i^g/ml) values of AI2O3 NPs (45 nm) tested against Klebsiella 
spp (n=6) 
ESBL positive Klebsiella spp 4 (66.67%) 
isolates 
50% 
50% 
MIC 
1800 
3600 
isolates 
25% 
75% 
MBC 
3600 
7200 
Non- ESBL Klebsiella spp 2 (33.33%) 
isolates 
50% 
50% 
MIC 
1800 
3600 
isolates 
50% 
50% 
MBC 
3600 
7200 
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Table 48 shows the effects of size on the antibacterial activity of AgNPs. We can see that 
the smaller size AgNPs present the best antibacterial activity. The MIC value of 2 nm 
water soluble AgNPs tested against all standard bacterial strains were very low (in the 
range of 3-3.25 |.ig/ml), indicating very good bacteriostatic activity, while for 5-10 nm 
AgNPs dispersion MIC ranged from 11-12.50, for 15 nm water soluble AgNPs MIC 
ranged from 15-16, for 35-50 nm AgNPs powder MIC ranged from 400-450, and for 100 
nm AgNPs powder MIC ranged from 1200-1300 ^g/ml, respectively. 
Table 48. MIC (pg/ml) of different sizes silver nanoparticles tested against standard 
strains 
Standard bacterial strain 
E. coli ATCC 25922 
£. CO//MTCC1591 
E. coli DH5a 
P. aeruginosa ATCC 25619 
P. aeruginosa ATCC 27853 
P. aeruginosa UYCC1>5A\ 
S. aureus ATCC 25923 
S. aureus MTCC 96 
S. epidermidis ATCC 155 
5. epidermidis MTCC 3615 
S. mutants MTCC 497 
B.subtilisMTCCni 
2 nm 
3.13 
3.00 
3.13 
3.25 
3.25 
3.13 
3.25 
3.25 
3.25 
3.00 
3.00 
3.13 
5-lOnni 
11.25 
11.00 
12.00 
12.50 
12.00 
12.50 
13.00 
12.50 
12.50 
12.00 
11.25 
11.25 
15 nm 
16 
15 
15 
16 
15 
16 
16 
16 
16 
15 
16 
16 
35-50nm 
400 
400 
450 
400 
400 
450 
400 
450 
400 
400 
400 
450 
lOOnm 
1300 
1300 
1250 
1250 
1200 
1300 
1300 
1250 
1250 
1250 
1200 
1300 
Table 49 shows the effects of size on the antibacterial activity of AgNPs. Thus the 
smaller size AgNPs present the best bactericidal activity. The MBC value of 2 nm water 
soluble AgNPs tested against all standard bacterial strains were very low (in the range of 
6.00-6.50 ng/ml), indicating very good bactericidal activity, while for 5-10 nm AgNPs 
dispersion MBC ranged from 22-26, for 15 nm water soluble AgNPs MBC ranged from 
30-32, for 35-50 nm AgNPs powder MBC ranged from 800-900, and for 100 nm AgNPs 
powder MBC ranged from 2400-2600 ng/ml, respectively. 
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Table 49. MBC ()ig/ml) of different sizes silver nanoparticles tested against standard 
strains 
Standard bacterial strain 
E. coliATCC25922 
E.coli MTCC 1591 
E. coli DH5a 
P. aeruginosa ATCC 25619 
P. aeruginosa ATCC 27853 
P. aeruginosa MTCC 3541 
S. aureus ATCC 25923 
S. aureus MTCC 96 
S. epidermidis ATCC 155 
S. epidermidis MTCC 3615 
S. mutants MTCC 497 
B. subtilis MTCC 121 
2 nm 
6.25 
6.00 
6.25 
6.50 
6.50 
6.25 
6.50 
6.50 
6.50 
6.00 
6.00 
6.25 
5-lOnm 
22.5 
22 
24 
25 
24 
25 
26 
25 
25 
24 
22.5 
22.5 
15 nm 
32 
30 
30 
32 
30 
32 
32 
32 
32 
30 
32 
32 
35-50nm 
800 
800 
900 
800 
800 
900 
800 
900 
800 
800 
800 
900 
lOOnm 
2600 
2600 
2500 
2500 
2400 
2600 
2600 
2500 
2500 
2500 
2400 
2600 
4.7, Determination of antibacterial activity of NFS by well-diffusion method 
4.7.1, Determination of antibacterial activity of AgNPs 
To check further the antibacterial effect of different AgNPs, the antibacterial activity of 
AgNPs was tested by well-diffusion methods for identification of inhibition zone with 50 
Hg/ml for 2, 5-10 and 15 nm AgNPs, and at 200 |ig/ml for 35-50 and 100 nm AgNPs 
against various clinical bacterial isolates by measuring the zone of inhibition (ZOI). The 
ZOI reflects the magnitude of the susceptibility to the bacteria. Figure 34 shows the ZOI 
(mm) of 2, 5-10, 15, 35-50 and 100 nm AgNPs tested against E. coli ATCC 25922, E. 
coli MTCC 1591, £. coli DH5a and ESBL and non ESBL clinical strains of E. coli and 
Klebsiella spp. Fig. 34 shown that 35-50 and 100 nm AgNPs shows least ZOI i.e., 5-7 
mm and 3.5-5 mm, respectively (due to large size), while 2 and 5-lOnm AgNPs shows 
15-18 and 13-16 mm ZOI, respectively (due to small size). We also found that increasing 
the concentration of 35-50 and lOOnm AgNPs powder did not show a consistent increase 
in the zone size because the nanoparticles settled at the bottom of the wells in the plates 
and the particle solution was not able to diffuse properly in the agar medium. 
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Figure 34. Zone of inhibition of various AgNPs against E. coli and Klebsiella spp. 
Figure 35 shows the ZOI (mm) of 2, 5-10, 15, 35-50 and 100 nm AgNPs tested against P. 
aeruginosa ATCC 27853, P. aeruginosa ATCC 25619, P. aeruginosa MTCC 3541, and 
ESBL, MBL and non ESBL clinical strains of P. aeruginosa. Figure 35 shown that 35-50 
and 100 nm AgNPs shows least ZOI i.e., 5-7 mm and 4-5 mm, respectively (due to large 
size), while 2 and 5-10 nm AgNPs shows 16-18, and 14-17 mm ZOI, respectively (due to 
small size). AgNPs with small size showed greater and significant ZOI. 
2nm 5-lOnm 15nm35-50nml00nm 
AgNPs 
• P. aeruginosa ATCC 25619 
• P. aeruginosa ATCC 27853 
• P. aeruginosa MTCC 3541 
• P. aeruginosa ESBL 
• P. aeruginosa MBL 
• P. aeruginosa non- ESBL 
Figure 35. Zone of inhibition of various AgNPs against P. aeruginosa strains 
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Figure 36 shows the ZOl (mm) of 2, 5-10, 15, 35-50 and 100 nm AgNPs tested against S. 
aureus ATCC 25923, S. aureus MTCC 96, and MRSA and MSSA isolates. Figure 36 
shown that 35-50 and 100 nm AgNPs shows least ZOI i.e., 6-8 mm and 5-6 mm, 
respectively (due to large size), while 2 and 5-10 nm AgNPs shows 17-18, and 15-16 mm 
ZOI, respectively (due to small size). 
IS. aureus ATCC 25923 
IS. aureus MTCC 96 
I MRSA 
IMSAA 
2nm 5-10 nm 15nm 35-50nml00nm 
AgNPs 
Figure 36. Zone of inhibition of different size AgNPs against S. aureus strains 
Figure 37 showed the ZOI (mm) of 2, 5-10, 15, 35-50 and 100 nm AgNPs tested against 
S. epidermidis ATCC 155, 5". epidermidis MTCC 3615, and MS CONS and MS CONS. 
Figure 37 shown that 35-50 and 100 nm AgNPs shows least ZOI i.e., 5 - 6.5 mm and 4 -
4.5 mm, respectively (due to large size), while 2 and 5-10 nm AgNPs shows 16-19, and 
15-17 mm ZOI, respectively (due to small size). 
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Figure 37. Zone of inhibition of different size AgNPs against S. epidermidis strains 
Figure 38 shows the ZOI (mm) of 2 nm, 5-lOnm, I5nm, 35-50nm and 100 nm AgNPs 
tested against S. mutants MTCC 497 and B. subtilis MTCC 121. Figure 38 shown that 35-
50 and 100 nm AgNPs shows least ZOI i.e., 7-8 mm and 5-6 mm, respectively (due to 
large size), while 2 and 5-1 Onm AgNPs shows 18-21, and 18-20 mm ZOI, respectively 
(due to small size). 
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Figure 38. Zone of inhibition of different size AgNPs against S. mutants MTCC 497 and 
B, subtilis MTCC 121. 
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4.7.2. Determination of antibacterial activity of ZnO NPs 
Figure 39 shows the ZOI (mm) of 20 nm and 70nm ZnO NPs tested against E. coli ATCC 
25922, E. coli MTCC 1591, £•. coli DH5a and ESBL and non ESBL clinical strains of E. 
coli and Klebsiella spp. Fig. 39 shows ZOI of 20 nm ZnO ranged Irom 9 to 12 mm at 200 
Hg/ml, while 70 nm ZnO NPs had ZOI in the range of 8-10 mm, respectively at the same 
concentration. It was found that ZnO NPs was able to inhibit bacterial growth and shows 
a clear and significant ZOI. The presence of an inhibition zone clearly indicated the 
antibacterial potential of ZnO NPs. We found that increasing the ZnO NPs concentration 
did not show a consistent increase in the zone size because the nanoparticles settled at the 
bottom of the wells in the plates and the particle solution was not able to diffuse properly 
in the agar medium. 
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Figure 39. Zone of inhibition of 20 and 70 nm ZnO NPs against E. coli and Klebsiella spp. 
Figure 40 shows the ZOI (mm) of 20 and 70 nm ZnO NPs tested against P. aeruginosa 
ATCC 27853, P. aeruginosa ATCC 25619, P. aeruginosa MTCC 3541, and ESBL, MBL 
and non ESBL clinical strains of P. aeruginosa. Figure 40 clearly shows that the ZOI of 
20 nm ZnO ranged from 10 to 11 mm at 200 ^ig/ml, while 70 nm ZnO NPs had ZOI in 
the range of 8-10 mm, respectively at the same concentration. It was found that ZnO NPs 
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was able to inhibit bacterial growth and shows a clear and significant ZOI. The presence 
of an inhibition zone clearly indicated the antibacterial potential of ZnO NPs and 20nm 
ZnO NPs had greater ZOI in comparison to 70 nm. We found that increasing the ZnO 
NPs concentration did not show a consistent increase in the zone size because the 
nanoparticles settled at the bottom of the wells in the plates and the particle solution was 
not able to diffuse properly in the agar medium. 
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Figure 40. Zone of inhibition of 20 and 70 nm ZnO NPs against P. aeruginosa strains. 
Figure 41 shows the ZOI (mm) of 20 and 70 nm ZnO NPs tested against S. aureus ATCC 
25923, S. aureus MTCC 96, and MRS A and MSSA isolates. Figure 41 clearly shows that 
the ZOI of 20 nm ZnO ranged from 9 to 11 mm at 200 ^ig/ml, while 70 nm ZnO NPs had 
ZOI in the range of 8-9.5 mm, respectively at the same concentration. It was found that 
ZnO NPs was able to inhibit bacterial growth and shows a clear and significant ZOI. The 
presence of an inhibition zone clearly indicated the antibacterial potential of ZnO NPs 
and 20 nm ZnO NPs had greater ZOI in comparison to 70 nm. We found that increasing 
the ZnO NPs concentration did not show a consistent increase in the zone size because 
the nanoparticles settled at the bottom of the wells in the plates and the particle solution 
was not able to diffuse properly in the agar medium. 
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Figure 43 shows the ZOI (mm) of 20 and 70 nm ZnO NPs tested against S. mutants 
MTCC 497 and B. subtilis MTCC 121. Figure 43 clearly shows that the ZOI of 20 nm 
ZnO for S. mutants MTCC 497 were 11mm and for B. subtilis MTCC 121 ZOI were 12 
mm, respectively, at 200 |ag/ml, while ZOI of 70 nm ZnO NPs were found to be 9 mm for 
S. mutants MTCC 497 and 10 mm for B. subtilis MTCC 121, respectively at the same 
concentration. Results suggest that B. subtilis MTCC 121 show greater ZOI than S. 
mutants MTCC 497. It was found that ZnO NPs was able to inhibit bacterial growth and 
shows a clear and significant ZOI. The presence of an inhibition zone clearly indicated 
the antibacterial potential of ZnO NPs and 20 nm ZnO NPs had greater ZOI in 
comparison to 70 nm. We found that increasing the ZnO NPs concentration did not show 
a consistent increase in the zone size because the nanoparticles settled at the bottom of 
the wells in the plates and the particle solution was not able to diffuse properly in the agar 
medium. 
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Figure 43. Zone of inhibition of 20 and 70 nm ZnO NPs against S. mutants MTCC 
497and B. subtilis MTCC 121. 
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Figure 41. Zone of inhibition of 20 and 70 nm ZnO NPs against S. aureus strains 
Figure 42 shows the ZOI (mm) of 20 and 70nm ZnO NPs tested against S. epidermidis 
ATCC 155, S. epidermidis MTCC 3615, and MS CONS and MS CONS. Figure 42 
clearly shows that the ZOI of 20 nm ZnO ranged from 10 to 11 mm at 200 ^g/ml, while 
70 nm ZnO NPs had ZOI in the range of 8-9 mm, respectively at the same concentration. 
It was found that ZnO NPs was able to inhibit bacterial growth and shows a clear and 
significant ZOI. The presence of an inhibition zone clearly indicated the antibacterial 
potential of ZnO NPs and 20 nm ZnO NPs had greater ZOI in comparison to 70 nm. We 
found that increasing the ZnO NPs concentration did not show a consistent increase in the 
zone size because the nanoparticles settled at the bottom of the wells in the plates and the 
particle solution was not able to diffuse properly in the agar medium. 
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Figure 42. Zone of inhibition of 20 and 70 nm ZnO NPs against S. epidermidis strains 
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4.8. Mechanism of interaction of nanoparticJes with bacterial cells 
4.8.1. Characterization of nanoparticles and bacterial interaction by scanning 
electron microscopy (SEM) 
4.8.1.1. SEM analysis of the E. coli, P. aeruginosa and S. aureus cells treated with 
AgNPs 
The morphological changes of E. coli cells were observed by SEM (Fig 44). The native 
E. were typically rod-shaped, smooth surface and damage on the cell surface was not 
detected (Fig 44a). However, in AgNPs treated group, instead of normal rod-shaped cells, 
irregular fragments appeared. The surface of the cell walls of treated E. coli was severely 
disrupted and the original rod shape has swollen into bigger size, with depression on the 
surface compared to the native E. coli (Fig 44 b & c). In case of P. aeruginosa cells, after 
treatments with AgNPs, structural changes in the morphology of bacteria were clearly 
observed as the surfaces of the cells were damaged severely compare to native cells (Fig 
45 b & c). Some cells showed large leakage, others misshapen and fragmentary. They 
showed only changes of cell surface due to increased permeability, this study showed not 
only morphological changes of cell surface but also cell fragments formed through 
damage of cell membranes (Fig 45d). The cell fragments could be the products derived 
from leakage of cytoplasmic contents in damaged cells. However, in case of S. aureus 
cells, native cells were typically spherical in shape. The cell surface was intact and 
damage was not seen (Fig 46a-d). However, in the cells treated with AgNPs, there were 
many irregular fragments appeared on the cell surface and the original spherical shape 
has swollen into bigger size with many depression on the surface and substantial loss of 
membrane integrity were also observed, indicating the damage of cell membrane as well 
as cell wall. It is presumed that the death of microbial cells may be due to damage of the 
microbial enzymes or cell membrane (Fig 46al-dl). 
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Figure 44. SEM micrographs of E. coli: (a) control and (b, c) after treatment with AgNPs 
(5-10 nm). (Arrows indicate extensive damage of bacterial cells) 
Figure 45. SEM micrographs of P. aeruginosa: (a) control and (b-d) after treatment with 
AgNPs (5-10 nm). (Arrows indicate changes in the morphology of cell surface and cell 
fragmentation). 
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Figure 46. SEM micrographs of 5. aureus: (a-d) control and (al-dl) after treatment with 
AgNPs (5-10 nm). (Arrows indicate changes in the morphology and depression on cell 
surface). 
4.8.1.2. SEM analysis of the E. coU, P. aeruginosa and S. aureus cells treated with 
ZnO NPs 
The morphological changes of bacterial cells were observed by SEM. In E. coli cells, 
cells of control group were typically rod-shaped. Each cell size was almost same and 
damage on the cell surface was not detected (Fig 47a). However, in ZnO NPs treated 
group, instead of normal rod-shaped cells, irregular fragments appeared and the original 
rod shape has swollen into bigger size, with high agglomeration of the cells. One can 
clearly see that treatment of the bacteria with ZnO NPs have led to considerable damage 
to some E. coli and the damage has caused the breakdown of the membrane of the 
bacteria. It was also observed that ZnO NPs adhered to the bacterial cell wall surface and 
most of the cells were lysed and liberated their internal contents and the other intact cell 
walls were specified with enlarged soft appearance and attached with noticeable amounts 
ofZnONPs(Fig47b-d). 
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Figure 47. SEM micrographs of E. coli: (a) control and (b-d) after treatment with ZnO 
NPs (70 nm). 
In case of P. aeruginosa cells, after treatments with ZnO NPs, structural changes in the 
morphology of bacteria were clearly observed as the surfaces of the cells were damaged 
severely compare to native cells (Fig 48a). Some cells showed large leakage, others 
misshapen and fragmentary. The morphology of treated bacterial cells was significantly 
changed and showed major damage, which was characterized by disorganized and 
distorted cell surfaces. Clusters of NPs were found to anchor to the bacterial cell wall 
(Fig 48b-d). 
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Figure 48. SEM micrographs of P. aeruginosa (a) control and (b-d) after treatment with 
ZnO NPs (70 nm). 
In S. aureus cells, cells of control group were typically grape-shaped. The cell surface 
was intact and damage was not seen (Fig 49 a & b). However, in the cells treated with 
ZnO NPs it was observed that the morphology of S. aureus was extremely vigorous on 
the cells, most of the cells were lysed and liberated their internal contents and the other 
intact cell walls were specified with enlarged soft appearance and attached with 
noticeable amounts of ZnO NPs (Fig 49al). With regard to the mechanism of 
antibacterial action of NPs ZnO, substantial loss of membrane integrity as seen by 
changes in cell morphology of bacterial surface was observed and has led to considerable 
damage to S. aureus and the damage has caused the breakdown of the membrane of the 
bacteria (Fig 49b 1). 
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Figure 49. SEM micrographs of 5. aureus: (a-b) control and (al-bl) after treatment with 
ZnO NPs (70 nm). 
4.8.1.3. SEM analysis of the E. coli, P. aeruginosa and S. aureus cells treated with 
AI2O3 NPs 
The morphological changes of bacterial cells were observed by SEM. In E. coli cells, 
cells of control group were typically rod-shaped. Each cell size was almost same and 
damage on the cell surface was not detected (Fig 50a). The morphology of treated 
bacterial cells was significantly changed and showed major damage, which was 
characterized by the formation of "pits" in their cell walls. Clusters of NPs were found to 
anchor to the bacterial cell wall (Fig 50b-d), possibly at sites that are rich in negatively 
charged functional groups. 
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Figure 50. SEM micrographs of £. coli: (a) control and (b-d) after treatment with AI2O3 
NPs (<50 nm). 
The morphological changes of bacterial cells were observed by SEM. In P. aeruginosa 
cells, cells of control group were typically rod-shaped. Each cell size was almost same 
and damage on the cell surface was not detected (Fig 51a). The morphology of treated 
bacterial cells was significantly changed and showed major damage, which was 
characterized by disorganized and distorted cell surfaces. Clusters of NPs were found to 
anchor to the bacterial cell wall (Fig 51 b-d). 
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Figure 51. SEM micrographs of/*, aeruginosa: (a) control and (b-d) after treatment with 
AI2O3 NPs (<50 nm). (White arrow indicate the attached NPs and red the distorted 
bacterial cells. 
In S. aureus cells, cells of control group were typically grape-shaped. The cell surface 
was intact and damage was not seen (Fig 52a). However, in the cells of AI2O3 NPs treated 
group, SEM images clearly indicated the change in cell shape and agglomerated particles 
on the cell wall. S. aureus, the spherical-shaped cell has broken down to smaller size and 
it is presumed that the death of microbial cells may be due to damage of the microbial 
enzymes or cell membrane. The alumina interacted cells shows distorted cell 
morphology, indicating the distortion on bacterial cells (Fig 52b-d). 
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Figure 52. SEM micrographs of S. aureus: (a) control and (b-d) after treatment with 
AI2O3 MPs (<50 nm). (Black arrow indicate the attached MPs and red the distorted 
bacterial cells. 
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4.8.2. Characterization of nanoparticies and bacterial interaction by high resolution-
transmission electron microscopy (HR-TEM) 
4.8.2.1. HR-TEM analysis of the E. coH, P. aeruginosa and S. aureus cells treated 
with AgNPs 
The internal structure of the untreated E. coli cells appeared to be normal, showing a 
multilayered cell surface consisting of an outer membrane, a peptidoglycan layer in the 
periplasmic space, and a cytoplasmic membrane (Fig. 53 a). Meanwhile, the bacterial 
cells after AgNPs treatment appeared to be seriously damaged (Fig. 53 b-c). The cells 
showed aberrant morphology; they were cracked and ruptured. Electron-dense particles 
or precipitates were also observed around damaged bacterial cells. Damaged cells showed 
either localized or complete separation of the cell membrane from the cell wall (Fig. 53 
b-c). The cellular degradation was also accompanied by electron-translucent cytoplasm 
and cellular disruption in the damaged cells. It is clear from Figure 53 (c) & (d) that the 
nanoparticies anchor the cell at several sites and cause damage at various sites in the 
membrane, which could resuh in cell lysis. Nanoparticies that accumulated in the 
membrane as well as some penetrating the cells can also be discerned in the HR-TEM 
micrograph. 
Figure 53. HR-TEM images of E. coli cells, (a) Untreated, (b-c) Treated with AgNPs 
(5-10 nm) and (d) enlarged view of the membrane of this cell. Red arrow indicates 
AgNPs attachment on membrane and black & white showed partially damaged 
membranes at various sites. 
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The HR-TEM images of P. aeruginosa showed the surface of native cells was smooth 
and intact (Fig. 54a), while membrane of treated cells was damaged severely; many pits 
and gaps appeared in the micrograph, and their membrane was fragmentary (Fig 54 b). 
From the figure 54 (b) & (c) it is very clear that AgNPs were attached to the surface of 
bacterial cell wall, permeated the cell membrane and entered into the cell interior. In 
addition, electron-dense particles or precipitates were also observed around damaged 
bacterial cells. As a result, we tend to speculate that reactive oxygen species may be 
generated from the surface of AgNPs; interact with the cell wall and membrane, damage 
the cell membrane, increase the cell permeability and leak the intracellular contents by 
cell disruption. 
Figure 54. HR-TEM images of P. aeruginosa cells, (a) Untreated, (b-c) Treated with 
AgNPs (5-10 nm). White arrow indicates AgNPs attachment on membrane, red showed 
partially damaged membranes at various sites. 
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The untreated 5'. aureus cells retained their coccal morphology and seemed to be normal 
(Fig 55 a-d). In contrast, S. aureus cells treated with the AgNPs appeared to undergo 
lysis, their cell wall was breakdown, resulting in the release of their cellular contents into 
the surrounding environment, and finally became disrupted (Fig 55 al-dl & a2-d2). In 
cross section, the untreated cells of S. aureus showed normal cell characteristics and 
homogeneous electron density in the cytoplasm. Their cell walls and membranes were 
intact, showing a well-preserved peptidoglycan layer and cytoplasmic membrane (Fig 55 
a-d). However, significant morphological changes were observed in S. aureus cells 
treated with the AgNPs. They showed lysed cells with broken walls and membranes and 
decreases and heterogeneity in electron density in the cytoplasm. The localized separation 
of the cell membrane from the cell wall could be discerned (Fig 55 al-dl & a2-d2). 
Figure 55. HR-TEM images of S. aureus cells, (a-d) Untreated, (al-dl) treated with 
AgNPs (5-10 nm) at 30 ng/ml and (a2-d2) at 100 ^g/ml. Arrows indicates the partially 
damaged membranes and cell walls at various sites. 
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4.8.2.2. HR-TEM analysis of the E. coli, P. aeruginosa and S. aureus cells treated 
with ZnO NPs 
Figure 56a shows thin sections of E. coli grown in free LB liquid medium. The E. coli 
cell wall is composed of an organized triple membrane containing a thin inner layer of 
peptidoglycan between an outer membrane and a cytoplasmic membrane (Fig. 56a). 
However, E. coli treated with ZnO NPs shows changes in the morphology of the cells 
(Fig. 56b-d). It is interesting to note that cell elongation, without any sign of the onset of 
a cellular division process and disorganization in the cell wall, was observed (Fig. 56c-d). 
The cell membrane in E. coli is extensively damaged and, most probably, the intracellular 
content has leaked out. 
20Onni 
Figure 56, HR-TEM images of E. coli cells, (a) Untreated, (b-d) treated with ZnO NPs 
(70 nm). 
In cross section, the untreated cells of P. aeruginosa showed normal cell characteristics. 
The internal structure of the untreated P. aeruginosa cells appeared to be normal, 
showing a multilayered cell surface consisting of an outer membrane, a peptidoglycan 
layer in the periplasmic space, and a cytoplasmic membrane (Fig, 57a). However, 
significant morphological changes were observed in P. aeruginosa cells treated with ZnO 
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NPs. They showed lysed cells with broken walls and membranes. Damaged cells showed 
either localized or complete separation of the cell membrane from the cell wall (Fig. 57b-
c). The cellular degradation was also accompanied by electron-translucent cytoplasm and 
cellular disruption in the damaged cells. 
Figure 57. HR-TEM images of P. aeruginosa cells, (a) Untreated, (b-c) treated with ZnO 
NPs (70 nm). 
The untreated S. aureus cells retained their coccal morphology and seemed to be normal 
(Fig. 58a). In contrast, 5'. aureus cells treated with the ZnO NPs appeared to undergo 
lysis, their cell wall was breakdown, resulting in the release of their cellular contents into 
the surrounding environment, and finally became disrupted (Fig. 58b-d). In cross section, 
the untreated cells of 5. aureus showed normal cell characteristics and homogeneous 
electron density in the cytoplasm. Their cell walls and membranes were intact, showing a 
well-preserved peptidoglycan layer and cytoplasmic membrane (Fig. 58a). However, 
significant morphological changes were observed in S. aureus cells treated with the ZnO 
NPs. They showed lysed cells with broken walls and membranes and decreases and 
heterogeneity in electron density in the cytoplasm. The localized separation of the cell 
membrane fi-om the cell wall could be discerned (Fig. 58b-d). 
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Figure 58. HR-TEM images of S. aureus cells, (a-d) Untreated, (b-d) treated with ZnO 
NPs (70 nm). Arrows indicates the partially damaged membranes and cell walls at 
various sites. 
4.8.2.3. HR-TEM analysis of the E. coll, P. aeruginosa and S. aureus cells treated 
with AI2O3 NPs 
Figure 59 (a) shows ultra thin sections of E. coli grown in free LB liquid medium. This 
bacterium is a moderately sized Gram-negative bacillus that presents a tubular form. The 
E. coli Gram-negative cell wall is composed of an organized triple membrane containing 
a thin inner layer of peptidoglycan between an outer membrane and a cytoplasmic 
membrane (Fig 59a). E. coli cells diluted in PBS showed normal morphology having 
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many filaments, such as flagella and fimbriae (Fig. 59b).The fimbriae were peritrichous, 
approximately 7 nm wide, and up to 900 nm long. After treatment with AI2O3 NPs, E. 
coli exhibited extensive injury to the cell membrane. The cytoplasmic region appeared to 
have significantly changed, becoming inhomogeneous as compared to the control. It is 
clear from the image that the nanoparticles have attached at first to the outer membrane 
of the ceil which has further lead to cell breakage finally resulting in cell damage and cell 
lysis (Fig. 60a). However, the nanoparticles have attached to the outer wall of the cell in 
the beginning in the treated bacteria, as well as inside the cytoplasm (Fig. 60a-d). NPs of 
smaller size were found to be uniformly distributed inside the cells whereas agglomerated 
particles having bigger size adhered on the membrane (Fig. 60a-d). 
Figure 59. HR-TEM ultrastructural images of £. coli cells (A-B) 
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Figure 60. HR-TEM images of E. coli cells treated with AI2O3 NPs (<50 nm). (a-b) at 
low and (c-d at higher magnification. Red arrow indicates nanoparticles attachment on 
membrane, white arrow showed partially damaged membranes at various sites and yellow 
indicates nanoparticles inside the cell. 
The internal structure of the untreated P. aeruginosa cells appeared to be normal, 
showing a multilayered ceil surface consisting of an outer membrane, a peptidoglycan 
layer in the periplasmic space, and a cytoplasmic membrane (Fig. 61 a), while membrane 
of treated cells were damaged severely; many pits and gaps appeared in the micrograph, 
and their membrane was fragmentary. Damaged cells showed either localized or 
complete separation of the cell membrane from the cell wall (Fig. 61b-d). The cellular 
degradation was also accompanied by electron-translucent cytoplasm and cellular 
disruption in the damaged cells. The cells showed aberrant morphology; they were 
cracked and ruptured. Electron-dense particles or precipitates were also observed around 
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damaged bacterial cells. Nanoparticles that accumulated in the membrane as well as some 
penetrating the cells can also be discerned in the HR-TEM micrograph. Figure 61 (c) & 
(d), clearly shows that the nanoparticles enter inside the bacterial cells and anchor the cell 
at several sites and cause damage at various sites in the membrane, which could result in 
cell lysis. 
Figure 61. HR-TEM images of P. aeruginosa (a) untreated, (b-d) 
treated with AI2O3 NPs (<50 nm). White arrows indicate nanoparticles 
attachment on membrane surface & inside the cells, while red arrows 
indicate damaged membrane at various sites. 
154 
(Results 
In ultrathin section, the untreated cells of S. aureus showed normal cell characteristics 
and homogeneous electron density in the cytoplasm. Their cell walls and membranes 
were intact, showing a well-preserved peptidoglycan layer and cytoplasmic membrane 
(Fig. 62a-c). However, significant morphological changes were observed in S. aureus 
cells treated with the AI2O3 NPs. The localized separation of the cell membrane from the 
cell wall could be discerned. It is clear from the image that the nanoparticles have 
attached at first to the outer membrane of the cell which has further lead to cell breakage 
finally resulting in cell damage and cell lysis (Fig, 62, al-cl). However, the nanoparticles 
have attached to the outer wall of the cell in the beginning, and further, they have entered 
the inner wall of the cell which can be seen in the images (Fig. 62, al). In case of S. 
aureus, owing to the damage of the cell membrane, the disorganized intracellular 
contents have leaked out resulting in damage of the bacterial cells, whereas cellular 
division was represented for S. aureus growth. 
Figure 62. HR-TEM images of S. aureus (a-c) untreated, (al-cl) treated with AI2O3 NPs 
(<50 nm). Red arrow indicates nanoparticles attachment on membrane surface & inside 
the cells, while black arrows indicate damaged membrane at various sites. 
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4.9. Screening of biofilm formation by E. coll, S. aureus and P. aeruginosa 
4.9.1. Screening of biofilm formation on CRA 
Table 50 (a) shows that out of 40 isolates of E. coli, 52 of S. aureus and 55 of P. 
aeruginosa tested for biofilm formation by CRA method, 26 (65%) isolates of E. coli, 41 
(78.85%) isolates of S". aureus and 33 (60%) isolates of P. aeruginosa produced black 
colonies. However only 14 (35%) isolates of £. coli, 25 (48.08%) isolates of 5". aureus 
and 15 (27.27%) isolates of P. aeruginosa colonies were black in color with dry 
crystalline consistency which is indicative of biofilm formation. 12(30%) E. coli, 
16(30,77%) S. aureus, 18 (32.23%) P. aeruginosa isolates were black in color but were 
not dry and crystalline and were indeterminate for biofilm formation. These isolates were 
also taken as negative for biofilm formation. 14(35%) E. coli, 11 (21.15%) 5". aureus and 
22(40%) P. aeruginosa isolates produced pink colonies which were taken as negative for 
biofilm formation (Fig. 63). 
Table SOa. Screening of E. coli (n=40), S. aureus (n=52) and P. aeruginosa (n=55) 
isolates for biofilm formation by Congo Red Agar (CRA) method. 
Colony Appearance on 
(CRA) 
Pink /Red (negative) 
Black colonies without dry 
crystalline consistency 
(indeterminate) 
Black colonies with dry 
crystalline consistency 
(positive) 
E. coli 
(%) 
14(35) 
12(30) 
14(35) 
S. aureus 
(%) 
11 (21.15) 
16(30.77) 
25 (48.08) 
P. aeruginosa 
(%) 
22(40) 
18(32.73) 
15(27.27) 
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Figure 63: Screening of biofilm formation on BHI agar supplemented with Congo red (a) 
E. coli, (b) P. aeruginosa and (c) S. aureus (black colonies). 
4.9,2. Screening of biofilm formation by TCP method 
In the quantitative assay for the biofilm production, the isolates were classified as highly 
biofilm producing (strongly adherent), moderate adherent isolates and non- biofilm 
producers (weak/non-adherent). Quantitative microtitre assay for biofilm formation was 
strongly positive in 8(20%) isolates of £. coli, 6(11.54%) S. aureus and 10 (18.2%) P. 
aeruginosa (62%) while the remaining isolates were either moderate adherent (14 (35%) 
E. coli, 30(57.69%) S. aureus and 28(50.9%) P. aeruginosa) or weak/non- biofilm 
producers (18 (45% E. coli, 16(30.77%) S. aureus and 17(30.9%) P. aeruginosa) (Table 
50b). Isolates screened for biofilm formation by microtitre plate assay method are shown 
in figure 64. 
Table 50b. Screening of E. coli (n=40), S. aureus (n=52) and P. aeruginosa (n=55) 
isolates for biofilm formation by Tissue Culture Plate (TCP) Method. 
Biofilm production (TCP) 
Weak/Non(< 0.120 OD) 
Moderate (0.12-0.24 OD) 
High (> 0.24 OD) 
E. coli 
(%) 
18(45) 
14(35) 
8(20) 
S. aureus (%) 
16(30.77) 
30 (57.69) 
6(11.54) 
P. aeruginosa (%) 
17(30.9) 
28(50.9) 
10(18.2) 
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Figure 64. Screening of biofilm producers by TCP method: high, moderate and non 
slime producers differentiated with crystal violet staining were shown on 96 well 
tissue culture plate. 
4.9,3. Screening of biofilm formation by Tube method 
Qualitative tube method of biofilm screening of bacterial isolates showed that 18 (45%) 
isolates of E. coli, 33(63.46%) isolates of 5'. aureus and 32(58.18%) isolates of P. 
aeruginosa were positive for biofilm production (table 50c). Most of the isolates showed 
thick blue ring at the liquid-air interface. Some of the isolates showing biofilm formation 
by tube method are shown in figure 65. 
Table 50c. Screening of E. coli (n=40), S. aureus (n=52) and P. aeruginosa (n=55) 
isolates for biofilm formation by Tube method. 
Biofilm Production 
0/1 (weak/ non) 
2 +(moderate) 
3 + (strong) 
E. coli (%) 
14(35) 
12(30) 
6(15) 
S. aureus (%) 
19 (36.54) 
25 (48.08) 
8(15.39) 
P. aeruginosa (%) 
23(41.82) 
20(36.36) 
12(21.82) 
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Figure 65. Screening of biofilm formation by tube method by E. coli (1), /*. aeruginosa 
(2) and S. aureus (3). A: High- biofilm producer, B: Moderate- biofilm producer, C: Non 
biofilm producer. 
4.10. Characterization of antibiofllm activity of AgNPs 
4.10.1. Characterization of antibiofllm activity of AgNPs on CRA plates 
Biofilm formation is detected in many organisms synthesizing exopolysachharides. The 
biofilm is made up of microorganisms adhering to the surface coated with slime- the 
exopolysachharide matrix which protects the microbes fi-om the unfavorable 
environmental factors. Biofilm formation by E. coli, P. aeruginosa, and S. aureus were 
tested by growing the organism in Brain heart infusion agar supplemented with Congo 
red (BHIC) with and without silver nanoparticles. When the colonies were grown without 
AgNPs in the medium, the organisms appeared as dry crystalline black colonies, 
indicating the production of exopolysachharides, which is the prerequisite for the 
formation of biofilm (Fig. 66). Whereas when the organisms were grown on BHIC with 
AgNPs, the organisms did not survive. During the treatment with reduced concentrations 
of AgNPs (10 ng/ml), the organisms continued to grow, but AgNPs treatment has 
inhibited the synthesis of exopolysachharides, indicated by the absence of dry crystalline 
black colonies (Fig. 66). It was found that higher concentration of AgNPs inhibited 
bacterial growth by more than 98%. When the exopolysachharide synthesis is arrested, 
the organism cannot form biofilm. It was also observed that 20|ig/ml of AgNPs 
significantly arrested biofilm formation without affecting viability, whereas 50|ig/ml 
completely blocked the biofilm formation and inhibited the growth of the organism itself. 
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Figure 66. Effects of AgNPs (5-10 nm) on biofilm formation in BHI agar supplemented 
with Congo red. The appearance of black crystalline colonies indicate the exo-
polysachharide production by E. coli (a) P. aeruginosa (b) and S. aureus (C), whereas the 
addition of 50 |ig/ml 5-10 nm AgNPs blocked the exopolysachharide synthesis by E. 
coli (al) P. aeruginosa (bl) and S. aureus (CI) and also inhibited the growth of the 
organism itself. 
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4.10.2. Characterization of antibiofilm activity of AgNPs by confocal laser scanning 
microscopy 
CLSM analysis of biofilms formation by E. coli (Fig 67), P. aeruginosa (Fig 68), and S. 
aureus (Fig 69), was performed to examine the effects of coating of AgNPs (5-10 nm) on 
biofilm architecture using AgNPs-coated glass cover slips in a 12-well microtiter plate. 
To visualize bacterial cells and the surrounding glycocalyx matrix (which is indicative of 
bacterial biofilm formation), double staining was performed using propidium iodide and 
ConA- FITC. Bacterial cells stained red and were easily identified by their size and 
morphologic features, when using propidium iodide. Con A-FITC binds to mannose 
residues resuUing in green staining and indicating the presence of a bacterial glycocalyx. 
Although, we observed the marked colocalization of green Con A-FITC staining with 
clusters of bacterial cells, the staining of the matrix was not homogeneously distributed. 
The presence of dark areas within the biofilm can be explained by the existing water 
channels, the heterogeneous production of the matrix and the types of exopolysachharides 
within the biofilm, as well as the absence of Con A-FITC binding to the matrix. When 
CLSM images with red and green fluorescent intensities were superimposed, yellow 
color (green+red) revealed that the extracellular-ConA-FITC-reactive polysaccharide 
(green) was produced in the intracellular spaces (red), indicating thereby that 
extracellular polysaccharides were produced as a capsular component in biofilm. We 
observed that interconnected bacteria were encased in a scaffolding network composed of 
extracellular matrix, suggesting a 3-dimensional architecture of biofilm formations. The 
micrographs suggest that the biofilm formed on uncoated AgNPs surfaces covered a 
larger surface area and had a definite architecture (Fig. 67-69, first panels). However, the 
biofilms formed on coverslips coated with AgNPs showed no or few spread cells with no 
distinct pattern of arrangement. S. aureus cells exhibited shape distortions, indentations 
(Fig 69) and P. aeruginosa cells exhibited shape distortions and slight elongation (Fig 68) 
after exposure to AgNPs. The cells grown in the presence of 30 ng/ml AgNPs show a 
complete absence of clumped cells and were individually scattered over the surface rather 
than in any arrangement. Uncoated cover slips surfaces supported a massive biofilm 
formation all bacterial cells, while AgNPs-coated surfaces dramatically restricted 
bacterial colonization. 
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Figure 67. CLSM micrographs of E. coli biofilm. The first panels from left to right 
represent CLSM images of native E. coli biofilm. Most of the bacteria were rod shaped, 
with interconnected bacteria being encased in a scaffolding network composed of an 
extracellular matrix, suggesting a 3-dimensional architecture of biofilm formations. Red 
color is PI staining of bacterial nucleic acids and green fluorescent staining (Con A-
FITC) around bacteria indicates the presence of exopolysachharides. Whereas, the second 
panels from left to right represent CLSM images of E. coli biofilm treated with AgNPs 
(5-10 nm) and most of the cells were dead and no exopolysachharides (green fluorescent) 
was observed. The number of live bacterial cells was reduced significantly, and the 3-
dimensional structure was also disrupted. Magnification XI00. 
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Figure 68. CLSM micrographs of P. aeruginosa biofilm. The first panels from left to 
right represent CLSM images of native P. aeruginosa biofilm. Most of the bacteria were 
rod shaped, with interconnected bacteria being encased in a scaffolding network 
composed of an extracellular matrix, suggesting a 3-dimensional architecture of biofilm 
formations. Red color is PI staining of bacterial nucleic acids and green fluorescent 
staining (Con A-FITC) around bacteria indicates the presence of exopolysachharides. 
Whereas, the second panels from left to right represent CLSM images of P. aeruginosa 
biofilm treated with AgNPs (5-10 nm) and most of the cells were dead and no 
exopolysachharides (green fluorescent) was observed. The number of live bacterial cells 
was reduced significantly, and the 3-dimensional structure was also disrupted. 
Magnification XI00. 
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Figure 69. CLSM micrographs of S. aureus biofilm. The first panels from left to tight 
represent CLSM images of native S. aureus biofilm. Most of the bacteria were cocci 
shaped, with interconnected bacteria being encased in a scaffolding network composed of 
an extracellular glycocalyx matrix, suggesting a 3-dimensional architecture of biofilm 
formations. Red color is PI staining of bacterial nucleic acids and green fluorescent 
staining (Con A-FITC) around bacteria indicates the presence of glycocalyx and cells 
were eiicased in a glycocalyx matrix. Whereas, the second panels from left to right 
represent CLSM images of 5*. aureus biofilm treated with AgNPs (5-10 nm) and most of 
the cells exhibited shape distortions and slight elongation and almost no 
exopolysachharides (green fluorescent) was observed. The number of live bacterial cells 
was reduced significantly, and the 3-dimensionai structure was also disrupted. 
Magnificafion XIOO. 
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4.10,3. Characterization of antibiofilm activity of AgNPs by scanning electron 
microscopy 
The biofilm grown on glass slide for 24 h was observed using scanning electron 
microscopy. Irregularly shaped spaces resembling water channels were observed among 
dense structures and biofilm formed by the native strain have aggregated and clumped 
bacterial cells. The E. coli (Fig 70a), P. aeruginosa (Fig. 71 a) and S. aureus (Fig. 72a) 
cultures grown without AgNPs exhibit the expected normal cellular morphology with 
smooth cell surfaces. Under the same growth conditions but in the presence of 5-10 nm 
AgNPs (20 ng/ml); E. coli (Fig. 70b), P. aeruginosa (Fig. 71b) and S. aureus (Fig. 72b) 
cells, shows changes in morphology and it was also examined that AgNPs inhibit 
bacterial colonization on the surfaces. The apparent biofilm formed by S. aureus has very 
few cells individually scattered along the surface. The cells were arranged in short chains 
with absence of exopolysachharides matrix. The biofilm formed by the S. aureus was 
very much patchy (Fig. 72a). More specifically, an obvious increase in the roughness of 
the cell surface suggested that it has been damaged by the nanoparticles. Microscope 
evaluation of the surfaces clearly shows that the AgNPs treated glass surfaces do not 
allow bacterial colonization and biofilm formation compared to the untreated controls. 
Untreated glass surfaces supported a massive biofilm formation by E. coli, P. aeruginosa 
and S. aureus (Fig. 70a, 71a, 72a), while AgNPs treated glass surfaces shows 
dramatically restricted bacterial colonization and biofilm formation (Fig. 70b, 71b, 72b). 
These results suggest that AgNPs are effective in restraining bacterial colonization of the 
surface. 
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Figure 70. SEM images of E. coli biofilms developed on the glass slide surface at 24 hrs 
of incubation. Untreated (a) and treated (b) with AgNPs (5-10 nm) at (30 ng/ml). 
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Figure 71. SEM images of P. aeruginosa biofilms developed on the glass slide surface at 
24 hrs of incubation. Untreated (a) and treated (b) with AgNPs (5-10 nm) at (30 ng/ml). 
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Figure 72. SEM images of S. aureus biofilms developed on the glass slide surface at 24 
hrs of incubation. Untreated (a) and treated (b) with AgNPs (5-10 nm) (30 ^ig/ml). 
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4.11. Evaluation of toxicological effects of ZnO NPs in mice in vivo 
4.11.1. Biochemical observations 
4.11.1.1. Analysis of liver-function biomarker after 1 week of treatment ZnO NPs 
It was observed that the ALB level was decreased at all doses and this decreased was 
statistically significant at 0.5-, 3-, and 5-g/kg (p<0.05). However, decreased in the TP 
levels was also noticed in all groups but were statistically significant (p<0.05) at 0.5- and 
5-g/kg, respectively. Though decreased TIBL levels were also observed at all doses but 
were not statistically significant. The ALP level in serum is often tested along with 
SGOT and SGPT to evaluate the damaged or diseased liver. In liver dysfunction, the 
levels of the above enzymes have been shown to rise. Increased ALP values were 
observed at all doses but statistically significant {p <0.05) at high- and exceptionally 
high-doses (3- & 5-g/kg). In the present study, a decrease in SGOT level was noticed at 
all doses compared to control but statistically not significant. An increased SGPT levels 
were also observed at all doses but were statistically not significant (Table 51a). 
Table 51a. Change in liver-function biomarkers after 1 week exposure to increasing 
doses of ZnO NPs in mice (mean±S.D.) 
Dose 
(g/kg) 
0.5 
1 
Control 
ALB 
(g/dL) 
3.1iO.I4* 
3.5±0.07 
3.2±0.07* 
3.1 ±0.07* 
3.8i{).14 
TP 
(g/dL) 
5.4±0.14* 
5.9±0.2) 
5.7±0.56 
5.4±0.35* 
6.5±0.07 
TIBL 
(mg/dL) 
1.5±0.79 
L4±0.47 
0.8±0.28 
0.9±0.13 
1.0±0.09 
SGOT 
(U/L) 
207.1 ±80.93 
177.3±27.93 
I35.1±7.I3 
163.9±26.66 
217.9±37.85 
SGPT 
(U/L) 
73.8±I8.92 
7L3±11.16 
80.4±13.72 
72.9±4.21 
5L2±L45 
ALP J 
251.5±30.94 
2%.8±22.38 
403.3±6I.68* 
459.9±70.61* 
263.9±104.37 
*Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: ALB (0.005) and 
ALP (0.008). 
4.11.1.2. Analysis of liver-function biomarker after 2 week of treatment 
It was noticed that ALB was decreased at all doses but were statistically significant {p 
<0.05) at high- and exceptionally high-dose (3- & 5-g/kg). However, no obvious changes 
were observed in the TP levels in all groups and these changes were statistically not 
significant. The TIBL levels were decreased in all groups of treated mice but the value 
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was statistically significant only at high-dose (3-g/kg) only. A statistically significant 
{p <0.05) increased in the ALP values were observed only at high doses (3- & 5-g/kg). 
However, decreased in the SGOT levels were noticed at all doses compared to the control 
group but were statistically not significant. Similarly, no remarkable changes were 
observed in the SGPT levels in all groups of treated mice and were statistically not 
significant (Table 51b). 
Table 51b. Change in liver-function biomarkers after 2 week exposure to increasing 
doses of ZnO NPs in mice (mean±S.D.) 
r Dose 
l(g/Kg) 
1 Control 
ALB 
(g/dL) 
3.5±0.49 
3.6±0.28 
3.2±0.21* 
3.0±0.10* 
3.8±0.14 
TP 
(g/dL) 
6.7±1.13 
6.1±0.14 
5.7±0.28 
5.9i0.51 
6.5±0.07 
TIBL 
(rag/dL) 
0.67±0.06 
0.6±0.02 
0.5±0.28* 
0.7±0.9 
1.1 ±0.09 
SGOT 
(U/L) 
163.9±17.12 
I84.3±4.14 
164.1 ±22.83 
220.9±14.70 
217.9±37.85 
SGPT 
(U/L) 
44.3±12.10 
50.3±0.85 
52.0±I1.10 
51.2±1.45 
51.2±1.45 
ALP ^ 
(U/L) 
189.4±57.6.-. 
385.7±30.86 
659.1 ±49.62* 
401.1±85.05* 
263.9±104.37 
* Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: ALP (0.000) & 
SGOT (0.016). 
4.n.l.3. Analysis of liver-function biomarker after 3 week of treatment 
Decreased in the ALB level was observed in all groups of treated mice, but statistically 
significant at exceptionally high-dose (5-g/kg). No significant change in the TP levels 
were notice in all groups of treated mice. Although decreased in the TIBL level was 
observed in all groups but this decreased was statistically significant only at low-dose 
(0.5-g/kg). An increased in the ALP values were observed at all doses but this increased 
was statistically significant {p <0.05) only at low doses (0.5-g/kg). A decrease in the 
SGOT levels was noticed in all groups of treated mice compared to the control group and 
was statistically not significant. Similarly, an increased in the SGPT levels were observed 
in all groups of treated mice but were statistically not significant (Table 51c). 
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Table 51c. Change in liver-function biomarkers after 3 week exposure to increasing 
doses of ZnO NPs in mice (mean±S.D.) 
Dose 
(g/Kg) 
0.5 
1 
3 
5 
Control 
ALB 
(g/dL) 
3.6±0.30 
3.3±0.07 
3.5±0.25 
3.1 ±0.30* 
3.8±0.14 
TP 
(g/dL) 
6.6±0.30 
6.3±0.14 
6.6±0.36 
6.2±0.41 
6.5±0.07 
TIBL 
(mg/dL) 
0.3±0.14* 
0.9±0.24 
0.6±0.31 
0.8±0.14 
1.0±0.09 
SCOT 
(U/L) 
I77.5±11.79 
183.8±60.23 
159.2±37.79 
203.7±15.47 
217.9±37.85 
SGPT 
(U/L) 
73.7±27.05 
84.9±5.36 
64.8± 14.94 
69.3±13.57 
51.3±1.45 
ALP 
(U/L) 1 
529.9± 145.89* 
401.4± 130.89 
388.3±31.44 
297.4±80.74 
263.9±104.37 
*Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: TIBL (0.032). 
4.n.L4, Analysis of liver-function biomarker after 4 week of treatment 
After 4 week of treatment it was observed that the level of ALB decreased in all groups 
of mice, but this decreased was statistically significant at exceptionally high-dose (5-
g/kg) (p <0.05). No obvious changes were notice for TP in all groups compared to the 
control. It was also observed that the TIBL levels were decreased in all groups and but 
this decreased was statistically significant at high-dose (3-g/kg). Increased ALP values 
were observed at all doses but this increased was statistically significant (p <0.05) at I-
and 5-g/kg. No significant changes were notice in the SGOT levels compared to the 
control group. Although increased SGPT levels were observed in all groups but were 
statistically not significant (Table 5Id). 
Table 51d. Change in liver-function biomarkers after 4 week exposure to increasing 
doses of ZnO NPs in mice (mean±S.D.) 
Dose 
(g/Kg) 
0.5 
3 
^Tontrol 
ALB 
(g/dL) 
3.5±0.30 
3.8±0.20 
3.3±0.45 
3.2±0.35* 
3.8±0.14 
TP 
(g/dL) 
6.6±I.I0 
8.2±0.61 
5.7±0.70 
6.0±0.85 
6.5±0.07 
TIBL 
(mg/dL) 
1.2±0.86 
0.7±0.34 
0.3±0.09* 
0.6±0.45 
I.0i0.09 
SGOT 
(U/L) 
162.) ±18.36 
2I8.6±30.28 
213.6±25.45 
202.7±9.11 
2I7.9±37.85 
SGPT 
(U/L) 
85.7±15.34 
78.1±4.6I 
86.0±40.90 
82.9±9.82 
51.3±1.45 
ALP 1 
(U/L) 1 
296.9±8.22 
539.9±79.02* 
362.3±133.18 
507.1 ±132.98* 
263.9±104.37 
•Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: ALP (0.040) & 
TP (0.032). 
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4.11.1.5. Analysis of kidney-function biomarkers after 1 week of treatment of ZnO NPs 
The level of BUN reflects the filtration functional status of nephrons. In the present 
study, no significant changes were observed in all groups of treated mice; indicating the 
filtration ftinction of glomerulus remains unaffected. However, it was observed that the 
UA levels decreased in all groups of treated mice and this decreased was statistically 
significant (p<0.05) at all doses (Table 52a). The interesting finding of increased UA 
clearance remains to be explained. 
Table 52a. Change in kidney-function biomarkers after 1 week exposure to 
increasing doses of ZnO NPs in mice (mean±S.D.) 
p 
^ 
Dose 
0.5 g/Kg 
Ig/Kg 
3 g/Kg 
5 g/Kg 
Control 
BUN(mg/dL) 
24.66±0.54 
20.48±3.98 
16.46±4.15 
18.28±3.25 
23.66±1.49 
UA(mg/dL) 
5.30±0.14* 
5.00±0.00* 
5.00±0.28* 
5.65±0.21* 
6.85±0.21 
CR(mg/dL) M 
0.45±0.07 
0.55±0.07 
0.60±0.00 
0.5at0.28 
0.40±0.42 
•Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: UA (0.001). 
4.11.1.6. Analysis of kidney-function biomarkers after 2 week of treatment of ZnO NPs 
In the present study, however, no obvious change in the BUN and CR levels was notice at 
all doses. However, it was observed that the UA levels decreased in all groups of treated 
mice and interestingly this decreased was statistically significant (p<0.05) at all doses 
(Table 52b). 
Table 52b. Change in kidney-function biomarkers after 2 week exposure to 
increasing doses of ZnO NPs in mice (mean±S.D.) 
• Dose 
I 0.5 g/Kg 
Ig/Kg 
3 g/Kg 
5 g/Kg 
1 Control 
BUN(mg/dL) 
25.70±9.22 
18.82±0.27 
18.18±3.38 
20.95±1.34 
23.66±1.49 
UA(mg/dL) 
2.85±0.21* 
4.65±0.21* 
4.86±0.15* 
3.76±0.11* 
6.85±0.21 
CR(mg/dL) 
0.60±0.I4 
0.60±0.00 
0.4ftt0.17 
0.46±0.15 
0.40±0.42 
•Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: 2"^ * week-UA (0.00). 
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4.I1.I.7. Analysis of kidney-function biomarkers after 3 week of treatment of ZnO 
In the present study, no obvious change was noticed in the BUN level at all doses, except 
at middle-dose (1-g/kg); at this dose the BUN level decreased and this decreased was 
statistically significant (p<0.05). It was also observed that the CR levels increases in all 
groups of treated mice but this increased was statistically significant at exceptionally 
high-dose (5-g/kg). The level of UA decreased in all groups and were interestingly 
statistically significant (/7<0.05) at 0.5-, 1- and 3-g/kg (Table 52c). 
Table 52c. Change in kidney-function biomarkers after 3 week exposure to 
increasing doses of ZnO NPs in mice (mean±S.D.) 
I Dose BUN(mg/dL) UA(mg/dL) CR(mg/dL) 
I 0.5g/Kg Ig/Kg 3g/Kg 5g/Kg 
Control 
I7.73±0.93 
13.84±9.75* 
I9.04±0.89 
24.57±3.62 
23.66±1.49 
4.33±0.11* 
5.20±0.14* 
4.40±0.20* 
6.4±1.I6 
6.85±0.21 
0.63±0.05 
0.40±0.14 
0.63±0.n 
OJOtO.lO* 
0.40±0.42 
*Represents significant difference fi-om the control group (Dunnett's, <0.05). 
4.11.1.8. Analysis of kidney-function biomarkers after 4 week of treatment of ZnO NPs 
In the present study, BUN did not show obvious change at all doses compared to control 
and remained statistically insignificant, indicating unaffected functional status of 
nephrons. The CR levels increased in all groups of treated mice but were statistically 
significant (p<Q.Q5) at high- and exceptionally high-dose (3- & 5-g/kg). Decreased in UA 
level was notice in all groups of treated mice but this decreased were statistically 
significant (/7<0.05) at 0.5- and 3-g/kg (Table 52d). 
Table 52d. Change in kidney-function biomarkers after 4 week exposure to 
Dose 
• 0.5g/Kg 
• Ig/Kg 
• 3g/Kg 
• Sg/Kg 
W' Control 
BUN(mg/dL) 
21.03±4.47 
26.16±5.48 
21.64±0.96 
24.57±3.62 
23.66±1.49 
UA(mg/dL) 
4.63±0.25* 
5.46±0.15 
4.60±0.43* 
6.4±1.16 
6.85±0.21 
CR(mg/dL) 
0.60±0.10 
0.53±0.05 
0.66±0.05* 
0.70±0.10* 
0.40±0.42 
•Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups: - UA (0.006) 
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4.11.1.9. Change in lipid profile and glucose level after 1 week of treatment of ZnO NPs 
In the present study, no statistically significant changes were observed for CHO, TG and 
GLU at all doses compared to the control. The level of HDL decreased in all groups of 
mice but this decreased was statistically significant {p <0.05) at exceptionally high-dose 
(5-g/kg) (Table 53a). 
Table 53a, Change in lipid profile and glucose level after 1 week of exposure to ZnO 
NPs (meaniS.D.) in mice. 
P Dose 
0.50 g/Kg 
1.00 g/Kg 
3.00 g/Kg 
5.00 g/Kg 
Control 
CHO(mg/dL) 
139.25±0.35 
122.45±15.34 
124.80±14.28 
130.25± 15.34 
135.65±5.44 
HDL(mg/dL) 
70.00±6.08 
57.60±2.26 
61.95±5.30 
49.00±8.34* 
76.05±4.31 
TG(mg/dL) 
158.82±41.60 
161.35±33.27 
336.14± 11.87 
378.16±30.90 
231.82± 112.49 
GLlJ(mg/dL) 
144.85±20.01 
126.20±41.43 
194.80±93.90 
199.60±]5.83 
170.30±3.39 
I 
*Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: HDL (0.028) & TG (0.037). 
4.11.1.10. Change in lipid profile and glucose level after 2 week of treatment of ZnO NPs 
No statistically significant changes were notice in the CHO, TG and GLU levels at all doses 
compared to the control. The level of HDL decreased in all groups of mice and interestingly 
this decreased was statistically significant {p <0.05) at all given doses (Table 53b). 
Table 53b. Change in lipid profile and glucose level in serum of mice after 2 week 
with exposure to ZnO NPs (mean±S.D.) 
i Dose 
0.50 g/Kg 
1.00 g/Kg 
3.00 g/Kg 
5.00 g/Kg j 
Control 
CHO(mg/dL) 
106.95±24.11 
I38.75±3.32 
134.90±6.20 
162.27±24.08 
135.65±5.44 
HDL(mg/dL) 
50.65±3.40* 
54.8(>i:9.33* 
50.33±2.75* 
59.23±2.85* 
76.05±4.31 
TG(mg/dL) 
162.18±22.58 
99.16±7.12 
157.98±35.77 
265.55±147.06 
231.82± 112.49 
GLU(mg/dL) 
I23.60±2.54 
I55.05±17.88 
13L23±37.01 
119.67±10.18 
170.30±3.39 
•Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: HDL (0.003). 
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4.11.1.11. Change in lipid profile and glucose level after 3 week of treatment with 
ZnO NPs 
In the present study, no statistically significant (p >0.05) changes were observed for 
CHO, HDL, TG and GLU at all doses compared to the control group (Table 53c). 
Table 53c. Change in lipid profile and glucose level in serum of mice after 3 week of 
exposure to ZnO NPs (mean±S.D.) 
' Dose 
0.50 g/Kg 
1.00 g/Kg 
3.00g/Kg 
5.00 g/Kg 
Control 
CHO(mg/dL) 
143.67± 15.49 
133.30±17.53 
137.97±2.17 
]23.53±22.85 
135.65±5.44 
HDL(mg/dL) 
74.33±8.79 
68.15±22.41 
69.90±17.56 
86.03± 17.65 
76.05±4.31 
TG(mg/dL) 
270.67± 17.34 
382.97± 184.56 
197.83±13.07 
187.70±103.18 
231.82±n2.49 
GLU(mg/dL) 
210.57±13.55 
185.50±54.16 
178.33±31.08 
132.13±38.53 
170.30±3.39 
*Represents significant difference from the control group (Dunnett's, <0.05). 
4.11.1.12. Change in lipid profile and glucose level after 4 week of treatment of ZnO 
NPs 
No statistically significant (p >0.05) changes were also observed for CHO, HDL, TG and 
GLU at all doses compared to control after 4 week of exposure to ZnO NPs (Table 53d). 
Table 53d. Change in lipid profile and glucose level in serum of mice after 4 week of 
exposure to ZnO NPs (mean±S.D.) 
Dose 
0.50 g/Kg 
1.00 g/Kg 
3.00 g/Kg 
5.00 g/Kg 
Control 
CHO(mg/dL) 
144.67±7.80 
I47.80±14.87 
136.40± 18.60 
152.43±33.28 
135.65±5.44 
HDL(mg/dL) 
84.10±3.85 
89.03±3.66 
94.86±I9.94 
92.13±23.90 
76.05±4.31 
TG(mg/dL) 
234.86±70.08 
180.61 ±10.45 
148.49±30.26 
151.51 ±84.24 
231.82±112.49 
GLU(mg/dL) 
194.93±33.62 
201.4fti:51.47 
U2.00±33.21 
223.43±87.28 
I70.3a±3.39 
•Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: not significant. 
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4.11.2. Histopathological observations of liver, kidney and spleen after 
intraperitoneal administration of ZnO NPs 
Histopathology of liver from control group (Fig 73 a & a') revealed intact hepatocellular 
architecture, normal hepatic laminae and intervening sinusoids. One week and two 
treatments had no obvious effect on the hepatic cytoarchitecture at low- (0.5-g/kg), 
middle- (1-g/kg) and high-dose (3-g/kg), however, exceptionally high-dose (5-g/kg) 
group showed minor vesicular changes having zones of non-specific hepatocellular 
damage (Fig 73 b & c). While, after 3"^ ' (Fig 73d) and 4**' (Fig 73e) week of exposure to 
similar dose (5-g/kg); congested sinusoid, inflammatory cells in the liver and hepatocytes 
with cytoplasmic vesicles were observed (Fig 73 d & e). Control group of kidney (Fig 74 
a & a') showed normal microstructure of renal corpuscle and renal tubules. One week's 
treatment had no perceptible effect on kidney structure at any doses, and was similar to 
that of control. The tubular epithelium was intact (Fig 74b). However, two weeks 
treatment had mild effect in terms of damage to the tubular epithelium at exceptionally 
high dose (5-g/kg) (Fig 74c). While, after 3"* (Fig 74d) and 4* (Fig 74e) week of 
exposure to similar dose (5-g/kg); damage to tubular epithelium of kidney and renal cast 
in the tubular lumen were observed (Fig 74 d & e). Spleen fi-om control group had normal 
histology where red and white pulp could be identified clearly (Fig 75 a & a') and large 
cells (megakaryocytes) were occasionally noticed. After one week of treatment no 
observable changes were noticed at any doses and were very akin to control (Fig 75b). 
However, at exceptionally high dose (5-g/kg) after two week of treatment slight increased 
in the size of megakaryocytes was seen (Fig 75c). While, after 3"^"^  and 4* week of 
exposure to similar dose (5-g/kg) megakaryocyte hyperplasia was observed in the red 
pulp in the spleen and the number of megakaryocytes in the spleen were increased as 
compare to control group (Fig 75 d & e). Thus, T' and 2"^ week treatment had not 
perceptible effect at exceptionally high-dose on the cytoarchitecture on liver, kidney and 
spleen however, 3'^ '' and 4* weeks treatment had only sporadic mild effects on these 
organs. 
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Figure73. Histopathological observation of mice liver after intraperitoneal administration 
of 5-g/kg of ZnO NPs. Control (a & a'): Show normal hepatic cords and sinusoids (red 
arrow). 1 week treatment group (b): Shows vesicular changes (black arrow). 2 week 
treatment group (c): Shows sinusoid (red arrow) and vesicular changes in hepatocytes 
(black arrow). 3 week treatment group (d): Shows hepatocyte with cytoplasmic vesicles 
(yellow arrow) and congested sinusoid (red arrows). 4 week treatment group (e): Shows 
hepatocyte with cytoplasmic vesicles (yellow arrows) and Kupffer cells in sinusoid (red 
arrows). H & E stain, original magnification, X400. 
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Figure74. Histopathological observation of mice kidney after intraperitoneal 
administration of 5g/kg of ZnO NPs. Control (a & a'): Shows normal glomerulus 
(yellow arrow) and renal tubules with intact epithelium (red arrow). 1 week treatment 
group (b): Shows normal glomerulus (yellow arrow) and intact renal tubule (red arrow). 
2 week treatment group (c): Shows damaged tubular epithelium (black arrow). 3 week 
treatment group (d): Shows renal tubules with intact epithelium (red arrow) and 
damaged tubular epithelium (black arrow). 4 week treatment group (e): Shows renal 
tubules with intact epithelium (red arrow) and with damaged tubular epithelium (black 
arrow). H & E stain, original magnification, X400. 
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Figure 75. Histopathological observation of mice spleen after intraperitoneal 
administration of 5-g/kg of ZnO NPs. Control (a & a'): Shows white pulp (white arrow) 
and red pulp (red arrow). 1 «& 2 week treatment groups (b & c), respectively: Shows 
white pulp (white arrow), red pulp (red arrow) and megakaryocyte (black arrow). 3 and 4 
week treatment groups (d & e) respectively: Shows white pulp (white arrow), red pulp 
(red arrow) and multiple megakaryocytes (black arrow). H & E stain, original 
magnification, X400. 
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4.11.3, Transmission electron microscopic observations of liver, kidney and spleen 
after intraperitoneal administration of ZnO NPs 
4.11.3.1. Ultrastructure changes of liver in mice 
Examination under transmission electron microscope the hepatocytes of control mice 
showed the normal ultrastructural pattern; round nucleus with homogeneous chromatin, 
intact nuclear membrane, scattered mitochondria and rough endoplasmic reticulum (Fig 
76a). The 1*' and 2""* week of mice treated with exceptionally high-dose (5-g/kg) of ZnO 
NPs showed quite comparable ultrastructural appearance to those of the control. 
However, slight nuclear chromatin condensation could occasionally observed (Fig 76 b & 
c). However, the 3^^ and 4* week ZnO NPs treated mice with similar dose showed mild 
hepatocellular injury as evidenced by nuclear chromatin condensation and margination; 
dilation of rough endoplasmic reticulum, and swollen mitochondria with distorted cristae 
and cytoplasm appeared to be contains numerous vacuoles (Fig 76 d & e). These 
alteration in ultrastructural features suggested that long-term exposure (up to 28 days) to 
low- (0.5-g/kg), middle- (1-g/kg) and high-dose (3-g/kg) of ZnO NPs did not have 
distinct damaging effects on cell organelles; whereas exceptionally high-dose (5-g/kg) of 
ZnO NPs resulted into features suggestive of early cell necrosis. 
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Figure 76. Transmission electron microscopic observation of mice liver after 
intraperitoneal administration of 5-g/kg ZnO NPs. Control group (a): Showing a normal 
hepatocyte with smooth and rounded euchromatic nucleus (N), prominent nuclear 
membrane (red arrow), regular rough endoplasmic reticulum (white arrow) and many 
round or oval mitochondria with normal cristae (M). Mice exposed for 1 and 2 week (b 
& c) respectively: Showing many mitochondria (M) with normal cristae very similar to 
normal hepatocyte architecture as observed in the control. However, slight condensation 
of chromatin with normal nuclear membrane (c, red arrow) and moderately dilated rough 
endoplasmic reticulum was also observed (c, white arrow). Mice exposed for 3 and 4 
week (d & e) respectively: Showing elongated and swollen mitochondria (M) in 
hepatocytes with some mild-to-moderate distorted cristae (d & e) and dilated & irregular 
rough endoplasmic reticulum (white arrow, d & e). The cytoplasm contains numerous 
vacuoles (black arrow, d & e). Magnification (a, b, c: 2000X; d & e: 2500X). 
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4.11.3.2. Ultrastructure changes of kidney in mice 
The examination kidney from control group of mice under transmission electron 
microscope showed the normal ultrastructural pattern. The nucleus is rounded 
euchromatic with prominent nuclear membrane. The cytoplasm of the proximal 
convoluted tubules (PCT) contains numerous normal elongated mitochondria (Fig 77a). 
The 1"* and 2"'' week of mice treated to exceptionally high- dose (5-g/kg) of ZnO NPs 
showed almost similar ultrastructural appearance to those of the control however, slight 
elongation of mitochondria could be noticed (Fig 77 b & c). The mitochondria were 
markedly affected when mice were exposed for 3 and 4 week with similar dose (5-g/kg) 
of ZnO NPs. Changes in mitochondria was particularly evident in many proximal 
convoluted tubules (Fig 77 d & e). Mitochondria appeared to be highly polymorphic with 
variations in size and shape and some of them were swollen, had lost their cristae and 
contained vacuoles (Fig 77 d & e), suggesting mild disturbance of mitochondrial 
functions. The results suggested that long-term exposure (up to 28 days) to low- (0.5-
g/kg), middle- (1-g/kg) and high-dose (3-g/kg) of ZnO NPs did not displayed sign of any 
significant cellular damage; whereas exceptionally high-dose (5-g/kg) of ZnO NPs 
caused subtle but definitive cytological changes in the epithelial cells of PCT. Thus the 
long-term ZnO NPs exposures particularly at high dose may be advised with caution. 
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Figure 77: Transmission electron microscopic observation of mice kidney after 
intraperitoneal administration of 5-g/kg ZnO NPs. Control group (a & a'): Showmg the 
epithelial cells of the proximal convoluted tubule (PCT) with euchromatic nucleus (N), 
prominent nuclear membrane. Mitochondria (M) in the PCT have a relatively uniform 
size, shape & matrical density. Mice exposed for 1 and 2 week (b & c) respectively: 
Shows many mitochondria with normal cristae (M) as observed in the control group. 
Mice exposed for 3 and 4 week (d & e) respectively: Shows polymorphic mitochondria 
(white arrow, d & e). Some mitochondria revealed swelling and vacuoiation in 
mitochondrial matrix (red arrow, d & e). Magnification (a: 2000X; a', b & c: 2500X; d & 
e: 3000X). l 
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4.11.3.3. Ultrastructure changes of spleen in mice 
The changes of splenocyte ultrastructure in the mouse spleen are presented in figure 78. 
The mice from control group presented a normal cytological structure pattern on electron 
microscopy examination. It was observed that the untreated mouse splenocyte (in the 
control group) contained round nucleus with homogeneous chromatin (Fig 78 a). 
However, noticeable morphological changes in splenic tissue were observed in the mice 
after exposure to exceptionally high-dose (5-g/kg) of ZnO NPs. The ultrastructure of 
splenocyte of 1^ ' and 2"*^  week ZnO NPs (5-g/kg) treated mice indicates slight nuclear 
chromatin condensation and irregularity of nuclear membrane (Fig 78 b & c). However, 
mice exposed for 3 and 4 week with similar dose (5-g/kg) showed loss of cytoplasm, 
mitochondrial swelling and vacuolation, nuclear chromatin condensation and 
vacuolization in splenocyte and even cell necrosis (Fig 78 d & e). The nuclear membrane 
was indistinct in some with irregular nuclear shapes. These results suggested that long-
term exposure to exceptionally high-dose of ZnO NPs (5-g/kg) may lead to splenocyte 
necrosis. However, no significant changes were observed in spleen when mice were 
exposed for 1, 2, 3 and 4 week at low- (0.5 g/kg), middle- (Ig/kg) and high-dose (3-g/kg) 
ZnO NPs. 
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Figure 78. Transmission electron microscopic observation of mice spleen after 
intraperitoneal administration of 5-g/kg of ZnO NPs. Control (a & a'): Shows 
splenocyte with round nucleus (N) having homogeneous chromatin. Mice exposed for 1 
and 2 week respectively (b & c): Showing slight condensation of nuclear chromatin (red 
arrow) and irregular nuclear membrane. Mice exposed for 3 and 4 week (d & e) 
respectively: Shows edema of nuclear membrane (black arrow, e), nuclear chromatin 
condensation (red arrow, d & e), irregularity of the nuclear membrane (white arrow, d & 
e) and many vacuoles in splenocyte (yellow arrows, d). Note: (N) nucleus of splenic cells 
surrounded by cytoplasm (Cy) and mitochondria (M) in the cytoplasm. Magnification 
(2500X) 
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4.11.4. Evaluation of toxicological effects of AgNPs in mice in vivo 
4.11.4.1. Biochemical observations 
4.11.4.1.1. Analysis of liver-function biomarkers after 1 week of treatment with AgNPs 
TTie TIBL level was decreased in all groups of treated mice when compared with control, 
and interestingly this decreased was statistically significant (p<0.05) at 0.5-, I-and 5-
g/kg. Decreased in the ALB level were also observed in all groups of mice compared to 
control but this decreased was significant (p<0.05) at 0.5- and 3-g/kg respectively. No 
significant changes in the TP level were notice in all groups of treated mice compared to 
control. Decreased in SGOT and increase in SGPT levels were observed in all groups of 
treated mice compared to control but were statistically not significant. No remarkable 
changes were observed in the ALP level in all groups of treated mice compared to control 
(Table 54a). 
Table 54a. Change in liver-function biomarkers after 1 week exposure to increasing 
doses of AgNPs in mice (mean±S.D.) 
Dose 
(g/Kg) 
0.5 1 
Con 
TIBL 
(mg/dL) 
1.0±0.60* 
1.4±0.25 
0.8±0.15* 
0.9±0.10* 
2.2±0.63 
TP 
(g/dL) 
6.1±0.32 
6.5±0.79 
5.9±0.30 
6.5±1.13 
7.9±0.98 
ALB 
(g/dL) 
2.5±0.05* 
3.3±0.75 
2.3±0.17* 
2.9±0.70 
4.4±0.91 
SGOT 
(U/L) 
150.7±9.01 
214.0±43.31 
239.0±47.12 
249.3±8I.59 
272.2±97.94 
SGPT 
(U/L) 
45.0±6.00 
44.7±6.50 
74.0±20.66 
58.0±26.00 
45.0±4.35 
ALP 9 
(U/L) 
199.3±5.I3 
223.3±105.87 
140.0±64.37 1 
114.0±56.10 
202.0±28.00 " 
*Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: not significant. 
4.11.4.1.2. Analysis of liver-function biomarkers after 2 week of treatment AgNPs 
A statistically significant decreased in the TIBL level was noticed in all groups of treated 
mice when compared with control (p<0.05). The ALB level was also decreased in all 
groups of treated mice compared to control but the changes were statistically significant 
(p<0.05) at 0.5-, 3- and 5-g/kg. No significant changes were noficed in the TP level in all 
groups of treated mice compared to control. In addition, no obvious changes were also 
observed in SGOT and ALP levels compared to control. Although an increase in the 
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SGPT levels were noticed in all groups of treated mice, this increased was statistically 
significant (p<0.Q5) at exceptionally high-dose (5-g/kg) (Table 54b). 
Table 54b, Change in liver-function biomarkers after 2 week exposure to 
increasing doses of AgNPs in mice (mean±S.D.) 
Dose 
(g/Kg) 
0.5 
1 
3 
5 
Con 
TIBL 
(mg/dL) 
0.9±0.32* 
0.9±0.11* 
0.7±0.10* 
0.9±0.30* 
2.2±0.63 
TP 
(g/dL) 
7.3±1.40 
7.6±1.15 
6.0±0.30 
5.7±0.70 
7.9±0.98 
ALB 
(g/dL) 
2.M).64* 
3.6±0.51 
2.4±0.10* 
1.8±0.25* 
4.4±0.91 
SCOT 
(U/L) 
443.3±70.23 
206.0±70.54 
225.7±56.36 
180.7±65.30 
272.2±97.94 
SGPT 
(U/L) 
55.3±7.63 
53.0±8.18 
65.7±22.72 
92.0±24.33* 
45.0±4.35 
ALP 
(U/L) 
290.0± 169.22 
195.3±86.84 
339.0±113.76 
249.0±81.79 
202.0±28.00 
*Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: TIBL (0.005), ALB 
(0.003), SCOT (0.010) and SGPT (0.035). 
4.1L4.L3. Analysis of liver-function biomarkers after 3 week treatment of AgNPs 
Decreased in the TIBL level was noticed in all groups of treated mice compared to 
control, but this decreased was statistically significant (p<0.05) at 0.5-, 3- and 5-g/kg. No 
significant changes in the ALB, TP and ALP levels were noticed in all groups of treated 
mice compared to the control group. No obvious changes were also noticed in the SCOT 
level in all groups of treated mice, except at exceptionally high-dose (5-g/kg); and at this 
dose the level of SGOT increased and this increased was statistically significant (p<0.05). 
The SGPT level was increased in all groups of treated mice compared to control, 
however, this increased was statistically significant (p<0.05) at high-dose (3-g/kg) 
(Table 54c). 
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Table 54c. Change in liver-function biomarkers after 3 week exposure to increasing 
doses of AgNPs in mice (mean±S.D.) 
Dose 
(g/kg) 
0.5 
L 
Con 
TIBL 
(mg/dL) 
0.9±0.35* 
1.1±0.62 
0.9±0.25* 
0.8±0.80* 
2.2±0.63 
TP 
(g/dL) 
7.l±1.90 
8.7±2.78 
8.1 ±2.65 
6.8±1.32 
7.9±0.98 
ALB 
(g/dL) 
3.4±0.80 
3.0i0.69 
2.4±1.21 
2.9±0.36 
4.4±0.91 
SCOT 
(U/L) 
163.3±8.62 
235.7±42.92 
236.7±133.66 
469.7±145.22* 
272.2±97.94 
SGPT 
(U/L) 
48.3±I5.I7 
77.7±12.58 
88.7±32.02* 
82.0±34.51 
45.0±4.35 
ALP 
(U/L) 
236.0±123.07 
216.7±193.33 
124.3±73.90 
206.7±69.37 
202.0±28.00 
*Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: TIBL (0.047) & 
SGOT (0.035). 
4.1L4.L4, Analysis of liver-function biomarkers after 4 week treatment of AgNPs 
The TIBL level were decreased in all groups of treated mice, but this decreased was 
statistically significant (p<0.05) at 0.5-, 1- and 5-g/kg when compared with control. The 
TP level was decreased in all groups of treated mice and interestingly, this decreased was 
statistically significant {p <0.05) at all doses compared to the control group. ALB levels 
were also decreased in all groups of mice and but this decreased was statistically 
significant {p <0.05) at 1- and 5-g/kg. An increased in the SGOT levels were observed in 
all groups of treated mice compared to control, except at high-dose (3-g/kg), but this 
increased was statistically not significant. Increased in the SGPT levels were noticed in 
all groups of mice compared to control but this increased was statistically significant (p 
<0.05) at high-dose (3-g/kg). No significant changes were observed in the ALP level 
compared to control after 4 week of exposure to AgNPs (Table 54d). 
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Table 54d. Change in liver-function biomarkers after 4 week exposure to increasing 
doses of AgNPs in mice (meaniS.D.) 
Dose 
(g/Kg) 
0.5 
i 3 
5 
Con 
TIBL 
(mg/dL) 
O.7±0.O5* 
0.8±0.05* 
1.4±0.55 
0.9±0.21* 
2.2±0.63 
TP 
(s/dL) 
5.6±0.20* 
5.2±0.17* 
5.6i0.26* 
4.7±].34* 
7.9±0.98 
ALB 
(S/dL) 
2.9±0.58 
I.5±0.26* 
2.7±1.20 
2.1±0.9I* 
4.4±0.9I 
SCOT 
(U/L) 
309.(>i:281.60 
413.7±330.53 
194.0±II6.04 
425.3±298.42 
272.2±97.94 
SGPT 
(U/L) 
77.7±30.23 
76.7±20.23 
I00.3±40.64* 
5I.0±16.37 
45.0±4.35 
ALP 1 
(U/L) ' 
236.6±47.01 
I93.0±50.n 
I98.a±40.95 
I18.7±12.58 
202.0±28.00 
* Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: TIBL (0.017), TP 
(0.007) and ALB (0.046). 
4.11.4.1.5. Analysis of kidney-function biomarkers after 1 week treatment of AgNPs 
In the present study, no obvious changes were observed for UA and BUN in all groups of 
treated mice compared to control and these changes were also not statistically significant. 
Although decreased in CR level was noticed in all groups of treated mice compared to 
control but this decreased was significantly significant (p<0.05) at high-dose (3-g/kg) 
(Table 55a). 
Table 55a. Change in kidney-function biomarkers after 1 week exposure to 
increasing doses of AgNPs in mice (mean±S.D.) 
I Dose 
, 0.50 g/Kg 
1.00 g/Kg 
3.00 g/Kg 
15.00 g/Kg 
1 Control 
UA(mg/dL) 
5.50±i.56 
6.26±0.15 
4.70±0.87 
5.26±0.96 
4.15±0.91 
CR(mg/dL) 
0.27±0.05 
0.30±0.00 
0.23±0.05* 
0.30±0.l0 
0.40±0.00 
BUN(mg/dL) j 
15.60±5.54 
15.46±4.91 
12.97±5.56 
20.12±6.78 
22.29±l.ll 
*Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: not significant 
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4.11.4.1.6. Analysis of kidney-function biomarkers after 2 week treatment of AgNPs 
No obvious changes were observed for UA and BUN in all groups of treated mice 
compared to control and these changes were also statistically not significant. A 
decreased in CR level was noticed in all groups of treated mice compared to control and 
this decreased was statistically significant (/KO.05) at high-dose (3- & 5-g/kg) 
(Table 55b). 
Table 55b. Change in kidney-function biomarkers after 2 week exposure to 
increasing doses of AgNPs in mice (mean±S.D.) 
Dose 
0.50 g/Kg 
1.00 g/Kg 
3.00 g/Kg 
5.00 g/Kg 
Control 
UA(mg/dL) 
5.93±1.15 
3.77±0.93 
5.30±0.44 
3.47±0.31 
4.15±0.91 
CR(mg/dL) 
0.30±0.10 
0.30d=0.00 
0.23±0.05* 
O.13±0.05* 
0.40±0.00 
BUN(mg/dL]| 
21.40±2.32 
17.51±7.99 
20.81±3.07 
19.55±2.62 
22.29±1.11 
*Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: UA (0.038) & CR 
(0.009). 
4.11.4.1.7. Analysis of kidney-function biomarkers after 3 week treatment of AgNPs 
In the present study, no remarkable changes were observed for UA and BUN in all 
groups of treated mice compared to control and all changes were statistically not 
significant. Although decreased in CR level was noticed in all groups of treated mice 
compared to control but this decreased was statistically significant (p<0.05) at 
exceptionally high-dose (5-g/kg) (Table 55c). 
Table 55c. Change in kidney-function biomarkers after 3 week exposure to 
increasing doses of AgNPs in mice (mean±S.D.) 
Dose 
0.50 g/Kg 
1.00 g/Kg 
3.00 g/Kg 
5.00 g/Kg 
Control 
UA(mg/dL) 
3.60±0.70 
3.80±0.91 
3.67±0.32 
3.77±0.35 
4.15±0.91 
CR(mg/dL) 
0.23±0.05 
0.37±0.05 
0.30±0.10 
0.23±0.05* 
0.40±0.00 
BUN(mg/dL) 
26.95±6.96 
29.06±7.43 
19.86±0.17 
19.17±3.55 
22.29±1.11 
*Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: not significant 
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4.11.4.1.8. Analysis of kidney-function biomarkers after 4 week treatment of AgNPs 
In the present study, no obvious change was observed for UA and BUN in all groups of 
treated mice compared to control and the changes were also statistically not significant. 
Although the decreased in CR level was noticed in all groups of treated mice compared to 
control but this decreased was significantly significant (^0.05) at exceptionally high-
dose (5-g/kg) (Table 55d). 
Table 55d. Change in kidney-function biomarkers after 4 week exposure to 
increasing doses of AgNPs in mice (meaniS.D.) 
Dose UA(mg/dL) CR(mg/dL) BUN(mg/dL) 
0.50 g/Kg 
I 1.00 g/Kg 
[ 3.00 g/Kg 
j 5.00 g/Kg 
I Control 
5.16±0.11 
6.70±3.04 
5.11±2.48 
a 3.75±1.06 
4.15±0.91 
0.30±0.10 
0.33±0.11 
0.35±0.13 
0.25±0.07* 
0.40±0.00 
22.68±6.82 
28.66±5.10 
22.57± 12.67 
18.37±0.47 
22.29±1.11 
*Represents significant difference from the control group (Dunnett's, <0.05). 
4.11.4.1.9. Change in lipid profile of mice after 1 week of treatment with AgNPs 
In the present study, no significant changes in TG and CHO levels were observed when 
compared with control. However, increase in HDL levels was noticed in all groups of 
treated mice and this increase was statistically significant (p <0.05) at 0.5- and 5-g/kg, 
respectively (Table 56a). 
Table 56a. Change in lipid profile after 1 week exposure to AgNPs (mean±S.D.) in mice 
f Dose 
[ 0.50 g/Kg 
1.00 g/Kg 
3.00 g/Kg 
5.00 g/Kg 
Control 
CHO(mg/dL) 
i24.67±24.70 
175.33±53.00 
115.67±42.83 
158.33±51.93 
191.00±I6.97 
TG(mg/dL) 
148.00±28.16 
203.67±71.62 
192.33±36.93 
145.67±40.27 
20I.50±43.13 
HDL(mg/dL 
99.00±6.57* 
80.67±2.51 
73.67±3.05 
87.33±2.51* 
76.05±4.31 
^Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: HDL (0.000) & 
GLU (0.006). 
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4.11.4.1.10. Change in lipid profile of mice after 2 week of treatment with AgNPs 
No remarkable changes in TG and CHO levels were observed when compared with 
control and were also statistically not significant. Although an increased in HDL levels 
was noticed in all groups of treated mice, but this increased was statistically significant 
ip <0.05) at 1-g/kg (Table 56b). 
Table 56b. Change in lipid profile after 2 week exposure to AgNPs (meaittS.D.) in mice 
Dose 
1 0.50gylCg 
1 1.00 g/Kg 
1 3.00 g/Kg 
5.00 g/Kg 
• Control 
CHO(mg/dL) 
I36.33±27.50 
177.67±52.29 
111.67±4.72 
117.00±26.21 
191.00±16.97 
TG(mg/dL) 
138.67±63.04 
159.33±29.14 
150.00±33.78 
139.67±42.52 
201.50±43.13 
HDMmg/dL) 
77.0O±3.0O 
103.00±5.00* 
82.00±2.65 
79.67±8.50 
76.05±4.31 
•Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: HDL (0.001). 
4.11.4.1.11. Change in lipid profile of mice after 3 week of treatment with AgNPs 
No obvious changes in TG and CHO levels were observed when compared with control 
and were statistically not significant. Although, decrease in HDL levels was noticed in all 
groups of treated mice, but this decrease was statistically significant {p <0.05) at 3-g/kg 
(Table 56c). 
Table 56c. Change in lipid profile after 3 week exposure to AgNPs (meaniS.D.) in mk« 
Dose CHO(mg/dL) TG(mg/dL) HDL(mg/dL) 
I 0.50 g/Kg 1.00 g/Kg 
3.00 g/Kg 
5.00 g/Kg 
Control 
12.67± 18.44 
58.00±57.58 
38.33±44.09 
I2.33±30.43 
I91.00±I6.97 
198.00±5.00 
219.67±36.11 
152.67±21.82 
159.33±44.60 
201.50±43.13 
1
1
1
71.00±2.64 
46.00±5.56* 
68.00±3.00 
73.0O±5.0O 
t
76.05±4.31 
•Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: HDL (0.000). 
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4.11.4.1.12. Change in lipid profile of mice after 4 week of treatment with AgNPs 
In the present study, no significant changes in TG level were observed compared to 
control group. The CHO level were decreased in all groups of treated mice compared to 
control but the decreased was statistically significant (p <0.05) at 0.5- and 5-g/kg. 
Although the HDL level was decreased in all groups of treated mice, except at 5-g/kg, 
however, this decreased was statistically significant (p <0.05) at 1 -g/kg (Table 56d). 
Table 56d. Change in lipid profile after 4 week exposure to AgNPs (mean±S.D.) 
Dose 
0.50 g/Kg 
1 1.00 g/Kg i 
3.00 g/Kg 
5.00 g/Kg 
Control 
CHO(mg/dL) 
97.33±7.02* 
156.00±48.66 
129.67± 19.65 
73.50±36.06* 
191.00±16.97 
TG(mg/dL) 
140.33±4.16 
]66.00±65.02 
190.00±2.64 
22I.50±27.57 
201.50±43.13 
HDL(mg/dL>| 
61.00±14.79 
28.67±5.03* 
57.50±32.54 
80.50±4.84 
76.05±4.31 
•Represents significant difference from the control group (Dunnett's, <0.05). 
Note: ANOVA test showing significant difference between groups-: CHO (0.022) & 
GLU (0.007). 
4.11.4.1.13. Change in blood glucose level 
In the present study, interestingly, it was observed that the glucose levels were decreased 
in all groups of treated mice when compared with control and this deceased was 
statistically significant (p <0.05) at all doses in 1^ ' week, at 0.5- and 5-g/kg in 2"'' week, at 
1-, 3- and 5- g/kg in 3 '^' week and at all doses in 4"^  week of treated mice (Fig 79 a & b). 
Decreased in glucose levels were not reported previously in animal models. 
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Figure 79a. Change in the blood glucose level of mice after 1 and 2 week while AgNPs 
suspension was injected intraperitoneally into abdominal cavity. Bars marked with an 
asterisk are significantly different from the control at the 5% confidence level 
(means ± SE). 
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Figure 79b. Change in the blood glucose level of mice after 3 and 4 week while AgNPs 
suspension was injected intraperitoneal ly into abdominal cavity. Bars marked with an 
asterisk are significantly different from the control at the 5% confidence level 
(means ± SE). 
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4.12. Histopathological observations of liver, kidney and spleen after intraperitoneal 
administration of AgNPs 
Histopathology of liver from control group (Fig 80a) revealed intact hepatocellular 
architecture, normal hepatic laminae and intervening sinusoids. One week treatment had 
no obvious effect on the hepatic cytoarchitecture (Fig 80b) at low- (0.5-g/kg), middle- (1-
g/kg), high- (3-g/kg) and exceptionally high-dose (5-g/kg) group and the structure were 
very akin to control. However, two week of exposure to exceptionally high-dose (5-g/kg) 
group showed minor changes having zones of non-specific hepatocellular damage (Fig 
80c). While, after 3"^ (Fig 80d) and 4'^  (Fig 80e) week of exposure to similar dose (5-
g/kg) showed inflammatory cells in the liver and vesicular change in the hepatocytes (Fig 
80 d & e) compare to control group. Control group of kidney showed normal 
microstructure of renal corpuscle and the renal tubular epithelium were intact (Fig 81 a & 
a'). One week's treatment had no perceptible effect on kidney structure at atiy doses, and 
was similar to that of control (Fig 81b). However, two weeks treatment had sporadic milo^^ "^  
effect in terms of damage to the tubular epithelium at exceptionally high-dose (5-g/kg) 
(Fig 81 c). While, after S"^"^  (Fig 81d) and 4* (Fig 81e) week of exposure to similar dose 
(5-g/kg); damage to tubular epithelium of kidney and renal cast in the tubular lumen were 
observed (Fig 81 d & e). Spleen fi-om control group had normal histology where red and 
white pulp could be identified clearly and large cells (megakaryocytes) were occasionally 
noticed (Fig 82 a & a'). After one week of treatment no observable changes were noticed 
at any doses and were very akin to control (Fig 82 b). However, at exceptionally high-
dose (5-g/kg) after two week of treatment slight increased in the size of megakaryocytes 
was seen (Fig 82 c). While, after 3"* and 4* week of exposure to similar dose (5-g/kg) 
megakaryocyte hyperplasia was observed in the red pulp in the spleen and the number of 
megakaryocytes in the spleen were increased as compare to control group (Fig 82 d & e). 
Thus, l"' and 2"'' week treatment had not perceptible effect at exceptionally high-dose on 
the cytoarchitecture on liver, kidney and spleen however, 3'"'' and 4"" weeks treatment had 
only sporadic mild effects on these organs. 
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Figure 80: Photomicrograph of mice liver after intraperitoneal administration of 5-g/kg 
of AgNPs. Control group (a & a'): Shows normal hepatic sinusoids (blue arrows). 1 & 
2 week treatment groups (b & c) respectively: Shows normal hepatic sinusoids (blue 
arrows, b) very akin to control and red arrow (c) indicate the site of non-specific damage 
of hepatocytes. 3 and 4 week treatment groups (d & e) respectively: Red arrow (d & e) 
indicates inflammatory cells in the liver & vesicular changes in hepatocytes liver. H & E 
stain, original magnification, X400. 
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Figure 81: Photomicrograph of mice itidney after intraperitoneal administration of 5-g/lcg 
of AgNPs. Control group (a & a'): Show normal intact renal tubular epithelium (blue 
arrow). 1 and 2 week treatment groups (b & c) respectively: Show normal intact renal 
tubular epithelium (blue arrow, b) and sporadic mild tubular epithelial damage (red 
arrow, c). 3 and 4 week treatment groups (d & e) respectively: Show damage to 
tubular epithelium of kidney, renal cast in the tubular lumen (red arrows, d & e). H & E 
stain, original magnification, X400. 
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Figure 82: Histopathological observation of mice spleen after intraperitoneal 
administration of 5-g/kg of AgNPs. Control group (a & a'): Show normal white pulp of 
spleen (blue arrow, a). 1 and 2 week treatment groups (b & c) respectively: Show 
normal splenic megakaryocytes (red arrows, b & c). 3 and 4 week treatment groups (d 
& e) respectively: Show multiple megakaryocytes (red arrows, d & e). H & E stain, 
original magnification, X400. 
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4.13. Transmission electron microscopic observations of liver, kidney and spleen 
after intraperitoneal administration of AgNPs 
4.13.1. Ultrastructure changes of liver in mice 
The ultra-structural examination of the liver sections of control group exhibited a round 
nucleus with homogeneous chromatin in hepatocytes, prominent nuclear membrane, 
round or oval mitochondria and normal rough endoplasmic reticulum (Fig 83a). The 
ultrastructure of hepatocyte of the liver after 1'' and 2"'' week exposure to exceptionally 
high-dose (5-g/kg) of AgNPs did not show any significant changes; however slight 
irregularities were seen in nuclear membrane and all other cell organelles were very 
much similar to control group (Fig 83 b & c). The mitochondrial ultra structural 
abnormalities were observed after 3'^ '' and 4"^  weeks of exposure to similar dose (5-g/kg) 
of AgNPs. The mitochondria became elongated, swollen and it matrix was of variable 
density (Fig 83 d & e). In the swollen mitochondria some mild-to-moderate distorted 
cristae and irregular rough endoplasmic reticulum with dilation were observed. No 
obvious changes were observed after V\ 2"^, S''^ and 4* weeks of exposed to low- (0.5-
g/kg), middle- (1-g/kg), and high-dose (3-g/kg) of AgNPs indicating that AgNPs were 
non toxic at these doses, whereas mild toxicity were observed at exceptionally high-dose 
(5-g/kg) after 3'^ '* and 4* weeks of exposure to AgNPs. The results suggested that long-
term exposure to exceptionally high-dose of AgNPs is more likely to cause hepatocyte 
mitochondrial abnormalities. 
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Figure 83. Transmission electron microscopic observation of mice liver after 
intraperitoneal administration of 5-g/kg of AgNPs. Control group (a & a'): Showing a 
normal hepatocyte with smooth and rounded euchromatic nucleus (N), prominent nuclear 
membrane (white arrow), regular rough endoplasmic reticulum (green arrow) and many 
round or oval mitochondria with normal cristae. Mice exposed for 1 and 2 week (b & c) 
respectively: Showing irregular nuclear (white arrow, b & c), many mitochondria with 
normal cristae (M) similar to control group. Mice exposed for 3 and 4 week (d & e) 
respectively: Shows elongated, tumescent and swollen mitochondria in hepatocytes with 
some mild-to-moderate distorted cristae (red arrows, d & e) and dilated rough 
endoplasmic reticulum (green arrow, d). Magnification (a, b, c: 2000X; d & e: 2500X) 
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4.13.2. Ultrastructure changes of kidney in mice 
Examination under transmission electron microscope; the kidney of control mice showed 
the normal ultrastructural pattern. The nucleus is rounded euchromatic with prominent 
nuclear membrane. Regarding the lining cells of the proximal convoluted tubule (PCT), 
the cytoplasm contains numerous normal elongated mitochondria (Fig 84a). The 1^^ and 
2"*^  week of treated mice with exceptionally high-dose (5-g/kg) of AgNPs showed almost 
the normal ultrastructural appearance to those of the control apart from slight elongated 
mitochondria and irregularity of nuclear membrane (Fig 84 b & c). The mitochondria 
were markedly affected when mice were exposed for 3'^ '' and 4'^  weeks with similar dose 
(5-g/kg) of AgNPs. A change in mitochondria was particularly evident in many PCTs. 
Mitochondria appeared to be highly polymorphic with variations in their size and shape 
and some of them were swollen, had lost their cristae and contained vacuoles (Fig 84 d & 
e), suggestive of mild disturbance of mitochondrial functions. Electron microscopy 
revealed less amount of mesangial matrix with slight thickening of the glomerular 
basement membrane (Fig 84e) compared to those of the control group. The results 
suggested that the long-term exposure of AgNPs particularly at exceptionally high-dose 
(5-g/kg) induced various degrees of damage to the architecture of PCT, such as cell 
swelling and lysis, cytoplasm and mitochondria vacuolation, nuclear membrane 
breakdown, cell shrinkage, nuclear condensation, and even necrosis. No obvious changes 
were observed at P\ 2"*^ , y^ and 4* week of mice liver when exposed at low- (0.5-g/kg), 
middle- (1-g/kg) and high-dose (3-g/kg) of AgNPs. 
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Figure 84. Transmission electron microscopic observation of mice kidney after 
intraperitoneal administration of 5-g/kg of AgNPs. Control group (a & a'): Showing the 
epithelial cells of the proximal convoluted tubule with euchromatic nuclei (N), prominent 
nuclear membrane (red arrow) and many mitochondria with normal cristae (M). Mice 
exposed for 1 and 2 week (b & c) respectively: Shows prominent nuclear membrane (red 
arrow) and many mitochondria with normal cristae (M) as similar to the control group. 
Mice exposed for 3 and 4 week (d & e) respectively: Shows elongated, swollen and 
vacuolated mitochondria with some mild-to-moderale distorted cristae (green arrows, d & 
e), mesangial matrix (Ms) with slightly thick basement membrane (BM). parts of 
podocytes (P) with fiised minor processes rest on a thick basement membrane (BM). 
Magnification (a, b, c: 2000X; d & e: 2500X) 
201 
Results 
4.13,3. Ultrastructure changes of spleen in mice witli AgNPs 
Splenocyte of the control mice showed a normal nucleus enveloped by smooth, intact 
nuclear membrane with abundant mitochondria inside the cytoplasm (Fig 85a). In 
contrast, splenic cells treated with exceptionally high-dose (5-g/kg) of AgNPs displayed 
several signs of cellular damage. The ultrastructure of splenocyte of \^ and 2"*^  week of 
treated mice with exceptionally high-dose (5-g/kg) of AgNPs indicates slight nuclear 
chromatin condensation and irregularity of nuclear membrane and slight loss of 
cytoplasm (Fig 85 b & c). However, mice exposed to 3"^  and 4"' week with similar dose 
(5-g/kg) of AgNPs indicate high degree of nuclear chromatin condensation, breakdown of 
nuclear membrane, mitochondria vacuolization in splenocyte, loss of cytoplasm and cell 
necrosis (Fig 85 d & e). The results suggested that long-term exposure to exceptionally 
high-dose (5-g/kg) of AgNPs caused splenocyte necrosis. However, no significant 
changes were observed when mice were exposed for 1, 2, 3 and 4 week at low- (0.5-
g/kg), middle- (1-g/kg), and high-dose (3-g/kg) of AgNPs. 
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Figure 85. Transmission electron microscopic observation of mice kidney after 
intraperitoneal administration of 5-g/kg of AgNPs. Control (a & a'): Shows splenocyte 
with a round nucleus (N) with homogeneous chromatin. Mice exposed for 1 and 2 week 
(b & c) respectively: Shows slight condensation of nuclear chromatin and irregular 
nuclear membrane. Mice exposed for 3 and 4 weeks (d & e) respectively: Shows 
irregularity of nuclear membrane (red arrow, d & e), dilated endoplasmic reticulum 
(white arrow, d) and mitochondrial vacuolation in splenocyte (yellows, e). Note: (N) 
nucleus of splenocyte surrounded by cytoplasm (Cy), mitochondria (M) and endoplasmic 
reticulum (ER). Magnification (2500X) 
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5. DISCUSSION 
Emergence and reemergence of multi-drug resistant (MDR) pathogens such as bacteria, 
fungi, and viruses remain a major health concern, which are responsible for causing a 
large number of deaths and hospitalizations each year worldwide (Desselberger, 2000: 
Tenover, 2006). Despite antimicrobial therapy, morbidity and mortality associated with 
these microbial infections remain high, partially as a result of the ability of these 
pathogens to develop resistance to virtually all classes of antibiotics (Desselberger. 
2000). Therefore, the development of new antimicrobial compounds or the modification 
of those available in order to improve antimicrobial activity for therapy, antisepsis or 
disinfection is a high priority area of research. In this endeavor, nanotechnology provides 
a means to modify key features of different materials, including metal and metal oxides 
nanoparticles (Duran et ah, 2010). A large group of these studies includes the 
implementation of nanotechnologics to create new antimicrobial nanomedicine with 
increased effectiveness and efficiency (Weir et al., 2008; Chun & Webster, 2009). 
Nanotechnology provides a good platform to modify and develop the important 
properties of metal in the form of nanoparticles having promising applications in 
diagnostics, biomarkers, cell labeling, contrast agents for biological imaging, 
antimicrobial agents, drug delivery systems and nano-drugs for treatment of various 
diseases (Singh & Singh, 2011). Therefore, researchers are shifting towards nanoparticles 
to solve the problem of emergence of MDR pathogens (Gemmell et al., 2006). It is well 
known that Ag ions and Ag-based compounds have strong antimicrobial effects (Klasen, 
2000; Spacciapoli et al., 2001; Fumo et al., 2004; Atiyeh et al., 2007), and many 
investigators are interested in using inorganic metal and metal oxides nanoparticles as 
antibacterial agents. The antibacterial activity of metal nanoparticles such as AgNPs in 
literature is well documented (Sondi & Salopek Sondi, 2004; Kim et al., 2007; Pal et al.. 
2007; Lara et al., 2010; Ansari et al., 2011 a & b). The considerable antimicrobial 
activities of metal oxide nanoparticles such as ZnO (Reddy et al., 2007; Zhang et al.. 
2010; Ansari et al., 2012 a & b), SiOz (Laura et al., 2006), AI2O3 (Sadiq et al., 2009) and 
their selective toxicity to biological systems suggest their potential application as 
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therapeutics, diagnostics, surgical devices and nanomedicine based antimicrobial agents. 
These inorganic nanoparticles have a distinct advantage over conventional chemical 
antimicrobial agents. The most important problem encountered by chemical antimicrobial 
agents is emergence of multidrug resistance. Generally, the antimicrobial mechanism of 
chemical agents depends on the specific binding with surface and metabolism of agents 
into the microorganism. Various microorganisms have evolved drug resistance over 
many generations. Thus far, these antimicrobial agents based on chemicals have been 
effective for therapy; however, they have been limited to use for medical devices and in 
prophylaxis in antimicrobial facilities. 
Microbes are unlikely to develop resistance against metal nanoparticles as they do against 
conventional and narrow target antibiotics, because the metal attacks a broad range of 
targets in the organisms, which means that they need to develop a range of mutations 
concurrently to protect themselves (Pal et al, 2007). Therefore, an alternative way to 
overcome the drug resistance of various microorganisms is needed desperately, especially 
for medical devices. In the present study, the antibacterial properties of different sizes of 
AgNPs (2, 5-10, 15, 35-50 & 100 nm), ZnO (20 &70 nm) and AI2O3 (45 & <50 nm) NPs 
have been evaluated against various drug resistant and non-resistant clinical isolates of E. 
coli (ESBL «& non-ESBL), P. aeruginosa (ESBL, non-ESBL & MBL), S. aureus (MRSA 
& MSSA) and Klebsiella spp of public concern and some standard bacterial strains by 
utilizing various in vitro susceptibility assays. Efforts have been made to understand the 
mechanism of actions of NPs by applying SEM and TEM. 
In vitro antibacterial activity and mode of action of AgNPs 
Ag ions and Ag salts have been used for decades as antimicrobial agents in various fields 
because of their growth-inhibitory action against microorganisms. Also, many other 
researchers have tried to measure the activity of metal ions against microorganisms e.g., 
studies of Russel and Hugo on the antimicrobial properties of Ag and Cu (Russel & 
Hugo, 1994). However, Ag ions or salts has only limited usefulness as an antimicrobial 
agent for several reasons, including the interfering effects of salts and the antimicrobial 
mechanism of the continuous release of enough concentration of Ag ion from the metal 
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form. In contrast, these kinds of limitations can be overcome by the use of AgNPs. 
However, to use AgNPs in various fields against microorganisms, it is essential to 
prepare the AgNPs with cost-effective methods and to know the mechanism of the 
antimicrobial effect. Plus, it is also important to enhance the antimicrobial effect. The 
nanosize allowed expansion of the contact surface of NPs with the microorganisms, and 
this nanoscale has applicability for medical devices by surface coating agents. 
In this study, five different sizes (2, 5-10, 15, 35-50 and 100 nm) of AgNPs were used to 
evaluate the antibacterial activity against various drug resistant and non-resistant clinical 
isolates of E. coli, P. aeruginosa, Klebsiella spp, and S. aureus by different methods such 
as time-dependent growth inhibition assay, MIC and MBC determination and well-
diffusion methods. In our study, the MIC value of different sizes of AgNPs were found to 
be lower than that of previously reported studies when tested against E. coli, P. 
aeruginosa and S. aureus and we also found that AgNPs showed size dependent 
antimicrobial activity against all clinical isolates. For E. coli, P. aeruginosa and S. 
aureus, the MIC values for small size AgNPs (2 & 5-10 nm) was found to be 3.13 and 
11.25 ng/ml, respectively (Table 3-12). Ayala-Nunez et al. (2009) and Martinez-
Castanon et al. (2008) also reported that the small size AgNPs exhibited low MIC, using 
the same method, but their results, compared with our 2 and 5-10 nm AgNPs, were 
slightly different. They reported a similar MIC i.e., 6.25-7.5 fig/ml for 7 nm (Martinez-
Castanon et al, 2008) and 12.5-25 |jg/ml for 9.8 nm (Fernandez et al, 2008), while a 
higher MIC i.e., 1800 ng/ml for lOnm was reported by Ayala-Nunez et al. (2009), 
although the particles used in the present work were smaller or same size as they used; 
this difference could be due to the methods by which AgNPs were synthesized, in the 
present work commercially available water soluble AgNPs were used. In the present 
work l5-nm AgNPs showed MIC values in the range of 16-64 tig/ml (Table 13-17). 35-
50 nm has MIC 400-1600 ^g/ml (Table 18-22) (Ayala-Nunez et al, 2009 reported higher 
MIC, 10790 |ug/ml for 30-40 nm AgNPs), while the MIC for 100 nm was in the range of 
1300-2600 |ig/ml (Table 23-27), while in previous study, Ayala-Nunez et al (2009) and 
Lara et al, (2010) reported MIC of 2250 i^g/ml and 6828.17 |jg/ml, respectively for 
lOOnm AgNPs, thus in this study, the small size AgNPs showed better antibacterial 
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activity compared to larger ones and was consistent with previous report. The size and 
shape dependent interaction of AgNPs with bacteria has also been reported (Morones et 
al, 2005; Panacek et al., 2006; Martinez-Castanon et al., 2008; Ayala-Nunez et al., 
2009). In the present work it was investigated that the small size (2 & 5-10 nm) AgNPs 
showed strong bacteriostatic (3.13-6.13ng/ml) and bactericidal (6.13-11.2 |ig/ml) effect 
compared to larger ones against representative Gram-negative bacteria {E. coli and P. 
aeruginosa) and Gram-positive bacteria {S. aureus) (Table 3-12). 
The bacterial growth curve for E. coli ATCC 25922, P. aeruginosa ATCC 27853, S. 
aureus ATCC 25923, ESBL & non-ESBL E. coli; ESBL, non-ESBL & MBL P. 
aeruginosa, MRSA and MSSA was monitored in LB broth supplemented with different 
sizes of AgNPs at different concentrations. It was observed that with increasing 
concentration of AgNPs, a reduction in bacterial growth was observed and this continued 
for 12 h. A complete reduction in bacterial growth was observed at concentration atl5 
Hg/ml for 2 nm (Fig 19-21), 25 ^g/ml for 5-10 nm (Fig 31a-33d), 35 tig/ml for 15 nm, 
while 35-50 nm and 100 nm AgNPs inhibited bacterial growth at higher concentration 
i.e., above 250 and 500 tig/ml (Fig 22-24), respectively, up to for 14 hrs. Culture without 
nanoparticles did not show any growth inhibition and reached stationary phase after 18 
hrs. In the present study it was observed that as the size of nanoparticles reduced; the 
antibacterial activity of AgNPs increased. The small sizes nanoparticles (2, 5-10 & 15 
nm) exhibited strong antibacterial activity and inhibited bacterial growth at a very low 
concentration (Fig 19-24). Though, the large size nanoparticles (35-50 and lOOnm) used 
in the present study also exhibited antibacterial activity and inhibited bacterial growth but 
at higher concentration (Fig 25-27). The present results corroborates with the earlier 
finding where the AgNPs elicited only a partial growth inhibition of 5. aureus at 100 
)xg/ml (Shrivastava et al, 2007), and a complete growth inhibition was observed in E. 
coli at 50 ^g/ml (Sondi & Salopek-Sondi, 2004) and in P. aeruginosa at 75 iJ.g/ml 
(Morones et al, 2005). In the present study an efficient and enhanced bactericidal activity 
for small size (2, 5-10 and 15 nm) AgNPs at a lower concentration was achieved, which 
have practical applications such as generation of potential antibacterial formulations. 
From the data, it is also evidenced that the bactericidal activity of AgNPs depends both 
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on size and the concentration of nanoparticles. This observation is in good agreement 
with the previous study (Sondi and Salopek-Sondi, 2004; Morones et al., 2005; Panacek 
et al, 2006). The present result on MIC and bacterial growth curve showed that AgNPs 
are effective antibacterial agents at very low concentration. Interestingly, it was also 
noticed that there was no significant difference between the bactericidal effects of AgNPs 
on drug-resistant and non-drug-resistant bacterial isolates. The present data suggest that 
the antibacterial activities of AgNPs are not affected by drug resistant mechanisms of 
bacterial isolates such as ESBL, MBL and MRS A and thus AgNPs can generally be 
called as broad spectrum antibacterial agents. These result further support the previous 
finding by other researchers, where it was shown that AgNPs exert the same effects on 
both drug-resistant and drug-susceptible bacteria (Ayala-Nunez et al, 2009; Lara et al, 
2010). The fact that the drug-resistant and drug-susceptible strains were affected by 
AgNPs in the same manner indicates that the drug-resistant proteins that give bacteria the 
capacity to avoid antibiotics do not affect the efficacy of nanosilver. In theory, a 
bactericidal agent is preferred clinically because bacterial killing should produce a taster 
resolution of the infection, improve clinical outcome, and reduce the possibility of the 
emergence of resistance and the spread of infection. If pathogens are killed rather than 
inhibited, resistance mutations that might otherwise emerge as the result of antibiotic 
pressure are eliminated (French, 2006). 
The mechanism by which the nanoparticles are able to penetrate the bacteria is not totally 
understood, but a previous report by some worker suggests that in the case of E. coU\ 
treated with AgNPs, the changes created in the membrane morphology may produce a 
significant increase in its permeability and affect proper transport through the plasma 
membrane (Sondi and Salopek-Sondi, 2004). In the present work, this mechanism could 
explain the numerous AgNPs attached to cell surface and found inside the bacteria. The 
observation of AgNPs attached to the cell membrane and inside the bacteria (Fig 53-54) 
is fundamental in the understanding of the bactericidal mechanism. As established by the 
theory of hard and soft acids and bases, silver will tend to have a higher affinity to react 
with phosphorus and sulfur compounds (Vitanov and Popov, 1983; Hatchett and Henry. 
1996). The membrane of the bacteria is well known to contain many sulfur-containing 
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proteins (Alcamo, 1997); these might be the preferential sites for the attachment of 
AgNPs. On the other hand, nanoparticles found inside will also tend to react with other 
sulfur-containing proteins in the interior of the cell, as well as with phosphorus-
containing compounds such as DNA (Feng et al., 2000). To conclude, the changes in 
morphology presented in the membrane of the bacteria, as well as the possible damage 
caused by the nanoparticles reacting with the DNA, will affect certain vital processes of 
bacteria such as the respiratory chain, and cell division, and thus finally cause the death 
ofthe cell (Alcamo, 1997). 
The obvious question is that how nanosize Ag particles act as biocidal agent against E. 
coli, P. aeruginosa and S. aureus. There are reports in the literature that show that 
electrostatic attraction between negatively charged bacterial cells and positively charged 
nanoparticles is crucial for the activity of nanoparticles as bactericidal materials 
(Hamouda and Baker, 2000; Stoimenov et al., 2002). The mechanism of the interaction 
between AgNPs and the constituents ofthe outer membrane of £. coli, P. aeruginosa and 
S. aureus were investigated by SEM and HR-TEM analysis and it was observed that, 
AgNPs somehow interact with "building elements" of the bacterial membrane, causing 
structural changes and degradation. Indeed, the HR-TEM analysis (Fig 53-54) confirms 
the incorporation of AgNPs into the membrane structure. This observation is crucial for 
explaining the antibacterial mode of these particles. HR-TEM micrograph clearly shows 
significant changes in and damage to membranes, however, AgNPs not only adhered on 
the surface of cell membrane, but also penetrated. inside the bacterial cells, cause 
formation of irregular-shaped pits and perforation on their surfaces (Fig 53-54). A 
bacterial membrane with this morphology exhibits a significant increase in permeability, 
leaving the bacterial cells incapable of properly regulating transport through the plasma 
membrane and, finally, causing cell death (Sondi and Salopek-Sondi 2004). In the present 
study, SEM and HR-TEM analysis revealed that the action of AgNPs was mild in S. 
aureus as compared with E. coli and P. aeruginosa; these results suggest that the 
antimicrobial effects of AgNPs may be associated with characterisfics of certain bacterial 
species. Bacteria have different membrane structures on the basis of which these are 
classified as Gram negative or Gram positive. The structural difference lies in the 
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organization of peptidoglycan, which is the key component of membrane structure. 
Gram-negative bacteria exhibit a thin layer of peptidoglycan (about 2-3 nm) between the 
cytoplasmic membrane and the outer cell wall. Outer membrane of E. coli cells is 
predominantly made up of tightly packed lipopolysaccharide (LPS) molecules, which 
provides an effective permeability barrier (Sondi and Salopek-Sondi, 2004). The overall 
charge of bacterial cells at biological pH values is negative because of excess number of 
carboxylic groups, which upon dissociation makes the cell surface negative. Since the 
opposite charges of bacteria and nanoparticles are attributed to their adhesion and 
bioactivity due to electrostatic forces, it is logical to state that binding of nanoparticles to 
the bacteria depends on the surface area available for such interactions. Since 
nanoparticles have larger surface area available for interactions, which is likely to 
proportionately enhance the bactericidal effect.than the large sized particles; hence they 
impart cytotoxicity to the microorganisms (Baker et al., 2005). Thus the lower efficacy of 
the AgNPs against S. aureus may derive from the difference as a point of membrane 
structure. The peptidoglycan layer is a specific membrane feature of bacterial species and 
not mammalian cells. Therefore, if the antibacterial effect of AgNPs is associated with 
the peptidoglycan layer, it will be easier and more specific to use AgNPs as an 
antibacterial agent. 
Amro et al. (2000) have shown that metal depletion may cause the formation of irregular-
shaped pits in the outer membrane and thus change the membrane permeability, which 
may lead to progressive release of LPS molecules and membrane proteins. Also, Sondi 
and Salopek-Sondi (2004) speculated that a similar mechanism may be responsible for 
the degradation of the membrane structure of E. coli during treatment with AgNPs. The 
TEM analysis and the existence of elementary silver in the membranes of treated bacteria 
as detected by EDAX, confirm the incorporation of AgNPs into the membrane structure. 
Recently, Kim and co-workers (2007) reported that the antimicrobial mechanism of 
AgNPs is related to the formation of free radicals and subsequent free radical-induced 
membrane damage through the ESR study. To determine the relationship between free-
radical and antimicrobial activity, they used the antioxidant NAC (N-acetylcystein) to test 
whether the antioxidant could influence AgNPs-induced antimicrobial activity. The 
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results of ESR and antioxidant study suggested that free radicals may be derived from the 
surface of AgNPs which may be responsible for the antimicrobial activity. 
In the present study, it was also investigated that the antibacterial activity of AgNPs 
varies when their size diminishes. Studies in the past have demonstrated that 
physicochemical properties of noble metal nanocrsytals are influenced by size (Pal et al., 
2007). Other researches also defined that the bactericidal and antiviral properties of 
AgNPs are size dependent and that the only nanoparticles that show a direct interaction 
with bacteria or virus preferentially have a diameter of-1-10 nm (Elechiguerra et al., 
2005; Morones et al., 2005). A smaller size implies the ability to reach structures that 
otherwise is not accessible to bigger nanoparticles (Ayala-Nunez et al., 2009). Since the 
size of AgNPs used in this study was very small (2 and 5-10 nm), it seems plausible that 
the mechanism of action would be similar to that previously reported (Morones et al., 
2005; Lok et al., 2006; Fernandez et al., 2008) through interaction of nanoparticles with 
bacterial cell membranes, possible penetration inside the bacterial cell damaging sulfur-
and phosphorus-containing molecules such as DNA. Finally the release of Ag^ ions by 
AgNPs also contributes with an additional effect. Martinez-Castanon et al. (2008) also 
reported that the 7 nm AgNPs shows the best antibacterial activity against E. coli and S. 
aureus. They reported that, because of their small size (7 nm) and greater surface area 
AgNPs can easily reach the nuclear content of the bacteria and thus the contact with 
bacteria is the greatest (Lok et al., 2006). 
Elechiguerra et al. (2005) have also studied the size-dependent interaction of different Ag 
NPs with the HIV- 1 virus. The authors observed that only nanoparticles in the 1-10 nm 
range appear to attach the virus. In this case, AgNPs preferentially interact with gpl20 
glycoprotein knobs, and thus blocking the virus from binding to host cells. Lok et al. 
(2006) have recently performed a proteomic analysis of the mode of antibacterial action 
of AgNPs (9.3 nm), concluding that the nanoparticles destabilize the outer membrane of 
E. coli cells which leads to collapse of the plasma membrane potential and depletion of 
the levels of intracellular ATP in a similar way as Ag^ ions proceed. They also observed 
that AgNPs show an antibacterial effect using micromolar (jM) levels while the same 
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effect is observed for AgNPs using nanomolar (nM) concentration levels. It has also been 
shown that partially oxidized AgNPs may be carriers of chemisorbed Ag"^  ions in large 
enough quantities to produce antibacterial activity (Lok et al., 2007). From 
physiochemical viewpoint the size of AgNPs used in the present study were 2 and 5-10 
nm. Indeed, it is known that smaller AgNPs are more effective in killing bacteria than 
larger ones, especially under 10 nm (Morones et al., 2005). This could be the reason why 
the small size AgNPs presents best antibacterial activity. It was well documented in 
literature that the smaller the particles size, greater the surface area and stronger the 
antibacterial activity (Jeong et al., 2005; Thiel et al., 2007). 
Morones et al. (2005) investigated that AgNPs act primarily in three ways against Gram-
negative bacteria: (1) nanoparticles mainly in the range of 1-10 nm attach to the surface 
of the cell membrane and drastically disturb its proper function, like permeability and 
respiration; (2) they are able to penetrate inside the bacteria and cause further damage by 
possibly interacting with sulfur- and phosphorus-containing compounds such as DNA; 
(3) nanoparticles release silver ions, which will have an additional contribution to the 
bactericidal effect of the AgNPs. It is believed that AgNPs after penetration into the 
bacteria inactivate their enzymes and generate hydrogen peroxide and thus finally cause 
bacterial cell death (Kokkoris et al., 2002). Lara et al. (2010) reported that the mode of 
action of AgNPs is similar to that of Ag ions, which forms complex with electron donor 
groups containing sulfur, oxygen or nitrogen atoms that are normally present as thiols or 
phosphates (McDonnell, 2007) on amino acids and nucleic acids. Like AgNPs, silver ions 
also exert their activity through a broad range of mechanisms, including denaturing the 
30s ribosome subunit, suppressing the expression of enzymes and proteins essential to 
ATP production (Yamanaka et al., 2005), inhibiting respiratory enzymes thereby 
inducing the production of reactive oxygen species (Matsumura et al., 2003; Yamanaka 
et al., 2005), binding and dimerizing RNA and DNA (Rai et al., 2009), and thus 
destabilizing and disrupting the outer membrane (Lok et al., 2006). 
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Antibiofilm properties ofAgNPs in vitro 
In recent years there has been considerable interest in the problems posed by the biofilm 
mode of bacterial and fungal growth. According to public announcement from national 
institute of health, "more than 60% of all microbial infection is caused by biofilms" 
(Lewis, 2001). Infections resulting from microbial biofilm formation remain a serious 
concern to the patients care worldwide. Particularly problematic are wound infections 
(Davis et al., 2008; Percival et al., 2008), with chronic wounds such as foot, leg, and 
pressure ulcers being particularly susceptible to biofilm infections (James et al., 2008). 
Apart from evaluating antibacterial activity of AgNPs, in the present study, all the 
clinical isolates were screened for biofilm formation as well as the antibiofilm efficacy of 
AgNPs were also investigated by using some recent techniques e.g., CLSM and SEM. In 
order to kill or remove biofilms, antimicrobials must penetrate the biofilm polysaccharide 
matrix to gain access to the microbial cells. Nanotechnology may provide the answer to 
penetrate such biofilms and reduce biofilm formation by the use of "nano 
fiinctionalization" surface techniques to prevent the biofilm formation. Biofilm 
formation by clinical isolates of E. coli, P. aeruginosa and 5". aureus were tested by 
Congo red agar, tube and tissue culture plate methods. However, the anfibiofilm efficacy 
of AgNPs was investigated by growing the organism on Congo red agar supplemented 
with and without AgNPs. When the colonies were grown without AgNPs, the organisms 
appeared as dry crystalline black colonies, indicating the production of 
exopolysachharides, which is a prerequisite for the formation of biofilm (Fig 66). 
Whereas when the organisms were grown with AgNPs, the organisms did not survive. 
During the treatment with reduced concentrations of AgNPs (10 ^g/ml), the organisms 
continued to grow, but AgNPs treatment had inhibited the synthesis of 
exopolysachharides as indicated by the absence of dry crystalline black colonies. 
However, at higher concentration of AgNPs (50 ng/ml) almost no growth was observed 
(Fig 66). Thus, when the exopolysachharide synthesis was arrested, the organism could 
not form biofilm. Similar results were also reported by Kalishwaralal and co-workers 
(2010) against P. aeruginosa and S. epidermidis biofilms and found that 100 nM of 
AgNPs resulted in a 95-98% reduction in biofilm (Kalishwaralal etal, 2010). It was also 
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cited in literature that if the surface of medical devices had an AgNPs coating then it was 
helpful in preventing bacterial adhesion and subsequent biofilm formation on the medical 
devices (Menno & Leo, 2011). 
Based on these results we continued to address the mechanism of action of AgNPs on 
biofilm forming bacterial species by applying CLSM and SEM. SEM was used to 
examine cell morphologies following exposure to the nanoparticles. E. coli (Fig 70a), P. 
aeruginosa (Fig 71a) and S. aureus (Fig 72a) cultures grown without nanoparticles 
exhibited the normal cellular morphology with smooth cell surfaces. Under the same 
growth conditions but in the presence of suspended AgNPs (30 fig/ml), E. coli (Fig 70b). 
P. aeruginosa (Fig 71b) and S. aureus (Fig 72b) bacteria presented a change in their 
morphology. More specifically, an obvious increase in the roughness of the cell surface 
suggested that it was damaged by the nanoparticles. Furthermore, numerous nanoparticles 
were also observed tightly associated on the cell surface, while some of the treated cells 
revealed pronounced damage of their cell wall. EPS within E. coli biofilms was not 
detected by SEM. SEM observations clearly indicated that AgNPs reduced the surface 
coverage by E. coli (Fig 70b), P. aeruginosa (Fig 71b) and S. aureus (Fig 72b) biofilms. 
The present results are an agreement with previously reported antibiofilm activity of 
nanocrystalline silver by Kostenko and co-workers (2010). They observed that 
nanocrystalline silver dramatically decreased viable cell numbers within the tested 
biofilms. SEM results showed that nanocrystalline silver reduced the surface coverage by 
P. aeruginosa biofilms. Prolonged treatment with nanocrystalline silver provided a 
further reduction in the surface coverage by MRSA biofilms. The surface coverage by E. 
coli biofilms was reduced by approximately 20% with the tested dressings after the first 
day (Kostenko et ah, 2010). 
There are only limited numbers of techniques available to demonstrate the presence of 
biofilms on medical devices or surfaces. The reason why the demonstration of bacterial 
biofilms is challenging is because it is difficult to stain both the bacteria and glycocalyx. 
Furthermore, light and electron microscopic techniques require a dehydration process that 
reduces the total volume of the matrix and thus alters its architecture (Akiyama ei al., 
2003). In order to achieve a fundamental understanding of the formation and presence of 
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bacterial biofilms, the analysis should include detection of the bacteria and the matrix. 
The most common methods of assessing biofilm heterogeneity are direct microscopic 
imaging of local biofilm morphology or microscopic measurement of the local biofilm 
thickness. For many applications, time lapse microscopy using confocal scanning laser 
microscopy (CLSM) is an ideal tool for monitoring at a spatial resolution of the order of 
micrometers, and this allows a non-destructive study of biofilms and examination through 
all the layers at different depths, thus making it is possible to reconstruct a three-
dimensional structure (Lawrence et al., 1999, Psaltis et al, 2007). The detection of the 
matrix can be achieved using a double-staining technique in combination with CLSM, 
which allows the simultaneous imaging of bacterial cells as well as glycocalyx within the 
biofilms (Kaniae/fl/.. 2007). 
Therefore, to visualize the bacterial cells and the surrounding glycocalyx matrix (which is 
indicative of bacterial biofilm formation), in the present study this powerful technique 
(CLSM) was employed to examine the effect of nanoparticles on glycocalyx matrix / 
exopolysachharides synthesis; double staining was performed using propidium iodide and 
ConA- FITC. In case of untreated E. coli (Fig 67), P. aeruginosa (Fig 68) and S. aureus 
(Fig 69), PI stain bacterial nucleic acids was fluorescent red, while, green fluorescent 
(Con A-FITC) around bacteria indicates the presence of exopolysachharides. Whereas, 
AgNPs treated samples of E. coli (Fig 67), P. aeruginosa (Fig 68) and S. aureus (Fig 69) 
showed that most of the cells were dead and no exopolysachharides (green fluorescent) 
was observed. The number of live bacterial cells was reduced significantly and its 3-
dimensional structure was also disrupted. It was observed that this inhibitory effect of 
AgNPs on the existing biofilm may due to be presence of water channels throughout the 
biofilm. Since in all biofilms water channels (pores) are present for nutrient 
transportation and AgNPs may directly diffuse through the exopolysachharides layer 
through the pores and thus imparting its antimicrobial function. Chaudhari et al. (2012) 
investigated the antibiofilm activity of AgNPs (51 nm) synthesized from B. megaterium 
and reported that AgNPs showed enhanced quorum quenching activity against S. aureus 
biofilm and prevention of biofilm formation which can be seen under inverted 
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microscope. They concluded that AgNPs might be involved in neutralizing these 
adhesive substances, thus preventing biofilm formation (Chaudhari et al., 2012). 
However, the exact mechanism of action of AgNPs in biofilm related studies is yet to be 
demonstrated. Although all previously tested silver dressings (e.g., acticoat 
nanocrystalline silver, silverlon, aquacel silver, silvercel, and polymem silver) against E. 
coli and ?. aeruginosa killed bacterial cells within biofilms and destroyed biofilm 
colonies (Kostenko et ah, 2010). It was believed that silver ions bound to bacterial cells 
and EPS also interfere with intermolecular forces in biofilms and facilitate biofilm 
dispersion (Chaw et al., 2005). Kostenko et al. (2010) reported that Acticoat 
nanocrystalline silver has the highest antibiofilm efficacy compared to Aquacel silver and 
Silverlon and thus the silver concentration alone cannot account for the antibiofilm 
efficacy of the silver dressings. The type of silver species present also plays a role 
(Kostenko et al., 2010). The reduction of the silver particle to the nanoscale level 
increases the relative surface area, which provides higher Ag^ release rates than for 
elemental silver particles (Dunn & Edwards-Jones, 2004). Moreover, nanoparticles have 
a higher capacity to attach to and penetrate bacterial membranes and accumulate inside 
cells, providing a continuous release of silver ions inside the cell (Rai et al., 200 )^; 
Kostenko et al., 2010). In the near future, the AgNPs may play a major role in the coating 
of medical devices and treatment of infections caused due to highly antibiotic resistant 
biofilms. 
In vitro antibacterial activity of metal oxide nanoparticles (ZnO & AI2O3) 
Apart from metal nanoparticles (AgNPs) used in the present study, the potential 
antibacterial activity of metal oxide nanoparticles as biocides or disinfectants, with a 
focus on the use of ZnO and AI2O3 nanoparticles were also investigated. Published 
studies on the ecotoxicity of metal oxide NPs (such as Si02, AI2O3, Fe304, Ti02, MgO 
and CaO, ZnO) to bacterial species are limited, even though their bactericidal properties 
have been reported in the biomedical literature (Stoimenov et al., 2002; Adams et al., 
2006; Brayner et al., 2006; Sadiq et al., 2009; Zhang et al., 2010). It is expected that 
these nanoparticles to be toxic to microbes in the environment. Nanoscale AI2O3, Si02 
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and ZnO offer greater surface area than their bulk counterparts, allowing for improved 
performance in established applications. There are a number of reasons for selecting 
these metal oxides nanoparticles for the study. ZnO is much more stable and has a longer 
life than organic-based disinfectants or antimicrobial agents. This is particularly 
important for harsh conditions such as high temperatures and/or pressures occurring 
during product manufacturing, storage and transportation (Stoimenov et al, 2002; Sawai, 
2003; Brayner et al., 2006). AI2O3 NPs have important applications in the ceramics 
industry (Zielinski et al., 1993) and can be used as an abrasive material, in heterogeneous 
catalysis, as an absorbent, as a biomaterial, and as reinforcements of metal-matrix 
composites (Ganguly & Poole, 2003; Sadiq et al, 2009). Yamamoto et al. (2004) 
investigated cytototoxic effects of metal oxide particles, including AI2O3 on murine 
fibroblasts and murine monocyte macrophages. They studied cytotoxicity as a function of 
shape, size, and surface area of the particles and also compared toxicity behavior of bulk 
and nanomaterials. There have been very few studies available in the literature on the 
interaction of the AI2O3 NPs with bacterial cells; however, the antibacterial activity of 
ZnO NPs has been documented. Considering the paucity of prior literature reports on the 
effect of ZnO and AI2O3 NPs on bacterial species, there was an urgent need to address the 
issue from the fundamental level of interactions between metal oxide nanoparticles and 
bacterial cells. In order to examine the antibacterial activity of the metal oxide 
nanoparticles on various microorganisms, in the present study, the possible growth-
inhibitory effect as well as the interaction of these metal oxides nanoparticles with E. 
coli, P. aeruginosa and S. aureus by applying SEM and HR-TEM were investigated. 
Although the antibacterial activity increased with dose for all treatments, these two 
nanoparticles behaved differently upon exposure to the same bacterial species. In the 
present study, two different size ZnO (20 & 70 nm) and two AI2O3 (45 & <50 nm) NPs 
were used to evaluate the antibacterial activity against various drug resistant and non-
resistant clinical isolates of E. coli, P. aeruginosa, Klebsiella spp, and S. aureus by 
different methods such as time-dependent growth inhibition assay, MIC and MBC 
determination and well-diffusion methods. In the present study, the MIC for 20 and 70 
nm ZnO NPs were found to be in the range of 500-4000 and 2000-8000 ng/ml. 
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respectively when tested against E. coli, P. aeruginosa and S. aureus (Table 28-37). This 
is in agreement with the earlier report which showed MIC in the range of 1000-8000 
Hg/ml for E. coli and 500-4000 |ig/ml for S. aureus, respectively (Emami-Karvani and 
Chehrazi et al., 2011). The present finding is consistent with the earlier report (Ansari et 
al., 2012 a & b). However, in another work, the MIC of the ZnO (800±300 nm) was 
found to be 5000 ^g/ml for E. coli and 10000 \ig/m\ for S. aureus (Applerot et al., 2009) 
which were remarkably higher. It was noticed that in both cases, the ZnO suspension with 
20 nm particles was more effective than the suspensions with 70 nm particle sizes. This 
can be explained on the basis of the generation of highly reactive oxygen species (such as 
0H~, H2O2, O2 ^~ and superoxide radical anions (*0~ )^) released on the surface of ZnO, 
which caused fatal damage to microorganisms (Sunada et al., 1998). The generated H2O2 
can penetrate the cell membrane and kill the bacteria (Fang et al., 2006). Once ZnO is 
attached to the cell membrane, the ZnO nanoparticles presumably remain tightly 
adsorbed on the surface of the leftover/dead bacteria preventing its further antibacterial 
action. However, ZnO nanoparticles continue to release peroxides into the medium even 
after the surface of the dead bacteria are completely covered by ZnO nanoparticles, 
thereby showing high bactericidal efficacy. From the results for MIC, it was confirmed 
that the smaller particle size shows enhanced activity due to the large surface area to 
volume ratio and the surface reactivity of ZnO (Padmavathy and Vijayaraghavan, 2008). 
The minimum concentrafion of ZnO NPs (70 nm) which inhibit the growth of all tested 
drug resistant and non-resistant bacterial isolates was found to be 50 |ig/ml. It was also 
observed that the growth rate was strongly inhibited at 500 fxg/ml and almost no growth 
was seen up to for 10 h at 1000 ng/ml (Fig 28-30). This is in agreement with previousl} 
published reports on the antibacterial properties of ZnO NPs which showed that the 
complete growth inhibition of S. aureus and E. coli at >1 mM and at >3.4 mM. 
respectively for ~ 13 nm ZnO NPs (Reddy et al., 2007) and at 5 mM in case of 5. aureus 
for 50-70 nm ZnO NPs (Jones et al., 2008). The toxicity of ZnO and other metal oxides 
towards human beings is observed at higher concentrations but low concentrations of 
ZnO are non-toxic towards human cells. It has been shown in earlier studies that ZnO 
protects against intestinal diseases by combating the detrimental effects of intestinal E. 
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coli strain (ETEC) by inhibiting the adhesion and internalization of the bacteria 
(Yamamoto et al, 2004). In the present study, very low concentration of the ZnO NPs 
was found to substantially inhibit the growth of all tested isolates which may be because 
of the size of ZnO NPs. These results are consistent with an earlier finding that the 
antibacterial activity of ZnO NPs varied with particle size (Yamamoto, 2001; 
Padmavathy and Vijayaraghavan, 2008). However, the environmental behavior may be 
more complex in nature depending upon physiochemical interactions of the particles or 
presence of microbial consortia, among other factors. Since most infection causing multi-
resistant bacterial strains have become a major threat to public health, the high 
antibacterial activity of ZnO NPs (70 nm) towards both the Gram-positive {S. aureus) and 
Gram-negative {E. coli, P. aeruginosa, Klebsiella spp) suggest their use as antibacterial 
agents in preventing both the superficial infections and outbreaks caused by the above 
pathogenic strains. 
The mechanism/interaction between the bacteria and ZnO NPs and its antibacterial 
activity has been further elucidated by SEM and HR-TEM. The SEM micrograph of 
tested bacteria i.e., E. coli, P. aeruginosa and S. aureus after treatment with ZnO NPs 
were shown in figure 47, 48 & 49, respectively. It is obvious from the images that the 
nanoparticles have attached at first to the outer membrane of the cell which has further 
lead to cell breakage and finally resulting in cell damage (Fig 47-49). However, HR-TEM 
micrograph shows that alternatively the cell membrane was extensively damaged and 
most probably, the intracellular content has leaked out resulting in damage of the 
bacterial cell (Fig 56-58). In both cases i.e.. Gram positive and Gram-negative bacteria, 
antibacterial activity of ZnO NPs can be attributed to the damage of cell membranes, 
which leads to leakage of cell contents and cell death. Though the exact mechanism by 
which the membrane damage is caused is not clear and it is still under debate. Several 
researchers have tried to explain the cause of damage of cell and cell walls by the 
incorporation of foreign material. Domenech and Prieto (1986) have described that the 
release of Zn^ "^  ions is responsible for the antibacterial activity (Domenech and Prieto, 
1986). ZnO is a stable compound, but when it dissolves in high concentrated medium or 
alkaline medium, it easily releases Zn^* ions from the compounds. In other reports, the 
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antibacterial activity has been ascribed to the photocatalytic reaction as well as the 
membrane damage caused by the release of H2O2 (Fu et al., 2005; Roselli et al., 2003: 
Domenech and Prieto 1986). Further studies are needed to conclude the relation of 
antibacterial activity with ZnO NPs. In the present study, it was tried to postulate a 
possible mechanism of the antibacterial activity of the ZnO NPs. Possibly at first, the 
ZnO NPs are attached to the outer wall of the cell, and gradually, they enter the cell 
causing damage to the internal contents of the cell which leads to cell death and 
destruction. However, the exact mechanism is still under debate. Cellular uptake of the 
ZnO NPs in E. coli cells have also been shown in some previous studies using TEM 
(Brayner et al., 2006; Huang et al., 2008; Tarn et al., 2008). In the previous study of 
Applerot and co-workers (2009), they reported the existence of elementary zinc in the 
membranes of the treated bacteria, as well as inside the cytoplasm by EDS (Energy 
dispersive X-ray spectroscopy) and flow cytrometry. They also reported that the 
antibacterial effects of ZnO result from the contact of the particles with the bacterial 
membrane and the production of ROS which plays a crucial role in causing its 
disorganization (Applerot et al., 2009). 
In case of AI2O3 NPs, the MIC for 45 and <50 nm were found to be in the range of 1600-
3200 and 1800-3600 |ig/ml, respectively when tested against E. coli, P. aeruginosa, 
Klebsiella spp and S. aureus (Table 38-47). There have been very few studies available in 
the literature on the interaction of the AI2O3 NPs with bacterial cells. One past study 
found no detrimental effect of alumina slurry between 62.5 and 250 mg/L concentration 
range on E. coli (Sawai et al., 1995). However, preliminary antibacterial studies 
performed using colony count assays with AI2O3 NPs demonstrated a mortality rate of 
57% to B. subtilis, 36% to E. coli, and 70% to P. fluorescens at a low concentration (20 
^g/ml) using Ig/L NaCl as the experimental medium (Jiang et al, 2009). A stud> on 
yeast cells demonstrated the membrane disruption property of AI2O3 NPs at high 
concentrations (>1000 |Jg/ml) (Garcia-Saucedo et al, 2011). In another assessment, 
toxicity and bioaccumulation of AI2O3 NPs to a range of sediment dwelling 
microorganisms (such as Tubifex tubifex, Hyalella azteca, Lumbriculus variegatus, and 
Corbicula fluminea) were observed and the toxicity was found to be more in nano- AI2O3 
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as compared to micrometer-sized AI2O3 toward tlie survival of H. azteca in a 14-day 
exposure period upon direct contact with a thin layer of 625 mg or 2500 mg of AI2O3 NPs 
(Stanley ef a/., 2010). 
In further experiments, ESBL and non-ESBL strains of E. coli and P. aeruginosa, MBL 
strain of P. aeruginosa, MRSA and MSSA strains of S. aureus were inoculated in liquid 
LB medium supplemented with increasing dosages of AI2O3 NPs. Increasing 
concentration of NPs progressively retarded the growth of tested bacterial strains. The 
concentration of 1000 |xg/ml was found to be mildly inhibitory for bacteria; however, at 
2000 |xg/ml no growth was noticed for about 6-8 hours (Fig 31-33). This result is in 
accordance with previously published data (Sadiq et al. 2009). Another study 
demonstrated the growth inhibitory effect of AI2O3 NPs on microalgae such as 
Scenedesmus sp. and Chlorella sp. A growth inhibitory effect of the nanoparticle was 
observed against both the species and an obvious decrease in the chlorophyll content was 
also observed in the cells treated with nanoparticles. An interaction of the nanoparticles 
with the cell surface was suggested as the possible mechanism for the toxicity (Sadiq et 
o/.,2011). 
The mechanisms of action of AI2O3 NPs on E. coli, P. aeruginosa and S. aureus were 
further confirmed by SEM and TEM analysis. SEM micrograph revealed that the 
morphology of treated bacterial cells was significantly changed and showed major 
damage, which was characterized by the formation of "pits" in their cell walls. Clusters 
of NPs were found to anchor to the bacterial cell wall of E. coli (Fig 50) and P. 
aeruginosa (Fig 51), possibly at sites that are rich in negatively charged functional 
groups. In case of S. aureus (Fig 52), change in cell shape and agglomerated particles on 
the cell wall was observed and the spherical-shaped cell was broken down to smaller size. 
HR-TEM analysis of thin sections allows direct visualization of morphological changes 
resulting in the bacterial cells upon contact with AI2O3 NPs (Fig 60-62). Moreover, 
damage and disorganization in the cell wall were observed (Fig 60-62). The cell 
membrane in E. coli (Fig 60) was extensively damaged and, most probably, the 
intracellular content had leaked out. Figure 60-62 shows AI2O3 NPs inside and outside 
the cell surrounded possibly by lipopolysaccharides released by the bacteria. Small size 
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NPs were uniformly distributed inside the cells while some agglomerated particles 
adhered outside the membrane as evident under TEM (Fig 60). Indeed, the HR-TEM 
analysis (Fig 60-62) confirmed the incorporation of AI2O3 NPs into the membrane 
structure. This observation was crucial for explaining the mode of antibacterial activity of 
these particles. HR-TEM micrograph clearly showed significant changes in and damage 
to membranes, however, AI2O3 NPs not only adhered at the surface of cell membrane, but 
also penetrated inside the bacterial cells, caused formation of irregular-shaped pits and 
perforation on their surfaces (Fig 60-62). A bacterial membrane with this morphology 
exhibits a significant increase in its permeability, leaving the bacterial cells incapable of 
properly regulating transport through the plasma membrane and, finally, causing cell 
death. This demonstrates that smaller NPs can enter the bacterial cells and may interact 
with the cellular macromolecules causing adverse effects to the extent of cell death. The 
NPs were also found in the dividing cells indicating transmission to the daughter cells as 
constituent of the cytoplasm. Non-specific diffusion, non-specific membrane damage and 
uptake are the possible mechanism through which the NPs could pass through the 
bacterial cell wall and membranes but the precise mechanism is still unknown. AI2O3 NPs 
were adsorbed onto bacterial surface and localized in the periplasmic compartment. 
AI2O3 NPs were accumulated in bacterial periplasm, confirming that association between 
NPs and bacteria is a prerequisite for the expression of their toxicity. The toxicity of 
AI2O3 NP could be partly explained by their dissolution. The induction of ROS by AI2O3 
NP may come from the presence of Al ions in NPs suspension (Simon-Deckers et ai, 
2009). Bactericidal effects were partly due to NPs induced production of intracellular 
ROS, but here it is proposed that the impairment of cell membrane integrity is the major 
cause of bacterial death. Taken together, these data give valuable information on the 
mechanisms leading to NP-induced bacterial death. In case of E. coli bacteria, cellular 
internalization of the nanoparticles has also been observed (Brayner et al. 2006). The 
influence of particle size of on the antibacterial activity of metal oxides has been reported 
in the literature; see for example Yamamoto (2001) and Makhluf (2005). One of the 
possible reasons for the damage could be direct interaction between AI2O3 NPs 
nanoparticles and the external membrane surface. More work is therefore needed to 
further confirm these observations. 
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HR-TEM made it possible to visualize the NPs' adhesion on bacteria. From Figure 60-62, 
AI2O3 were coating the whole bacterial cells. AI2O3 were rarely found in other areas of 
the grid except on the bacterial surface, showing a tendency for them to attach on the cell 
wall rather than to aggregate together. Further study is needed to better understand the 
toxicity differences among NPs. NPs, found inside cytoplasm, could have entered due to 
disruption of the cell membrane. 
There are several possible attachment mechanisms of oxide NPs to the bacterial surface: 
Van der Waals forces, electrostatic, hydrophobic and receptor-ligand interactions 
(McWhirter et al., 2002; Parikh and Chorover, 2006). The bacterial surface has negative 
charges. For the highly positively charged oxides, AI2O3 NPs negatively charged 
bacterial surfaces would attract these NPs. When the electrostatic repulsion between NPs 
and bacteria was weak, the receptor-ligand interactions may dominate between the 
oxides and bacteria. Such a bond formation was reported in bacterial adhesion to natural 
mineral surfaces (Deo et al., 2001; Omoike and Chorover, 2004). Carboxyl, amide, 
phosphate, hydroxyl groups and carbohydrate related moieties in the bacterial cell wall 
may provide sites for the molecular-scale interactions with the oxide NPs (Omoike and 
Chorover, 2004; Leone et al, 2007). Because AI2O3 NPs are much smaller than the 
bacterial cells, they coated around the bacteria by electrostatic attractive forces, 
neutralizing the bacterial surface charge and creating large aggregates. The large 
aggregates of NP-bacteria complexes would deposit quickly in the suspension. This 
indicates a particle size-dependant phenomenon. For negatively charged bacterial cells 
(few micrometers in size) they could readily capture NPs by electrostatic forces, while it 
would be difficult to attract bulk size particles. 
The decrease in cell viability as observed in the present study may be due to bacterial 
adhesion to the particle surfaces or vice-versa. Due to positive surface charges on the 
alumina NPs at near-neutral pH, an electrostatic interaction is possible between 
negatively charged E. coli cells and the particles, leading to bacterial adhesion onto NP 
surfaces or vice-versa. As the adhesion increased with increase in concentration of the 
particles in the suspension, a negative effect on growth was observed with respect to 
concentration. This electrostatic interaction between bacteria and particle surface, along 
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with hydrophobic interactions and polymer bridging, may be responsible for the 
phenomenon of bacterial adhesion onto the particles (Li & Logan, 2004). 
To date, there is still a lack of definite knowledge regarding the interaction of oxide NPs 
with the bacterial cell wall and possible mechanism for permeation of the NPs into the 
bacterial cells. A number of mechanisms have been proposed to infer the antibacterial 
behaviour of metal oxides. Makhluf et al. (2005) investigated the antibacterial behaviour 
of MgO and attributed the behaviour to the following mechanisms: production of active 
oxygen species due to the presence of MgO, interaction between MgO particles and 
membrane cell wall, penetration of individual MgO particles into cell and reformation of 
MgO within the cell. Stoimenov et al. (2002), on the other hand, suggested that the 
electrostatic interactions between the bacteria surface and nanoparticles be a possible 
reason. 
In vivo toxicological effects of metal oxide (ZnO) NPs 
ZnO and AgNPs have become one of the most widely applied nanomaterials in the 
biomedical and pharmacological fields, therefore an evaluation of their safety is 
extremely important. The increased production and use of ZnO NPs enhances the 
probability of exposure in occupational and environmental settings. This has culminated 
in some studies investigating the toxicity of ZnO NPs in different biological systems such 
as bacteria (Ansari et al, 2012 a & b) and mammalian cells (Wang et al., 2010a). In 
mammalian cells, the toxic effects of ZnO NPs such as membrane injury, inflammatory 
response, DNA damage and apoptosis have been demonstrated (Yang et al., 2009; 
Osman et al., 2010; Sharma et a/., 2011). The majority of these studies have been 
conducted using in vitro systems. However, unlike the in vivo systems, the complex cell-
cell and cell-matrix interactions as well as the diversity of cell types are not present in 
cultured cells. Studying the long term chronic effects of the test compound are also not 
possible without in vivo experiments. The importance of the in vivo studies in the area of 
nanomaterial toxicology has already been highlighted (Fischer & Chan, 2007). 
There are no existing guidelines or standard methodologies for risk assessment of 
nanomaterials. However, the "committees on toxicity (COT), mutagenicity (COM) and 
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carcinogenicity (COC) of chemicals in food, consumer products and the environment, 
UK" have suggested extrapolating the in vitro nanotoxicity findings to in vivo 
experiments and confirm the results (COT, COM, COC, 2005). The same committees 
have also advised on the importance of considering appropriate routes of exposure in the 
in vivo experiments. In case of engineered nanoparticles, the exposure and uptake can 
occur through different routes. This is keeping in view the fact that ZnO NPs can be 
ingested directly when used in food, food packaging, drug delivery and cosmetics. 
Workers involved in the synthesis of ZnO NPs can be exposed by unintentional hand-to-
mouth transfer of nanomaterials. When discharged accidentally into the environment, 
these nanoparticles may enter the human body through the food chain. Although there has 
been controversy regarding the safety of nano material use, ZnO has ordinarily been used 
in sunscreens because of its ability to filter ultraviolet light (Newman et al., 2009). The 
toxicological evaluation of ZnO reported by National Institute for Occupational Safety 
and Health (NIOSH, 2010) and Scientific Committee on Cosmetic Products and Non-
food products (SCCNFP, 2003) have been showed that the LD50 of normal ZnO for rats 
is more than 5-g/kg and 8-g/kg body weight, respectively and belongs to non-toxic 
chemicals demonstrated by a single oral ingestion. For ZnO NPs, only a few in vivo 
studies are available which were either focused on oral (Wang et al., 2008) or inhalation 
exposure (Wang et al, 2010b), while in the present study the route of administration of 
ZnO NPs is intraperitoneal. In the present work, the toxic effects of ZnO NPs at low-
(0.5-g/kg), middle- (1-g/kg), high- (3-g/kg) and exceptionally high-dose (5-g/kg) was 
investigated. The histopathological and ultrastructural changes resulting from ZnO NPs 
exposure was examined by light and electron microscopy. 
Total protein consists of ALB and globin, and ALB is synthesized by liver. The 
decreased of TP, ALB and TIBL levels which are important indicators of the hepatic 
injury, demonstrated that ZnO NPs induced hepatic injury. The significant decreased 
(?<0.05) in the TP levels in 1^ ' week (at low- & exceptionally high-dose), ALB level in 
1", 2"\ 3"^ and 4* week (at high- & exceptionally high-dose) and TIBL level in 2"^ " and 
4"^  week (at high-dose) of mice were noticed with the exposure of ZnO NPs indicate that 
the liver is in dysfunction. Thus the findings on TP and ALB are consistent with the 
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previous study of Song et al. (2010) and Wang et al. (2010b). SGOT, SGPT and ALP are 
also important indices to evaluate liver damage. In the present study, though SGOT and 
SGPT markers in blood serum were not significantly increased, but some mild adverse 
responses in liver might still have occurred. The previously reported study also showed 
similar results in the SGOT and SGPT levels (Wang et al, 2010). However, the level of 
ALP significantly increased (P<0.05) in 1'', 2"^ 4* week (at high- & exceptionally high-
dose) and 3'^ '' week (at low-dose) treated mice, indicating that liver damage might be 
induced by high-dose of ZnO NPs. The findings on ALP levels in the ZnO NPs exposed 
groups are consistent with the previously reported study (Wang et al, 2008; Sharma ei 
al., 2012). 
The blood BUN and CR are good indicators for renal function. If kidney function falls, 
the BUN and CR levels will rise (Wang et al, 2006). However, in the present study, no 
elevation in BUN was found in the low-, middle- or high-dose groups ZnO NPs treated 
mice. Similar result was obtained from other researches after ZnO NPs exposure (Sharma 
et al., 2012; Esmaeillou et al., 2013). In these studies, no significant changes were 
noticed in the BUN levels. However, the levels of CR were significant increased in 4"^  
week of treated mice at 3- & 5-g/kg. Similar results were also reported in previous study 
after oral exposure of ZnO NPs in mice (Wang et al., 2008). 
Interestingly, in the present study, HDL levels decreased significantly in P' week (at 5-
>nd g/kg) and 2 week at all doses, which has not been reported previously in animal models s. 
In man, ingesting high levels of zinc for several months also decreased the level of HDL 
cholesterol (U.S. Department of Health and Human Services, 2003) and the ZnO NPs 
may have had a similar effect in our study, although this effect requires further 
investigation. However, no significant differences in the TG, CHO and Glucose levels 
were noticed. These results indicate that ZnO NPs has no obvious affects on lipids 
metabolism. In the previous study, similar results on Glucose, CHO (Esmaeillou et al. 
2013) and TG levels (Wang et al., 2008) were also reported. 
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The light microscopic histopathologicai observation showed, congestion, granular 
degeneration in the hepatocytes, inflammatory cells in the liver and vesicular change in 
the hepatocytes at exceptionally high-dose (5-g/kg) of ZnO NPs when exposed for 3'^ '' and 
4* weeks (Fig 73 d & e). In the previous study the pathological lesions of liver were 
found at 1- and 5-g/kg/bw in mice treated to ZnO NPs, respectively (Wang et ah, 2008). 
The above results support the previous findings of Wang et al. (2008), Jung et al. (2010) 
and Esmaeillou et al. (2013) and they also observed liver damage in mice after oral 
exposure to ZnO NPs. 
The renal histopathologicai examination revealed damage of tubular epithelium, renal 
tubular dilatation and renal cast in the tubular lumen at exceptionally high-dose (5-g/kg) 
(Fig 74 d & e). In the previous study proteinaceous casts in renal tubule were observed at 
single oral dose of 20- and 120-nm ZnO NPs at 5-g/kg/ body weight (Wang et al, 2008). 
The present histopathologicai findings demonstrated that the ZnO NPs after 
intraperitoneal exposure could not cause severe renal damage at low-, middle- and high-
dose up to 4 weeks and the serum indicators also did not show obvious changes. 
Therefore, in this research, the elevated CR in 4* week treated mice could be partly 
caused by liver dysfUnction. 
Spleen from control group had normal histology where red and white pulp could be 
identified clearly and megakaryocytes were only occasionally noticed (Fig 75 a). After 
one and two week of treatment no observable changes were noticed at any doses and 
were very akin to control (Fig 75 b «& c). While, after 3'^ '^  and 4"" week of exposure to 
exceptionally high-dose of ZnO NPs, megakaryocyte hyperplasia was seen in the red 
pulp in the spleen and interestingly the number of megakaryocytes in the spleen of the 
treated mice were increased (Fig 75 d & e) as compare to control group. In the previous 
study slight enlargement of the splenic corpuscle was reported at 1- and 5-g/kg of 20- and 
120-nm of ZnO NPs after 2 week of exposure (Wang et al, 2008). Thus, 1'' and 2"'' week 
treatment had no remarkable effect at exceptionally high-dose on the cytoarchitecture on 
liver, kidney and spleen however, 3'^ and 4* weeks treatment had sporadic mild effects 
on these organs. 
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In vivo toxicological effects ofAgNPs 
Previously in vitro studies revealed that AgNPs showed cytotoxicity through reduced 
mitochondrial functions, increased membrane leakage, necrosis and induction of 
apoptosis (Braydich-Stolle et ah, 2005; Hsin et ah, 2008; Kvitek et ai, 2009; Miura and 
Shinohara, 2009; Choi et al., 2010). There is no direct correlation of biological markers 
of toxicity between in vivo and in vitro studies owing to the complexity of dose delivery, 
mono- vs co-cultures, endpoint evaluations as well as other factors of cellular interaction 
with different biological media (Seagrave et al., 2005; Sayes et al., 2007). Most of the in 
vivo studies on AgNPs have employed routes of administration such as inhalation (Sung 
et al., 2009), oral gavage (Kim et al., 2010), intratracheal instillation (Park et al., 2011) 
or intravenous injection (Xue et al., 2012). These studies revealed that AgNPs could 
distribute from the exposure site and become systemically available. Once nanoparticles 
enter the body, they may become systemically available regardless of route of 
administration and thus cause toxic effects. For nanoparticles of medical applications, 
their efficacy largely depends on the control of their distribution within the body. This 
makes it important to illustrate the concentration-time profiles in the blood and tissues of 
interest. From previous reports, it is well known that AgNPs have strong antimicrobial 
effects (Sondi & Salopek-Sondi, 2004; Kim et al., 2007; Ansari et al., 2011 a & b). and 
they have been found to induce mild cytotoxicity in vitro in a micronuclei assa> and 
CCK-8 assay in CHO cells (Maeng et al., 2006) and BRL 3A rat liver cells (Hussain et 
al., 2005). Since, AgNPs remain one of the most controversial research areas regarding 
their toxicity to biological systems. Therefore, the aim of present work was to assess the 
potential toxicity of AgNPs on different serum biochemical parameters. The 
histopathological and ultrastructural changes in liver, kidney and spleen resulting from 
AgNPs exposure have also been examined by light and electron microscopy following a 
single intraperitoneal injection of AgNPs in mice up to for 28-day. Intraperitoneal route 
of administration not only allows for avoidance of variability in absorption from the 
absorption sites, but also represents a potential exposure route of AgNPs for their medical 
and diagnostic applications. 
228 
(Discussion 
The significant decreased in the TP levels in 4* week (in all dose groups), ALB level in 
1'', 2"'' and 4* week and TIBL level in l", 2nd, 3"* and 4* week (in all dose groups) were 
noticed in mice treated with AgNPs indicate the liver is in dysfunction. The findings on 
TP and ALB are consistent with the previous study of Xue et al. (2012). SGOT, SGPT 
and ALP are also important indices to evaluate liver damage. In the present study, though 
SGOT and ALP markers in blood serum were not significantly increased, but some mild 
adverse responses in liver might still have occurred at exceptionally high-dose. However, 
the level of SGPT significantly increased (P<0.05) in 2"^ 3"^  and 4* week, indicating that 
inflammatory of liver might be induced by high-dose (3- & 5-g/kg) of AgNPs. The 
findings on the SGOT, SGPT, ALP, ALB and TP levels in the AgNP exposed groups are 
consistent with the previous report on 28-day repeated oral exposure (Kim et al., 2008) 
and 14-day intravenous exposure of AgNPs study in mice (Xue et al., 2012). The above 
results are consistent with the previous reports with respect to liver as the target organ at 
high-dose after long-term exposure of AgNPs. The results obtained in the present study 
indicate that mice exposed to AgNPs by a route that allowed immediate and complete 
systemic availability (i.e. intraperitoneal administration) exhibited few toxic or adverse 
health effects. 
The histopathological observation showed non-specific hepatocellular damage, 
inflammatory cells in the liver and vesicular change in the hepatocytes and loose 
cytoplasm of liver cells at 5-g/kg of AgNPs (Fig 80 d & e), which was consistent with the 
pathologic observation in 28-day and 90-day (Kim et ah, 2008 & 2010) oral toxicity and 
14-day intravenous toxicity study (Xue et al., 2012). In another study, 14-day oral 
exposure of colloidal AgNPs at dose of 5-g/kg, did not show any mortality, 
histopathological changes and no significant changes were observed in biochemical 
parameters (Maneewattanapinyo et al, 2011). While, in present study slight liver damage 
upon exposure to 5-g/kg of AgNPs was noted in 2"*^ , 3 '^' and 4"^  week of treated mice. The 
results suggested that AgNPs could be well tolerated in mice when given 
intraperitoneally at the dose level of 5-g/kg and no mortality was noted up to 4 week. 
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The UA and BUN did not show any significant changes in all treated groups in the 
present study. And this finding is consistent with the previous 28-day (Kim et ai, 2008) 
and 90-day (Kim et aL, 2010) oral toxicity studied of AgNPs; in which no significant 
changes were also observed in the UA and BUN levels. However, in present study a 
significant decrease (p<0.05) in the CR level was observed at high-dose in 1*', 2"'', 3'^ '' 
and 4* week of treated mice but such decrease in the CR level was not reported in the 
previous studies (Kim et aL, 2008 & 2010). The statistically significant decrement in CR 
level at high-dose as compared to control group may be because of the unique physico-
chemical properties of CR for example molecular mass 113 Da, radius 30 nm and its non-
binding nature with protein. Since the excretion of CR is done by the secretory activity of 
proximal convoluted tubules (PCT) (Perrone et aL, 1992); therefore, for the altered serum 
level of CR we should look at the structural and functional integrity of PCT rather than 
on glomerular filter. Thus the decreased level of CR with respect to renal dysfunction 
might be the result of the augmentation of CR secretion by PCT. Infact in high-dose (5-
g/kg) groups the PCT appeared overtly eosinophilic under light microscope, which might 
have been due to its altered functional status as a result of actual increase of mitochondria 
in the epithelial cells of PCT (as evidenced by TEM, Fig 84 d & e). 
No obvious differences in the TG level were observed after intraperitoneal exposure of 
AgNPs. In previously published work, similar result was also obtained by other 
researcher after oral exposure to AgNPs (Kim et aL, 2010). HDL level was significantly 
increased on 1^ ' and 2"'' week but were significantly decreased at 3'^ '' and 4"^  week. It was 
noticed that no significant differences in the CHO level in 1^ ', 2"'' and 3'^ '' week of treated 
mice, while significant decreased in the CHO levels was observed in 4"^  week in the low-
and exceptionally high-dose groups. Similar results were also noted on CHO levels in 
other previous studies (Maneewattanapinyo et aL, 2011; Xue et aL, 2012). These results 
indicate that AgNPs has no obvious affects on lipids metabolism. 
In the present study, one of the very interesting finding has been noticed. It was observed 
that the blood glucose level was significantly decrease (p<0.05) in all groups of treated 
mice compared to control for 1^ ', 2"**, 3'^ and 4^ '' week of mice after exposure of AgNPs. 
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However, in other previous studies in animal models no such significant changes were 
observed in the glucose levels after AgNPs exposure (Kim et al., 2008; Sung et al, 2009; 
Kim et al, 2010), suggest that AgNPs has the potential to decrease the blood glucose 
level after both short- and long-term exposure implicating their strong ftjture therapeutic 
application to reduce the glucose in diabetic patients. However more and more studies are 
required to explore the exact mode of action at molecular levels before being used in 
patient care. 
No remarkable histopathological changes were observed in kidneys when exposed for 
one and two week at low-, middle-, high- and exceptionally high-dose. The present 
results are in agreement with the previous work showing no remarkable changes in 
kidney when exposed to AgNPs for 14 days (Xue at al., 2012). However, after 3'^ '' and 4"^  
week of exposure, exceptionally high-dose group showed damage to tubular epithelium 
of kidney and renal cast in the tubular lumen were also observed (Fig 81 d & e). In the 
previous reports tubular dilation, cast formation and mineralization were occasionally 
observed in a dose-dependent manner when AgNPs (56 nm) were orally administrated 
over a period of 90 days in rats (Kim et al., 2010). 
Spleen from control group had normal histology where red and white pulp could be 
identified clearly and megakaryocytes were only occasionally noticed (Fig 82 a). After 
one and two week of treatment no observable changes were noticed at any doses of 
AgNPs (Fig 82 b «& c). Thus the present results are in agreement with the previous work 
showing no remarkable changes in spleen when exposed to AgNPs for 14 days (Xue at 
al., 2012). While, after '^'^ and 4* week of exposure, megakaryocyte hyperplasia was seen 
in the red pulp and the number of megakaryocytes in the treated mice were frequently 
increased (Fig 82 d & e) as compared to control group. 
Transmission electron microscopic study revealed that the administration of low-, 
middle- and high-dose ZnO and AgNPs did not show any significant changes in the 
ultrastructure of mice liver, kidney and spleen when exposed for 1^ ', 2""*, 3'^ '' and 4* week. 
However, when mice were exposed to exceptionally high-dose of ZnO and AgNPs for 3 
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and 4 weeks significant changes in the ultrastructure of liver, kidney and spleen were 
observed. The uhrastructural damages observed in liver hepatocytes were chromatin 
condensation, irregularity of nuclear membrane, swelling of mitochondria with regression 
of mitochondrial cristae, dilation of rough endoplasmic reticulum, vacuolation in the 
cytoplasm, suggesting an early necrosis and apoptosis of hepatocytes (Fig 76 d & e; 83 d 
& e). These were evident in all animals treated with exceptionally high-dose of ZnO and 
AgNPs for 3''^ and 4* week. The results suggested that long-term exposure with 
exceptionally high-dose of ZnO and AgNPs caused the mouse hepatocyte apoptosis. 
In the present study administration of exceptionally high-dose of ZnO and AgNPs for 3'^ '' 
and 4^*" weeks also induces significant damage in function and structure of kidney. Toxic 
effects of ZnO and AgNPs on kidneys were most prominent in convoluted segment of the 
proximal tubules. Changes in mitochondria were particularly evident in proximal 
convoluted tubules, and these changes had been observed repeatedly in the renal tissues 
from all mice sacrificed on S"^** and 4'^  week (Fig 77 d & e; Fig 84 d & e). Nuclear 
membrane degeneration, chromatin condensation, polymorphic mitochondria with 
vacuoles and swelling, dilation of rough endoplasmic reticulum and cytoplasmic vacuoles 
were signs of necrosis and apoptosis. Ultrastructrually, the glomerular basement 
membranes showed obvious thickening at exceptionally high-dose (Fig 84 d & e). 
Electron microscopy appeared to be a much more sensitive tool to detect structural 
changes in cellular organelles. More importantly, by means of electron microscopy, we 
demonstrated subtle but definitive renal toxicity, specifically at the level of mitochondrial 
changes, in the kidneys of mice exposed to a single exceptionally high-dose of ZnO and 
AgNPs for 28 days. Mitochondrial function is important in the regulation of cellular life 
and death, including disease states, and the disturbance in mitochondrial function and 
distribution can be accompanied by significant morphological alterations (Mumcuoglu et 
al, 2012). The mitochondrial swelling, degeneration of cristae and vacuoles in 
mitochondria observed in the present study may reflect the disturbances in oxy-reduction 
processes taking place in the organelle. These ultrastructure changes may indicate a 
phenotypic general mitochondrial dysfunction. Mitochondria are calcium-sensitive and 
calcium-dependent organelles (Lin et al, 2008). Mitochondrial changes observed in the 
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present study may reflect a disruption of calcium metabolism by ZnO and AgNPs. Future 
investigations to affirm this aspect is warranted. The nucleus is one of the most 
prominent cellular organelles within a eukaryotic cell and altered nuclear shape is 
considered to be important for cell function (Webster et al, 2009). Plus nuclear 
chromatin condensation is believed to suggest progressive inactivation of the nuclear 
component, probably due to inhibition of DNA repair and DNA methylation (Waisberg et 
al, 2003). In the present work, the administration of exceptionally high-dose of ZnO and 
AgNPs caused the presence of irregular nuclear shapes in the liver, kidney and spleen. 
Although, it is still not entirely clear how nuclear shape affects function, it has been 
speculated that changes in nuclear shape might lead to changes in chromosome 
organization vice-versa, which in turn can affect gene expression (He et al, 2008). The 
condensation of nucleus is believed to be one of the two major morphological features of 
apoptosis, the cell suicide program (Wang et al., 2011). 
There is dearth of information on electron microscopic ultrastructural changes in mice 
spleen after exposure of ZnO and AgNPs in literature. Therefore, to the best of our 
knowledge, for the first time in the present study the ultrastructural effects of ZnO and 
AgNPs on mice spleen was investigated. No significant ultrastructural changes in spleen 
were observed at low-, middle- and high-dose when mice were sacrificed on 1^ ', 2"**, 3'^ '' 
and 4* week. However, long-term exposure of mice with exceptionally high-dose of ZnO 
and AgNPs, it was observed ultrastructure changes in splenocyte of mouse spleen tissue, 
presenting significant splenocyte tumescent mitochondria, vacuolization, and apoptosis 
when exposed for 3'^ '' and 4"^  week (78 d & e; Fig 85 d & e). It was also observed 
splenocyte mitochondria swelling, nuclear membrane breakdown and chromatin 
condensation. However, further studies would be necessary to reach a final conclusion. 
To the best of my knowledge, this is the first report, of metal and metal oxide-related 
ultrastructural cell damage in organs other than the kidney and liver in mammals. This 
finding suggests that ZnO and AgNPs appear to be systemically toxic to mice at 
exceptionally high-dose on long-term exposure. The spleen is the largest immune organ 
in mammals, participating in immune response, generating lymphocytes, eliminating 
aging erythrocytes and storing blood. Wang et al. (2007) suggested that a fixed large dose 
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of 5 g/kg body weight of TiOa NPs exposure for 14 days did not remarkably increase the 
coefficient of the spleen, and did not cause abnormal pathology changes in the mouse 
spleen. The present study indicates that the acute and chronic spleen injury of mice is 
triggered by ZnO and AgNPs activation of the inflammatory or apoptotic genes that 
resulted in the damage of immune function, and apoptosis of the spleen. 
In the present work, however, no uitrastructural electron microscopic changes were 
observed in liver, kidney and spleen of the animals treated with 0.5-, 1 - and 3-g/kg of 
ZnO and AgNPs when sacrificed on 1^ ', 2" ,^ 3'^ '' and 4* week. However, the 
administration of exceptionally high-dose (5-g/kg) of ZnO and AgNPs resulted in 
sporadic or focal toxic changes in terms of nuclear chromatin condensation, 
mitochondrial swelling and vacuolation or even apoptosis in liver, kidney and spleen. 
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SUMMARY AND CONCLUSION 
Emergence and reemergence of multi-drug resistant (MDR) pathogens such as 
bacteria, fungi, and viruses remain major health concerns which are responsible 
for causing a large number of deaths and hospitalizations each year worldwide. 
Despite antimicrobial therapy, morbidity and mortality associated with these 
microbial infections remain high. Nanotechnology provides a good platform to 
modify and develop the desirable properties of metal in the form of nanoparticles 
having promising applications as antimicrobial agents. Though the in-vitro 
antimicrobial properties of NPs is available in the literature, but little is known on 
toxicological studies of NPs in vivo, therefore it is very important to find out the 
safety levels of these NPs when used in vivo. Therefore, the present work was 
planned to assess the antibacterial activity of metal (Ag) and metal oxide NPs 
(ZnO & AI2O3) in vitro against various clinical MDR bacterial isolates as well as 
the toxicological effects of Ag and ZnO NPs in vivo in mice using standard 
international procedures and techniques. 
To assess the antibacterial activity of NPs in vitro MIC/MBC, optical density 
measurement, well-diffusion, SEM, HR-TEM methods were used and to assess 
the toxicological effects of NPs in mice in vivo biochemical, light and electron 
microscopic methods were applied. 
Different size of NPs of Ag (2, 5-10, 15, 35-50 & 100 nm), ZnO (20 &70 nm) and 
AI2O3 (45 & <50 nm) were used to evaluate their antibacterial properties against 
various drug resistant and non-resistant clinical isolates of E. coli, P. aeruginosa, 
S. aureus and Klebsiella spp. 
Out of total 163 clinical bacterial isolates, Staphylococcus spp 62 (38.04% 1 
showed highest prevalence followed by P. aeruginosa 55 (33.7%), E. coll 40 
(24.5%) and Klebsiella spp 6 (3.7%). On screening Staphylococcus for methicillin 
sensitivity, 48%) S. aureus and 60%) Coagulase negative Staphylococci were found 
to be resistant. On screening for ESBL production, 80%) E. coli, 163% P. 
aeruginosa, and 66.7%> f Klebsiella sp. were found to be ESBL producers, 
whereas 7.3% P. aeruginosa were MBL positive. 
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The MIC values of small size AgNPs (2 & 5-10 nm) was found to be 3.13 and 
11.25 ^g/ml, respectively, while that of large size AgNPs (15, 35-50 & 100 nm) 
were in the range of 16-64, 400-1600 and 1300-2600 |ig/ml, respectively, against 
tested bacterial isolates. 
The MIC of ZnO NPs (20 and 70 nm) was found to be in the range of 500-4000 
and 2000-8000 ng/ml, respectively, whereas, that of AI2O3 NPs (45 and <50 nm) 
were observed in the range of 1600-3200 and 1800-3600 ^ig/ml, respectively. 
Bactericidal effects were partly due to NPs induced production of intracellular 
ROS, but we rather think that the impairment of cell membrane integrity is the 
major cause of bacterial death. Taken together, these data give valuable 
information on the mechanisms leading to NPs-induced bacterial death. However, 
another possible reason of the bacterial damage could be the direct interaction 
between NPs and bacterial membrane surface. 
NPs are much smaller than the bacterial cells, they coated around the bacteria cell 
by electrostatic forces, neutralizing the bacterial surface charge and creating large 
aggregates. The large aggregates of NP-bacteria complexes would deposit 
quickly in the suspension. This indicates a particle size-dependant phenomenon. 
For negatively charged bacterial cells (a few micrometers in size), they could 
readily capture NPs by electrostatic attractive forces, while it would be difficult to 
attract bulk particles. 
From the results of MIC, it was inferred that small size NPs shows enhanced 
activity possibly due to the large surface area to volume ratio and this can be 
explained on the basis of the generation of highly reactive oxygen species, which 
cause fatal damage to the bacterial cells. 
SEM and HR-TEM analysis revealed that the action of Ag, ZnO and AI2O3 NPs 
was mild in S. aureus as compared with E. coli and P. aeruginosa; these results 
suggest that the antimicrobial effects of NPs may be associated with 
characteristics of certain bacterial species. The lower efficacy of the NPs against 
S. aureus was possibly due to differences in membrane structure. 
It was observed from SEM and HR-TEM micrograph that NPs act primarily in 
four ways against bacteria: (1) nanoparticles attach to the surface of the bacterial 
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cell membrane and cause pit formation, perforation, disorganization and thus 
drastically disturb its proper function (2) they to penetrate inside the bacteria and 
cause further damage (3) NPs were accumulated in bacterial periplasm, 
confirming that association between NPs and bacteria is a prerequisite for the 
expression of their toxicity (4) nanoparticles release ions which will have an 
additional contribution to the bactericidal effect of the NPs and finally caused cell 
death. 
AgNPs show excellent antibiofilm properties against E.coli, P. aeruginosa and .S* 
aureus biofilms. AgNPs treated samples shows that most of the cells were dead 
and no exopolysachharides was observed. The CLSM micrograph shows that the 
number of live bacterial cells was reduced significantly as the concentration 
increased, and the 3-dimensionaI structure was also disrupted. 
SEM observations showed that AgNPs damage the cells and reduced the surface 
coverage by E. coli, P. aeruginosa and S. aureus biofilms. 
Treatment with ZnO and AgNPs caused changes in biochemical parameters such 
as TP, ALB, ALP, SGOT and CR reflected the renal and hepatic functions of 
experimental mice. 
Significant increased level of CR was observed at high and exceptionally high-
dose of ZnO NPs when exposed for 3 and 4 week indicate dysfunction of kidney. 
No significant changes were observed in the level of CHO, HDL, TG and GLU at 
all doses after 1, 3 and 4 week of exposure to ZnO NPs indicates that ZnO NPs 
had no adverse effects on the lipid and glucose metabolism, however, on week 2 
significant decreased in HDL level was noticed. 
Significant decreased in TIBL and ALB levels when mice were exposed to 
AgNPs for 1, 2, 3 and 4 week at all doses and significant increased in SGPT 
levels at high-dose indicates liver dysfunction. 
Significant decreased in CR levels were observed at high-dose of AgNPs also 
indicate kidney dysfunction. A decreased level of CR with respect to renal 
dysfunction might be the result of the augmentation of CR secretion by PCT. 
No remarkable changes in TG and CHO levels were observed at any doses of 
AgNPs indicate lipid metabolism was not affected when mice were exposed to 
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AgNPs for 1,2 and 3 weeks, however, significant decreased in CHO level were 
noticed at high-dose on week 4. 
One of the interesting finding of present work was that the glucose levels were 
significantly {p <0.05) decreased in all groups of treated mice at all doses in r \ 
2"^ 3"* and 4"^  week of treated mice. 
The light microscopic histopathological observation showed, congestion, granular 
degeneration in the hepatocytes, inflammatory cells in the liver and vesicular 
change in the hepatocytes at exceptionally high-dose (5-g/kg) of ZnO and AgNPs 
when mice were exposed for S^ '' and 4* weeks. No obvious effect on the hepatic 
cytoarchitecture of liver at low- (0.5-g/kg), middle- (1-g/kg) and high-dose (3-
g/kg) group were observed on 1, 2, 3 and 4 week of exposure to ZnO and AgNPs. 
Histopathological examination after one week treatment of ZnO and AgNPs had 
no perceptible effect on kidney structure at any doses; however, two weeks 
treatment had mild effect in terms of damage to the tubular epithelium at 
exceptionally high-dose (5-g/kg). While, after ^'^^ and "** week of exposure to 
similar dose damage to tubular epithelium of kidney and renal cast in the tubular 
lumen were observed. The renal histopathological examination revealed renal cast 
in the tubular lumen, damage of tubular epithelium and renal tubular dilatation at 
exceptionally high-dose (5-g/kg). 
Histopathological examination after one week treatment of ZnO and AgNPs had 
no observable changes in spleen structure at any doses and were very akin to 
control. However, at exceptionally high-dose (5-g/kg) after two week of treatment 
slight increased in the size of megakaryocytes was seen. After 3"* and 4* week of 
exposure to similar dose (5-g/kg) megakaryocyte hyperplasia was observed in the 
red pulp in the spleen and the number of megakaryocytes in the spleen were 
increased as compare to control group. 
There is paucity of literature on electron microscopic ultrastructural changes 
caused by ZnO and AgNPs in mice liver, kidney and spleen. Administration of 
low-, middle- and high-dose ZnO and AgNPs did not showed any significant 
changes in the ultrastructure of mice liver, kidney and spleen when exposed for 
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\^\ 2"^ *, 3'''* and 4* week suggest that ZnO and AgNPs were non toxic at these 
doses. 
Mice exposed to exceptionally high-dose of ZnO and AgNPs for 3 and 4 weeks 
showed significant changes in the ultrastructure of liver, kidney and spleen. The 
ultrastructural damages observed were chromatin condensation, irregularity of 
nuclear membrane, swelling of mitochondria, polymorphic mitochondria with 
vacuoles, dilation of rough endoplasmic reticulum, vacuolation on the cytoplasm. 
suggesting an early necrosis and apoptosis. 
No obvious changes were observed at \'\ 2"^ 3"* and 4* week of mice kidney 
when exposed at low- (0.5-g/kg), middle- (1-g/kg) and high-dose (3-g/kg) of 
AgNPs. Thus the long-term ZnO NPs exposures particularly at high dose may be 
advised with caution. 
No significant ultrastructural changes in spleen were observed at low-, middle-
and high-dose when mice were sacrificed on 1'', 2"^ 3"" and 4* week. However, 
long-term exposure of mice with exceptionally high-dose of ZnO and AgNPs, 
ultrastructure changes in splenocyte of mouse tissue presenting significant 
splenocyte tumescent mitochondria, vacuolization, and apoptosis when exposed 
for 3"* and 4"^  week. 
From the available literature it appears that this is the first report of metal and 
metal oxide NPs-related ultrastructural cell damage in spleen. 
Thus both the light and electron microscopic examinations revealed that liver. 
kidney and spleen were the main target organs for ZnO and AgNPs following 
intraperitoneal administration. These were evident in all animals treated with 
exceptionally high-dose of ZnO and AgNPs for 3"* and 4"^  week. The TEM results 
suggested that long-term exposure with exceptionally high-dose (5-g/kg) of ZnO 
and AgNPs caused the necrosis / apoptosis. 
The finding also suggests that ZnO and AgNPs appear to be systemically toxic to 
mice at exceptionally high-dose on long-term exposure and toxicity of 
nanoparticles is dependent on concentration and duration of exposure. 
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Interestingly, NPs inhibited bacterial growth of MSSA, MRSA, MRSE, ESBL 
and non ESBL E. coli, P. aeruginosa and Klebsiella spp regardless of the 
resistance mechanisms that confer importance to these bacteria as an emerging 
pathogen suggests that NPs are effective broad-spectrum antibacterial agents. 
It was concluded that the bactericidal activity of NPs depends both on size and the 
concentration of nanoparticles and it was further concluded that AgNPs shows 
better antibacterial activity followed by ZnO and AI2O3 NPs. 
The results suggested that ZnO and AgNPs could be well tolerated in mice when 
given intraperitoneally at the dose level of 5-g/kg and more interestingly no 
mortality was noted up to 4 week. 
The significant decreased in glucose level after AgNPs administration suggest that 
AgNPs has the potential to lowered the blood glucose level after short- and long-
term administration suggesting their future prospect as anti-hyperglycemic agents 
for diabetic patients. Though, additional work needs to be undertaken to elucidate 
the mechanisms at molecular levels before being applied as a therapeutic drug. 
In the future, Ag, ZnO and AI2O3 NPs-containing formulations may be utilized for 
external uses as antibacterial agents in ointments, lotions and surface coatings on 
various substrates to prevent microorganisms from attaching, colonizing, 
spreading and forming biofilms in indwelling medical devices. 
In the view of the present in vivo toxicological findings in mice it may be 
suggested that workers and researchers who are regularly exposed to 
nanoparticles should accordingly observe appropriate safety measures. In order to 
safeguard the human health and environment a risk assessment framework for 
nanoparticles should be built based upon their available toxicity studies. 
Data from this study will not only be useful for the toxicological evaluation of 
ZnO and AgNPs in animals, but will also shed light on future toxicological 
evaluation in humans. These results suggest the need for a complete risk 
assessment of any new engineered nanoparticle before its arrival into the 
consumer market. 
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